Alere 10-K 5 Jun 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	May 31, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	ALR
Entity Registrant Name	ALERE INC.
Entity Central Index Key	1,145,460
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		87,368,721
Entity Public Float			$ 3,615,096,669

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016		Dec. 31, 2015	[1]	Dec. 31, 2014	[1]
Income Statement [Abstract]
Net product sales	$ 456,024	$ 482,962	$ 468,502	$ 500,367	$ 472,959	$ 491,652	$ 481,352	$ 951,464	$ 973,004	$ 1,407,488	$ 1,445,963	$ 1,883,576		$ 1,946,330		$ 2,023,963
Services revenue	123,778	124,809	115,709	113,483	128,341	126,628	123,856	240,518	250,484	364,296	378,825	480,761		492,308		531,988
Net product sales and services revenue	579,802	607,771	584,211	613,850	601,300	618,280	605,208	1,191,982	1,223,488	1,771,784	1,824,788	2,364,337		2,438,638		2,555,951
License and royalty revenue	2,480	2,533	2,729	3,286	3,299	5,694	4,698	5,262	10,392	7,742	13,691	11,998		16,977		21,050
Net revenue	582,282	610,304	586,940	617,136	604,599	623,974	609,906	1,197,244	1,233,880	1,779,526	1,838,479	2,376,335		2,455,615		2,577,001
Cost of net product sales	239,059	249,837	241,324	297,125	245,429	258,787	237,805	491,161	496,592	730,220	742,021	978,347		1,039,146		1,063,000
Cost of services revenue	76,639	78,294	73,100	72,111	79,851	76,800	75,626	151,394	152,426	228,033	232,277	304,871		304,388		294,949
Cost of net product sales and services revenue	315,698	328,131	314,424	369,236	325,280	335,587	313,431	642,555	649,018	958,253	974,298	1,283,218		1,343,534		1,357,949
Cost of license and royalty revenue	641	535	1,391	650	1,137	1,344	1,950	1,926	3,294	2,567	4,431	3,250		3,781		5,592
Cost of net revenue	316,339	328,666	315,815	368,586	326,417	336,931	315,381	644,481	652,312	960,820	978,729	1,286,468		1,347,315		1,363,541
Gross profit	265,943	281,638	271,125	248,550	278,182	287,043	294,525	552,763	581,568	818,706	859,750	1,089,867		1,108,300		1,213,460
Operating expenses:
Research and development	31,430	28,446	27,062	28,228	36,011	27,198	28,016	55,508	55,214	86,938	91,225	112,122		119,453		144,828
Sales and marketing	101,966	102,444	100,640	110,891	106,724	107,906	108,918	203,084	216,824	305,050	323,548	403,055		434,439		513,049
General and administrative	148,540	136,854	114,956	118,986	101,306	61,173	92,691	251,810	153,864	400,350	255,170	563,776		374,156		453,163
Impairment and (gain) loss on dispositions, net	0	0	(3,810)	8,132	2,074	5,542	34,792	(3,810)	40,334	(3,810)	42,408	(3,810)		50,540		7,742
Operating income (loss)	(15,993)	13,894	32,277	(17,687)	32,067	85,224	30,108	46,171	115,332	30,178	147,399	14,724		129,712		94,678
Interest expense, including amortization of original issue discounts and deferred financing costs	(44,130)	(42,329)	(42,106)	(58,739)	(52,333)	(59,494)	(46,431)	(84,435)	(105,925)	(128,565)	(158,258)	(171,651)		(216,997)		(209,191)
Other income (expense), net	(1,159)	(3,912)	(1,349)	(1,743)	3,658	3,195	(2,367)	(5,261)	828	(6,420)	4,486	4,529		2,743		(3,407)
Loss from continuing operations before provision (benefit) for income taxes	(61,282)	(32,347)	(11,178)	(78,169)	(16,608)	28,925	(18,690)	(43,525)	10,235	(104,807)	(6,373)	(152,398)		(84,542)		(117,920)
Provision (benefit) for income taxes	(50,796)	2,582	(172)	(51,146)	(10,140)	15,788	(8,067)	2,410	7,721	(48,386)	(2,419)	35,376		(53,564)		71,030
Loss from continuing operations before equity earnings of unconsolidated entities, net of tax	(10,486)	(34,929)	(11,006)	(27,023)	(6,468)	13,137	(10,623)	(45,935)	2,514	(56,421)	(3,954)	(187,774)		(30,978)		(188,950)
Equity earnings of unconsolidated entities, net of tax	26,149	2,122	5,034	5,210	5,000	1,361	3,959	7,156	5,320	33,305	10,320	50,505		15,530		17,509
Loss from continuing operations	15,663	(32,807)	(5,972)	(21,813)	(1,468)	14,498	(6,664)	(38,779)	7,834	(23,116)	6,366	(137,269)		(15,448)		(171,441)
Income from discontinued operations, net of tax	0	0	0	2,736	0	0	216,777	0	216,777	0	216,777	0		219,513		138,318
Net income (loss)	15,663	(32,807)	(5,972)	(19,077)	(1,468)	14,498	210,113	(38,779)	224,611	(23,116)	223,143	(137,269)	[1]	204,065		(33,123)
Less: Net income attributable to non-controlling interests	207	143	103	(5)	(61)	359	88	246	447	453	386	350		381		30
Net income (loss) attributable to Alere Inc. and Subsidiaries	15,456	(32,950)	(6,075)	(19,072)	(1,407)	14,139	210,025	(39,025)	224,164	(23,569)	222,757	(137,619)		203,684		(33,153)
Preferred stock dividends	(5,366)	(5,308)	(5,309)	(5,367)	(5,369)	(5,308)	(5,250)	(10,617)	(10,558)	(15,983)	(15,927)	(21,350)		(21,293)		(21,293)
Net income (loss) available to common stockholders	$ 10,090	$ (38,258)	$ (11,384)	$ (24,439)	$ (6,776)	$ 8,831	$ 204,775	$ (49,642)	$ 213,606	$ (39,552)	$ 206,830	$ (158,969)		$ 182,391		$ (54,446)
Basic and Diluted net income (loss) per common share:
Loss from continuing operations	$ 0.12	$ (0.44)	$ (0.13)	$ (0.31)	$ (0.08)	$ 0.10	$ (0.14)	$ (0.57)	$ (0.04)	$ (0.45)	$ (0.12)	$ (1.83)		$ (0.43)		$ (2.33)
Income from discontinued operations	0	0	0		0	0	2.57	0	2.57	0	2.57	0		2.57		1.67
Net income (loss) per common share	$ 0.12	$ (0.44)	$ (0.13)	$ (0.31)	$ (0.08)	$ 0.10	$ 2.43	$ (0.57)	$ 2.53	$ (0.45)	$ 2.45	$ (1.83)		$ 2.14		$ (0.66)
Weighted-average shares - basic and diluted		86,737	86,646	85,953	85,895		84,338	86,692	84,758	86,708	85,141	86,796		85,420		82,938
[1]	Restated Values

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016		Dec. 31, 2015	[1]	Dec. 31, 2014	[1]
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ 15,663	$ (32,807)	$ (5,972)	$ (19,077)	$ (1,468)	$ 14,498	$ 210,113	$ (38,779)	$ 224,611	$ (23,116)	$ 223,143	$ (137,269)	[1]	$ 204,065		$ (33,123)
Other comprehensive loss, before tax:
Changes in cumulative translation adjustment												(122,287)		(146,438)		(166,448)
Unrealized losses on available for sale securities												0		0		(17)
Unrealized gains on hedging instruments												0		0		38
Minimum pension liability adjustment												(207)		(1,173)		(169)
Other comprehensive loss, before tax												(122,494)		(147,611)		(166,596)
Income tax provision (benefit) related to items of other comprehensive loss												127		56		(173)
Other comprehensive loss, net of tax												(122,621)		(147,667)		(166,423)
Comprehensive (loss) income	$ 24,404	$ (76,554)	$ 16,273	$ (42,975)	$ (89,800)	$ 60,491	$ 128,301	$ (60,281)	$ 188,792	$ (35,877)	$ 98,992	(259,890)		56,398		(199,546)
Less: Comprehensive income attributable to non-controlling interests												350		381		30
Comprehensive (loss) income attributable to Alere Inc. and Subsidiaries												$ (260,240)		$ 56,017		$ (199,576)
[1]	Restated Values

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	[1]	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 567,215		$ 566,213	$ 506,164	$ 490,663	$ 502,200		$ 479,381	$ 464,871	$ 414,495	$ 378,461	[1]	$ 355,431	[1]
Restricted cash	51,550		4,999	5,662	6,166	5,694		430,821	461,636	37,406
Marketable securities	76		75	74	71	164		157	175	173
Accounts receivable, net of allowances of $75,798 and $89,701 at December 31, 2016 and December 31, 2015, respectively	413,535		426,207	427,961	459,115	436,924		436,490	454,636	457,333
Inventories, net	308,920		349,378	334,492	351,015	350,949		376,057	379,545	388,481
Prepaid expenses and other current assets	118,607		124,390	124,877	106,629	114,514		121,023	125,559	117,924
Assets held for sale - current	0					4,165		25,312	28,631
Total current assets	1,459,903		1,471,262	1,399,230	1,413,659	1,414,610		1,900,012	1,948,785	1,453,773
Property, plant and equipment, net	441,190		446,313	438,787	445,218	446,039		445,872	448,891	447,326
Goodwill	2,759,366		2,805,682	2,811,545	2,839,692	2,836,915		2,842,921	2,853,551	2,880,164	2,926,666
Other intangible assets with indefinite lives	27,164		27,991	28,279	28,760	28,110		28,744	41,306	40,203
Finite-lived intangible assets, net	805,577		864,785	909,208	962,633	997,281		1,052,949	1,093,186	1,173,866
Restricted cash	2,171		42,438	42,589	43,388	43,228		44,148
Other non-current assets	14,966		16,219	16,290	17,927	18,078		19,635	21,845	25,052
Investments in unconsolidated entities	72,225		80,885	74,511	74,744	65,333		73,882	69,594	95,551
Deferred tax assets	20,483		56,638	18,638	16,124	13,993		5,380	5,381	6,360
Non-current income tax receivable and prepaid	45,234		39,472	41,500	41,215	41,236		2,537	2,611	2,545
Assets held for sale - non-current	0			12,223	11,813	13,337		126,048	129,194
Total assets	5,648,279		5,851,685	5,792,800	5,895,173	5,918,160		6,542,128	6,614,344	6,124,840
Current liabilities:
Short-term debt and current portion of long-term debt	82,370		41,424	43,681	193,044	199,992		604,092	629,371	95,299
Current portion of capital lease obligations	3,064		3,713	3,500	4,048	3,962		3,505	4,643	5,072
Accounts payable	195,879		211,476	194,235	165,800	195,752		194,246	186,941	195,980
Accrued expenses and other current liabilities	394,843		444,916	319,476	314,989	322,637		325,184	314,553	367,909
Liabilities related to assets held for sale - current	0					363		8,836	7,663
Total current liabilities	676,156		701,529	560,892	677,881	722,706		1,135,863	1,143,171	664,260
Long-term liabilities:
Long-term debt, net of current portion	2,858,205		2,905,067	2,920,789	2,823,654	2,831,166		2,944,014	2,912,147	2,987,422
Capital lease obligations, net of current portion	7,221		8,033	6,972	7,654	7,181		7,346	7,974	8,794
Deferred tax liabilities	119,098		52,513	140,864	144,483	147,618		226,976	243,298	262,117
Other long-term liabilities	155,992		137,582	148,165	155,842	154,193		121,855	131,578	123,428
Total long-term liabilities	3,140,516		3,103,195	3,216,790	3,131,633	3,140,158		3,309,794	3,306,524	3,381,761
Commitments and contingencies
Stockholders' equity:
Series B preferred stock, $0.001 par value (liquidation preference: $709,701 and $709,763 at December 31, 2016 and 2015, respectively); Authorized: 2,300 shares; Issued: 2,065 shares at December 31, 2016 and 2015, respectively; Outstanding: 1,774 shares at December 31, 2016 and 2015, respectively	606,406		606,406	606,406	606,468	606,468		606,468	606,468	606,468
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,770 shares and 94,043 shares at December 31, 2016 and 2015, respectively; Outstanding: 87,091 shares and 86,364 shares at December 31, 2016 and 2015, respectively	95		95	94	94	94		94	93	93
Additional paid-in capital	3,474,979		3,465,898	3,458,639	3,452,722	3,438,732		3,436,666	3,414,981	3,390,002
Accumulated deficit	(1,607,119)		(1,493,069)	(1,508,525)	(1,475,590)	(1,469,514)		(1,450,443)	(1,449,034)	(1,463,173)
Treasury stock, at cost, 7,679 shares at December 31, 2016 and 2015	(184,971)		(184,971)	(184,971)	(184,971)	(184,971)		(184,971)	(184,971)	(184,971)
Accumulated other comprehensive loss	(462,398)		(352,085)	(361,033)	(317,429)	(339,777)		(315,875)	(227,481)	(273,834)	(192,110)		(25,687)
Total stockholders' equity	1,826,992		2,042,274	2,010,610	2,081,294	2,051,032		2,091,939	2,160,056	2,074,585
Non-controlling interests	4,615		4,687	4,508	4,365	4,264		4,532	4,593	4,234
Total equity	1,831,607	[1]	2,046,961	2,015,118	2,085,659	2,055,296		2,096,471	2,164,649	2,078,819	$ 1,916,097	[1]	$ 2,079,904	[1]
Total liabilities and equity	$ 5,648,279		$ 5,851,685	$ 5,792,800	$ 5,895,173	$ 5,918,160		$ 6,542,128	$ 6,614,344	$ 6,124,840
[1]	Restated Values

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	[1]	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 75,798				$ 89,701
Series B preferred stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,701	$ 709,701	$ 709,701	$ 709,763	$ 709,763		$ 709,763	$ 709,763	$ 709,763
Series B preferred stock, shares authorized	2,300,000	2,300,000	2,300,000	2,300,000	2,300,000		2,300,000	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000	2,065,000	2,065,000	2,065,000		2,065,000	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000	1,774,000	1,774,000	1,774,000		1,774,000	1,774,000	1,774,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000	200,000,000	200,000,000	200,000,000		200,000,000	200,000,000	200,000,000
Common stock, shares issued	94,770,000	94,613,000	94,419,000	94,415,000	94,043,000		93,868,000	93,224,000	92,561,000
Common stock, shares outstanding	87,091,000	86,934,000	86,740,000	86,736,000	86,364,000		86,189,000	85,545,000	84,882,000
Treasury stock, shares	7,679,000	7,679,000	7,679,000	7,679,000	7,679,000		7,679,000	7,679,000	7,679,000
[1]	Restated Values

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) shares in Thousands, $ in Thousands		Total		Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock, at Cost [Member]	Accumulated Other Comprehensive Loss [Member]	Total Stockholders' Equity [Member]	Non-controlling Interests [Member]
Beginning Balance (As Previously Reported [Member]) at Dec. 31, 2012		$ 2,080,659	[1]	$ 606,468	$ 90	$ 3,319,168	$ (1,639,291)	$ (184,971)	$ (25,687)	$ 2,075,777	$ 4,882
Correction of prior period misstatements		(755)	[1]				(755)			(755)
Beginning Balance, Shares (As Previously Reported [Member]) at Dec. 31, 2012				1,774	89,666			7,679
Ending Balance at Dec. 31, 2013		2,079,904	[1]	$ 606,468	$ 90	3,319,168	(1,640,046)	$ (184,971)	(25,687)	2,075,022	4,882
Ending Balance, Shares at Dec. 31, 2013				1,774	89,666			7,679
Issuance of common stock under employee compensation plans		51,555	[1]		$ 2	51,553				51,555
Issuance of common stock under employee compensation plans, Shares					1,866
Preferred stock dividends		(21,293)	[1]			(21,293)				(21,293)
Stock-based compensation expense		12,452	[1]			12,452				12,452
Excess tax benefits on exercised stock options		(6,209)	[1]			(6,208)	(1)			(6,209)
Minimum pension liability adjustment		4	[1]						4	4
Changes in cumulative translation adjustment, net of tax		(166,448)	[1]						(166,448)	(166,448)
Unrealized net gain (loss) on hedging instruments and marketable securities, net of tax		21	[1]						21	21
Non-controlling interest capital contribution		(766)	[1]								(766)
Net income (loss) | As Previously Reported [Member]	[2]	(33,436)
Net income (loss)		(33,123)	[1]				(33,153)			(33,153)	30
Ending Balance at Dec. 31, 2014		1,916,097	[1]	$ 606,468	$ 92	3,355,672	(1,673,200)	$ (184,971)	(192,110)	1,911,951	4,146
Ending Balance, Shares at Dec. 31, 2014				1,774	91,532			7,679
Net income (loss) | As Previously Reported [Member]		210,428
Net income (loss)		210,113
Ending Balance (As Previously Reported [Member]) at Mar. 31, 2015		2,079,575
Ending Balance at Mar. 31, 2015		2,078,819
Beginning Balance at Dec. 31, 2014		1,916,097	[1]	$ 606,468	$ 92	3,355,672	(1,673,200)	$ (184,971)	(192,110)	1,911,951	4,146
Beginning Balance, Shares at Dec. 31, 2014				1,774	91,532			7,679
Net income (loss) | As Previously Reported [Member]		225,198
Net income (loss)		224,611
Ending Balance (As Previously Reported [Member]) at Jun. 30, 2015		2,165,677
Ending Balance at Jun. 30, 2015		2,164,649
Beginning Balance at Dec. 31, 2014		1,916,097	[1]	$ 606,468	$ 92	3,355,672	(1,673,200)	$ (184,971)	(192,110)	1,911,951	4,146
Beginning Balance, Shares at Dec. 31, 2014				1,774	91,532			7,679
Net income (loss) | As Previously Reported [Member]		222,817
Net income (loss)		223,143
Ending Balance (As Previously Reported [Member]) at Sep. 30, 2015		2,096,586
Ending Balance at Sep. 30, 2015		2,096,471
Beginning Balance at Dec. 31, 2014		1,916,097	[1]	$ 606,468	$ 92	3,355,672	(1,673,200)	$ (184,971)	(192,110)	1,911,951	4,146
Beginning Balance, Shares at Dec. 31, 2014				1,774	91,532			7,679
Issuance of common stock under employee compensation plans		79,185	[1]		$ 2	79,183				79,185
Issuance of common stock under employee compensation plans, Shares					2,600
Net issuance of common stock to settle taxes on restricted stock units		(4,168)	[1]			(4,168)				(4,168)
Net issuance of common stock to settle taxes on restricted stock units, Shares					(89)
Preferred stock dividends		(21,293)	[1]			(21,293)				(21,293)
Stock-based compensation expense		26,391	[1]			26,391				26,391
Excess tax benefits on exercised stock options		2,949	[1]			2,947	2			2,949
Minimum pension liability adjustment		(1,229)	[1]						(1,229)	(1,229)
Changes in cumulative translation adjustment, net of tax		(146,438)	[1]						(146,438)	(146,438)
Non-controlling interest capital contribution		50	[1]								50
Non-controlling interest dividend		(313)	[1]								(313)
Net income (loss) | As Previously Reported [Member]		206,757
Net income (loss)		204,065	[1]				203,684			203,684	381
Ending Balance (As Previously Reported [Member]) at Dec. 31, 2015		2,058,429
Ending Balance at Dec. 31, 2015		2,055,296	[1]	$ 606,468	$ 94	3,438,732	(1,469,514)	$ (184,971)	(339,777)	2,051,032	4,264
Ending Balance, Shares at Dec. 31, 2015				1,774	94,043			7,679
Beginning Balance (As Previously Reported [Member]) at Mar. 31, 2015		2,079,575
Beginning Balance at Mar. 31, 2015		2,078,819
Net income (loss) | As Previously Reported [Member]		14,770
Net income (loss)		14,498
Ending Balance (As Previously Reported [Member]) at Jun. 30, 2015		2,165,677
Ending Balance at Jun. 30, 2015		2,164,649
Net income (loss) | As Previously Reported [Member]		(2,381)
Net income (loss)		(1,468)
Ending Balance (As Previously Reported [Member]) at Sep. 30, 2015		2,096,586
Ending Balance at Sep. 30, 2015		2,096,471
Net income (loss) | As Previously Reported [Member]		(16,059)
Net income (loss)		(19,077)
Ending Balance (As Previously Reported [Member]) at Dec. 31, 2015		2,058,429
Ending Balance at Dec. 31, 2015		2,055,296	[1]	$ 606,468	$ 94	3,438,732	(1,469,514)	$ (184,971)	(339,777)	2,051,032	4,264
Ending Balance, Shares at Dec. 31, 2015				1,774	94,043			7,679
Net income (loss) | As Previously Reported [Member]		(9,977)
Net income (loss)		(5,972)
Ending Balance (As Previously Reported [Member]) at Mar. 31, 2016		2,084,788
Ending Balance at Mar. 31, 2016		2,085,659
Beginning Balance (As Previously Reported [Member]) at Dec. 31, 2015		2,058,429
Beginning Balance at Dec. 31, 2015		2,055,296	[1]	$ 606,468	$ 94	3,438,732	(1,469,514)	$ (184,971)	(339,777)	2,051,032	4,264
Beginning Balance, Shares at Dec. 31, 2015				1,774	94,043			7,679
Net income (loss) | As Previously Reported [Member]		(44,868)
Net income (loss)		(38,779)
Ending Balance (As Previously Reported [Member]) at Jun. 30, 2016		2,012,162
Ending Balance at Jun. 30, 2016		2,015,118
Beginning Balance (As Previously Reported [Member]) at Dec. 31, 2015		2,058,429
Beginning Balance at Dec. 31, 2015		2,055,296	[1]	$ 606,468	$ 94	3,438,732	(1,469,514)	$ (184,971)	(339,777)	2,051,032	4,264
Beginning Balance, Shares at Dec. 31, 2015				1,774	94,043			7,679
Net income (loss) | As Previously Reported [Member]		(22,841)
Net income (loss)		(23,116)
Ending Balance (As Previously Reported [Member]) at Sep. 30, 2016		2,050,369
Ending Balance at Sep. 30, 2016		2,046,961
Beginning Balance (As Previously Reported [Member]) at Dec. 31, 2015		2,058,429
Beginning Balance at Dec. 31, 2015		2,055,296	[1]	$ 606,468	$ 94	3,438,732	(1,469,514)	$ (184,971)	(339,777)	2,051,032	4,264
Beginning Balance, Shares at Dec. 31, 2015				1,774	94,043			7,679
Issuance of common stock under employee compensation plans		18,934	[1]		$ 1	18,933				18,934
Issuance of common stock under employee compensation plans, Shares					783
Preferred stock conversion		174	[1]	$ (62)	$ 5	236				174
Net issuance of common stock to settle taxes on restricted stock units		(2,843)	[1]			(2,843)				(2,843)
Net issuance of common stock to settle taxes on restricted stock units, Shares					(61)
Preferred stock dividends		(21,292)	[1]			(21,292)				(21,292)
Stock-based compensation expense		41,796	[1]			41,796				41,796
Excess tax benefits on exercised stock options		(568)	[1]			(583)	14			(569)	1
Minimum pension liability adjustment		(334)	[1]						(334)	(334)
Changes in cumulative translation adjustment, net of tax		(122,287)	[1]						(122,287)	(122,287)
Net income (loss)		(137,269)	[1]				(137,619)			(137,619)	350
Ending Balance at Dec. 31, 2016		1,831,607	[1]	$ 606,406	$ 95	$ 3,474,979	$ (1,607,119)	$ (184,971)	$ (462,398)	$ 1,826,992	$ 4,615
Ending Balance, Shares at Dec. 31, 2016				1,774	94,770			7,679
Beginning Balance (As Previously Reported [Member]) at Mar. 31, 2016		2,084,788
Beginning Balance at Mar. 31, 2016		2,085,659
Net income (loss) | As Previously Reported [Member]		(34,891)
Net income (loss)		(32,807)
Ending Balance (As Previously Reported [Member]) at Jun. 30, 2016		2,012,162
Ending Balance at Jun. 30, 2016		2,015,118
Net income (loss) | As Previously Reported [Member]		22,027
Net income (loss)		15,663
Ending Balance (As Previously Reported [Member]) at Sep. 30, 2016		2,050,369
Ending Balance at Sep. 30, 2016		$ 2,046,961
[1]	Restated Values
[2]	The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been previously revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due principally to a $19,236 increase in operating cash flow related to deferred income taxes and a $15,753 decrease in operating cash flow related to other non-current liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015.

Consolidated Statements of Equ7

Consolidated Statements of Equity (Parenthetical) - $ / shares	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	[1]	$ 0.001	$ 0.001	$ 0.001
Common Stock [Member]
Common stock, par value	$ 0.001				$ 0.001					$ 0.001
[1]	Restated Values

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Cash Flows from Operating Activities:
Net income (loss)	[1]	$ (137,269)	$ 204,065		$ (33,123)
Income from discontinued operations, net of tax		0	219,513	[1]	138,318	[1]
Income (loss) from continuing operations		(137,269)	(15,448)	[1]	(171,441)	[1]
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs		13,369	12,831	[1]	16,233	[1]
Depreciation and amortization		285,608	309,264	[1]	336,029	[1]
Non-cash stock-based compensation expense		41,796	26,391	[1]	12,452	[1]
Tax benefit related to discontinued operations retained by Alere Inc.		0	0	[1]	9,845	[1]
Impairment of inventory		2,667	15,597	[1]	3,124	[1]
Impairment of long-lived assets		1,792	3,708	[1]	7,019	[1]
Loss on sale of fixed assets		3,551	3,925	[1]	6,545	[1]
Equity earnings of unconsolidated entities, net of tax		(50,505)	(15,530)	[1]	(17,509)	[1]
Deferred income taxes		(36,010)	(99,389)	[1]	12,254	[1]
Loss on extinguishment of debt		0	19,886	[1]	0	[1]
Impairment and net (gain) loss on business disposition		(3,810)	50,540	[1]	7,742	[1]
Other non-cash items		(463)	28,782	[1]	4,965	[1]
Non-cash change in fair value of contingent consideration		(13,309)	(59,871)	[1]	7,677	[1]
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net		26,698	(6,680)	[1]	(4,264)	[1]
Inventories, net		(13,655)	(63,935)	[1]	(67,532)	[1]
Prepaid expenses and other current assets		(19,921)	(5,295)	[1]	(51,998)	[1]
Accounts payable		4,362	(10,783)	[1]	47,851	[1]
Accrued expenses and other current liabilities		51,490	22,643	[1]	37,886	[1]
Other non-current assets and liabilities		23,329	(3,357)	[1]	13,254	[1]
Cash paid for contingent consideration		(430)	(6,315)	[1]	(22,077)	[1]
Net cash provided by (used in) continuing operations		179,290	206,964	[1]	188,055	[1]
Net cash provided by (used in) discontinued operations		0	318	[1]	43,468	[1]
Net cash provided by operating activities		179,290	207,282	[1]	231,523	[1]
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash		(4,721)	(13,715)	[1]	(5,446)	[1]
Purchases of property, plant and equipment		(67,694)	(90,778)	[1]	(100,562)	[1]
Proceeds from sale of property, plant and equipment		1,428	2,099	[1]	1,486	[1]
Cash received from (used in) dispositions, net of cash divested		21,470	675,823	[1]	45,076	[1]
Cash paid for business acquisitions, net of cash acquired		(5,958)	(60,135)	[1]	(75)	[1]
Cash received from investments		0	0	[1]	198	[1]
Cash paid for equity investment		(184)	0	[1]	0	[1]
Proceeds from sale of equity investment		40,751	0	[1]	8,546	[1]
Cash received from sales of marketable securities		87	92	[1]	580	[1]
Cash received from equity method investments		16,989	26,136	[1]	980	[1]
Decrease (increase) in other assets		460	(1,794)	[1]	986	[1]
Net cash provided by (used in) continuing operations		2,628	537,728	[1]	(48,231)	[1]
Net cash used in discontinued operations		0	(209)	[1]	(8,972)	[1]
Net cash provided by (used in) investing activities		2,628	537,519	[1]	(57,203)	[1]
Cash Flows from Financing Activities:
Cash paid for financing costs		(29,187)	(16,188)	[1]	(1,528)	[1]
Cash paid for contingent consideration		(680)	(14,223)	[1]	(32,902)	[1]
Cash paid for dividends		(21,292)	(21,293)	[1]	(21,293)	[1]
Proceeds from issuance of common stock, net of issuance costs		18,934	79,185	[1]	51,555	[1]
Proceeds from issuance of short-term debt		0	1,511	[1]	806	[1]
Proceeds from issuance of long-term debt		459	2,162,162	[1]	58	[1]
Payments on short-term debt		(1,722)	(25,584)	[1]	0	[1]
Payments on long-term debt		(198,316)	(2,656,386)	[1]	(65,122)	[1]
Net proceeds (payments) under revolving credit facilities		126,017	(127,536)	[1]	(42,522)	[1]
Excess tax benefits on exercised stock options		0	0	[1]	972	[1]
Principal payments on capital lease obligations		(4,032)	(5,618)	[1]	(6,085)	[1]
Purchase of non-controlling interest		0	0	[1]	(623)	[1]
Other		0	(8,937)	[1]	0	[1]
Net cash used in continuing operations		(109,819)	(632,907)	[1]	(116,684)	[1]
Net cash used in discontinued operations		0	(76)	[1]	(1,471)	[1]
Net cash used in financing activities		(109,819)	(632,983)	[1]	(118,155)	[1]
Foreign exchange effect on cash and cash equivalents		(7,084)	(11,379)	[1]	(16,312)	[1]
Net increase (decrease) in cash and cash equivalents		65,015	100,439	[1]	39,853	[1]
Cash and cash equivalents, beginning of period - continuing operations	[1]	502,200	378,461		355,431
Cash and cash equivalents, beginning of period - discontinued operations	[1]	0	23,300		6,477
Cash and cash equivalents, end of period		567,215	502,200	[1]	401,761	[1]
Less: Cash and cash equivalents of discontinued operations, end of period		0	0	[1]	23,300	[1]
Cash and cash equivalents of continuing operations, end of period		$ 567,215	$ 502,200	[1]	$ 378,461	[1]
[1]	Restated Values

Description of Business and Bas

Description of Business and Basis of Presentation of Financial Information	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation of Financial Information	(1) Description of Business and Basis of Presentation of Financial Information Alere delivers reliable and actionable health information through rapid diagnostic tests, resulting in better clinical and economic healthcare outcomes globally. Our high-performance diagnostics for infectious disease, cardiometabolic disease and toxicology are designed to meet the growing global demand for accurate, easy-to-use Our operating segments are currently (i) professional diagnostics; (ii) consumer diagnostics; and (iii) other non-reportable. In January 2015, we sold our condition management, case management, wellbeing, wellness, and women’s and children’s health businesses, which we refer to collectively as our health management business. As a result of the sale of our health management business, which was the largest component of our former patient self-testing reporting segment, as well as certain other transactions in 2015, the only component of the patient self-testing reporting segment that was retained by Alere was the Alere Home Monitoring business. Therefore, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, we reported our financial information in two reportable operating segments: (i) professional diagnostics and (ii) consumer diagnostics, and Alere Home Monitoring was reported as a component of the professional diagnostics segment. Due to the nature of the operations of Alere Home Monitoring and the manner in which this business is conducted, in this Annual Report on Form 10-K, we will now report our Alere Home Monitoring business as a separate segment under the heading “other non-reportable segment.” Alere Home Monitoring distributes PT/INR coagulation monitors and facilitates the distribution of equipment and supplies to power and control customers’ implanted ventricular assist devices, or VADs, as well as telemonitoring services that allows VAD coordinators to monitor patients soon after discharge and receive alerts when critical patient values fall outside pre-established ranges. The consolidated financial statements include the accounts of Alere Inc. and its subsidiaries. Intercompany transactions and balances are eliminated and net earnings are reduced by the portion of the net earnings of subsidiaries applicable to non-controlling Certain amounts presented may not recalculate directly, due to rounding.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	12 Months Ended
	Dec. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Financial Statements	(2) Restatement of Previously Issued Financial Statements On April 12, 2017, management and the Audit Committee of our Board of Directors concluded that our financial statements as of December 31, 2015 and 2014 and for each of the years ended December 31, 2015, 2014 and 2013, and for each of the quarterly and year-to-date year-to-date This Annual Report on Form 10-K 10-K 10-K The Restatement was the result of the failure to correctly apply U.S. GAAP regarding the timing of revenue recognition primarily related to transactions in which we recognized revenue prior to full satisfaction of all contractual criteria for title and risk of loss passing to the customer as required by U.S. GAAP. The principal cause of these misstatements in the timing of revenue recognition is attributable to inappropriate conduct at our Standard Diagnostics subsidiary. These misstatements were primarily the result of conduct and practices initiated by a former employee in the sales organization. The inappropriate conduct and practices involved, among other things, misrepresentation and/or fabrication of documents used to validate revenue recognition that were intentionally concealed from our senior leadership team and our external auditors at the time of the transactions and during the global revenue recognition assessment conducted as part of the filing of the Annual Report on Form 10-K flows from operating activities, investing activities, or financing activities. There was no impact to net change in cash and cash equivalents for any previously reported periods. Certain corrections of classifications within the operating cash flow section were impacted by the Restatement, as set forth in the tables below. The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding restatement amounts (see Note 28 presenting the restated quarterly financial statements for 2016 and 2015): ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Year Ended December 31, 2015 As Previously Restatement Adjustment(1) As Restated Net product sales $ 1,954,031 $ (7,701 ) $ 1,946,330 Services revenue 492,308 — 492,308 Net product sales and services revenue 2,446,339 (7,701 ) 2,438,638 License and royalty revenue 16,977 — 16,977 Net revenue 2,463,316 (7,701 ) 2,455,615 Cost of net product sales 1,042,603 (3,457 ) 1,039,146 Cost of services revenue 304,388 — 304,388 Cost of net product sales and services revenue 1,346,991 (3,457 ) 1,343,534 Cost of license and royalty revenue 3,781 — 3,781 Cost of net revenue 1,350,772 (3,457 ) 1,347,315 Gross profit 1,112,544 (4,244 ) 1,108,300 Operating expenses: Research and development 119,453 — 119,453 Sales and marketing 435,131 (692 ) 434,439 General and administrative 369,570 4,586 374,156 Impairment and loss on dispositions, net 50,540 — 50,540 Operating income 137,850 (8,138 ) 129,712 Interest expense, including amortization of original issue discounts and deferred financing costs (216,997 ) — (216,997 ) Other income (expense), net (1,843 ) 4,586 2,743 Loss from continuing operations before provision (benefit) for income taxes (80,990 ) (3,552 ) (84,542 ) Provision (benefit) for income taxes (52,704 ) (860 ) (53,564 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (28,286 ) (2,692 ) (30,978 ) Equity earnings of unconsolidated entities, net of tax 15,530 — 15,530 Income (loss) from continuing operations (12,756 ) (2,692 ) (15,448 ) Income (loss) from discontinued operations, net of tax 219,513 — 219,513 Net income (loss) 206,757 (2,692 ) 204,065 Less: Net income attributable to non-controlling 381 — 381 Net income (loss) attributable to Alere Inc. and Subsidiaries 206,376 (2,692 ) 203,684 Preferred stock dividends (21,293 ) — (21,293 ) Net income (loss) available to common stockholders $ 185,083 $ (2,692 ) $ 182,391 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.40 ) $ (0.03 ) $ (0.43 ) Income (loss) from discontinued operations 2.57 — 2.57 Net income (loss) per common share $ 2.17 $ (0.03 ) $ 2.14 Weighted-average shares — basic and diluted 85,420 — 85,420 (1) All adjustments are related to the Standard Diagnostics revenue recognition matter, except for the $4,586 adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. Year Ended December 31, 2015 As Previously Restatement Adjustment(1) As Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 58,709 $ (2,692 ) $ 56,017 (1) The restatement adjustment to total comprehensive income (loss) attributable to Alere Inc. and Subsidiaries is comprised solely of the restatement adjustment to net income (loss) for the period. ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except par value) As of December 31, 2015 As Restatement Adjustment(2) As ASSETS Current assets: Cash and cash equivalents $ 502,200 $ — $ 502,200 Restricted cash 5,694 — 5,694 Marketable securities 164 — 164 Accounts receivable, net of allowances of $89,701 at December 31, 2015 445,833 (8,909 ) 436,924 Inventories, net 347,001 3,948 350,949 Prepaid expenses and other current assets 152,233 (37,719 ) 114,514 Assets held for sale — current 4,165 — 4,165 Total current assets 1,457,290 (42,680 ) 1,414,610 Property, plant and equipment, net 446,039 — 446,039 Goodwill 2,836,915 — 2,836,915 Other intangible assets with indefinite lives 28,110 — 28,110 Finite-lived intangible assets, net 997,281 — 997,281 Restricted cash 43,228 — 43,228 Other non-current 18,078 — 18,078 Investments in unconsolidated entities 65,333 — 65,333 Deferred tax assets 13,993 — 13,993 Non-current 3,517 37,719 41,236 Assets held for sale — non-current 13,337 — 13,337 Total assets $ 5,923,121 $ (4,961 ) $ 5,918,160 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 199,992 $ — $ 199,992 Current portion of capital lease obligations 3,962 — 3,962 Accounts payable 195,752 — 195,752 Accrued expenses and other current liabilities 324,465 (1,828 ) 322,637 Liabilities related to assets held for sale — current 363 — 363 Total current liabilities 724,534 (1,828 ) 722,706 Long-term liabilities: Long-term debt, net of current portion 2,831,166 — 2,831,166 Capital lease obligations, net of current portion 7,181 — 7,181 Deferred tax liabilities 147,618 — 147,618 Other long-term liabilities 154,193 — 154,193 Total long-term liabilities 3,140,158 — 3,140,158 Commitments and contingencies Stockholders’ equity: Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at December 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares at December 31, 20154; Outstanding: 1,774 shares at December 31, 2015 606,468 — 606,468 Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,043 shares at December 31, 2015, Outstanding: 86,364 shares at December 31, 2015 94 — 94 Additional paid-in 3,438,732 — 3,438,732 Accumulated deficit (1,466,381 ) (3,133 ) (1,469,514 ) Treasury stock, at cost, 7,679 shares at December 31, 2015 (184,971 ) — (184,971 ) Accumulated other comprehensive loss (339,777 ) — (339,777 ) Total stockholders’ equity 2,054,165 (3,133 ) 2,051,032 Non-controlling 4,264 — 4,264 Total equity 2,058,429 (3,133 ) 2,055,296 Total liabilities and equity $ 5,923,121 $ (4,961 ) $ 5,918,160 (1) The figures presented in this column represent the amounts that were presented originally in the Annual Report on Form 10-K 2015-03 2015-15 non-current (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities, except for the $37,719 classification adjustment between current assets and non-current ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Year Ended December 31, 2015 As Restatement Adjustment(1) As Cash Flows from Operating Activities: Net income (loss) $ 206,757 $ (2,692 ) $ 204,065 Income (loss) from discontinued operations, net of tax 219,513 — 219,513 Income (loss) from continuing operations (12,756 ) (2,692 ) (15,448 ) Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities: Non-cash 12,831 — 12,831 Depreciation and amortization 309,264 — 309,264 Non-cash 26,391 — 26,391 Impairment of inventory 15,597 — 15,597 Impairment of intangible and long-lived assets 3,708 — 3,708 Loss on sale of fixed assets 3,925 — 3,925 Equity earnings of unconsolidated entities, net of tax (15,530 ) — (15,530 ) Deferred income taxes (99,389 ) — (99,389 ) Loss on extinguishment of debt 19,886 — 19,886 Loss related to impairment and net loss on disposition 50,540 — 50,540 Other non-cash 28,782 — 28,782 Non-cash (59,871 ) — (59,871 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net (14,380 ) 7,700 (6,680 ) Inventories, net (60,478 ) (3,457 ) (63,935 ) Prepaid expenses and other current assets (43,014 ) 37,719 (5,295 ) Accounts payable (10,783 ) — (10,783 ) Accrued expenses and other current liabilities 24,194 (1,551 ) 22,643 Other non-current 34,362 (37,719 ) (3,357 ) Cash paid for contingent consideration (6,315 ) — (6,315 ) Net cash provided by continuing operations 206,964 — 206,964 Net cash provided by discontinued operations 318 — 318 Net cash provided by operating activities 207,282 — 207,282 Cash Flows from Investing Activities: Increase in restricted cash (13,715 ) — (13,715 ) Purchases of property, plant and equipment (90,778 ) — (90,778 ) Proceeds from sale of property, plant and equipment 2,099 — 2,099 Cash received from business dispositions, net of cash divested 675,823 — 675,823 Cash paid for business acquisitions, net of cash acquired (60,135 ) — (60,135 ) Cash received from sales of marketable securities 92 — 92 Cash received from equity method investments 26,136 — 26,136 (Increase) decrease in other assets (1,794 ) — (1,794 ) Net cash provided by (used in) continuing operations 537,728 — 537,728 Net cash used in discontinued operations (209 ) — (209 ) Net cash provided by (used in) investing activities 537,519 — 537,519 Cash Flows from Financing Activities: Cash paid for financing costs (16,188 ) — (16,188 ) Cash paid for contingent purchase price consideration (14,223 ) — (14,223 ) Cash paid for dividends (21,293 ) — (21,293 ) Proceeds from issuance of common stock, net of issuance costs 79,185 — 79,185 Proceeds from issuance of short-term debt 1,511 — 1,511 Proceeds from issuance of long-term debt 2,162,162 — 2,162,162 Payments on short-term debt (25,584 ) — (25,584 ) Payments on long-term debt (2,656,386 ) — (2,656,386 ) Net (payments) proceeds under revolving credit facilities (127,536 ) — (127,536 ) Principal payments on capital lease obligations (5,618 ) — (5,618 ) Other (8,937 ) — (8,937 ) Net cash provided by (used in) continuing operations (632,907 ) — (632,907 ) Net cash used in discontinued operations (76 ) — (76 ) Net cash provided by (used in) financing activities (632,983 ) — (632,983 ) Foreign exchange effect on cash and cash equivalents (11,379 ) — (11,379 ) Net increase in cash and cash equivalents 100,439 — 100,439 Cash and cash equivalents, beginning of period — continuing operations 378,461 — 378,461 Cash and cash equivalents, beginning of period — discontinued operations 23,300 — 23,300 Cash and cash equivalents, end of period 502,200 — 502,200 Less: Cash and cash equivalents of discontinued operations, end of period — — — Cash and cash equivalents of continuing operations, end of period $ 502,200 $ — $ 502,200 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities, except for the $37,719 classification adjustment between current assets and non-current ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Year Ended December 31, 2014 As Previously Restatement Adjustment(2) As Net product sales $ 2,022,240 $ 1,723 $ 2,023,963 Services revenue 531,988 — 531,988 Net product sales and services revenue 2,554,228 1,723 2,555,951 License and royalty revenue 21,050 — 21,050 Net revenue 2,575,278 1,723 2,577,001 Cost of net product sales 1,062,499 501 1,063,000 Cost of services revenue 294,949 — 294,949 Cost of net product sales and services revenue 1,357,448 501 1,357,949 Cost of license and royalty revenue 5,592 — 5,592 Cost of net revenue 1,363,040 501 1,363,541 Gross profit 1,212,238 1,222 1,213,460 Operating expenses: Research and development 144,828 — 144,828 Sales and marketing 512,961 88 513,049 General and administrative 453,628 (465 ) 453,163 Impairment and loss on dispositions, net 7,742 — 7,742 Operating income 93,079 1,599 94,678 Interest expense, including amortization of original issue discounts and deferred financing costs (209,191 ) — (209,191 ) Other income (expense), net (2,221 ) (1,186 ) (3,407 ) Loss from continuing operations before provision (benefit) for income taxes (118,333 ) 413 (117,920 ) Provision (benefit) for income taxes 70,930 100 71,030 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (189,263 ) 313 (188,950 ) Equity earnings of unconsolidated entities, net of tax 17,509 — 17,509 Income (loss) from continuing operations (171,754 ) 313 (171,441 ) Income (loss) from discontinued operations, net of tax 138,318 — 138,318 Net income (loss) (33,436 ) 313 (33,123 ) Less: Net income attributable to non-controlling 30 — 30 Net income (loss) attributable to Alere Inc. and Subsidiaries (33,466 ) 313 (33,153 ) Preferred stock dividends (21,293 ) — (21,293 ) Net income (loss) available to common stockholders $ (54,759 ) $ 313 $ (54,446 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (2.33 ) $ — $ (2.33 ) Income (loss) from discontinued operations 1.67 — 1.67 Net income (loss) per common share $ (0.66 ) $ — $ (0.66 ) Weighted-average shares — basic and diluted 82,938 — 82,938 (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K 10-K/A 10-K (2) All adjustments are related to the Standard Diagnostics revenue recognition matter, except for the $(1,186) adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. Year Ended December 31, 2014 As Previously Restatement Adjustment(2) As Restated Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (199,889 ) $ 313 $ (199,576 ) (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K 10-K/A (2) The restatement adjustment to total comprehensive income (loss) attributable to Alere Inc. and Subsidiaries is comprised solely of the restatement adjustment to net income (loss) for the period. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Year Ended December 31, 2014 As Previously Restatement Adjustment(2) As Cash Flows from Operating Activities: Net income (loss) $ (33,436 ) $ 313 $ (33,123 ) Income (loss) from discontinued operations, net of tax 138,318 — 138,318 Income (loss) from continuing operations (171,754 ) 313 (171,441 ) Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities: Non-cash 16,233 — 16,233 Depreciation and amortization 336,029 — 336,029 Non-cash 12,452 — 12,452 Tax benefit related to discontinued operations retained by Alere Inc. 9,845 — 9,845 Impairment of inventory 3,124 — 3,124 Impairment of intangible and long-lived assets 7,019 — 7,019 Loss on sale of fixed assets 6,545 — 6,545 Equity earnings of unconsolidated entities, net of tax (17,509 ) — (17,509 ) Deferred income taxes 12,254 — 12,254 Loss related to impairment and net loss on disposition 7,742 — 7,742 Other non-cash 4,965 — 4,965 Non-cash 7,677 — 7,677 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net (3,262 ) (1,002 ) (4,264 ) Inventories, net (68,033 ) 501 (67,532 ) Prepaid expenses and other current assets (51,998 ) — (51,998 ) Accounts payable 47,851 — 47,851 Accrued expenses and other current liabilities 37,698 188 37,886 Other non-current 13,254 — 13,254 Cash paid for contingent consideration (22,077 ) — (22,077 ) Net cash provided by continuing operations 188,055 — 188,055 Net cash provided by discontinued operations 43,468 — 43,468 Net cash provided by operating activities 231,523 — 231,523 Cash Flows from Investing Activities: Increase in restricted cash (5,446 ) — (5,446 ) Purchases of property, plant and equipment (100,562 ) — (100,562 ) Proceeds from sale of property, plant and equipment 1,486 — 1,486 Cash received from business dispositions, net of cash divested 45,076 — 45,076 Cash paid for business acquisitions, net of cash acquired (75 ) — (75 ) Cash received from investments 198 — 198 Proceeds from sale of equity investment 8,546 — 8,546 Cash received from sales of marketable securities 580 — 580 Cash received from equity method investments 980 — 980 (Increase) decrease in other assets 986 — 986 Net cash provided by (used in) continuing operations (48,231 ) — (48,231 ) Net cash used in discontinued operations (8,972 ) — (8,972 ) Net cash provided by (used in) investing activities (57,203 ) — (57,203 ) Cash Flows from Financing Activities: Cash paid for financing costs (1,528 ) — (1,528 ) Cash paid for contingent purchase price consideration (32,902 ) — (32,902 ) Cash paid for dividends (21,293 ) — (21,293 ) Proceeds from issuance of common stock, net of issuance costs 51,555 — 51,555 Proceeds from issuance of short-term debt 806 — 806 Proceeds from issuance of long-term debt 58 — 58 Payments on long-term debt (65,122 ) — (65,122 ) Net (payments) proceeds under revolving credit facilities (42,522 ) — (42,522 ) Excess tax benefits on exercised stock options 972 — 972 Principal payments on capital lease obligations (6,085 ) — (6,085 ) Purchase of non-controlling (623 ) — (623 ) Net cash provided by (used in) continuing operations (116,684 ) — (116,684 ) Net cash used in discontinued operations (1,471 ) — (1,471 ) Net cash provided by (used in) financing activities (118,155 ) — (118,155 ) Foreign exchange effect on cash and cash equivalents (16,312 ) — (16,312 ) Net increase in cash and cash equivalents 39,853 — 39,853 Cash and cash equivalents, beginning of period – continuing operations 355,431 — 355,431 Cash and cash equivalents, beginning of period – discontinued operations 6,477 — 6,477 Cash and cash equivalents, end of period 401,761 — 401,761 Less: Cash and cash equivalents of discontinued operations, end of period 23,300 — 23,300 Cash and cash equivalents of continuing operations, end of period $ 378,461 $ — $ 378,461 (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K 10-K/A non-current 10-K (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities.

Merger Agreement

Merger Agreement	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Merger Agreement	(3) Merger Agreement Merger Agreement with Abbott Laboratories On January 30, 2016, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Abbott Laboratories, or Abbott. The Merger Agreement provides for the merger of a wholly owned subsidiary of Abbott with and into Alere, or the merger, with Alere surviving the merger as a wholly owned subsidiary of Abbott, or the surviving corporation. Under the terms of the Merger Agreement, prior to its amendment (as described herein), holders of shares of our common stock were entitled to receive $56.00 in cash, without interest, in exchange for each share of common stock. On April 13, 2017, Abbott and Alere entered into an Amendment to Agreement and Plan of Merger, or the Merger Agreement Amendment which amends the Merger Agreement (as amended by the Merger Agreement Amendment, the Amended Merger Agreement), which provides, among other things, that the holders of shares of our common stock will receive $51.00 in cash, without interest, in exchange for each share of common stock. Other than as expressly modified pursuant to the Merger Agreement Amendment, the Merger Agreement remains in full force and effect. The Amended Merger Agreement has been approved by our Board of Directors. Each share of our Series B Preferred Stock issued and outstanding immediately prior to the effective time of the merger will remain issued and outstanding immediately following the consummation of the merger as one share of Series B Convertible Preferred Stock, par value $0.001 per share, of the surviving corporation. Completion of the merger pursuant to the Amended Merger Agreement is subject to customary closing conditions, including (1) the adoption of the Amended Merger Agreement by the affirmative vote of the holders of at least a majority of all outstanding shares of our common stock, (2) there being no judgment or law enjoining or otherwise prohibiting the consummation of the merger, (3) the expiration of the waiting period applicable to the merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or the HSR Act, and receipt of other required antitrust approvals and (4) the absence of a Material Adverse Effect (as defined in the Amended Merger Agreement). Under the terms of the Amended Merger Agreement, Abbott has agreed to make certain divestitures if necessary to obtain the consent of the antitrust authorities to the transaction contemplated by the Amended Merger Agreement, subject to certain exceptions set forth in the Amended Merger Agreement. The obligation of each of the parties to consummate the merger is also conditioned on the other party’s representations and warranties being true and correct (subject to certain materiality exceptions) and the other party having performed in all material respects its obligations under the Amended Merger Agreement. The Amended Merger Agreement contains certain termination rights that allow the Amended Merger Agreement to be terminated in certain circumstances. In addition, the Merger Agreement Amendment extends the date after which each of Alere and Abbott would have a right to terminate the Amended Merger Agreement to September 30, 2017, subject to the terms and conditions set forth in the Amended Merger Agreement. The Merger Agreement Amendment reduces the termination fee that Alere may be required to pay Abbott under specified circumstances to $161 million, from $177 million. The Merger Agreement Amendment also provides that neither any matter set forth in Alere’s public filings made with the Securities and Exchange Commission, or SEC, between January 1, 2014 and April 13, 2017 nor any matter of which Abbott or any of Abbott’s representatives was made aware prior to April 13, 2017 could be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur. Further, in addition to the qualifications set forth in the original Merger Agreement, the Amendment qualifies all of our representations and warranties made in the Amended Merger Agreement (including those made in the original Merger Agreement) by all matters set forth in our public filings made with the SEC between January 1, 2014 and April 13, 2017 and any matter known by Abbott or any of Abbott’s representatives prior to April 13, 2017. In addition, the Merger Agreement Amendment changes Abbott’s commitment to provide Alere’s employees that continue with Abbott with specified levels of compensation and benefits to be a commitment through the first anniversary of the closing of the merger, rather than through December 31, 2017 and a 2018 long-term incentive award to each continuing employee employed by Abbott or its subsidiaries at the time annual long-term awards are made generally that is no less favorable than the long-term incentive award made to similarly situated employees of Abbott generally. Antitrust Clearance On May 2, 2016, Abbott and Alere received a request for additional information, or a “second request,” from the United States Federal Trade Commission, or the FTC, relating to Abbott’s potential acquisition of Alere. The second request was issued under the HSR Act. In addition, Abbott has agreed voluntarily to provide the FTC at least 60 days advance notice before certifying substantial compliance with the second request and to extend the waiting period imposed by the HSR Act to not less than 60 days after Abbott and Alere have certified substantial compliance with the second request, unless the period is further extended voluntarily by the parties or terminated sooner by the FTC. On June 23, 2016, Abbott and Alere received a request for additional information, or a “supplemental information request,” from the Canadian Competition Bureau, or the Bureau, relating to Abbott’s potential acquisition of Alere. The supplemental information request was issued under the Competition Act of Canada, or the Competition Act. The effect of the supplemental information request is to extend the waiting period imposed by the Competition Act until 30 days after Abbott and Alere have each complied with the supplemental information request, unless the period is extended voluntarily by the parties or terminated sooner by the Bureau. On January 25, 2017, the European Commission approved the merger under the EU Merger Regulation. The approval is conditional on, and the merger may not be completed until, Abbott has entered into binding agreements to divest the epoc and Triage product lines, as well as Alere’s activities relating to the commercialization of BNP assays to customers of Danaher for use on Beckman-Coulter laboratory analyzers, to one or more purchasers. The purchasers and terms of sale need to be approved by the European Commission. As of the date of the filing of this Annual Report on Form 10-K, On April 20, 2017, the South Korean antitrust authority informed Abbott that it would be expanding its review period by 90 days. As of the filing of this Annual Report on Form 10-K, For information relating to the litigation with Abbott and the Settlement Agreement with Abbott, see Note 13(c).

Assets Held for Sale

Assets Held for Sale	12 Months Ended
	Dec. 31, 2016
Assets Held for Sale	(26) Impairment and (Gain) Loss on Dispositions, Net In January 2016, we completed the sale of our Alere E-Santé E-Santé In November 2015, we completed the sale of the BBI business. We received cash consideration of approximately $106.4 million, net of a final working capital adjustment, and we are eligible to receive contingent consideration payments of up to $46.6 million upon the achievement of a certain milestone. The net assets disposed of in connection with the disposition of the BBI business were valued at an aggregate of $66.5 million and the value of the allocated goodwill was $49.2 million. Because the aggregate value of the net assets and goodwill disposed of in the transaction exceeded the closing cash consideration, we recorded a $9.3 million loss in 2015 on the disposition of the BBI business. In July 2015, we sold certain assets of our Inverness Medical Innovations Australia Pty Ltd business, which was part of our professional diagnostics reporting unit and business segment, for AUD 0.2 million (approximately $0.1 million as of the date of disposition) in cash proceeds and, as a result of this transaction, we recorded a loss of $1.2 million during 2015. In May 2015, we sold our Alere Analytics business, which was part of our professional diagnostics reporting segment. Under the terms of the sale we received nominal consideration and agreed to contribute working capital of $2.7 million to Alere Analytics, of which $2.4 million was contributed in cash immediately prior to the closing of the sale and the remaining $0.3 million of which was deposited in escrow pending the performance by the buyers under certain contracts. As a result of this transaction we recorded a loss of $3.6 million during 2015. During 2015, before identifying a buyer for Alere Analytics, our management decided to close the business, and in connection with this decision we recorded an impairment charge of $26.7 million during the period, including the write-off In March 2015, we sold certain assets of our AdnaGen GmbH business, which was part of our professional diagnostics reporting unit and business segment, for approximately $4.6 million in cash proceeds and, as a result of this transaction, we recorded a loss of $0.3 million during 2015. In March 2015, we sold our Gesellschaft fur Patientenhilfe DGP GmbH subsidiary, which was part of our professional diagnostics reporting unit and business segment, for € We recorded additional charges of approximately $0.8 million in connection with certain other business closures or divestitures during 2015. In December 2014, our management decided to close our Alere Connect, LLC subsidiary located in Scottsdale, Arizona. In connection with this decision, we recorded an impairment charge of $10.8 million. During 2015, in connection with this decision, we recorded impairment charges of $1.1 million, consisting primarily of severance costs, inventory write-offs and other closure-related expenses. In November 2014, we sold BioNote to the former owner of that company who was also its Chief Executive Officer while it was owned by us. We received cash consideration of KRW 48.0 billion (approximately $43.2 million at the date of disposition), resulting in a gain on disposition of $6.5 million. In October 2014, we sold our subsidiary Mologic Ltd., located in the United Kingdom, to former owners of the company who were also members of management while it was owned by us. The consideration received was nominal, resulting in a loss on disposition of $2.8 million. The financial results for the above businesses are immaterial to our consolidated financial results.
Alere Accountable Care Solutions, LLC ("ACS") [Member]
Assets Held for Sale	(4) Discontinued Operations On January 9, 2015, we completed the sale of our health management business to OptumHealth Care Solutions for a purchase price of $599.9 million. We used the net cash proceeds of the sale to repay $575.0 million in aggregate principal amount of outstanding indebtedness under our prior credit facility. We accounted for our divestiture of the health management business in accordance with Accounting Standards Update, or ASU, No. 2014-08. On October 10, 2014, we completed the sale of our ACS subsidiary, or ACS, to ACS Acquisition, LLC (the “Purchaser”), pursuant to the terms of a Membership Interest Purchase Agreement with the Purchaser and Sumit Nagpal. In connection with the sale of ACS, we also agreed to sell our subsidiary Wellogic ME FZ — LLC (“Wellogic,” together with ACS, the “ACS Companies”) to the Purchaser, which we completed in June 2015. The ACS Companies were included in our former patient self-testing segment prior to the sale. The purchase price for the ACS Companies consisted of cash proceeds of $2.00 at closing and contingent consideration of up to an aggregate of $7.0 million, consisting of (i) payments based on the gross revenues of the ACS Companies, (ii) payments to be made in connection with financing transactions by the Purchaser or the ACS Companies and (iii) payments to be made in connection with a sale by the Purchaser of the ACS Companies. In connection with the sale, we agreed to reimburse the Purchaser for up to $750,000 of the Purchaser’s and the ACS Companies’ transitional expenses. We accounted for our divestiture of the ACS Companies in accordance with Accounting Standards Codification, or ASC, 205, Presentation of Financial Statements. The following summarized financial information related to the businesses of the ACS Companies and the health management business has been segregated from continuing operations and has been reported as discontinued operations in our consolidated statements of operations for the applicable periods. The results of the health management business are included in the 2014 and 2015 periods presented, given our January 9, 2015 divestiture of this business. The results of the ACS Companies, other than Wellogic, are included in 2014, given our October 31, 2014 divestiture of this business. Neither the health management business nor the ACS Companies are reported in 2016. The results are as follows (in thousands): For The Years Ended December 31, 2015 2014 Net revenue $ 7,373 $ 359,496 Cost of net revenue (4,413 ) (203,115 ) Research and development — — Sales and marketing (996 ) (56,808 ) General and administrative (5,001 ) (99,383 ) Interest expense (9 ) (506 ) Other income (expense), net 160 (1,799 ) Gain on disposal 364,850 — Income (loss) from discontinued operations before provision (benefit) for income taxes 361,964 (2,115 ) Provision (benefit) for income taxes 142,451 (140,433 ) Income (loss) from discontinued operations, net of tax $ 219,513 $ 138,318
Assets Held-for-sale [Member]
Assets Held for Sale	(25) Assets Held for Sale (a) Sale of Alere E-Santé In January 2016, we completed the sale of our Alere E-Santé E-Santé E-Santé (b) Sale of TechLab Equity Method Investment As of December 31, 2015, we continued to meet the held for sale criteria with respect to our 49% investment in TechLab. Accordingly, we have classified our investment in TechLab, with a value of approximately $13.3 million, in assets held for sale — non-current On September 16, 2016, we completed the sale of our 49% interest in the TechLab business and, in connection with such sale, we recorded a gain in equity earnings of unconsolidated entities of $29.9 million.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(5) Summary of Significant Accounting Policies (a) Use of Estimates To prepare our financial statements in conformity with accounting principles generally accepted in the United States of America, our management must make estimates, judgments and assumptions that may affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from such estimates under different assumptions or conditions. (b) Foreign Currencies In general, the functional currencies of our foreign subsidiaries are the local currencies. For the purpose of consolidating the financial statements of our foreign subsidiaries, all assets and liabilities of the foreign subsidiaries are translated into U.S. dollars using the exchange rate at each balance sheet date, while the stockholders’ equity accounts are translated at historical exchange rates. Translation gains and losses that result from the conversion of the balance sheets of the foreign subsidiaries into U.S. dollars are recorded to cumulative translation adjustment, which is a component of accumulated other comprehensive loss (Note 17) within stockholders’ equity. The revenue and expenses of our foreign subsidiaries are translated using the average of the rates of exchange in effect during each fiscal month. Net realized and unrealized foreign currency exchange transaction losses of $4.5 million, $4.8 million and $2.2 million during 2016, 2015 and 2014, respectively, are included as a component of other income (expense), net in the consolidated statements of operations. (c) Cash and Cash Equivalents We consider all highly-liquid investments purchased with original maturities of three months or less at the date of acquisition to be cash equivalents. Cash equivalents consisted of money market funds at December 31, 2016 and 2015. (d) Restricted Cash We had restricted cash of $53.7 million and $48.9 million as of December 31, 2016 and 2015, respectively. Of the $48.9 million restricted cash as of December 31, 2015, $43.2 million was classified as non-current non-current (e) Marketable Securities Securities classified as available-for-sale available-for-sale, (f) Inventories Inventories are stated at the lower of cost (first-in, first-out) work-in-process work-in-process (g) Property, Plant and Equipment We record property, plant and equipment at historical cost or, in the case of a business combination, at fair value on the date of the business combination. Depreciation is computed using the straight-line method based on the following estimated useful lives of the related assets: machinery, laboratory equipment and tooling, 1-15 4- 50 1-10 2-16 (h) Goodwill Goodwill relates to amounts that arose in connection with our various business combinations and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the acquisition method of accounting. Goodwill is not amortized, but is subject to periodic review for impairment. We test goodwill and other intangible assets with indefinite lives at the reporting unit level for impairment on an annual basis and between annual tests, if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that would indicate potential impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business and an adverse action or assessment by a regulator. In performing the annual goodwill impairment test, we utilize the two-step after-tax after-tax If the carrying value of a reporting unit exceeds its estimated fair value, we are required to perform the second step, or Step 2, of the annual goodwill impairment test to measure the amount of impairment loss, if any. Step 2 of the goodwill impairment test compares the implied fair value of a reporting unit’s goodwill to its carrying value. The implied fair value of goodwill is calculated as the difference between the fair value of the reporting unit and the estimated fair value of its assets and liabilities. To the extent this amount is below the carrying value of goodwill, an impairment charge is recorded to write down the carrying value to its implied value. Impairment charges related to goodwill have no impact on our cash balances or on compliance with financial covenants under our Credit Agreement. 2016 Annual Goodwill Impairment Test We conducted our 2016 annual impairment test for our reporting units during the fourth quarter of 2016. Key assumptions (which vary by reporting unit) used in determining fair value under the DCF approach included discount rates ranging from 10.0% to 14.5%, projected compound average revenue growth rates of 3.4% to 5.6%, and terminal value growth rates of 3.0% to 4.0%. In determining the appropriate discount rate, we considered the WACC for each reporting unit, which among other factors considers the cost of common equity capital and the marginal cost of debt of market participants. Key assumptions (which again vary by reporting unit) used in determining fair value under the market approaches were based on observed market multiples of enterprise value to revenue and EBITDA for both comparable publicly-traded companies and recent merger and acquisition transactions involving similar companies to estimate appropriate controlling basis multiples to apply to each of the reporting units. Based on the multiples implied by this market data, we selected multiples of revenue of 0.6 to 3.1 times and multiples of EBITDA of 8.3 to 12.3 times. In assessing the reasonableness of our estimated fair values of the reporting units, management compared the results of the valuation analyses against our then-current market capitalization to imply a control premium. Based on this analysis, the implied control premium was within the range of comparable industry transactions. The Step 1 impairment test indicated the estimated fair value of the professional diagnostics, consumer diagnostics, and other non-reportable (i) Impairment of Other Long-lived Tangible and Intangible Assets Our intangible assets consist primarily of core technology, in-process non-competition The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. We amortize the majority of our intangible assets on a straight-line basis, as this methodology most closely approximates the pattern of economic benefits for these assets. We evaluate long-lived tangible and intangible assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment are present with respect to long-lived tangible and intangible assets used in operations and undiscounted future cash flows are not expected to be sufficient to recover the assets’ carrying amount, additional analysis is performed as appropriate and the carrying value of the long-lived assets is reduced to the estimated fair value, if this is lower, and an impairment loss is charged to expense in the period the impairment is identified. Factors we generally consider important which could trigger an impairment review on the carrying value of other long-lived tangible and intangible assets include the following: (1) significant underperformance relative to expected historical or projected future operating results, (2) significant changes in the manner of our use of acquired assets or the strategy for our overall business, (3) underutilization of our tangible assets, (4) discontinuance of product lines by ourselves or our customers, (5) significant negative industry or economic trends, (6) significant decline in our stock price for a sustained period, (7) significant decline in our market capitalization relative to net book value and (8) goodwill impairment identified during an impairment review. (j) Acquired In-process Acquired IPR&D represents the fair value assigned to research and development assets that we acquire as part of business combinations, and which have not been completed at the date of acquisition. The acquired IPR&D is capitalized as an intangible asset and tested for impairment at least annually until commercialization, after which time the IPR&D is amortized over its estimated useful life. We utilize a discounted probable future cash flow model on a project-by-project (k) Business Acquisitions Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. Significant judgment is required in estimating the fair value of intangible assets and in assigning their respective useful lives. The fair value estimates are based on available historical information and on future expectations and assumptions deemed reasonable by management, but are inherently uncertain. We generally employ the income method to estimate the fair value of intangible assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants, and include the amount and timing of future cash flows (including expected growth rates and profitability), the underlying product life cycles, economic barriers to entry, a brand’s relative market position and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions. Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. During 2016, 2015 and 2014, we expensed acquisition-related costs of $1.0 million, $0.5 million and $0.9 million, respectively, in general and administrative expense. (l) Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our income tax provision in the period of enactment. We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversal of existing taxable temporary differences, projected future taxable income, tax-planning We account for uncertain tax positions using a “more-likely-than-not” During November 2015, the FASB issued Accounting Standards Update No. 2015-17, 2015-17, 2015-17 non-current 2015-17 (m) Revenue Recognition We primarily recognize revenue when the following four basic criteria have been met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the fee is fixed or determinable and (4) collection is reasonably assured. The majority of our revenue is derived from product sales. We recognize revenue upon transfer of the title and risk of loss of the products to third-party customers, less a reserve for estimated product returns and other incentive arrangements including rebates. Determination of the reserve for estimated product returns and allowances is based on our management’s analyses and judgments regarding certain conditions. For products that include installation, if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For sales that include customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of our products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered and accepted by the customer. Some of our sales transactions qualify as multiple-element arrangements which require us to identify separate units of accounting within the arrangement and allocate the transaction consideration across these separate accounting units. For arrangements that include non-software For software and software-related products, we use the relative fair value method to allocate transaction consideration to each unit of accounting, whereby the evidence used in the determination of fair value estimates are based solely on vendor specific objective evidence. To the extent that vendor specific objective evidence does not exist for delivered elements of the transaction, we apply the residual method. Additionally, with respect to our health management business (which was included in discontinued operations for all periods presented in our financial statements included in this Annual Report on Form 10-K fee-based fee-based at-risk We also receive license and royalty revenue from agreements with third-party licensees. Revenue from fixed fee license and royalty agreements is recognized on a straight-line basis over the obligation period of the related license agreements, or at the time when we have no further obligations. License and royalty fees that the licensees calculate based on their sales, which we have the right to audit under most of our agreements, are generally recognized upon receipt of the license or royalty payments unless we are able to reasonably estimate the fees as they are earned. License and royalty fees that are determinable prior to the receipt thereof are recognized in the period they are earned. (n) Employee Stock-based Compensation Arrangements We account for share-based payments in accordance with ASC 718, Compensation — Stock Compensation Our stock option plans provide for grants of options to employees to purchase common stock at or above the fair market value of such shares on the grant date of the award. The options generally vest over a four-year period, beginning on the date of grant, with a graded vesting schedule of 25% at the end of each of the four years. The fair value of each option grant is estimated on the date of grant primarily using a Black-Scholes option-pricing method. We use historical data to estimate the expected price volatility and the expected forfeiture rate. The contractual term of our stock option awards is ten (o) Net Income (Loss) per Common Share Net income (loss) per common share is based upon the weighted-average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year (Note 14). (p) Other Operating Expenses We expense advertising costs, other than for direct-response advertising, as incurred. In 2016, 2015 and 2014, advertising costs amounted to $5.6 million, $9.0 million and $8.0 million, respectively, and are included in sales and marketing expenses in the accompanying consolidated statements of operations. Shipping and handling costs are included in cost of net revenue in the accompanying consolidated statements of operations. When we charge our customers for shipping and handling costs, these costs are recorded along with product revenues. Legal fees incurred by us are included in general and administrative expenses and are expensed in the period such costs are incurred. Payments to third parties in connection with the resolution of legal disputes, investigations or other contingencies are included in general and administrative expenses and are expensed when an unfavorable outcome is probable and the amount of loss can be reasonably estimated in accordance with ASC 450 — Contingencies. (q) Direct-response Advertising In connection with our mail order diabetes business, we incurred direct-response advertising and associated costs in connection with the placement of advertisements. Direct-response advertising and associated costs payable to third parties for the period presented are capitalized and amortized to selling, general and administrative expenses on an accelerated basis in the month following the broadcast month. Management assesses the realizability of the amounts of direct-response advertising costs reported as assets at each balance sheet date by comparing the net carrying value of capitalized advertising to the net present value of estimated future orders expected to result directly from such advertising. Advertising that does not meet the capitalization requirements is expensed in the current period. Any change in existing accounting rules or a business change that impacts expected future orders or that shortens the period over which such net future benefits are estimated to be realized could result in accelerated charges against our earnings. Whether there is an impairment loss or not is determined by comparing the net carrying value of direct-response advertising costs capitalized as assets at each balance sheet date to the probable remaining future orders expected to result directly from such advertising. If the net carrying value of the assets exceeds the probable remaining future orders expected to result directly from such assets, an impairment loss is recognized in an amount equal to that excess. Future benefits are determined by calculating the net present value of estimated future orders per cost pool. Net present value is calculated based upon the value of an order multiplied by the estimated future orders. Estimate of future orders is determined based on historical customer reorder rates. We perform the impairment test of our direct-response advertising asset in the quarter following the advertising broadcast quarter. (r) Concentration of Credit Risk, Off-Balance Financial instruments that potentially subject us to concentration of credit risk primarily consist of cash and cash equivalents and accounts receivable. We invest our excess cash primarily in high quality securities and limit the amount of our credit exposure to any one financial institution. We do not require collateral or other securities to support customer receivables; however, we perform on-going At December 31, 2016 and 2015, no individual customer’s accounts receivable balance was more than 10% of our aggregate accounts receivable. During 2016, 2015 and 2014, no one customer represented more than 10% of our net revenue. (s) Financial Instruments and Fair Value of Financial Instruments Our primary financial instruments at December 31, 2016 and 2015 consisted of cash equivalents, restricted cash, marketable securities, accounts receivable, accounts payable and debt. We apply fair value measurement accounting to either record or disclose the value of our financial assets and liabilities in our financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Described below are the three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 (t) Software for Internal Use or for Resale We may capitalize certain costs associated with the development of internal-use We also develop software for resale or lease to external parties and expense the costs of developing software for resale or lease incurred before establishment of technological feasibility of the underlying software. The costs incurred from establishment of technological feasibility until general release of the software are capitalized, and the capitalized software is amortized over its estimated useful life. Capitalized software for resale or lease is included in computer software and equipment within property, plant and equipment. (u) Research and Development Our research and development programs focus on the development of cardiometabolic, infectious disease and toxicology products. Research and development costs are expensed as incurred. Payments received from external parties to fund our research and development activities reduce the recorded research and development expenses. (v) Leases We lease certain facilities and equipment from external parties under operating leases. Rent expense related to operating leases is recorded in the income statement as incurred or on a straight-line basis if there are material escalation clauses. We also lease machinery, laboratory equipment, tooling and other equipment under capital leases. In determining whether a lease is a capital or an operating lease, we estimate the expected term of the lease, which includes certain renewable options as required by lease accounting guidance. Rent deferrals, landlord incentives and rent escalations are included in calculation of minimum lease payments when performing the capital lease tests and when calculating the rent expense for operating leases. Leased property, plant and equipment that meet the capital lease criteria are capitalized at the lower of the present value of the minimum lease payments or the fair value of the underlying asset at the inception date of the lease. Assets under capital leases are depreciated on a straight-line basis over the lease term. Leasehold improvements are capitalized and amortized over the shorter of their estimated useful lives or the remainder of the expected term of the lease. (w) Recent Accounting Pronouncements Recently Issued Standards In March 2017, the FASB issued ASU No. 2017-07, 2017-07. 2017-07 2017-07 2017-07 In January 2017, the FASB issued ASU No. 2017-04, 2017-04. 2017-04 2017-04 2017-04 In January 2017, the FASB issued ASU No. 2017-01, 2017-01. 2017-01 2017-01 2017-01 In December 2016, the FASB issued ASU No. 2016-20, 2016-20. 2016-20 2014-09, 2016-20 2016-20 In December 2016, the FASB issued ASU No. 2016-19, 2016-19. 2016-19 2016-19 2016-19 In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, 2016-18. 2016-18 beginning-of-period end-of-period 2016-18 2016-18 In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, 2016-16. 2016-16 2016-16 2016-16 In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, 2016-15. 2016-15 zero-coupon 2016-15 2016-15 In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, 2016-12. 2016-12: 606-10-25-7; non-cash 2016-12 2016-12 In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, 2016-10. 2016-10 2016-10 2016-10 In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting 2016-09. 2016-09 2016-09 2016-09 In March 2016, the FASB issued ASU No. 2016-07, Investments — Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, 2016-07. 2016-07 step-by-step 2016-07 2016-07 available-for-sale 2016-07 2016-07 In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), 2016-02. 2016-02 right-of-use 2016-02 2016-02 In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, 2015-11. 2015-11 in-scope 2015-11 2015-11 2015-11 In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers 2014-09, 2014-09 one-year 2014-09 We believe that there were no other accounting standards recently issued that had or are expected to have a material impact on our consolidated financial statements. Recently Adopted Standards In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, 2015-16. 2015-16 2015-16 2015-16. In July 2015, the FASB issued ASU No. 2015-12, Plan Accounting: Defined Benefit Pension Plans (Topic 960), Defined Contribution Pension Plans (Topic 962), and Health and Welfare Benefit Plans (Topic 965) — I. Fully Benefit-Responsive Investment Contracts, II. Plan Investment Disclosures, and III. Measurement Date Practical Expedient 2015-12. 2015-12 month-end year-end, month-end. 2015-12 2015-12 In April 2015, the FASB issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30): 2015-03. 2015-03 2015-03 No. 2015-15, Interest — Imputation of Interest (Subtopic 835-30) Line-of-Credit 18, 2015 EITF Meeting) 2015-15. 2015-15 line-of-credit 2015-03. ASU 2015-03 2015-15, non-current In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): 2014-15. 2014-15 2014-15 2014-15. 2014-15 In June 2014, the FASB issued ASU No. 2014-12, Compensation — Stock Compensation (Topic 718) — Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period 2014-12. 2014-12 2014-12 2014-12. 2014-12

Other Balance Sheet Information

Other Balance Sheet Information	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Balance Sheet Information	(6) Other Balance Sheet Information Components of selected captions in the consolidated balance sheets consist of (in thousands): December 31, 2016 2015 (As Inventories, net: Raw materials $ 97,652 $ 130,171 Work-in-process 69,086 69,178 Finished goods 142,182 151,600 $ 308,920 $ 350,949 December 31, 2016 2015 (As Prepaid expenses and other current assets: Prepaid expenses $ 28,685 $ 28,041 Prepaid income tax 10,248 12,482 Income taxes receivable 21,445 199 Royalty receivable 7,908 7,757 Other taxes receivable 19,478 15,333 Cash advances 4,097 3,902 Pension receivable 1,347 1,373 Grant receivable 182 651 Employee loans 73 123 Security deposits 3,232 7,014 Other receivable — 15,938 Other 21,912 21,701 $ 118,607 $ 114,514 December 31, 2016 2015 Property, plant and equipment, net: Machinery, laboratory equipment and tooling $ 507,355 $ 469,413 Land and buildings 166,852 169,226 Leasehold improvements 60,119 55,999 Computer software and equipment 176,609 161,192 Furniture and fixtures 29,544 27,325 940,479 883,155 Less: Accumulated depreciation (499,289 ) (437,116 ) $ 441,190 $ 446,039 December 31, 2016 2015 (As Accrued expenses and other current liabilities: Compensation and compensation-related $ 76,556 $ 80,468 Litigation settlements 42,910 4,856 Royalty obligations 20,339 18,912 Deferred revenue 24,309 40,998 Income taxes payable 23,278 14,245 Other taxes payable 30,937 28,320 Acquisition-related obligations 2,382 5,705 Other 174,132 129,133 $ 394,843 $ 322,637

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Business Combinations	(7) Business Combinations Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. Net assets acquired are recorded at their estimated fair value and are subject to adjustment upon finalization of the fair value analysis. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. (a) Acquisition in 2016 EDTS On February 11, 2016, we acquired all of the outstanding shares of European Drug Testing Services EDTS AB, or EDTS, located in Lidingo, Sweden, a provider of services related to on-site Our consolidated statements of operations for 2016 included revenue totaling approximately $5.2 million related to this business. Goodwill has been recognized in the acquisition and amounted to approximately $2.1 million, which is not deductible for tax purposes. A summary of the fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,060 Intangible assets 4,220 Total assets acquired $ 7,766 Current liabilities $ 368 Non-current 928 Total liabilities assumed $ 1,296 Net assets acquired $ 6,470 Cash paid $ 6,470 The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- average Useful Life Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete 570 3.0 years Total intangible assets $ 4,220 (b) Acquisitions in 2015 US Diagnostics On July 10, 2015, we acquired substantially all of the assets of US Diagnostics, Inc., or USD, located in Huntsville, Alabama, a provider of instant on-site Our consolidated statements of operations for 2016 and 2015 included revenue totaling approximately $21.8 million and $10.7 million, respectively, related to this business. Goodwill has been recognized in the acquisition and amounted to approximately $29.4 million, which is deductible for tax purposes. A summary of the fair values of the net assets acquired from USD is as follows (in thousands): Total Current assets $ 4,698 Property, plant and equipment 182 Goodwill 29,365 Intangible assets 27,100 Total assets acquired $ 61,345 Current liabilities $ 1,210 Total liabilities assumed $ 1,210 Net assets acquired $ 60,135 Cash paid $ 60,135 The following are the intangible assets acquired in connection with the USD acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Total Weighted- average Useful Life Trademarks $ 1,600 10.0 years Customer relationships 24,800 13.0 years Non-compete 700 2.0 years Total intangible assets $ 27,100

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	(8) Goodwill and Other Intangible Assets The following is a summary of goodwill and other intangible assets as of December 31, 2016 (dollars in thousands): Gross Carrying Amount Accumulated Amortization and Impairment Losses Net Carrying Weighted- average Useful Life Amortized intangible assets: Core technology and patents $ 899,878 $ 519,698 $ 380,180 15.1 years Other intangible assets: Supplier relationships 17,027 16,090 937 9.1 years Trademarks and trade names 239,714 191,707 48,007 10.7 years License agreements 10,885 10,885 — 7.0 years Customer relationships 1,415,919 1,066,001 349,918 16.6 years Manufacturing know-how 19,600 18,369 1,231 7.6 years Other 106,373 81,069 25,304 7.6 years Total other intangible assets 1,809,518 1,384,121 425,397 Total intangible assets with finite lives $ 2,709,396 $ 1,903,819 $ 805,577 Intangible assets with indefinite lives: Goodwill $ 2,759,366 Other intangible assets(1) 27,164 Total intangible assets with indefinite lives $ 2,786,530 (1) Primarily includes in-process The following is a summary of goodwill and other intangible assets as of December 31, 2015 (dollars in thousands): Gross Accumulated Net Weighted- Amortized intangible assets: Core technology and patents $ 907,629 $ 468,497 $ 439,132 15.1 years Other intangible assets: Supplier relationships 17,599 16,218 1,381 9.2 years Trademarks and trade names 242,473 176,325 66,148 10.7 years License agreements 10,963 10,944 19 7.0 years Customer relationships 1,441,386 985,844 455,542 16.6 years Manufacturing know-how 19,181 16,744 2,437 7.7 years Other 108,217 75,595 32,622 7.7 years Total other intangible assets 1,839,819 1,281,670 558,149 Total intangible assets with finite lives $ 2,747,448 $ 1,750,167 $ 997,281 Intangible assets with indefinite lives: Goodwill $ 2,836,915 Other intangible assets(1) 28,110 Total intangible assets with indefinite lives $ 2,865,025 (1) Primarily includes in-process During 2016 and 2015, we performed our annual impairment test of our in-process in-process in-process The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible assets and the expected future cash flows to be derived from those intangible assets. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the underlying license agreements, if applicable, or the period of time the assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets on patterns in which the economic benefits are expected to be realized. We amortize the majority of our intangible assets on a straight-line basis, as this methodology most closely approximates the pattern of economic benefits for these assets. Amortization expense of intangible assets, which in the aggregate amounted to $180.5 million, $210.5 million and $237.2 million in 2016, 2015 and 2014, respectively, is included in cost of net revenue, research and development, sales and marketing and general and administrative expenses in the accompanying consolidated statements of operations. The allocation of amortization expense to the expense categories is based on the intended usage and the expected benefits of the intangible assets in relation to the expense categories. The following is a summary of estimated aggregate amortization expense of intangible assets for each of the five succeeding fiscal years as of December 31, 2016 (in thousands): 2017 $ 139,827 2018 $ 116,326 2019 $ 102,824 2020 $ 84,893 2021 $ 68,762 During the fourth quarter, we perform our annual impairment tests of the carrying value of our goodwill by reporting unit. For further discussion see Note 5(h). Goodwill amounts for our professional diagnostics, consumer diagnostics and other non-reportable reporting segments are summarized as follows (in thousands): Professional Consumer Other non- Total Goodwill at December 31, 2014 $ 2,847,406 $ 54,991 $ 24,269 $ 2,926,666 Acquisitions(1) 32,970 — — 32,970 Dispositions(2) (58,612 ) — — (58,612 ) Other(3) (53,080 ) (11,029 ) — (64,109 ) Goodwill at December 31, 2015 $ 2,768,684 $ 43,962 $ 24,269 $ 2,836,915 Acquisitions(1) 2,060 — — 2,060 Other(3) (70,910 ) (8,699 ) — (79,609 ) Goodwill at December 31, 2016 $ 2,699,834 $ 35,263 $ 24,269 $ 2,759,366 (1) Includes initial purchase price allocation and purchase accounting adjustments. (2) Reflects write-off (3) These amounts relate primarily to adjustments resulting from fluctuations in foreign currency exchange rates. We generally expense costs incurred for the internal development of intangible assets, except for costs that are incurred to establish patents and trademarks, such as legal fees for initiating, filing and obtaining the patents and trademarks. As of December 31, 2016 and 2015, we had approximately $8.7 million and $8.9 million, respectively, of costs capitalized, net of amortization, in connection with establishing patents and trademarks which are included in other intangible assets, net, in the accompanying consolidated balance sheets. Upon the initial filing of the patents and trademarks, we commence amortization of such intangible assets over their estimated useful lives. Costs incurred to maintain the patents and trademarks are expensed as incurred.

Long-term Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-term Debt	(9) Long-term Debt We had the following long-term debt balances outstanding (in thousands) as of December 31, 2016 and 2015, respectively: December 31, 2016 December 31, 2015 A term loans(1)(2)(3) $ 544,745 $ 575,746 B term loans(1)(2)(3) 952,664 965,740 Revolving loans(1)(2)(3) 125,000 — 7.25% Senior notes(2)(3) 442,709 446,320 6.5% Senior subordinated notes(2)(3) 415,102 419,209 6.375% Senior subordinated notes(2)(3) 412,831 418,133 3% Convertible senior subordinated notes(4) — 149,839 Other lines of credit 1,124 136 Other 46,400 56,035 2,940,575 3,031,158 Less: Short-term debt and current portion of long-term debt (82,370 ) (199,992 ) Long-term debt $ 2,858,205 $ 2,831,166 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully below in this Note 9, (i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes due 2018, or the 7.25% senior notes, our 6.5% senior subordinated notes due 2020, or the 6.5% senior subordinated notes, our 6.375% senior subordinated notes due 2023, or the 6.375% senior subordinated notes, and our 3% convertible senior subordinated notes due 2016, or the 3% convertible senior subordinated notes, as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K 10-Q 10-Q 10-Q 10-Q (3) See Note 30, Subsequent Events, for information regarding the April 2017 and May 2017 amendments to the Credit Agreement and the May 2017 and June 2017 consent solicitations to the holders of our 7.25% senior notes, our 6.5% senior subordinated notes and our 6.375% senior subordinated notes as a result of, among other things, our failure to timely furnish to the holders of such debt our financial statements for the year ended December 31, 2016 and the quarter ended March 31, 2017. (4) The principal amount of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheets as of December 31, 2015, as these notes matured (and were fully paid and discharged) in May 2016. In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for 2016, 2015 and 2014, respectively, as follows (in thousands): 2016 2015 2014 Secured credit facility(1)(4) $ 72,543 $ 38,335 $ — Prior credit facility(2)(3) — 49,437 99,399 7.25% Senior notes(4) 36,172 34,103 34,098 6.375% Senior subordinated notes(4) 28,599 14,549 — 6.5% Senior subordinated notes(4) 29,717 28,987 29,057 8.625% Senior subordinated notes(4) — 44,219 37,092 3% Convertible senior subordinated notes 1,847 4,984 4,984 Other 2,773 2,383 4,561 $ 171,651 $ 216,997 $ 209,191 (1) Includes “A” term loans, “B” term loans, and revolving loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” B-2” (3) For 2015, the amount includes a $3.5 million loss on extinguishment of debt associated with our prior credit facility. (4) For 2016, 2015 and 2014, the amounts include $4.5 million, $1.1 million and $1.5 million, respectively, related to the amortization of fees paid for certain debt modifications. The following describes each of the debt instruments listed above: (a) Secured Credit Facility On June 18, 2015, we entered into a Credit Agreement, or secured credit facility, with certain lenders, Goldman Sachs Bank USA, as B term loan administrative agent, General Electric Capital Corporation as pro rata administrative agent and collateral agent, and certain other agents and arrangers, and, along with certain of our subsidiaries, a related guaranty and security agreement. The secured credit facility provides for (i) term loans in the aggregate initial principal amount of $1.7 billion (consisting of “A” term loans in the aggregate initial principal amount of $650.0 million and “B” term loans in the aggregate initial principal amount of $1.05 billion), all of which were drawn at closing, and (ii) subject to our continued compliance with the terms of the secured credit facility, a $250.0 million revolving line of credit (which revolving line of credit includes a $50.0 million sublimit for the issuance of letters of credit); no amount was drawn under the revolving credit facility at closing. We used approximately $1.68 billion of the proceeds of the term loans drawn at closing to repay in full all indebtedness outstanding under our prior credit facility, whereupon such agreement was terminated, and to pay various fees and expenses associated with the transactions contemplated by the secured credit facility. Subject to certain limits and restrictions, we may use the remaining proceeds of the term loans, the proceeds of any revolving credit loans and the proceeds of any incremental term loans (described below) or incremental revolving credit commitments (described below) to finance permitted acquisitions, to finance capital expenditures, to provide working capital and for other general corporate purposes. In November 2015, we used $115.0 million of the net cash proceeds from our sale of the BBI business (which represented all of the net proceeds from the closing of the sale prior to giving effect to the final working capital adjustment) to repay $115.0 million in aggregate principal amount of outstanding “A” term loans and “B” term loans under the secured credit facility. We must repay the “A” term loans in nineteen consecutive quarterly installments, which repayments began on September 30, 2015 and will continue through March 31, 2020, followed by a final installment on June 18, 2020; after giving effect to the prepayment of a portion of the “A” term loans in connection with our sale of the BBI business, the principal amount of each remaining installment through March 31, 2020 is approximately $7.6 million, and the principal amount of the final installment is approximately $461.9 million. We must repay the “B” term loans in twenty-seven consecutive quarterly installments, which repayments began on September 30, 2015 and will continue through March 31, 2022, followed by a final installment on June 18, 2022; after giving effect to the prepayment of a portion of the “B” term loans in connection with our sale of the BBI business, the principal amount of each remaining installment through March 31, 2022 is approximately $2.4 million, and the principal amount of the final installment is approximately $912.5 million. We may repay any borrowings under the secured credit facility revolving line of credit at any time (without any premium or penalty, other than customary LIBOR breakage costs, if applicable), but in no event later than June 18, 2020. We are required to make mandatory prepayments of the term loans and, after all term loans have been repaid, any revolving credit loans in various amounts if we have Excess Cash Flow (as defined in the Credit Agreement, and commencing in respect of our fiscal year ended December 31, 2016), if we issue certain types of debt, if we make certain sales of assets outside the ordinary course of business above certain thresholds, or if we suffer certain property loss events above certain thresholds. We did not have any Excess Cash Flow for 2016 and therefore are not required to make any payments in connection therewith in 2017. We may make optional prepayments of the term loans from time to time without any premium or penalty (subject to payment of customary LIBOR breakage costs, if applicable). The “A” term loans and any borrowings under the revolving credit facility bear interest at a rate per annum per annum per annum April and August 2016 Amendments to Secured Credit Facility On April 22, 2016, we and the requisite lenders under the Credit Agreement entered into an amendment to the Credit Agreement, or the April 2016 Amendment. Pursuant to the April 2016 Amendment, these requisite lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, (x) our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and certain related deliverables for the year ended December 31, 2015 by the applicable deadline under the Credit Agreement, (y) any restatement of certain financial statements as a result of our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, or (z) any breach of any representation or affirmative covenant as a result of certain deliverables being incorrect when delivered, which breach was discovered as part of the audit of our financial statements for the year ended December 31, 2015, to the extent that such breach was due to our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, and (ii) extend the deadlines for delivery of the financial statements for the year ended December 31, 2015, the financial statements for the quarter ended March 31, 2016 and certain related deliverables. Under the terms of this amendment, we were required to deliver our unaudited financial statements for the three months ended March 31, 2016 and certain related deliverables on or before August 18, 2016. We made the required deliveries before that date. In connection with this amendment, we paid, among other fees and expenses, consent fees to the consenting lenders in the aggregate amount of $4.5 million. The amendment was deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt. The amendment also increased the applicable interest rate margins for all loans outstanding under our secured credit facility by 0.25% per annum for the period from July 1, 2016 to the date of delivery of such financial reports and related deliverables under our secured credit facility. On August 18, 2016, we and the requisite lenders under the Credit Agreement entered into a further amendment to the Credit Agreement pursuant to which these requisite lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) (x) the financial statements and certain related deliverables for the three months ended March 31, 2016, which we refer to as the Q1 Financial Reports, by the applicable deadline under the Credit Agreement or (y) the financial statements and certain related deliverables for the three months ended June 30, 2016, which we refer to as the Q2 Financial Reports, by the applicable deadline under the Credit Agreement, and (ii) extend the deadline for delivery of the Q1 Financial Reports to August 25, 2016 and the deadline for the delivery of the Q2 Financial Reports to September 13, 2016. We delivered the Q1 Financial Reports and the Q2 Financial Reports prior to the deadlines set forth in this amendment to the Credit Agreement. In connection with this amendment, we paid, among other fees and expenses, consent fees to the consenting lenders in the aggregate amount of $2.2 million. The amendment was deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt. See Note 30 for information regarding the April 2017 and May 2017 amendments to the Credit Agreement as a result of our failure to timely furnish to the lenders our annual financial statements for the year ended December 31, 2016 and the quarter ended March 31, 2017. As of December 31, 2016, accrued interest related to the secured credit facility amounted to $0.6 million. Subject to our pro forma We must comply with various financial and non-financial non-financial The lenders under the secured credit facility are entitled to accelerate repayment of the loans and terminate the revolving credit commitments thereunder upon the occurrence of any of various events of default as described in the Credit Agreement. The merger under the Amended Merger Agreement described in Note 3 will, if consummated, constitute an event of default under the Credit Agreement. Borrowings under the secured credit facility are guaranteed by substantially all of our domestic subsidiaries (other than unrestricted subsidiaries and domestic subsidiaries of certain of our foreign subsidiaries) and are secured by the stock of substantially all of our domestic subsidiaries (other than unrestricted subsidiaries and domestic subsidiaries of certain of our foreign subsidiaries), portions of the stock of certain of our foreign subsidiaries, and substantially all of our and our guarantor subsidiaries’ other property and assets, in each case subject to various exceptions. As of December 31, 2016, aggregate borrowings under the secured credit facility amounted to $1.6 billion, consisting of “A” term loans in the aggregate outstanding principal amount of $544.7 million (giving effect to the installment repayment that was due on such date) (which amount reflects original issue discounts and debt issuance costs related to such indebtedness) and “B” term loans in the aggregate outstanding principal amount of $952.7 million (giving effect to the installment repayment that was due on such date) (which amount reflects original issue discounts and debt issuance costs related to such indebtedness) and revolving loans in the aggregate outstanding principal amount of $125.0 million. As of December 31, 2016, we were in compliance with the maximum consolidated secured net leverage ratio under the secured credit facility. (b) Prior Credit Facility In connection with our entry into the secured credit facility on June 18, 2015, we repaid in full all outstanding indebtedness under and terminated our prior senior credit agreement, or prior credit facility, dated as of June 30, 2011, as amended from time to time, with certain lenders, General Electric Capital Corporation as administrative agent and collateral agent, and certain other agents and arrangers, and certain related guaranty and security agreements. The aggregate outstanding principal amount of the loans repaid under our prior credit facility in connection with the termination thereof was approximately $1.65 billion. We assessed this repayment on a lender-by-lender (c) 6.375% Senior Subordinated Notes On June 24, 2015, we sold a total of $425.0 million aggregate principal amount of 6.375% senior subordinated notes in a private placement to initial purchasers, who agreed to resell the notes only to qualified institutional buyers and to persons outside the United States; we sold the 6.375% senior subordinated notes at an initial offering price of 100%. Net proceeds from this offering amounted to $417.3 million, which were net of the initial purchasers’ discount and offering expenses totaling approximately $7.7 million. The 6.375% senior subordinated notes were issued under a supplemental indenture dated June 24, 2015, or the 6.375% Indenture. The 6.375% senior subordinated notes accrue interest at the rate of 6.375% per annum We may, at our option, redeem the 6.375% senior subordinated notes, in whole or part, at any time (which may be more than once) on or after July 1, 2018 by paying the principal amount of the notes being redeemed plus a declining premium, plus accrued and unpaid interest to (but excluding) the redemption date. The premium declines from 4.781% during the twelve months on and after July 1, 2018, to 3.188% during the twelve months on and after July 1, 2019, to 1.594% during the twelve months on and after July 1, 2020, to zero on and after July 1, 2021. In addition, at any time (which may be more than once) prior to July 1, 2018, we may, at our option, redeem up to 35% of the aggregate principal amount of the 6.375% senior subordinated notes with money that we raise in certain qualifying equity offerings, so long as (i) we pay 106.375% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to (but excluding) the redemption date; (ii) we redeem the 6.375% senior subordinated notes within 90 days of completing such equity offering; and (iii) at least 65% of the aggregate principal amount of the 6.375% senior subordinated notes remains outstanding afterwards. In addition, at any time (which may be more than once) prior to July 1, 2018, we may, at our option, redeem some or all of the 6.375% senior subordinated notes by paying the principal amount of the 6.375% senior subordinated notes being redeemed plus a make-whole premium, plus accrued and unpaid interest to (but excluding) the redemption date. If a change of control occurs, subject to specified conditions, we must give holders of the 6.375% senior subordinated notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to (but excluding) the date of the purchase. The merger under the Amended Merger Agreement described in Note 3 will, if consummated, constitute a change of control under the 6.375% Indenture. If we or our restricted subsidiaries engage in asset sales, we or they generally must either invest the net cash proceeds from such sales in our or their businesses within a specified period of time, repay senior indebtedness or make an offer to purchase a principal amount of the 6.375% senior subordinated notes (on a pro rata basis with respect to the 6.375% senior subordinated notes and our 6.5% senior subordinated notes) equal to the excess net cash proceeds, subject to certain exceptions. The purchase price of the 6.375% senior subordinated notes would be 100% of their principal amount, plus accrued and unpaid interest. The 6.375% Indenture provides that we and our restricted subsidiaries must comply with various covenants, which are subject to certain important exceptions and qualifications, which are set forth in the 6.375% Indenture. At any time the 6.375% senior subordinated notes are rated investment grade, certain covenants will be suspended with respect to them. The 6.375% Indenture contains events of default entitling the trustee or the holders of the requisite percentage of the aggregate outstanding principal amount of the 6.375% senior subordinated notes to declare all amounts owed pursuant to the 6.375% senior subordinated notes immediately payable if any such event of default occurs. The 6.375% senior subordinated notes are our senior subordinated unsecured obligations, are subordinated in right of payment to all of our existing and future senior debt, including our borrowings under our secured credit facility and our 7.25% senior notes, and are equal in right of payment with all of our existing and future senior subordinated debt, including our 6.5% senior subordinated notes. Our obligations under the 6.375% senior subordinated notes and the 6.375% Indenture are fully and unconditionally guaranteed, jointly and severally, on a senior subordinated unsecured basis by certain of our domestic subsidiaries, and the obligations of such domestic subsidiaries under their guarantees are subordinated in right of payment to all of their existing and future senior debt and equal in right of payment to all of their existing and future senior subordinated debt. See Note 29 for guarantor financial information. May 2016 Waivers with respect to Senior Notes and Senior Subordinated Notes On April 29, 2016, we commenced consent solicitations relating to our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 7.25% senior notes, which we refer to collectively as the Notes. The consent solicitations were made to holders of record of the Notes as of April 28, 2016, and such solicitations were completed on May 9, 2016. Pursuant to the consent solicitations, the requisite holders of each series of Notes agreed to extend the deadline for delivery of certain financial information and to waive, through and until 5:00 p.m., New York City time, on August 31, 2016, any default or event of default that occurred, is continuing or may occur under the indentures under which the Notes were issued (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, our Annual Report on Form 10-K 10-Q, As of December 31, 2016, accrued interest related to the 6.375% senior subordinated notes amounted to $13.5 million. See Note 30 for information regarding the May 2017 and June 2017 consent solicitations made to the holders of our 6.375% senior subordinated notes relating to our failure to timely furnish to such holders of such notes this Annual Report on Form 10-K (d) 7.25% Senior Notes On December 11, 2012, we sold a total of $450.0 million aggregate principal amount of 7.25% senior notes in a private placement to initial purchasers, who agreed to resell the notes only to qualified institutional buyers and to persons outside the United States; we sold the 7.25% senior notes at an initial offering price of 100%. Net proceeds from this offering amounted to $443.2 million, which was net of the underwriters’ commissions and offering expenses totaling $6.8 million. These notes were subsequently exchanged for new notes having substantially the same terms in an exchange offer registered under the Securities Act. We used $267.4 million of the net proceeds to purchase $248.2 million outstanding principal amount of our former 7.875% senior notes due 2016, or the 7.875% senior notes, and $170.0 million to pay down a portion of the outstanding balance under the revolving line of credit under our prior credit facility. The 7.25% senior notes were issued under a supplemental indenture dated as of August 11, 2009, as amended or supplemented, or the 7.25% Indenture. The 7.25% senior notes accrue interest at the rate of 7.25% per annum. Interest on the 7.25% senior notes is payable semi-annually on June 15 and December 15, beginning on June 15, 2013. The 7.25% senior notes mature on July 1, 2018, unless earlier redeemed. Upon such maturity, we will be required to pay the principal amount of $450 million, plus all accrued and unpaid interest. Management expects that the acquisition of Alere by Abbott pursuant to the terms of the Amended Merger Agreement will take place prior to the maturity date of July 1, 2018 and, if this expectation is correct, the holders of the 7.25% senior notes will have the rights set forth in connection with such transaction as set forth in the following paragraph. In the event that the transactions contemplated by the Amended Merger Agreement do not close, we expect that we would be able to pay such principal and accrued interest by one or a combination of the following: refinancing such indebtedness as we have done in the past, using available cash resources, or utilizing amounts available under the revolving credit facility. If a change of control occurs, subject to specified conditions, we must give holders of the 7.25% senior notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to (but excluding) the date of the purchase. The merger under the Amended Merger Agreement described in Note 3 will, if consummated, constitute a change of control under the 7.25% Indenture. We may redeem the 7.25% senior notes, in whole or part, at any time by paying the principal amount of the notes being redeemed plus a declining premium, plus accrued and unpaid interest to, but excluding, the redemption date. The premium declines from 1.813% during the six months on and after December 15, 2016 to zero on and after June 15, 2017. If we, or our subsidiaries, engage in asset sales, we, or they, generally must either invest the net cash proceeds from such sales in our or their businesses within a specified period of time, prepay certain indebtedness or make an offer to purchase a principal amount of the 7.25% senior notes equal to the excess net cash proceeds, subject to certain exceptions. The purchase price of the notes would be 100% of their principal amount, plus accrued and unpaid interest. The 7.25% Indenture provides that we and our subsidiaries must comply with various customary covenants, which are subject to certain important exceptions and qualifications, which are set forth in the 7.25% Indenture. At any time the 7.25% senior notes are rated investment grade, certain covenants will be suspended with respect to them. The 7.25% Indenture contains customary events of default entitling the trustee or the holders of the requisite percentage of the aggregate outstanding principal amount of the 7.25% senior notes to declare all amounts owed pursuant to the 7.25% senior notes immediately payable if any such event of default occurs. The 7.25% senior notes are our senior unsecured obligations, are senior in right of payment to all of our existing and future subordinated debt, including our 6.375% senior subordinated notes and our 6.5% senior subordinated notes, and are equal in right of payment to all of our existing and future senior debt, including our borrowings under our secured credit facility. Our obligations under the 7.25% senior notes and the 7.25% Indenture are fully and unconditionally guaranteed, jointly and severally, on an unsecured senior basis by certain of our domestic subsidiaries, and the obligations of such domestic subsidiaries under their guarantees are equal in right of payment to all of their existing and future senior debt and senior in right of payment to all of their existing and future subordinated debt. See Note 29 for guarantor financial information. As of December 31, 2016, accrued interest related to the 7.25% senior notes amounted to $1.4 million. See Note 30 for information regarding the May 2017 and June 2017 consent solicitations made to the holders of our 7.25% senior notes relating to our failure to timely furnish to such holders of such notes this Annual Report on Form 10-K (e) 6.5% Senior Subordinated Notes In May 2013, we sold a total of $425.0 million aggregate principal amount of 6.5% senior subordinated notes in a private placement to initial purchasers, who agreed to resell the notes only to qualified institutional buyers and to persons outside the United States. We sold the 6.5% senior subordinated notes at an initial offering price of 100%. Net proceeds from this offering amounted to $417.7 million, which were net of the underwriters’ commissions and offering expenses totaling approximately $7.3 million. These notes were subsequently exchanged for new notes having substantially the same terms in an exchange offer registered under the Securities Act. In May 2013, we used $200.6 million of the net proceeds of our sale of the 6.5% senior subordinated notes to purchase $190.6 million outstanding principal amount of our former 9% senior subordinated notes, or the 9% senior subordinated notes. In June 2013, we redeemed the remaining $209.4 million outstanding principal amount of the 9% senior subordinated notes. The 6.5% senior subordinated notes were issued under a supplemental indenture dated as of May 24, 2013, or the 6.5% Indenture. The 6.5% senior subordinated notes accrue interest at the rate of 6.5% per annum. Interest on the 6.5% senior subordinated notes is payable semi-annually on June 15 and December 15, beginning on December 15, 2013. The 6.5% senior subordinated notes mature on June 15, 2020, unless earlier redeemed. We may, at our option, redeem the 6.5% senior subordinated notes, in whole or part, at any time (which may be more than once) on or after June 15, 2016, by paying the principal amount of the notes being redeemed plus a declining premium, plus accrued and unpaid interest to (but excluding) the redemption date. The premium declines from 3.250% during the twelve months on and after June 15, 2016 to 1.625% during the twelve months on and after June 15, 2017 to zero on and after June 15, 2018. In addition, at any time (which may be more than once) prior to June 15, 2016, we may, at our option, redeem up to 35% of the aggregate principal amount of the 6.5% senior subordinated notes with money that we raise in certain equity offerings, so long as (i) we pay 106.5% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to (but excluding) the redemption date; (ii) we redeem the 6.5% senior subordinated notes within 90 days of completing such equity offering; and (iii) at least 65% of the aggregate principal amount of the 6.5% senior subordinated notes remains outstanding afterwards. In addition, at any time (which may be more than once) prior to June 15, 2016, we may, at our option, redeem some or all of the 6.5% senior subordinated notes by paying the principal amount of the 6.5% senior subordinated notes being redeemed plus a make-whole premium, plus accrued and unpaid interest to (but excluding) the redemption date. If a change of control occurs, subject to specified conditions, we must give holders of the 6.5% senior subordinated notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to (but excluding) the date of the purchase. The merger under the Amended Merger Agreement described in Note 3 will, if consummated, constitute a change of control under the 6.5% Indenture. If we or our subsidiaries engage in asset sales, we or they generally must either invest the net cash proceeds from such sales in our or their businesses within a specified period of time, repay senior indebtedness or make an offer to purchase a principal amount of the 6.5% senior subordinated notes (on a pro rata basis with respect to the 6.5% senior subordinated notes and our 6.375% senior subordinated notes) equal to the excess net cash proceeds, subject to certain exceptions. The purchase price of the 6.5% senior subordinated notes would be 100% of their principal amount, plus accrued and unpaid interest. The 6.5% Indenture provides that we and our subsidiaries must comply with various customary covenants, which are subject to certain important exceptions and qualifications, which are set forth in the 6.5% Indenture. At any time the 6.5% senior subordinated notes are rated investment grade, certain covenants will be suspended with respect to them. The 6.5% Indenture contains customary events of default entitling the trustee or the holders of the requisite percentage of the aggregate outstanding principal amount of the 6.5% senior subordinated notes to declare all amounts owed pursuant to the 6.5% senior subordinated notes immediately payable if any such event of default occurs. The 6.5% senior subordinated notes are our senior subordinated unsecured obligations, are subordinated in right of payment to all of our existing and future senior debt, including our borrowings under our secured credit facility and our 7.25% senior notes, and are equal in right of payment with our 6.375% senior subordinated notes. Our obligations under the 6.5% senior subordinated notes and the 6.5% Indenture are fully and unconditionally guaranteed, jointly and severally, on a senior subordinated unsecured basis by certain of our domestic subsidiaries, and the obligations of such domestic subsidiaries under their guarantees are subordinated in right of payment to all of their existing and future senior debt and equal in right of payment to all of their existing and future senior subordinated debt. See Note 29 for guarantor financial information. As of December 31, 2016, accrued interest related to the 6.5% senior subordinated notes amounted to $1.2 million. See Note 30 for information regarding the May 2017 and June 2017

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	(10) Fair Value Measurements Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Described below are the three levels of inputs that may be used to measure fair value: Level 1 — Level 2 — Level 3 — The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2016 and 2015, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description December 31, 2016 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Marketable securities $ 76 $ 76 $ — $ — Total assets $ 76 $ 76 $ — $ — Liabilities: Contingent consideration obligations(1) $ 43,200 $ — $ — $ 43,200 Total liabilities $ 43,200 $ — $ — $ 43,200 Description December 31, 2015 Quoted Prices in Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Marketable securities $ 164 $ 164 $ — $ — Total assets $ 164 $ 164 $ — $ — Liabilities: Contingent consideration obligations(1) $ 57,744 $ — $ — $ 57,744 Total liabilities $ 57,744 $ — $ — $ 57,744 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out earn-out Changes in the fair value of our Level 3 contingent consideration obligations during the years ended December 31, 2016 and 2015 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2014 $ 139,671 Payments (22,073 ) Fair value adjustments (59,871 ) Foreign currency adjustments 17 Fair value of contingent consideration obligations, December 31, 2015 $ 57,744 Payments (1,236 ) Fair value adjustments (13,309 ) Foreign currency adjustments 1 Fair value of contingent consideration obligations, December 31, 2016 $ 43,200 At December 31, 2016 and 2015, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values. The carrying amount and estimated fair value of our long-term debt (including the current portion) was $2.9 billion at December 31, 2016. The carrying amount and estimated fair value of our long-term debt (including the current portion) were $3.1 billion and $3.0 billion, respectively, at December 31, 2015. The estimated fair value of our long-term debt was determined using information derived from available market sources (Level 2 in the fair value hierarchy), including open-market trades and market quotes observed at or near year end, and may not be representative of actual values that could have been or will be realized in the future.

Capital Leases

Capital Leases	12 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Capital Leases	(11) Capital Leases The following is a schedule of the future minimum lease payments under capital leases as of December 31, 2016 (in thousands): 2017 $ 3,064 2018 2,583 2019 2,869 2020 790 2021 457 Thereafter 522 Total future minimum lease payments 10,285 Less: Current portion (3,064 ) $ 7,221 At December 31, 2016 and 2015, the capitalized amounts of the building, machinery and equipment and computer equipment under capital leases were as follows (in thousands): December 31, December 31, Machinery, laboratory equipment and tooling $ 26,794 $ 24,258 Computer equipment 208 888 Furniture and fixtures 1,106 606 Vehicles 206 197 Leasehold improvements — 927 28,314 26,876 Less: Accumulated amortization (10,165 ) (9,214 ) $ 18,149 $ 17,662 The amortization expense of assets recorded under capital leases is included in depreciation and amortization expense of property, plant and equipment.

Postretirement Benefit Plans

Postretirement Benefit Plans	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Postretirement Benefit Plans	(12) Postretirement Benefit Plans (a) Employee Savings Plans Our company and several of our U.S.-based subsidiaries sponsor various 401(k) savings plans, to which eligible domestic employees may voluntarily contribute a portion of their income, subject to statutory limitations. In addition to the participants’ own contributions to these 401(k) savings plans, we match such contributions up to a designated level. Total matching contributions related to employee savings plans were $5.8 million, $5.8 million and $9.2 million in 2016, 2015 and 2014, respectively. (b) U.K. Pension Plans Our subsidiary in England, Unipath Ltd., or Unipath, has a Defined Benefit Pension Plan established for certain of its employees, which is frozen as of December 31, 2016. Changes in benefit obligations, plan assets, funded status and amounts recognized on the accompanying balance sheet as of and for the years ended December 31, 2016 and 2015, for our Defined Benefit Plan were as follows (in thousands): 2016 2015 Change in projected benefit obligation Benefit obligation at beginning of year $ 21,499 $ 22,560 Interest cost 721 784 Actuarial loss (gain) 5,426 (638 ) Benefits paid (324 ) (179 ) Foreign exchange impact (4,308 ) (1,028 ) Benefit obligation at end of year $ 23,014 $ 21,499 Change in plan assets Fair value of plan assets at beginning of year $ 18,485 $ 18,120 Actual return on plan assets 3,297 491 Employer contribution 814 917 Benefits paid (324 ) (179 ) Foreign exchange impact (3,652 ) (864 ) Fair value of plan assets at end of year $ 18,620 $ 18,485 Funded status $ (4,394 ) $ (3,014 ) Accumulated benefit obligation $ 23,014 $ 21,499 The net amounts recognized in the accompanying consolidated balance sheets are shown in long-term liabilities and were $4.4 million and $3.0 million, respectively, at December 31, 2016 and 2015. Included in the change in projected benefit obligation is an actuarial loss of $5.4 million and gain of $0.6 million for the years ended December 31, 2016 and 2015, respectively. As of December 31, 2016, the amortization of actuarial gain/loss is expected to be approximately $0.5 million in 2017. The following represents the amounts recognized in other comprehensive loss, related to our Unipath Defined Benefit Pension Plan for the years ended December 31, 2016 and 2015 (in thousands): 2016 2015 Amortization of net loss $ (279 ) $ (332 ) Amortization of prior service cost (275 ) (310 ) New actuarial loss (3,247 ) (55 ) Foreign exchange impact 4,991 (1,134 ) Total $ 1,190 $ (1,831 ) As of December 31, 2016, the amortization of prior service cost is expected to be approximately $0.2 million in 2017. Amounts recognized in accumulated other comprehensive loss at December 31, 2016 and 2015 are as follows: 2016 2015 Net actuarial loss $ 6,967 $ 5,109 Prior service cost 1,744 2,412 Net amount recognized $ 8,711 $ 7,521 The measurement dates used to determine plan assets and benefit obligations for the Defined Benefit Plan were December 31, 2016 and 2015. The following table provides the weighted-average actuarial assumptions: 2016 2015 Assumptions used to determine benefit obligations(1): Discount rate 2.70 % 3.70 % Rate of compensation increase 4.05 % 3.95 % Assumptions used to determine net periodic benefit cost(2): Discount rate 3.70 % 3.55 % Expected long-term return on plan assets 6.55 % 6.50 % Rate of compensation increase 3.95 % 3.85 % (1) The actuarial assumptions used to compute the unfunded status for the plan are based upon information available as of December 31, 2016 and 2015. (2) The actuarial assumptions used to compute the net periodic pension benefit cost are based upon the information available as of the beginning of the presented year. The actuarial assumptions are reviewed on an annual basis. We base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The overall expected long-term rate of return on plan assets assumption was determined based on historical investment return rates on portfolios with a high proportion of equity securities, and was calculated using a weighted-average of the expected returns for each asset class held by the Plan. The long-term expected return on assets is net of investment expenses. The annual net periodic benefit costs of the Defined Benefit Plan are as follows (in thousands): 2016 2015 2014 Service cost $ — $ — $ — Interest cost 721 784 938 Expected return on plan assets (1,119 ) (1,183 ) (1,022 ) Amortization of net loss 279 332 267 Amortization of prior service cost 275 310 438 Net periodic benefit cost $ 156 $ 243 $ 621 The plan assets of the Defined Benefit Plan comprise a mix of stocks and fixed income securities and other investments. At December 31, 2016, these stocks and fixed income securities represented 72% and 28%, respectively, of the market value of the pension assets. We expect to contribute approximately £0.6 million (or $0.7 million at December 31, 2016) to the Defined Benefit Plan in 2017. We expect that the benefits to be paid to plan participants will range between approximately $0.2 million and $0.3 million per year for each of the next five years and that benefits totaling $0.4 million will be paid annually for the five years thereafter. Our overall investment strategy is to ensure the investments are spread across a range of investments varying by both investment class and geographical location which is achieved by investing largely in equity and fixed income funds. Spreading the investments in this manner reduces the risk of a decline in a particular market having a substantial impact on the whole fund. The target allocation for the plan assets is a 70% holding in equities (both in the U.K. and overseas), with the remaining assets invested in investment grade corporate bonds. The fair values of our pension plan assets at December 31, 2016 and 2015 by asset category are presented in the following table (Level 2 in the fair value hierarchy). Plan Assets at December 31, Asset Category 2016 2015 Equity securities: U.K. equities $ 5,965 $ 6,096 Overseas equities 3,005 3,119 U.S. equities 4,379 3,781 Debt securities — corporate bonds 5,194 4,984 Other — cash 77 505 Total plan assets $ 18,620 $ 18,485 The table above presents the fair value of our plan’s assets in accordance with the fair value hierarchy.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(13) Commitments and Contingencies (a) Operating Leases We have operating lease commitments for certain of our facilities and equipment that expire on various dates through 2028. The following schedule outlines future minimum annual rental payments under these leases at December 31, 2016 (in thousands): 2017 $ 37,801 2018 30,852 2019 24,894 2020 21,492 2021 16,830 Thereafter 38,600 $ 170,469 Rent expense relating to operating leases was approximately $41.6 million, $41.8 million and $48.4 million during 2016, 2015 and 2014, respectively. (b) Acquisition-related Contingent Consideration Obligations We have contractual contingent purchase price consideration obligations related to certain of our acquisitions. We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving certain performance targets, including product development milestones or financial metrics. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted earn-out Increases or decreases in the fair values of the contingent consideration obligations may result from, among other things, changes in discount periods and rates, changes in the timing and amount of earn-out earn-out The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions (in thousands): Acquisition Acquisition Date Acquisition Date Fair Value Maximum Remaining Earn-out as of December 31, 2016 Remaining Earn-out Period as of December 31, 2016 Estimated Fair Value as Estimated Fair Value as Payments Made During 2016 TwistDx, Inc.(1) March 11, 2010 $ 35,600 $ 102,694 2017 — 2025 (3) $ 35,700 $ 47,800 $ 553 Epocal(2) February 1, 2013 $ 75,000 $ 19,600 2017 — 2018 3,000 4,700 — Other Various $ 30,373 $ — 4,500 5,244 683 $ 43,200 $ 57,744 $ 1,236 (1) The terms of the acquisition agreement require us to pay earn-outs upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out (c) Legal Proceedings Litigation with Abbott Laboratories After entering into the original Merger Agreement, Abbott informed Alere that it had serious concerns about, among other things, the accuracy of various representations, warranties and covenants made by Alere in the original Merger Agreement. Abbott indicated that these concerns related to the delay in the filing of Alere’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 as well as governmental investigations previously announced by Alere. Abbott requested information from Alere about these and other matters, citing contractual rights to receive information under the original Merger Agreement. In the initial meeting in which Abbott expressed its concerns to Alere, as part of a discussion about potential paths forward, Abbott requested that Alere agree to terminate the original Merger Agreement in return for a payment by Abbott to Alere in the range of between $30 and $50 million in respect of Alere’s transaction expenses. Alere’s Board of Directors promptly rejected that request. In these discussions, Abbott affirmed its commitment to abide by its obligations under the original Merger Agreement. On August 25, 2016, Alere filed a complaint against Abbott in the Delaware Chancery Court, and filed an accompanying motion to expedite the proceedings, asking the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to obtaining antitrust approvals as required by the original Merger Agreement. On September 29, 2016, the Delaware Chancery Court entered an order that, among other things, adopted a detailed schedule setting forth actions required to be taken by specified dates in order to obtain all antitrust clearances required by the original merger agreement. On November 3, 2016, Abbott filed a complaint against Alere in the Delaware Chancery Court asserting a claim against Alere for breach of contract from Alere’s alleged refusal to provide Abbott with certain information under the original Merger Agreement. On February 1, 2017, Alere filed a motion to dismiss Abbott’s November 3 complaint. On December 7, 2016, Abbott filed a complaint (which was subsequently amended after the various actions were consolidated) in the Delaware Chancery Court seeking a declaration that Alere had experienced a Material Adverse Effect (as such term is defined in the original Merger Agreement) and that Abbott could terminate the original Merger Agreement. On February 1, 2017, Abbott filed its answer to the complaint Alere had filed on August 25, 2016, and Alere filed an answer to Abbott’s amended complaint as well as counterclaims against Abbott. Alere’s counterclaims requested a declaratory judgment that, among other things, (i) there had been no Material Adverse Effect (as such term is defined in the original Merger Agreement); and (ii) Abbott had breached the parties’ original Merger Agreement and breached the implied covenant of good faith and fair dealing. Settlement Agreement relating to the Amended Merger Agreement Concurrently with the execution of the Merger Agreement Amendment, Alere and Abbott entered into a settlement agreement, or the Settlement Agreement. The Settlement Agreement released claims arising out of or related to the merger, and resolved the parties’ litigation that had been pending in Delaware Chancery Court. The Settlement Agreement provided reciprocal releases, except for any potential antitrust claims by Alere to the extent they relate to developments after August 25, 2016, which would not be released until the parties obtain all consents and regulatory clearances necessary for closing. Abbott’s potential claims based on information not excluded from the definition of Material Adverse Effect in the Amended Merger Agreement were also not released. Finally, the Settlement Agreement provided for dismissal of the Delaware litigation with prejudice, with the exception of the non-released antitrust claims, which were dismissed without prejudice. Arriva Medical Billing Number Arriva Medical is our durable medical equipment, or DME, supply business that furnishes diabetic testing supplies via mail order, including blood glucose monitors, test strips, lancets, lancing devices, and control solutions, as well as other related medical supplies in the United States. These products are generally covered by Medicare, Medicaid and other third-party payers. Competition for Medicare-reimbursed diabetes testing supplies, which represents the majority of our Arriva Medical business, changed significantly in 2013 as a result of implementation by CMS of a competitive bidding process to limit the number of eligible suppliers and the fees for which they may be reimbursed. Based on the most recent bidding process, we estimate that CMS currently reimburses approximately ten suppliers who have agreed to accept a contractual reimbursement rate for mail-order diabetic testing supplies for the period from July 2016 to December 2018 that is substantially lower than the established fee schedule for these products. Arriva Medical is one of those approximately ten suppliers that was awarded a national mail-order contract. Suppliers that were not awarded contracts are unable to be reimbursed by Medicare for mail-order diabetic testing supplies. On October 12, 2016, Arriva Medical received a notice, dated October 5, 2016, that its Medicare enrollment would be revoked by CMS, based on CMS’ assertion that, over a five-year period, out of approximately 5.7 million Medicare claims made for about one million unique beneficiaries, Arriva had allegedly submitted claims for 211 Medicare beneficiaries who were deceased on the date their products were shipped (even if the products were appropriately ordered in advance of the patient’s death). Arriva Medical’s initial appeal of this determination was denied by CMS, and Arriva’s Medicare enrollment was revoked effective November 4, 2016, pending the outcome of further appeals. Arriva Medical conducted an investigation into the issue and does not believe that it received or, if received, retained, any Medicare reimbursement for the DME items at issue for these 211 Medicare beneficiaries. In addition, CMS subsequently provided notice that Arriva Medical’s competitive bidding contract would be terminated as a result of the revocation of its enrollment. On December 27, 2016, Arriva Medical filed an appeal for an administrative law judge, or ALJ, hearing seeking to permanently reinstate Arriva’s Medicare enrollment status retroactive to the November 4, 2016 revocation date. On April 25, 2017, the ALJ upheld CMS’s revocation of Arriva Medical’s Medicare enrollment. Arriva Medical intends to proceed with the administrative appeals process by appealing the ALJ decision to the Department Appeals Board. On December 28, 2016, Arriva Medical also filed a complaint in Federal District Court for the District of Columbia requesting a temporary restraining order, or TRO, and preliminary injunction, or PI, to prohibit CMS from terminating Arriva Medical’s competitive bidding contract and requesting that the court require CMS to reinstate Arriva’s Medicare billing status until due process could be provided in the form of the completion of the administrative appeals process prescribed by regulation. In conjunction with this case, on January 4, 2017, CMS agreed through its counsel that it would not revoke the competitive bidding contract while the administrative appeals process was underway, which mooted the request for the TRO. On March 9, 2017, the Federal District Court for the District of Columbia denied the PI to prohibit CMS from terminating Arriva Medical’s competitive bidding contract and also denied CMS’s motion to dismiss Arriva Medical’s complaint. On April 17, 2017, the court issued an order dismissing Arriva Medical’s complaint. We are unable, at this time, to determine the outcome of these pending legal matters related to Arriva Medical’s billing number. U.S. Securities and Exchange Commission Subpoena On August 28, 2015, we received a subpoena from the SEC which indicated that it is conducting a formal investigation of Alere. The SEC’s subpoena relates to, among other things, (i) our previously filed restatement and revision to our financial statements, including the accounting for deferred taxes for discontinued operations, as well as our tax strategies and policies and (ii) our sales practices and dealings with third parties (including distributors and foreign government officials) in Africa relating to sales to government entities. On January 14, 2016, we received a second subpoena from the SEC in connection with this formal investigation seeking, among other things, additional information related to sales of products and services to end-users in Africa, as well as revenue recognition relating to sales of products and services to end-users in Africa. We have also received, from time to time, requests in connection with the investigation to voluntarily produce additional information to the SEC, including information pertaining to certain other countries in Asia and Latin America, as well as additional information on revenue recognition matters and revisions to our financial statements referenced in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. We are cooperating with the SEC and have provided documents in response to the subpoenas and voluntary requests and we have made witnesses available to be interviewed by the SEC. We are unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it. Department of Justice Grand Jury Subpoena On March 11, 2016, we received a grand jury subpoena from the United States Department of Justice requiring the production of documents relating to, among other things, sales, sales practices and dealings with third parties (including distributors and foreign governmental officials) in Africa, Asia and Latin America and other matters related to the U.S. Foreign Corrupt Practices Act. We are cooperating with the Department of Justice and have provided information in response to the subpoena. We are unable to predict when this matter will be resolved or what further action, if any, the Department of Justice may take in connection with it. Securities Class Actions On April 21, 2016 and May 4, 2016 two class action lawsuits captioned Godinez Alere Inc. Breton Alere Inc. and Rule 10b-5 under On November 14, 2016, a class action lawsuit captioned Khalid Alere Inc. 10b-5 We are unable at this time to determine the outcome of these class action lawsuits or our potential liability, if any. Matters Relating to our San Diego Facility On October 9, 2012, we received a warning letter from the FDA referencing inspectional observations set forth in a Form FDA 483 received in June 2012. The observations were the result of an inspection of our San Diego facility conducted earlier during 2012 relating to our Alere Triage products, which resulted in two recalls of certain Alere Triage products and revised release specifications for our Alere Triage meter-based products. In September 2014, as follow up to a further inspection of our San Diego facility, the FDA notified us that this inspection was classified “voluntary action indicated,” meaning that the objectionable conditions or practices found in the inspection did not meet the threshold of significance requiring regulatory action, but that formal close-out In May 2012, we also received a subpoena from the Office of Inspector General of the Department of Health and Human Services, or the OIG, seeking documents relating primarily to the quality control testing and performance characteristics of Alere Triage products. We are cooperating with the government and are responding to the investigation, which is ongoing. We have been engaged in discussions with the government about this matter, including a resolution of potential related False Claims Act and common law liability exposure for the products under review. As a result of these discussions, management has accrued, as of December 31, 2016, an aggregate of $35.0 million for potential liability of the claims related to this matter (this amount is included in general and administrative expenses in our consolidated statements of operations for the year ended December 31, 2016). We would need to obtain certain approvals before we could agree to any proposed resolution. There can be no assurance that future discussions with the government to resolve these matters will be successful, that the approvals we need will be obtained or that any potential settlement will be agreed to or finalized. We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them. Based on the ongoing uncertainties and potentially wide range of outcomes associated with any potential resolution of the matter under investigation by the OIG, the ultimate amount of potential liability may materially exceed the $35.0 million accrual we have established. INRatio Class Actions On May 26, 2016, a class action lawsuit captioned Dina Andren Sidney Bludman v. Alere Inc., et al. We are unable, at this time, to determine the outcome of these class action lawsuits or our potential liability, if any. Another class action lawsuit captioned J.E, J.D., and all others similarly situated v. Alere Inc., Alere San Diego, Inc. and Alere Home Monitoring, Inc., Claims in the Ordinary Course and Other Matters We are also party to certain other legal proceedings and other governmental investigations, or are requested to provide information in connection with such proceedings or investigations. For example, in December 2014, we and our subsidiary, Avee Laboratories Inc., or Avee, received subpoenas from the United States Attorney for the District of New Jersey seeking marketing materials and other documents relating primarily to billing and marketing practices related to toxicology testing. In addition, we received a U.S. Department of Justice criminal subpoena addressed to Alere Toxicology Services, Inc. on July 1, 2016 which seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for specific patient samples tested at our Austin, Texas pain management laboratory and payments made to physicians. We are cooperating with these investigations and are providing documents in response to both subpoenas. We and our subsidiary, Arriva Medical, LLC, are also in the process of responding to Civil Investigative Demands, or CIDs, from the United States Attorney’s office for the Middle District of Tennessee and the U.S. Department of Justice in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The most recent of the CIDs related to this matter was received in May 2017. The CIDs request patient and insurance billing and medical records, records related to interactions with third parties, and correspondence related to the same, communications with customers and terms of sale for diabetic products, dating back to January 2010. In an unrelated matter, in January 2017, our subsidiary Alere Home Monitoring, Inc., which offers home self-testing anticoagulation monitoring and VAD services and products, received a CID from the United States Attorney’s Office for the District of Massachusetts. The January 2017 CID, which covers similar subject matter to a letter request from the Department of Justice Civil Division dating back to June 2015, is broad in scope, but is understood to be primarily focused on obtaining records and information about Alere Home Monitoring, Inc.’s billing practices and policies relating to the frequency at which PT/INR self-testing is prescribed and performed since 2006. In addition, in March 2017, Alere Home Monitoring, Inc. received a second letter request from the Department of Justice Civil Division seeking additional information regarding billing frequencies of PT/INR self-testing beyond the original scope of the June 2015 request. We are cooperating with these various unrelated investigations and are providing documents and information responsive to each of the CIDs and letter requests. We cannot predict what effect, if any, these investigations, or any resulting claims, could have on us or our subsidiaries. We have received, from time to time, additional subpoenas and requests for information from the United States Department of Justice, other federal government agencies and state attorneys general, and we have, in each of these cases, cooperated with the applicable governmental entity in responding to the applicable subpoena or request for information. For example, in May 2016, we received a subpoena from the U.S. Attorney for the District of New Jersey, which seeks various documents related to the accuracy, reliability and performance of the INRatio system, including documents relating to prior interactions with the FDA and others regarding the system. Our diabetes, toxicology and patient self-testing businesses are subject to audit and claims for reimbursement brought in the ordinary course by: private third-party payers, including health insurers; Zone Program Integrity Contractors, or ZPICs; and Medicare Administrative Contractors, or MACs, to monitor compliance with coverage and reimbursement rules and guidelines. These types of audits and claims can include, but are not limited to, claims relating to proper documentation and support, claims relating to the medical necessity of certain testing or billing practices are not in accord with applicable rules and guidelines and can lead to assertions or determinations that certain claims should not have been, or will no longer be, paid by the private third-party payer or by Medicare or Medicaid. In such cases, the payer or program may seek to recoup or offset amounts they assert have been paid in error. Our businesses may also be subject at any time to other commercial disputes, product liability claims, personal injury claims, including claims arising from or relating to product recalls, negligence claims, third-party subpoenas or various other lawsuits arising in the ordinary course of business, including infringement, employment or investor matters, disputes regarding the payment of contingent consideration obligations and we expect that this will continue to be the case in the future. For example, several individuals have filed suits against us alleging personal injury claims in connection with the use of our INRatio products (which are in addition to the class action suits described above). In addition, the former shareholders of Ionian Technologies Inc. filed a lawsuit against us in May 2017 alleging, among other things, that they are owed $30 million in earn-out payments under the agreement pursuant to which we acquired Ionian Technologies. Such lawsuits or claims generally seek damages or reimbursement, sometimes in substantial amounts. There are possible unfavorable outcomes related to litigation or governmental investigations that could materially impact our business, results of operations, financial condition, and cash flows.

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Net Income (Loss) Per Common Share	(14) Net Income (Loss) Per Common Share The following tables set forth the computation of basic and diluted net income (loss) per common share (in thousands, except per share amounts): 2016 2015 (As 2014 (As Restated) Basic and diluted net income (loss) per common share: Numerator: Loss from continuing operations $ (137,269 ) $ (15,448 ) $ (171,441 ) Preferred stock dividends (21,350 ) (21,293 ) (21,293 ) Loss from continuing operations attributable to common shares (158,619 ) (36,741 ) (192,734 ) Less: Net income attributable to non-controlling 350 381 30 Loss from continuing operations attributable to Alere Inc. and Subsidiaries (158,969 ) (37,122 ) (192,764 ) Income from discontinued operations — 219,513 138,318 Net income (loss) available to common stockholders $ (158,969 ) $ 182,391 $ (54,446 ) Denominator: Weighted-average common shares outstanding — basic and diluted 86,796 85,420 82,938 Basic and diluted net income (loss) per common share: Loss from continuing operations attributable to Alere Inc. and Subsidiaries $ (1.83 ) $ (0.43 ) $ (2.33 ) Income from discontinued operations — 2.57 1.67 Basic and diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries $ (1.83 ) $ 2.14 $ (0.66 ) The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share for our continuing operations because the inclusion thereof would be antidilutive (in thousands): 2016 2015 2014 Denominator: Options to purchase shares of common stock and RSUs 6,774 6,793 7,140 Warrants — 4 4 Conversion shares related to 3% convertible senior subordinated notes 1,267 3,411 3,411 Conversion shares related to subordinated convertible promissory notes — — 27 Conversion shares related to Series B convertible preferred stock 10,238 10,239 10,239 Common stock equivalents related to the settlement of a contingent consideration obligation — 14 — Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 18,279 20,461 20,821

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	(15) Stockholders’ Equity (a) Common Stock As of December 31, 2016, we had 200.0 million shares of common stock, $0.001 par value, authorized, of which 7.7 million shares were held in treasury and 87.1 million shares were outstanding, 11.5 million shares were reserved for issuance upon grant and exercise or vesting of equity awards under current equity compensation plans, and 1.7 million shares were reserved for issuance under our employee stock purchase plan. As of December 31, 2016, we also had shares of common stock reserved for issuance upon conversion of 1.8 million shares of our Series B convertible preferred stock, with an aggregate liquidation preference of approximately $709.7 million, convertible under certain circumstances at $69.32 per share into 10.2 million shares of our common stock. (b) Preferred Stock As of December 31, 2016, we had 5.0 million shares of preferred stock, $0.001 par value, authorized, of which 2.3 million shares were designated as Series B Convertible Perpetual Preferred Stock, or Series B preferred stock. In connection with our acquisition of Matria, we issued shares of the Series B preferred stock and through June 30, 2011 paid all dividends on outstanding shares of Series B preferred stock in additional shares of Series B preferred stock. Subsequent to June 30, 2011 all dividends on outstanding shares of Series B preferred stock were paid in cash. At December 31, 2016, there were 1.8 million shares of Series B preferred stock outstanding with a fair value of approximately $590.6 million. Each share of Series B preferred stock, which has a liquidation preference of $400.00 per share, is convertible, at the option of the holder and only upon certain circumstances, into 5.7703 shares of our common stock, plus cash in lieu of fractional shares. The initial conversion price is $69.32 per share, subject to adjustment upon the occurrence of certain events, but will not be adjusted for accumulated and unpaid dividends. Upon a conversion of shares of the Series B preferred stock, we may, at our option, satisfy the entire conversion obligation in cash or through a combination of cash and common stock. Series B preferred stock outstanding at December 31, 2016 would convert into 10.2 million shares of our common stock, which are reserved. As of December 31, 2016, 154 shares of our Series B preferred stock have been converted into 888 shares of common stock. Generally, the shares of Series B preferred stock are convertible, at the option of the holder, if during any calendar quarter beginning with the second calendar quarter after the issuance date of the Series B preferred stock, the closing sale price of our common stock for each of 20 or more trading days within any period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 130% of the conversion price per share of common stock in effect on the last trading day of the immediately preceding calendar quarter. In addition, the shares of Series B preferred stock are convertible, at the option of the holder, in certain other circumstances, including those relating to the trading price of the Series B preferred stock and upon the occurrence of certain fundamental changes or major corporate transactions. We also have the right, under certain circumstances relating to the trading price of our common stock, to force conversion of the Series B preferred stock. Depending on the timing of any such forced conversion, we may have to make certain payments relating to foregone dividends, which payments we can make, at our option, in the form of cash, shares of our common stock, or a combination of cash and shares of our common stock. Each share of Series B preferred stock accrues dividends at $12.00, or 3%, per annum, payable quarterly on January 15, April 15, July 15 and October 15 of each year, commencing following the first full calendar quarter after the issuance date. Dividends on the Series B preferred stock are cumulative from the date of issuance. For the years ended December 31, 2016, 2015 and 2014, Series B preferred stock dividends amounted to $21.3 million, $21.3 million and $21.3 million respectively, which reduced earnings available to common stockholders for purposes of calculating net loss per common share in each of 2016, 2015 and 2014 (Note 14). Accrued dividends are payable only if declared by our board of directors and, upon conversion by the Series B preferred stockholder, holders will not receive any cash payment representing accumulated dividends. If our board of directors declares a dividend payable, we have the right to pay the dividends in cash, shares of common stock, additional shares of Series B preferred stock or a similar convertible preferred stock or any combination thereof. The holders of Series B preferred stock have liquidation preferences over the holders of our common stock and other classes of stock, if any, outstanding at the time of liquidation. Upon liquidation, the holders of outstanding Series B preferred stock would receive an amount equal to $400.00 per share of Series B preferred stock, plus any accumulated and unpaid dividends. As of December 31, 2016, the liquidation preference of the outstanding Series B preferred stock was $709.8 million. The holders of the Series B preferred stock have no voting rights, except with respect to matters affecting the Series B preferred stock (including the creation of a senior preferred stock). We evaluated the terms and provisions of our Series B preferred stock to determine if it qualified for derivative accounting treatment. Based on our evaluation, these securities do not qualify for derivative accounting. (c) Stock Options and Awards In 2010, we adopted the Alere Inc. 2010 Stock Option and Incentive Plan, or the 2010 Plan, which replaced our 2001 Stock Option and Incentive Plan, or the 2001 Plan. The 2010 Plan currently allows for the issuance of up to 16.1 million shares of common stock and other awards. The 2010 Plan is administered by the Compensation Committee of the Board of Directors, which selects the individuals eligible to receive awards, determines or modifies the terms and conditions of the awards granted, accelerates the vesting schedule of any award and generally administers and interprets the 2010 Plan. The 2010 Plan permits the granting of incentive and nonqualified stock options with terms of up to ten years and the granting of stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, performance share awards and dividend equivalent rights. For awards granted before April 23, 2015, the 2010 Plan generally provides for automatic vesting acceleration of all options, and automatic removal of conditions and restrictions on all restricted stock awards, restricted stock units and performance share awards upon a change in control, as defined in the 2010 Plan. For awards granted on or after April 23, 2015, the 2010 Plan generally provides for such acceleration if either (i) no provision is made for the assumption, continuation or substitution of awards upon such a change of control or (ii) provision is made for the assumption, continuation or substitution of such awards upon such a change of control and, within one year of such change of control, we terminate the award recipient’s employment without cause, as defined in the 2010 Plan, or the award recipient terminates his or her employment for good reason, as defined in the 2010 Plan (or, in the case of a director, his or her service as a director is terminated for any reason). As of December 31, 2016, 2015 and 2014, there were 6.1 million, 7.9 million and 2.8 million shares, respectively, available for future grant under the 2010 Plan. In 2001, we adopted our 2001 Employee Stock Purchase Plan, or our ESPP, under which eligible employees are allowed to purchase shares of our common stock at a discount through periodic payroll deductions. Purchases may occur at the end of every six-month The following summarizes all stock option activity during the year ended December 31, 2016 (in thousands, except exercise price): Stock Options Weighted- average Exercise Price Weighted (in years) Aggregate (in millions) Outstanding at January 1, 2014 11,441 $ 37.66 Granted 1,287 $ 36.84 Exercised (1,512 ) $ 28.29 Canceled/expired/forfeited (3,852 ) $ 46.66 Outstanding at December 31, 2014 7,364 $ 34.68 Granted 2,399 $ 46.47 Exercised (2,168 ) $ 34.26 Canceled/expired/forfeited (1,454 ) $ 38.91 Outstanding at December 31, 2015 6,141 $ 38.43 Granted 6 $ 35.80 Exercised (437 ) $ 34.68 Canceled/expired/forfeited (369 ) $ 45.33 Outstanding at December 31, 2016 5,341 $ 38.25 6.30 $ 26.1 Exercisable at December 31, 2016 3,351 $ 34.81 5.28 $ 24.0 Total vested and expected to vest as of December 31, 2016 5,211 $ 38.06 6.26 $ 26.1 The aggregate intrinsic value of stock options exercised during 2016, 2015 and 2014 was $5.0 million, $31.4 million and $14.9 million, respectively. As of December 31, 2016, there was $35.2 million of unrecognized compensation cost related to outstanding stock options. Such costs are expected to be recognized over a weighted-average period of 1.17 years. The following summarizes all restricted stock unit activity during the year ended December 31, 2016 (in thousands, except grant date fair value): Restricted Stock Units Weighted- average Fair Value Nonvested at January 1, 2016 650 $ 31.00 Granted 1,069 $ 52.03 Vested (261 ) $ 31.84 Forfeited (46 ) $ 45.39 Nonvested at December 31, 2016 1,412 $ 46.29 The fair values of our restricted stock units, or RSUs, are based on the market value of our stock on the date of grant. The weighted-average grant date fair value of RSUs granted during 2016, 2015 and 2014 was $52.03, $28.04 and $35.99 respectively. The aggregate intrinsic value of the RSUs as of December 31, 2016 was $55.0 million and the weighted-average remaining contractual term is 1.04 years. The aggregate intrinsic value of the RSUs expected to vest as of December 31, 2016 was $51.0 million and the weighted-average remaining vesting period is 1.03 years. As of December 31, 2016, there was $49.7 million of unrecognized compensation cost related to RSUs, which is expected to be recognized over a weighted-average remaining vesting period of 1.03 years. The following summarizes all stock appreciation rights, or SARs, activity during the year ended December 31, 2016 (in thousands): Stock Appreciation Rights Nonvested at January 1, 2016 188 Granted 22 Exercised (41 ) Forfeited. (24 ) Nonvested at December 31, 2016 145 The total cash paid in settlement of SARs exercised in 2016, 2015 and 2014 was $0.8 million, $1.1 million and $0.9 million, respectively, which was recorded under liability accounting. As of December 31, 2016, 2015 and 2014, the accrual related to SARs was $1.9 million, $2.0 million and $2.4 million, respectively, which was recorded in other long-term liabilities.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	(16) Stock-based Compensation We recorded stock-based compensation expense in our consolidated statements of operations for the years ended December 31, 2016, 2015 and 2014, respectively, as follows (in thousands): 2016 2015 2014 Cost of net revenue $ 2,054 $ 1,198 $ 1,180 Research and development 1,905 1,195 (41 ) Sales and marketing 8,991 4,794 3,940 General and administrative 28,846 19,204 7,373 41,796 26,391 12,452 Benefit for income taxes (520 ) (8,815 ) (2,891 ) Stock-based compensation, net of tax $ 41,276 $ 17,576 $ 9,561 In connection with the departure of three of our senior executives in June 2014, we recorded a reversal of stock-based compensation expense in the amount of $5.6 million during the second quarter of 2014 relating to the termination of their stock option awards following their resignations. Of the $5.6 million reversal, $2.2 million was recorded through research and development and $3.4 million through general and administrative. The excess tax benefits from the exercise of stock options and the vesting of RSU’s are reported as financing cash flows in our consolidated statements of cash flows. For the years ended December 31, 2016 and 2015 there were no excess tax benefits generated and for the year ended 2014, excess tax benefits generated from option exercises and the vesting of RSU’s amounted to $1.0 million. The following assumptions were used to estimate the fair value of options granted during the years ended December 31, 2016, 2015 and 2014, using a Black-Scholes option-pricing model: 2016 2015 2014 Risk-free interest rate 1.27 % 1.62 % 1.77 % Expected dividend yield — — — Expected life 5.44 years 5.59 years 5.78 years Expected volatility 35 % 33 % 36 % The weighted-average fair value under a Black-Scholes option pricing model of options granted during 2016, 2015 and 2014 was $11.66, $15.01 and $14.05 per share, respectively. All options granted during these periods were granted at or above the fair market value on the date of grant. For the year ended December 31, 2016, we recorded compensation expense of $1.5 million related to our ESPP, which is included in the table above. The fair value of the option component of the ESPP shares was estimated at the date of grant using a Black-Scholes option pricing model and assumed an expected volatility of 36%, a risk-free interest rate of 0.49% and an expected life of 181 days. The 2016 charge is included in the employee’s respective cost classification in the table above. For the year ended December 31, 2015, we recorded compensation expense of $1.9 million related to our ESPP, which is included in the table above. The fair value of the option component of the ESPP shares was estimated at the date of grant using a Black-Scholes option pricing model and assumed an expected volatility of 30% and 29%, a risk-free interest rate of 0.11% and 0.13% and an expected life of 181 days and 184 days, for each of the two respective offering periods. The 2015 charge is included in the employees’ respective cost classification in the table above. For the year ended December 31, 2014, we recorded compensation expense of $2.6 million related to our ESPP, which is included in the table above. The fair value of the option component of the ESPP shares was estimated at the date of grant using a Black-Scholes option pricing model and assumed an expected volatility of 35% and 32%, a risk-free interest rate of 0.09% and 0.06% and an expected life of 181 days and 184 days, for each of the two respective offering periods. The 2014 charge is included in the employees’ respective cost classification in the table above.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Accumulated Other Comprehensive Loss	(17) Accumulated Other Comprehensive Loss Accumulated other comprehensive loss consisted of the following (in thousands): Cumulative Translation Adjustment Pension Liability Adjustment Other(1) Accumulated Other Comprehensive Loss Balance at December 31, 2013 $ (18,649 ) $ (7,017 ) $ (21 ) $ (25,687 ) Period change (166,448 ) 4 21 (166,423 ) Balance at December 31, 2014 (185,097 ) (7,013 ) — (192,110 ) Period change (146,438 ) (1,229 ) — (147,667 ) Balance at December 31, 2015 (331,535 ) (8,242 ) — (339,777 ) Period change (122,287 ) (334 ) — (122,621 ) Balance at December 31, 2016 $ (453,822 ) $ (8,576 ) $ — $ (462,398 ) (1) Other represents unrealized gains (losses) on available-for-sale

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	(18) Income Taxes Income (loss) before provision (benefit) for income taxes consists of the following (in thousands): Continuing operations, excluding equity earnings of unconsolidated entities: 2016 2015 (As Restated) 2014 (As Restated) United States $ (339,940 ) $ (226,051 ) $ (184,936 ) Foreign 187,542 141,509 67,016 $ (152,398 ) $ (84,542 ) $ (117,920 ) Our primary temporary differences that give rise to deferred tax assets and liabilities are net operating losses (NOLs), capital loss carryforwards, tax credit carryforwards, nondeductible reserves and accruals, and differences in basis of the tangible and intangible assets. The income tax effects of these temporary differences, are as follows (in thousands): 2016 2015 (As Restated)(1) Deferred tax assets: NOL and capital loss carryforwards $ 274,796 $ 207,812 Tax credit carryforwards 123,216 107,750 Nondeductible reserves 40,936 45,053 Accrued liabilities 48,423 26,490 Difference between book and tax bases of tangible assets 4,388 1,735 Difference between book and tax bases of intangible assets 17,735 19,678 Deferred revenue 7,190 7,426 All other 9,765 16,477 Gross deferred tax assets 526,449 432,421 Less: Valuation allowance (323,272 ) (248,307 ) Total deferred tax assets 203,177 184,114 Deferred tax liabilities: Difference between book and tax bases of tangible assets 18,104 20,990 Difference between book and tax bases of intangible assets 233,646 277,871 Debt 7,075 2,344 Difference between book and tax bases of investment in subsidiaries 29,625 — Other 13,342 16,534 Total deferred tax liabilities 301,792 317,739 Net deferred tax liabilities $ (98,615 ) $ (133,625 ) (1) In addition to the impact from the Restatement, we have also corrected in this table the reported amounts for deferred tax assets for NOL and capital loss carryforwards and the valuation allowance to correct an error. We have previously reported deferred tax assets for NOL and capital loss carryforwards of $221,728 and a total valuation allowance of $262,223. These amounts were each reduced by $13,916 to correct the error. This adjustment has no impact on the consolidated balance sheet or results of operations for any period presented. During November 2015, the FASB issued Accounting Standards Update No. 2015-17, 2015-17, “Balance Sheet Classification of Deferred Taxes” non-current non-current 2016 2015 (As Restated) Net non-current $ 20,483 $ 13,993 Net non-current (119,098 ) (147,618 ) Net deferred tax liabilities $ (98,615 ) $ (133,625 ) As of December 31, 2016, our gross (tax effected) federal, state and foreign net operating loss carryforwards were approximately $173.9 million ($60.9 million), $1,032.8 million ($70.1 million), and $505.6 million ($81.5 million), respectively. If not utilized, a portion of the federal, state and foreign net operating loss carryforwards will begin to expire in 2020, 2017 and 2017, respectively. Certain foreign net operating loss carryforwards can be carried forward indefinitely. As of December 31, 2016, our gross (tax effected) federal, state and foreign capital loss carryforwards were approximately $223.3 million ($78.2 million), $223.3 million ($11.2 million) and $5.1 million ($1.1 million), respectively. If not utilized, a portion of the federal capital loss carryforwards will begin to expire in 2017. In addition, substantially all of the foreign capital loss carryforwards can be carried forward indefinitely. As of December 31, 2016, we had $6.3 million of U.S. federal research and development credit carryforward and $21.6 million of state research and development credit carryforward, $7.9 million of U.S. federal Alternative Minimum Tax (“AMT”) credit carryforwards, $93.9 million of U.S. foreign tax credit carryforwards and $1.1 million of other foreign tax credit carryforwards. If not utilized, a portion of the U.S. federal research and development credit and U.S. foreign tax credit will begin to expire in 2026 and 2018, respectively. Of the $21.6 million state research and development credit, $6.8 million was generated in California, which can be carried forward indefinitely. The U.S. federal AMT credit can also be carried forward indefinitely. All U.S. federal loss carryforwards and credits are subject to the limitations imposed by Section 382 and 383 of the Internal Revenue Code, and may be limited in the event of certain cumulative changes in ownership interests of significant shareholders over a three-year period in excess of 50%. Sections 382 and 383 impose an annual limitation on the use of these loss carryforwards or credits to an amount equal to the value of the company at the time of certain ownership changes multiplied by the long-term tax exempt rate. Additionally, certain state and foreign losses and credits may be subject to similar limitations based on local provisions. These loss and tax credit carryforwards may be available to reduce future U.S. federal, state and foreign taxable income and taxes, if any, and are subject to review and possible adjustment by the appropriate tax authorities when utilized. The accounting guidance for income taxes provides that the future realization of deferred tax assets depends on the existence of sufficient taxable income in future periods. Possible sources of taxable income include taxable income in carryback periods, the future reversal of existing taxable temporary differences recorded as a deferred tax liability, tax-planning The estimated amount of undistributed earnings of our foreign subsidiaries is $550.5 million at December 31, 2016. Aside from the $2.8 million of foreign withholding taxes that we previously provided on certain undistributed earnings, no amounts for U.S. income tax have been provided on undistributed earnings of our foreign subsidiaries because we consider such earnings to be indefinitely reinvested. In the event of distribution of those earnings we would be subject to both U.S. income and foreign withholding taxes, which potentially would be offset by U.S. foreign tax credits. Determination of the amount of tax liability that would be incurred is not practicable because of the complexities associated with this hypothetical calculation. The following table presents the components of our provision (benefit) for income taxes (in thousands) for continuing operations: 2016 2015 (As Restated) 2014 (As Restated) Current: Federal $ 5,168 $ (12,027 ) $ 3,949 State 1,606 2,331 487 Foreign 64,612 55,519 54,340 71,386 45,823 58,776 Deferred: Federal (49,569 ) (71,748 ) 25,629 State 8,059 (8,572 ) (4,142 ) Foreign 5,500 (19,067 ) (9,233 ) (36,010 ) (99,387 ) 12,254 Total provision (benefit) for income taxes $ 35,376 $ (53,564 ) $ 71,030 In addition to the impact from the restatement, we also reclassified $1.5 million of provision and $2.9 million of provision in 2015 and 2014, respectively, from the current federal provision to the current foreign provision to correct an error in classification. The following table presents a reconciliation from the U.S. statutory tax rate to our effective tax rate, for continuing operations, excluding equity earnings of unconsolidated subsidiaries: 2016 2015 (As Restated) 2014 (As Restated) Statutory rate 35 % 35 % 35 % Stock-based compensation (3 ) (1 ) (1 ) Rate differential on foreign earnings 18 18 4 Impact of foreign inclusion — — (2 ) U.S. federal research and development credit 2 2 1 State income taxes, net of federal benefit (3 ) 6 3 Contingent consideration 3 25 (3 ) Rate changes 1 1 (3 ) Return to provision (2 ) 4 19 Other permanent items (2 ) (1 ) 3 Change in valuation allowance (40 ) (8 ) (73 ) Foreign dividends, net (11 ) (12 ) (19 ) Uncertain tax positions (5 ) (5 ) (19 ) Withholding taxes — (2 ) (6 ) Sale of business (3 ) — — Non-deductible (4 ) — — Gain on sale of equity investments (9 ) — — Effective tax rate (23 )% 62 % (61 )% The provision for income taxes increased by $89.0 million to a $35.4 million expense in 2016, from a $53.6 million benefit in 2015. The effective tax rate in 2016 was (23%) compared to a tax rate of 62% in 2015. The increase in the provision for income taxes from 2015 to 2016 is primarily related to changes in our jurisdictional mix of income (loss), the increase in our valuation allowance particularly related to our U.S. federal and state net deferred tax assets and the tax impact of contingent consideration income. The primary components of the 2016 provision for income taxes related to foreign income taxes, the increase in our valuation allowance relating to U.S. net deferred tax assets, and the increase in reserves for uncertain tax positions partially offset by U.S. federal and state income tax benefits. The primary components of the 2015 benefit for income taxes related to U.S. federal and state income tax benefits from operating losses, the tax impact of contingent consideration income not recognized for tax purposes and certain return-to-provision The impact on the rate in 2014 through 2016 relating to contingent consideration is due to fair value accounting used for contingent consideration on stock acquisitions with no corresponding inside tax basis for tax purposes. Change in valuation allowances primarily relates to the establishment of a valuation allowance against our U.S. federal and state net deferred tax assets, as well as foreign attribute carryforwards where it is not more likely than not that these tax attributes will be realized. In December 2015, Congress signed into law the Protecting Americans from Tax Hikes Act which retroactively extended the U.S. federal research and development credit from January 1, 2015 through December 31, 2015 and permanently extended the credit going forward. As a result, we recognized the retroactive benefit of the 2015 U.S. federal research and development credit of approximately $2.1 million as a discrete item in the fourth quarter of 2015, the period in which the legislation was enacted. During the year ended December 31, 2016, we increased the gross unrecognized tax benefits for uncertain tax positions excluding interest and penalties by $10.6 million to a total of $131.4 million. The primary reason for the increase relates to the potential taxability of certain income in certain foreign jurisdictions. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for uncertain tax positions excluding interest and penalties is as follows (in thousands): Amount Balance as of January 1, 2014 $ 30,394 Additions for tax positions related to prior years 20,797 Additions for tax positions related to current year 3,217 Reductions for tax positions related to prior years (4,477 ) Balance as of December 31, 2014 49,931 Additions for tax positions related to prior years 823 Additions for tax positions related to current year 71,505 Reductions for tax positions related to prior years (1,552 ) Balance as of December 31, 2015 $ 120,707 Additions for tax positions related to prior years 3,296 Additions for tax positions related to current year 11,062 Reductions for tax positions related to prior years (3,711 ) Balance as of December 31, 2016 $ 131,354 Included in the balance of unrecognized tax benefits as of December 31, 2016 is $73.8 million of tax benefits that, if recognized, would affect the effective tax rate. We believe that it is reasonably possible that approximately $9.7 million of net unrecognized tax benefits (excluding interest and penalties) may be recognized by December 31, 2017 as a result of the expiration of the relevant statutes of limitations. Interest and penalties related to income tax liabilities are included in income tax expense. The total net amount of interest and penalties recorded in 2016, 2015 and 2014 was $2.9 million, $1.4 million and $1.1 million, respectively. The total net amount of accrued interest and penalties recorded on the consolidated balance sheet at December 31, 2016, 2015 and 2014 was $6.6 million, $3.7 million and $2.3 million, respectively. The U.S. federal statute of limitations remains open for tax years 2013 through present. The U.S. state statute of limitations varies by state and generally remains open for tax years 2011 through present. The foreign statute of limitations varies between 2010 through present. Also, U.S. federal, state and foreign attribute carryforwards from prior years may still be adjusted upon examination by tax authorities if they are used in an open year. We are currently under income tax examination by the IRS and a number of state and foreign tax authorities. We cannot currently estimate the impact of these audits due to the uncertainties associated with the tax examinations. Management does not expect material changes in tax positions as a result of these ongoing audits.

Financial Information by Segmen

Financial Information by Segment	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Financial Information by Segment	(19) Financial Information by Segment Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our operating segments are currently (i) professional diagnostics; (ii) consumer diagnostics; and (iii) other non-reportable. Our corporate and other segment consists primarily of corporate expenses and assets that are not used in assessing operating segment performance and are necessary to reconcile the operating segments’ performance to the consolidated results. In January 2015, we sold our health management business. As a result of the sale of our health management business, which was the largest component of our former patient self-testing reporting segment, as well as certain other transactions in 2015, the only component of the patient self-testing reporting segment that was retained by Alere was the Alere Home Monitoring business. Therefore, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, we reported our financial information in two operating segments: (i) professional diagnostics and (ii) consumer diagnostics, and Alere Home Monitoring was reported as a component of the professional diagnostics segment. Due to the nature of the operations of Alere Home Monitoring and the manner in which this business is conducted, in this Annual Report on Form 10-K, we will now report our Alere Home Monitoring business as a separate operating segment under the heading “other non-reportable segment.” Alere Home Monitoring distributes PT/INR coagulation monitors and facilitates the distribution of equipment and supplies to power and control customers’ implanted ventricular assist devices, or VADs, as well as telemonitoring services that allows VAD coordinators to monitor patients soon after discharge and receive alerts when critical patient values fall outside pre-established ranges. The information provided in this Annual Report on Form 10-K 2016 Professional Diagnostics Consumer Diagnostics Other Non- Reportable Corporate and Other Total Net revenue $ 2,159,680 $ 74,152 $ 142,503 $ — $ 2,376,335 Operating income (loss) $ 302,759 $ 475 $ 25,250 $ (313,760 ) $ 14,724 Depreciation and amortization $ 253,853 $ 5,266 $ 17,651 $ 8,838 $ 285,608 Restructuring charge $ 15,890 $ — $ — $ 21,995 $ 37,885 Stock-based compensation $ — $ — $ — $ 41,796 $ 41,796 Assets $ 5,199,806 $ 175,362 $ 87,193 $ 185,918 $ 5,648,279 Expenditures for property, plant and equipment $ 58,151 $ 1,508 $ 4,169 $ 3,866 $ 67,694 2015 Professional Diagnostics Consumer Diagnostics Other Non- Reportable Corporate and Other Total Net revenue, as restated $ 2,241,391 $ 85,128 $ 129,096 $ — $ 2,455,615 Operating income (loss) , as restated $ 330,664 $ 2,872 $ 13,000 $ (216,824 ) $ 129,712 Depreciation and amortization $ 282,411 $ 2,836 $ 16,912 $ 7,105 $ 309,264 Restructuring charge $ 14,305 $ — $ — $ 1,362 $ 15,667 Stock-based compensation $ — $ — $ — $ 26,391 $ 26,391 Assets $ 5,515,576 $ 172,551 $ 99,364 $ 130,669 $ 5,918,160 Expenditures for property, plant and equipment $ 73,490 $ 1,403 $ 3,175 $ 12,710 $ 90,778 2014 Professional Diagnostics Consumer Diagnostics Other Non- Reportable Segment Corporate and Other Total Net revenue, as restated $ 2,369,885 $ 89,087 $ 118,029 $ — $ 2,577,001 Operating income (loss) , as restated $ 160,805 $ 11,921 $ 12,233 $ (90,281 ) $ 94,678 Depreciation and amortization $ 318,051 $ 692 $ 13,831 $ 3,455 $ 336,029 Restructuring charge $ 44,503 $ — $ — $ 14,235 $ 58,738 Stock-based compensation $ — $ — $ — $ 12,452 $ 12,452 Expenditures for property, plant and equipment $ 76,111 $ 3,360 $ 3,023 $ 18,068 $ 100,562 The following tables summarize our net revenue from the professional diagnostics reporting segment by groups of similar products and services for 2016, 2015 and 2014 (in thousands): 2016 2015 (As Restated) 2014 (As Restated) Cardiometabolic $ 622,468 $ 703,553 $ 725,423 Infectious disease 776,153 710,178 723,715 Toxicology 608,635 618,362 644,621 Other 140,426 192,321 255,076 Professional diagnostics net product sales and services revenue 2,147,682 2,224,414 2,348,835 License and royalty revenue 11,998 16,977 21,050 Professional diagnostics net revenue $ 2,159,680 $ 2,241,391 $ 2,369,885 The following tables summarize our net revenue for all segments by geographic area for 2016, 2015 and 2014, respectively, and our long-lived tangible assets by geographic area as of December 31, 2016 and 2015, respectively (in thousands): 2016 2015 (As 2014 (As Revenue by Geographic Area: United States $ 1,294,013 $ 1,372,039 $ 1,366,739 Europe 401,692 437,653 533,116 Elsewhere(1) 680,630 645,923 677,146 $ 2,376,335 $ 2,455,615 $ 2,577,001 (1) Includes, among many others, the following countries: China, India, Japan, South Korea, Brazil, Canada, Uganda and Nigeria. December 31, 2016 2015 Long-lived Tangible Assets by Geographic Area: United States $ 267,519 $ 261,385 United Kingdom 21,342 26,512 China 30,161 28,705 Elsewhere(1) 122,168 129,437 $ 441,190 $ 446,039 (1) Includes, among many others, the following countries: South Korea, Germany, Norway, Canada and Brazil.

Other Arrangements

Other Arrangements	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Arrangements	(20) Other Arrangements In September 2014, we entered into a contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, to develop diagnostic countermeasures for pandemic influenza. Under the terms of the contract, BARDA will provide up to $12.9 million to us to support the development of a rapid, molecular, low-cost PCR-like In February 2013, we entered into an agreement with the Bill & Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of validated, low-cost, low-resource In addition to the February 2013 grant discussed above, we have also been awarded several smaller grants by the Gates Foundation in the aggregate amount of approximately $3.5 million to support the elimination of malaria. We incurred qualifying expenses totaling approximately $1.3 million and $0.5 million for the twelve months ended December 31, 2016 and 2015, respectively. In December 2016 we received $0.8 million of funding associated with these grants. As of December 31, 2016, $1.3 million under these grants is recorded as restricted cash and $1.2 million is recorded as deferred grant funding on our consolidated balance sheet.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	(21) Related Party Transactions (a) Divestiture of ACS Companies On October 10, 2014, we completed the sale of ACS to ACS Acquisition, LLC (the “Purchaser”), pursuant to the terms of a Membership Interest Purchase Agreement with the Purchaser and Sumit Nagpal. In connection with the sale of ACS, in June 2015 we also sold our subsidiary Wellogic ME FZ — LLC (“Wellogic,” together with ACS, the “ACS Companies”) to the Purchaser. See Note 4. Mr. Nagpal was a director of Wellogic and served as the chief executive officer and a director of ACS until his resignation on September 2, 2014. Mr. Nagpal was also the owner of Method Factory, Inc., the company that sold the business and assets of ACS to Alere in 2011 and that sold Wellogic to us in 2012. (b) SPD Joint Venture In May 2007, we completed the formation of SPD Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with Procter & Gamble, or P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed We had a net payable to SPD of $3.7 million as of December 31, 2016 and $1.2 million as of December 31, 2015. The $3.7 million net payable balance as of December 31, 2016 is net of a receivable of approximately $1.2 million for costs incurred in connection with our 2008 SPD-related SPD-related SPD-related Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, a portion of the tests are sold to P&G for distribution to third-party customers in North America. We defer our profit on products sold to SPD until the products are sold through to the customer. As a result of these related transactions, we have recorded $7.9 million and $9.9 million of trade receivables which are included in accounts receivable on our consolidated balance sheets as of December 31, 2016 and 2015, respectively, and $34.2 million and $23.6 million of trade accounts payable which are included in accounts payable on our consolidated balance sheets as of December 31, 2016 and 2015, respectively. During 2016 and 2015, we received $13.6 million and $23.4 million, respectively, in cash from SPD as a distribution of earnings, which are included in cash flows from investing activities in our consolidated statements of cash flows. The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption As of December 31, 2016 2015 Accounts receivable, net of allowances $ 7,855 $ 9,873 Prepaid expenses and other current assets $ 7,486 $ 6,602 Other non-current $ 6,122 $ 8,895 Accounts payable $ 34,216 $ 24,887 As previously disclosed, SPD is currently involved in civil litigation brought by a competitor in the United States with respect to the advertising of one of SPD’s products in the United States. The district court issued an injunction with respect to sales and advertising of such product and determined that SPD violated certain laws with respect to the advertising of such product. SPD’s appeal of this decision was unsuccessful. The competitor’s request for damages is now pending before the district court with a trial date set for June 2017 at the earliest. In addition, a class action lawsuit was filed against SPD and P&G in the United States District Court for the Central District of California alleging violations of certain laws in connection with the sales and advertising of one of SPD’s products, which claims are based on similar grounds as those described above. On August 19, 2016, the class action lawsuit was dismissed with prejudice. The plaintiffs appealed the district court’s decision but, in March 2017, they voluntarily dismissed this class action suit. There may be additional lawsuits against SPD or us relating to this matter in the future. The ultimate resolution of these matters, including the amount of any damages that may be required to be paid, is not known at this time, nor is the potential impact that any pending litigation or future litigation may have on SPD or us, including whether any such resolution or any damages imposed by a court would have a material adverse impact on SPD and, ultimately, by virtue of our 50% interest in SPD, on our financial position or results of operations. (c) Entrustment Loan Arrangement with SPD Shanghai Our subsidiary Alere (Shanghai) Diagnostics Co., Ltd., or Alere Shanghai, and SPD’s subsidiary SPD Trading (Shanghai) Co., Ltd., or SPD Shanghai, entered into an entrustment loan arrangement for a maximum of CNY 23.0 million (approximately $3.3 million at December 31, 2016), in order to finance the latter’s short-term working capital needs, with the Royal Bank of Scotland (China) Co., Ltd. Shanghai Branch, or RBS. The agreement governs the setting up of an Entrustment Loan Account with RBS, into which Alere Shanghai deposits certain monies. This restricted cash account provides a guarantee to RBS of amounts borrowed from RBS by SPD Shanghai. The Alere Shanghai RBS account is recorded as restricted cash on our balance sheet and amounted to $3.3 million at December 31, 2016. (d) TechLab On September 16, 2016, we sold our 49% interest in TechLab Inc., a company that provides diagnostic testing products used by physicians and other health care customers to diagnose, treat, and monitor intestinal diseases and other medical conditions. Prior to this sale, we accounted for this interest in TechLab as an equity method investment. Alere served as a distributor of TechLab products prior to the September 16, 2016 sale and will remain the principal global distributor of TechLab products pursuant to the terms of a distribution agreement with TechLab. We had trade payables owed to Techlab of $1.4 million and $3.2 million as of December 31, 2016 and 2015, respectively. We made product purchases from Techlab of $29.9 million, $27.1 million and $24.8 million during the years ended December 31, 2016, 2015 and 2014, respectively. As a result of the September 16, 2016 sale of our interest in TechLab, we recorded a gain in equity earnings of unconsolidated entities of $29.9 million, with the associated tax effect of $11.2 million recorded in the provision for income taxes.

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2016
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	(22) Valuation and Qualifying Accounts We have established reserves against accounts receivable for doubtful accounts, product returns, discounts and other allowances. The activity in the table below includes all accounts receivable reserves. Provisions for doubtful accounts are recorded as a component of general and administrative expenses. Provisions for returns, discounts and other allowances are charged against net product sales. The following table sets forth activities in our accounts receivable reserve accounts (in thousands): Balance at Beginning of Period Provision Amounts Charged Against Reserves Balance at End of Period Year ended December 31, 2014 $ 69,146 $ 42,477 $ (35,460 ) $ 76,163 Year ended December 31, 2015 $ 76,163 $ 45,279 $ (31,741 ) $ 89,701 Year ended December 31, 2016 $ 89,701 $ 48,748 $ (62,651 ) $ 75,798 We have established reserves against obsolete and slow-moving inventories. The activity in the table below includes all inventory reserves. Provisions for obsolete and slow-moving inventories are recorded as a component of cost of net product sales. The following table sets forth activities in our inventory reserve accounts (in thousands): Balance at Provision Amounts Balance at Year ended December 31, 2014 $ 21,437 $ 12,818 $ (6,907 ) $ 27,348 Year ended December 31, 2015 $ 27,348 $ 21,592 $ (11,165 ) $ 37,775 Year ended December 31, 2016 $ 37,775 $ 10,640 $ (19,977 ) $ 28,438 We have established a valuation allowance against our deferred tax assets based on the weight of available positive and negative evidence, including our estimates of future income by the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable. The following table sets forth activities in our deferred tax accounts (in thousands): Balance at Additions Amounts Balance at Year ended December 31, 2014 $ 84,315 $ 143,454 $ 864 $ 228,633 Year ended December 31, 2015, As Restated $ 228,633 $ 19,674 $ — $ 248,307 Year ended December 31, 2016 $ 248,307 $ 74,965 $ — $ 323,272

Restructuring Activities

Restructuring Activities	12 Months Ended
	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Restructuring Activities	(23) Restructuring Activities The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the years ended December 31, 2016, 2015 and 2014 (in thousands): Statement of Operations Caption 2016 2015 2014 Cost of net revenue $ 5,991 $ 3,816 $ 11,760 Research and development 4,052 2,752 9,800 Sales and marketing 1,798 3,004 11,350 General and administrative 26,033 6,071 25,786 Total operating expenses 37,874 15,643 58,696 Interest expense, including amortization of original issue discounts and deferred financing costs 11 24 42 Total charges $ 37,885 $ 15,667 $ 58,738 (a) 2016 Restructuring Plans During 2016, management developed world-wide cost reduction plans to reduce costs and improve operational efficiencies within our professional diagnostics and corporate and other business segments, primarily impacting our manufacturing and supply chain, and research and development groups, as well as closing certain business locations in Europe and the United States. The following table summarizes the restructuring activities related to the 2016 restructuring plans for the year ended December 31, 2016 (in thousands): Professional Diagnostics 2016 Severance-related costs $ 6,217 Facility and transition costs 3,010 Cash charges 9,227 Fixed asset and inventory impairments 443 Total charges $ 9,670 Corporate and Other 2016 Severance-related costs $ 346 Facility and transition costs 21,649 Total cash charges $ 21,995 We anticipate incurring approximately $1.7 million in additional costs under our 2016 restructuring plans related to our professional diagnostics business segment. We anticipate incurring $2.7 million in additional costs under our existing 2016 restructuring plans relating to our corporate and other business segment. As of December 31, 2016, $7.6 million in severance and transition costs arising under our 2016 restructuring plans remain unpaid. (b) Restructuring Plans Prior to 2016 In 2014, management developed world-wide cost reduction plans to reduce costs and improve operational efficiencies within our professional diagnostics and corporate and other business segments, primarily impacting our global sales and marketing, information technology, and research and development groups, as well as closing certain business locations in Europe and Asia. In 2013, management developed cost reduction plans impacting businesses in the United States, Europe and Asia Pacific regions. In 2011, management developed plans to consolidate operating activities among certain of our United States, European and Asia Pacific subsidiaries, including transferring the manufacturing of our Panbio products from Australia to our Standard Diagnostics facility in South Korea and eliminating redundant costs among our Axis-Shield subsidiaries. Additionally, in 2008, management developed and initiated plans to transition the Cholestech business to our San Diego, California facility. All of the plans from 2008 to 2013 impacted our professional diagnostics business segment. The following table summarizes the restructuring activities related to our active restructuring plans prior to 2016 for the years ended December 31, 2016, 2015 and 2014 and since inception of these restructuring plans (in thousands): Professional Diagnostics 2016 2015 2014 Since Severance-related costs $ 3,219 $ 7,143 $ 29,071 $ 65,094 Facility and transition costs 1,257 4,542 4,399 19,738 Other exit costs 11 24 42 833 Cash charges 4,487 11,709 33,512 85,665 Fixed asset and inventory impairments 1,555 678 10,991 19,961 Intangible asset impairments — — — 686 Other non-cash 178 1,918 — 2,160 Total charges $ 6,220 $ 14,305 $ 44,503 $ 108,472 Corporate and Other 2016 2015 2014 Since Severance-related costs $ — $ 1,376 $ 2,901 $ 4,277 Facility and transition costs — (14 ) 11,334 11,322 Cash charges $ — $ 1,362 $ 14,235 $ 15,599 We anticipate incurring approximately $2.1 million in additional costs under these plans related to our professional diagnostics business segment, primarily related to the closure of our manufacturing facility in Israel. As of December 31, 2016, $3.3 million in cash charges remain unpaid, primarily related to severance costs and facility lease obligations. (c) Restructuring Reserves The following table summarizes our restructuring reserves related to the plans described above, of which $10.6 million is included in accrued expenses and other current liabilities and $0.3 million is included in other long-term liabilities on our consolidated balance sheets (in thousands): Severance- related Costs Facility and Transition Costs Other Exit Costs Total Balance, December 31, 2013 992 1,781 367 3,140 Cash charges 31,972 15,733 42 47,747 Payments (27,394 ) (7,345 ) (119 ) (34,858 ) Currency adjustments (980 ) (301 ) — (1,281 ) Balance, December 31, 2014 4,590 9,868 290 14,748 Cash charges 8,519 4,528 24 13,071 Payments (11,145 ) (12,222 ) (134 ) (23,501 ) Currency adjustments (331 ) (208 ) — (539 ) Balance, December 31, 2015 $ 1,633 $ 1,966 $ 180 $ 3,779 Cash charges 9,782 25,916 11 35,709 Payments (7,890 ) (20,331 ) (152 ) (28,373 ) Currency adjustments (186 ) (39 ) — (225 ) Balance, December 31, 2016 $ 3,339 $ 7,512 $ 39 $ 10,890

Equity Investments

Equity Investments	12 Months Ended
	Dec. 31, 2016
Equity Method Investments and Joint Ventures [Abstract]
Equity Investments	(24) Equity Investments We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, Investments — Equity Method and Joint Ventures, (a) SPD We recorded earnings of $19.0 million, $14.3 million and $16.2 million for the years ended December 31, 2016, 2015 and 2014, respectively, in equity earnings of unconsolidated entities, net of tax, in our consolidated statements of operations, which represented our 50% share of SPD’s net income for the respective periods and elimination of intercompany profit in inventory related to sales from Alere to SPD which is reflected in SPD’s net income. We received dividends of $13.6 million during 2016. (b) TechLab We recorded earnings of $1.8 million, $1.5 million and $1.6 million for the years ended December 31, 2016, 2015 and 2014, respectively, in equity earnings of unconsolidated entities, net of tax, in our consolidated statements of operations, which represented our minority share of TechLab’s net income for the respective periods. On September 16, 2016, we completed the sale of our 49% interest in the TechLab business and, in connection with such sale, we recorded a gain in equity earnings of unconsolidated entities of $29.9 million. Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Combined Condensed Results of Operations For The Years Ended December 31, 2016 2015 2014 Net revenue $ 209,239 $ 202,611 $ 211,370 Gross profit $ 151,912 $ 147,386 $ 160,192 Net income after taxes $ 41,616 $ 32,457 $ 35,646 Combined Condensed Balance Sheets As of December 31, 2016 2015 Current assets $ 75,248 $ 71,542 Non-current 20,578 30,802 Total assets $ 95,826 $ 102,344 Current liabilities $ 44,234 $ 37,609 Non-current 3,875 5,157 Total liabilities $ 48,109 $ 42,766 The dividends we received in cash as a return from capital from our equity investments have been included in cash flows from investing activities in our consolidated statements of cash flows for all the periods presented.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	(27) Supplemental Cash Flow Information Cash Paid for Interest and Income Taxes: During 2016, 2015 and 2014, we made cash payments for interest totaling $157.7 million, $167.6 million and $192.1 million, respectively. During 2016, 2015 and 2014, total net cash paid for income taxes was $70.9 million, $55.2 million and $58.8 million, respectively.

Restated Quarterly Financial In

Restated Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Restated Quarterly Financial Information (Unaudited)	(28) Restated Quarterly Financial Information (Unaudited) The information set forth below for the first three quarters and year-to-date periods in fiscal year 2016 and for all quarters and year-to-date periods in fiscal year 2015 has been restated to correct the misstatements described in Note 2. In addition, we have also made adjustments related to (a) misstatements in the classification of certain amounts between current assets, noncurrent assets and current liabilities, (b) misstatements in the classification of certain legal-related charges between non-operating expenses and operating expenses, and (c) misstatements to general and administrative expenses to correct the timing of bad debt expenses and fair value adjustments related to contingent consideration liabilities from acquisitions. The operating results for any given quarter are not necessarily indicative of results for any future periods. Amounts are computed independently each quarter, therefore, the sum of the quarterly amounts may not equal the total amount for the respective year due to rounding. The following tables reconcile the amounts as previously reported in the applicable financial statement to the corresponding restated amounts. All financial statements are unaudited. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended September 30, 2016 As Previously Restatement As Restated Net product sales $ 456,096 $ (72 ) $ 456,024 Services revenue 123,778 — 123,778 Net product sales and services revenue 579,874 (72 ) 579,802 License and royalty revenue 2,480 — 2,480 Net revenue 582,354 (72 ) 582,282 Cost of net product sales 238,946 113 239,059 Cost of services revenue 76,639 — 76,639 Cost of net product sales and services revenue 315,585 113 315,698 Cost of license and royalty revenue 641 — 641 Cost of net revenue 316,226 113 316,339 Gross profit 266,128 (185 ) 265,943 Operating expenses: — Research and development 31,430 — 31,430 Sales and marketing 101,979 (13 ) 101,966 General and administrative 129,287 19,253 148,540 Impairment and (gain) loss on dispositions, net — — — Operating income 3,432 (19,425 ) (15,993 ) Interest expense, including amortization of original issue discounts and deferred financing costs (44,130 ) — (44,130 ) Other income (expense), net (14,312 ) 13,153 (1,159 ) Loss from continuing operations before provision (benefit) for income taxes (55,010 ) (6,272 ) (61,282 ) Provision (benefit) for income taxes (50,888 ) 92 (50,796 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (4,122 ) (6,364 ) (10,486 ) Equity earnings of unconsolidated entities, net of tax 26,149 — 26,149 Income (loss) from continuing operations 22,027 (6,364 ) 15,663 Income (loss) from discontinued operations, net of tax — — — Net income (loss) 22,027 (6,364 ) 15,663 Less: Net income attributable to non-controlling 207 — 207 Net income (loss) attributable to Alere Inc. and Subsidiaries 21,820 (6,364 ) 15,456 Preferred stock dividends (5,366 ) — (5,366 ) Net income (loss) available to common stockholders $ 16,454 $ (6,364 ) $ 10,090 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ 0.19 $ (0.07 ) $ 0.12 Income (loss) from discontinued operations — — — Net income (loss) per common share $ 0.19 $ (0.07 ) $ 0.12 Weighted-average shares—basic 86,753 — 86,753 Weighted-average shares—diluted 87,885 — 87,885 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 30,768 $ (6,364 ) $ 24,404 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $1,700 adjustment to increase bad debt expense, (b) a $4,400 adjustment of additional expense related to a correction in the measurement of an acquisition-related contingent consideration obligation and (c) a $13,153 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Nine Months Ended September 30, 2016 As Previously Restatement As Net product sales $ 1,399,613 $ 7,875 $ 1,407,488 Services revenue 364,296 — 364,296 Net product sales and services revenue 1,763,909 7,875 1,771,784 License and royalty revenue 7,742 — 7,742 Net revenue 1,771,651 7,875 1,779,526 Cost of net product sales 726,805 3,415 730,220 Cost of services revenue 228,033 — 228,033 Cost of net product sales and services revenue 954,838 3,415 958,253 Cost of license and royalty revenue 2,567 — 2,567 Cost of net revenue 957,405 3,415 960,820 Gross profit 814,246 4,460 818,706 Operating expenses: — — — Research and development 86,938 — 86,938 Sales and marketing 304,308 742 305,050 General and administrative 372,597 27,753 400,350 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 54,213 (24,035 ) 30,178 Interest expense, including amortization of original issue discounts and deferred financing costs (128,565 ) — (128,565 ) Other income (expense), net (29,773 ) 23,353 (6,420 ) Loss from continuing operations before provision (benefit) for income taxes (104,125 ) (682 ) (104,807 ) Provision (benefit) for income taxes (47,979 ) (407 ) (48,386 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (56,146 ) (275 ) (56,421 ) Equity earnings of unconsolidated entities, net of tax 33,305 — 33,305 Income (loss) from continuing operations (22,841 ) (275 ) (23,116 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (22,841 ) (275 ) (23,116 ) Less: Net income attributable to non-controlling 453 — 453 Net income (loss) attributable to Alere Inc. and Subsidiaries (23,294 ) (275 ) (23,569 ) Preferred stock dividends (15,983 ) — (15,983 ) Net income (loss) available to common stockholders $ (39,277 ) $ (275 ) $ (39,552 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.45 ) $ (0.00 ) $ (0.45 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.45 ) $ (0.00 ) $ (0.45 ) Weighted-average shares—basic and diluted 86,708 — 86,708 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (35,602 ) $ (275 ) $ (35,877 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $4,400 adjustment of additional expense related to the correction in the measurement of an acquisition-related contingent consideration obligation and (b) a $23,353 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, 2016 As Previously Restatement As Restated Net product sales $ 483,746 $ (784 ) $ 482,962 Services revenue 124,809 — 124,809 Net product sales and services revenue 608,555 (784 ) 607,771 License and royalty revenue 2,533 — 2,533 Net revenue 611,088 (784 ) 610,304 Cost of net product sales 250,398 (561 ) 249,837 Cost of services revenue 78,294 — 78,294 Cost of net product sales and services revenue 328,692 (561 ) 328,131 Cost of license and royalty revenue 535 — 535 Cost of net revenue 329,227 (561 ) 328,666 Gross profit 281,861 (223 ) 281,638 Operating expenses: — Research and development 28,446 — 28,446 Sales and marketing 102,516 (72 ) 102,444 General and administrative 128,354 8,500 136,854 Impairment and (gain) loss on dispositions, net — — — Operating income 22,545 (8,651 ) 13,894 Interest expense, including amortization of original issue discounts and deferred financing costs (42,329 ) — (42,329 ) Other income (expense), net (14,112 ) 10,200 (3,912 ) Loss from continuing operations before provision (benefit) for income taxes (33,896 ) 1,549 (32,347 ) Provision (benefit) for income taxes 3,117 (535 ) 2,582 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (37,013 ) 2,084 (34,929 ) Equity earnings of unconsolidated entities, net of tax 2,122 — 2,122 Income (loss) from continuing operations (34,891 ) 2,084 (32,807 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (34,891 ) 2,084 (32,807 ) Less: Net income attributable to non-controlling 143 — 143 Net income (loss) attributable to Alere Inc. and Subsidiaries (35,034 ) 2,084 (32,950 ) Preferred stock dividends (5,308 ) — (5,308 ) Net income (loss) available to common stockholders $ (40,342 ) $ 2,084 $ (38,258 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.46 ) $ 0.02 $ (0.44 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.46 ) $ 0.02 $ (0.44 ) Weighted-average shares—basic and diluted 86,737 — 86,737 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (78,638 ) $ 2,084 $ (76,554 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $1,700 adjustment to decrease bad debt expense and (b) a $10,200 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Six Months Ended June 30, 2016 As Previously Reported Restatement As Restated Net product sales $ 943,517 $ 7,947 $ 951,464 Services revenue 240,518 — 240,518 Net product sales and services revenue 1,184,035 7,947 1,191,982 License and royalty revenue 5,262 — 5,262 Net revenue 1,189,297 7,947 1,197,244 Cost of net product sales 487,859 3,302 491,161 Cost of services revenue 151,394 — 151,394 Cost of net product sales and services revenue 639,253 3,302 642,555 Cost of license and royalty revenue 1,926 — 1,926 Cost of net revenue 641,179 3,302 644,481 Gross profit 548,118 4,645 552,763 Operating expenses: — — — Research and development 55,508 — 55,508 Sales and marketing 202,329 755 203,084 General and administrative 243,310 8,500 251,810 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 50,781 (4,610 ) 46,171 Interest expense, including amortization of original issue discounts and deferred financing costs (84,435 ) — (84,435 ) Other income (expense), net (15,461 ) 10,200 (5,261 ) Loss from continuing operations before provision (benefit) for income taxes (49,115 ) 5,590 (43,525 ) Provision (benefit) for income taxes 2,909 (499 ) 2,410 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (52,024 ) 6,089 (45,935 ) Equity earnings of unconsolidated entities, net of tax 7,156 — 7,156 Income (loss) from continuing operations (44,868 ) 6,089 (38,779 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (44,868 ) 6,089 (38,779 ) Less: Net income attributable to non-controlling 246 — 246 Net income (loss) attributable to Alere Inc. and Subsidiaries (45,114 ) 6,089 (39,025 ) Preferred stock dividends (10,617 ) — (10,617 ) Net income (loss) available to common stockholders $ (55,731 ) $ 6,089 $ (49,642 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.64 ) $ 0.07 $ (0.57 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.64 ) $ 0.07 $ (0.57 ) Weighted-average shares—basic and diluted 86,692 — 86,692 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (66,370 ) $ 6,089 $ (60,281 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $1,700 adjustment to decrease bad debt expense and (b) a $10,200 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2016 As Previously Restatement As Restated Net product sales $ 459,771 $ 8,731 $ 468,502 Services revenue 115,709 — 115,709 Net product sales and services revenue 575,480 8,731 584,211 License and royalty revenue 2,729 — 2,729 Net revenue 578,209 8,731 586,940 Cost of net product sales 237,461 3,863 241,324 Cost of services revenue 73,100 — 73,100 Cost of net product sales and services revenue 310,561 3,863 314,424 Cost of license and royalty revenue 1,391 — 1,391 Cost of net revenue 311,952 3,863 315,815 Gross profit 266,257 4,868 271,125 Operating expenses: — Research and development 27,062 — 27,062 Sales and marketing 99,813 827 100,640 General and administrative 114,956 — 114,956 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 28,236 4,041 32,277 Interest expense, including amortization of original issue discounts and deferred financing costs (42,106 ) — (42,106 ) Other income (expense), net (1,349 ) — (1,349 ) Loss from continuing operations before provision (benefit) for income taxes (15,219 ) 4,041 (11,178 ) Provision (benefit) for income taxes (208 ) 36 (172 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (15,011 ) 4,005 (11,006 ) Equity earnings of unconsolidated entities, net of tax 5,034 — 5,034 Income (loss) from continuing operations (9,977 ) 4,005 (5,972 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (9,977 ) 4,005 (5,972 ) Less: Net income attributable to non-controlling 103 — 103 Net income (loss) attributable to Alere Inc. and Subsidiaries (10,080 ) 4,005 (6,075 ) Preferred stock dividends (5,309 ) — (5,309 ) Net income (loss) available to common stockholders $ (15,389 ) $ 4,005 $ (11,384 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.18 ) $ 0.05 $ (0.13 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.18 ) $ 0.05 $ (0.13 ) Weighted-average shares—basic and diluted 86,646 — 86,646 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 12,268 $ 4,005 $ 16,273 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended December 31, 2015 As Previously Restatement As Net product sales $ 506,516 $ (6,149 ) $ 500,367 Services revenue 113,483 — 113,483 Net product sales and services revenue 619,999 (6,149 ) 613,850 License and royalty revenue 3,286 — 3,286 Net revenue 623,285 (6,149 ) 617,136 Cost of net product sales 298,795 (1,670 ) 297,125 Cost of services revenue 72,111 — 72,111 Cost of net product sales and services revenue 370,906 (1,670 ) 369,236 Cost of license and royalty revenue (650 ) — (650 ) Cost of net revenue 370,256 (1,670 ) 368,586 Gross profit 253,029 (4,479 ) 248,550 Operating expenses: Research and development 28,228 — 28,228 Sales and marketing 111,535 (644 ) 110,891 General and administrative 114,400 4,586 118,986 Impairment and (gain) loss on dispositions, net 8,132 — 8,132 Operating income (9,266 ) (8,421 ) (17,687 ) Interest expense, including amortization of original issue discounts and deferred financing costs (58,739 ) — (58,739 ) Other income (expense), net (6,329 ) 4,586 (1,743 ) Loss from continuing operations before provision (benefit) for income taxes (74,334 ) (3,835 ) (78,169 ) Provision (benefit) for income taxes (50,329 ) (817 ) (51,146 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (24,005 ) (3,018 ) (27,023 ) Equity earnings of unconsolidated entities, net of tax 5,210 — 5,210 Income (loss) from continuing operations (18,795 ) (3,018 ) (21,813 ) Income (loss) from discontinued operations, net of tax 2,736 — 2,736 Net income (loss) (16,059 ) (3,018 ) (19,077 ) Less: Net income attributable to non-controlling (5 ) — (5 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (16,054 ) (3,018 ) (19,072 ) Preferred stock dividends (5,367 ) — (5,367 ) Net income (loss) available to common stockholders $ (21,421 ) $ (3,018 ) $ (24,439 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.28 ) $ (0.03 ) $ (0.31 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.28 ) $ (0.03 ) $ (0.31 ) Weighted-average shares—basic and diluted 85,953 — 85,953 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (39,957 ) $ (3,018 ) $ (42,975 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustment to increase general and administrative expenses due to a $4,586 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended September 30, 2015 As Previously Restatement As Restated Net product sales $ 472,128 $ 831 $ 472,959 Services revenue 128,341 — 128,341 Net product sales and services revenue 600,469 831 601,300 License and royalty revenue 3,299 — 3,299 Net revenue 603,768 831 604,599 Cost of net product sales 245,814 (385 ) 245,429 Cost of services revenue 79,851 — 79,851 Cost of net product sales and services revenue 325,665 (385 ) 325,280 Cost of license and royalty revenue 1,137 — 1,137 Cost of net revenue 326,802 (385 ) 326,417 Gross profit 276,966 1,216 278,182 Operating expenses: Research and development 36,011 — 36,011 Sales and marketing 106,493 231 106,724 General and administrative 101,306 — 101,306 Impairment and (gain) loss on dispositions, net 2,074 — 2,074 Operating income 31,082 985 32,067 Interest expense, including amortization of original issue discounts and deferred financing costs (52,333 ) — (52,333 ) Other income (expense), net 3,658 — 3,658 Loss from continuing operations before provision (benefit) for income taxes (17,593 ) 985 (16,608 ) Provision (benefit) for income taxes (10,212 ) 72 (10,140 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (7,381 ) 913 (6,468 ) Equity earnings of unconsolidated entities, net of tax 5,000 — 5,000 Income (loss) from continuing operations (2,381 ) 913 (1,468 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (2,381 ) 913 (1,468 ) Less: Net income attributable to non-controlling (61 ) — (61 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (2,320 ) 913 (1,407 ) Preferred stock dividends (5,369 ) — (5,369 ) Net income (loss) available to common stockholders $ (7,689 ) $ 913 $ (6,776 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.09 ) $ 0.01 $ (0.08 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.09 ) $ 0.01 $ (0.08 ) Weighted-average shares—basic and diluted 85,895 — 85,895 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (90,713 ) $ 913 $ (89,800 ) (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Quarterly Report on Form 10-Q for the period ended September 30, 2015 due most significantly to a $1,724 adjustment to increase revenue, a $1,087 adjustment to decrease other income and an $8,712 adjustment to decrease benefit for income taxes, with an overall impact of a $7,882 adjustment to decrease net income, which were identified during the preparation of the Annual Report on Form 10-K for 2015. (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Nine Months Ended September 30, 2015 As Previously Restatement As Restated Net product sales $ 1,447,515 $ (1,552 ) $ 1,445,963 Services revenue 378,825 — 378,825 Net product sales and services revenue 1,826,340 (1,552 ) 1,824,788 License and royalty revenue 13,691 — 13,691 Net revenue 1,840,031 (1,552 ) 1,838,479 Cost of net product sales 743,808 (1,787 ) 742,021 Cost of services revenue 232,277 — 232,277 Cost of net product sales and services revenue 976,085 (1,787 ) 974,298 Cost of license and royalty revenue 4,431 — 4,431 Cost of net revenue 980,516 (1,787 ) 978,729 Gross profit 859,515 235 859,750 Operating expenses: Research and development 91,225 — 91,225 Sales and marketing 323,596 (48 ) 323,548 General and administrative 255,170 — 255,170 Impairment and (gain) loss on dispositions, net 42,408 — 42,408 Operating income 147,116 283 147,399 Interest expense, including amortization of original issue discounts and deferred financing costs (158,258 ) — (158,258 ) Other income (expense), net 4,486 — 4,486 Loss from continuing operations before provision (benefit) for income taxes (6,656 ) 283 (6,373 ) Provision (benefit) for income taxes (2,376 ) (43 ) (2,419 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (4,280 ) 326 (3,954 ) Equity earnings of unconsolidated entities, net of tax 10,320 — 10,320 Income (loss) from continuing operations 6,040 326 6,366 Income (loss) from discontinued operations, net of tax 216,777 — 216,777 Net income (loss) 222,817 326 223,143 Less: Net income attributable to non-controlling 386 — 386 Net income (loss) attributable to Alere Inc. and Subsidiaries 222,431 326 222,757 Preferred stock dividends (15,927 ) — (15,927 ) Net income (loss) available to common stockholders $ 206,504 $ 326 $ 206,830 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.12 ) $ 0.00 $ (0.12 ) Income (loss) from discontinued operations 2.57 — 2.57 Net income (loss) per common share $ 2.45 $ 0.00 $ 2.45 Weighted-average shares—basic and diluted 85,141 — 85,141 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 98,666 $ 326 $ 98,992 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, Form 10-K (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, 2015 As Previously Restatement As Net product sales $ 491,049 $ 603 $ 491,652 Services revenue 126,628 — 126,628 Net product sales and services revenue 617,677 603 618,280 License and royalty revenue 5,694 — 5,694 Net revenue 623,371 603 623,974 Cost of net product sales 257,893 894 258,787 Cost of services revenue 76,800 — 76,800 Cost of net product sales and services revenue 334,693 894 335,587 Cost of license and royalty revenue 1,344 — 1,344 Cost of net revenue 336,037 894 336,931 Gross profit 287,334 (291 ) 287,043 Operating expenses: Research and development 27,198 — 27,198 Sales and marketing 108,024 (118 ) 107,906 General and administrative 61,173 — 61,173 Impairment and (gain) loss on dispositions, net 5,542 — 5,542 Operating income 85,397 (173 ) 85,224 Interest expense, including amortization of original issue discounts and deferred financing costs (59,494 ) — (59,494 ) Other income (expense), net 3,195 — 3,195 Loss from continuing operations before provision (benefit) for income taxes 29,098 (173 ) 28,925 Provision (benefit) for income taxes 15,689 99 15,788 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax 13,409 (272 ) 13,137 Equity earnings of unconsolidated entities, net of tax 1,361 — 1,361 Income (loss) from continuing operations 14,770 (272 ) 14,498 Income (loss) from discontinued operations, net of tax — — — Net income (loss) 14,770 (272 ) 14,498 Less: Net income attributable to non-controlling 359 — 359 Net income (loss) attributable to Alere Inc. and Subsidiaries 14,411 (272 ) 14,139 Preferred stock dividends (5,308 ) — (5,308 ) Net income (loss) available to common stockholders $ 9,103 $ (272 ) $ 8,831 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ 0.11 $ (0.01 ) $ 0.10 Income (loss) from discontinued operations — — — Net income (loss) per common share $ 0.11 $ (0.01 ) $ 0.10 Weighted-average shares — basic 85,173 — 85,173 Weighted-average shares — diluted 86,635 — 86,635 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 60,763 $ (272 ) $ 60,491 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended June 30, 2016 and, in connection with the presentation in such Form 10-Q, Form 10-K (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Six Months Ended June 30, 2015 As Previously Restatement As Net product sales $ 975,387 $ (2,383 ) $ 973,004 Services revenue 250,484 — 250,484 Net product sales and services revenue 1,225,871 (2,383 ) 1,223,488 License and royalty revenue 10,392 — 10,392 Net revenue 1,236,263 (2,383 ) 1,233,880 Cost of net product sales 497,994 (1,402 ) 496,592 Cost of services revenue 152,426 — 152,426 Cost of net product sales and services revenue 650,420 (1,402 ) 649,018 Cost of license and royalty revenue 3,294 — 3,294 Cost of net revenue 653,714 (1,402 ) 652,312 Gross profit 582,549 (981 ) 581,568 Operating expenses: Research and development 55,214 — 55,214 Sales and marketing 217,103 (279 ) 216,824 General and administrative 153,864 — 153,864 Impairment and (gain) loss on dispositions, net 40,334 — 40,334 Operating income 116,034 (702 ) 115,332 Interest expense, including amortization of original issue discounts and deferred financing costs (105,925 ) — (105,925 ) Other income (expense), net 828 — 828 Loss from continuing operations before provision (benefit) for income taxes 10,937 (702 ) 10,235 Provision (benefit) for income taxes 7,836 (115 ) 7,721 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax 3,101 (587 ) 2,514 Equity earnings of unconsolidated entities, net of tax 5,320 — 5,320 Income (loss) from continuing operations 8,421 (587 ) 7,834 Income (loss) from discontinued operations, net of tax 216,777 — 216,777 Net income (loss) 225,198 (587 ) 224,611 Less: Net income attributable to non-controlling 447 — 447 Net income (loss) attributable to Alere Inc. and Subsidiaries 224,751 (587 ) 224,164 Preferred stock dividends (10,558 ) — (10,558 ) Net income (loss) available to common stockholders $ 214,193 $ (587 ) $ 213,606 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.03 ) $ (0.01 ) $ (0.04 ) Income (loss) from discontinued operations 2.57 — 2.57 Net income (loss) per common share $ 2.54 $ (0.01 ) $ 2.53 Weighted-average shares — basic and diluted 84,758 — 84,758 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 189,379 $ (587 ) $ 188,792 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2015 As Previously Restatement As Net product sales $ 484,338 $ (2,986 ) $ 481,352 Services revenue 123,856 — 123,856 Net product sales and services revenue 608,194 (2,986 ) 605,208 License and royalty revenue 4,698 — 4,698 Net revenue 612,892 (2,986 ) 609,906 Cost of net product sales 240,101 (2,296 ) 237,805 Cost of services revenue 75,626 — 75,626 Cost of net product sales and services revenue 315,727 (2,296 ) 313,431 Cost of license and royalty revenue 1,950 — 1,950 Cost of net revenue 317,677 (2,296 ) 315,381 Gross profit 295,215 (690 ) 294,525 Operating expenses: — Research and development 28,016 — 28,016 Sales and marketing 109,079 (161 ) 108,918 General and administrative 92,691 — 92,691 Impairment and (gain) loss on dispositions, net 34,792 — 34,792 Operating income 30,637 (529 ) 30,108 Interest expense, including amortization of original issue discounts and deferred financing costs (46,431 ) — (46,431 ) Other income (expense), net (2,367 ) — (2,367 ) Loss from continuing operations before provision (benefit) for income taxes (18,161 ) (529 ) (18,690 ) Provision (benefit) for income taxes (7,853 ) (214 ) (8,067 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (10,308 ) (315 ) (10,623 ) Equity earnings of unconsolidated entities, net of tax 3,959 — 3,959 Income (loss) from continuing operations (6,349 ) (315 ) (6,664 ) Income (loss) from discontinued operations, net of tax 216,777 — 216,777 Net income (loss) 210,428 (315 ) 210,113 Less: Net income attributable to non-controlling 88 — 88 Net income (loss) attributable to Alere Inc. and Subsidiaries 210,340 (315 ) 210,025 Preferred stock dividends (5,250 ) — (5,250 ) Net income (loss) available to common stockholders $ 205,090 $ (315 ) $ 204,775 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.14 ) $ (0.00 ) $ (0.14 ) Income (loss) from discontinued operations 2.57 — 2.57 Net income (loss) per common share $ 2.43 $ (0.00 ) $ 2.43 Weighted-average shares—basic and diluted 84,338 — 84,338 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 128,616 $ (315 ) $ 128,301 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended March 31, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Quarterly Report on Form 10-Q for the period ended March 31, 2015 due to a $4,739 adjustment to increase revenue, a $1,509 adjustment to increase cost of revenue, a $1,097 adjustment to increase other expense and a $933 adjustment to decrease benefit for income taxes with an overall impact of a $1,200 adjustment to increase net income, which were identified during the preparation of the Annual Report on Form 10-K for 2015. (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (in thousands, except par value) (unaudited) As of September 30, 2016 As Previously Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 566,213 $ — $ 566,213 Restricted cash 4,999 — 4,999 Marketable securities 75 — 75 Accounts receivable, net of allowance 427,241 (1,034 ) 426,207 Inventories, net 348,845 533 349,378 Prepaid expenses and other current assets 163,833 (39,443 ) 124,390 Total current assets 1,511,206 (39,944 ) 1,471,262 Property, plant and equipment, net 446,313 — 446,313 Goodwill 2,805,682 — 2,805,682 Other intangible assets with indefinite lives 27,991 — 27,991 Finite-lived intangible assets, net 864,785 — 864,785 Restricted cash 42,438 — 42,438 Other non-current 16,219 — 16,219 Investments in unconsolidated ent

Guarantor Financial Information

Guarantor Financial Information	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Guarantor Financial Information	(29) Guarantor Financial Information Our 7.25% senior notes, our 6.5% senior subordinated notes and our 6.375% senior subordinated notes are guaranteed, and before their redemption on October 1, 2015, our 8.625% senior subordinated notes were guaranteed, by certain of our consolidated 100% owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, audited balance sheets as of December 31, 2016 and 2015, the related statements of operations, statements of comprehensive loss and cash flows for each of the three years in the period ended December 31, 2016, respectively, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Non-Guarantor We have extensive transactions and relationships between various members of our consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties. As discussed in Note 5(w), effective January 1, 2016, we adopted ASU 2015-03 2015-15, non-current For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification. Prior periods have been presented on a basis that is consistent with the current period, giving retrospective effect to the impact of discontinued operations. We are restating our consolidated financial statements as of December 31, 2015 and for the years ended December 31, 2015 and 2014 and for each of the quarterly and year-to-date periods in 2015 and the first three quarterly and year-to-date periods in 2016. For more information on the Restatement, see Note 2. The adjustments to the Guarantor consolidating statements of cash flows did not impact previously reported net cash flows from operating activities, investing activities, or financing activities and as a result, there was no net impact to net change in cash and cash equivalents for any previously reported periods. Certain corrections of classifications within the operating cash flow section were impacted by the Restatement. The following schedules reconcile the amounts as previously reported in guarantor financial information, consolidating financial statements to the corresponding restated amounts: Year Ended December 31, 2015 Restated Consolidating Statement of Operations-Issuer (in thousands) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 3,279 $ — $ 3,279 Sales and marketing $ 5,901 $ — $ 5,901 General and administrative $ 119,520 $ 4,500 $ 124,020 Loss from continuing operations before benefit for income taxes $ (430,174 ) $ — $ (430,174 ) Benefit for income taxes $ (151,406 ) $ — $ (151,406 ) Loss from continuing operations $ (14,668 ) $ (2,692 ) $ (17,360 ) As of December 31, 2015 Restated Consolidating Balance Sheet-Issuer As Previously Restatement Adjustment As Restated Total current assets $ 1,385,453 $ — $ 1,385,453 Total assets $ 6,729,213 $ (3,133 ) $ 6,726,080 Total current liabilities $ 1,397,394 $ — $ 1,397,394 Total long-term liabilities $ 3,277,654 $ — $ 3,277,654 Total equity $ 2,054,165 $ (3,133 ) $ 2,051,032 Total liabilities and equity $ 6,729,213 $ (3,133 ) $ 6,726,080 (1) The figures presented in this column represent the amounts that were presented originally in the 2015 Annual Report on Form 10-K, as adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $33,866 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the issuer financial statements as of December 31, 2015. (2) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K for 2015 due to a $52,410 adjustment to increase current deferred tax assets, a $616,637 adjustment to increase current intercompany receivable, a $105,298 adjustment to increase non-current deferred tax assets, a $616,637 adjustment to increase current liabilities and a $157,708 adjustment to increase deferred tax liabilities, which were identified during the preparation of the Quarterly Report on Form 10-Q for the period ended September 30, 2016. Year Ended December 31, 2014 Restated Consolidating Statement of Operations-Issuer As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 5,630 $ — $ 5,630 Sales and marketing $ 7,598 $ — $ 7,598 General and administrative $ 93,952 $ (1,486 ) $ 92,466 Loss from continuing operations before benefit for income taxes $ (326,899 ) $ — $ (326,899 ) Benefit for income taxes $ (20,865 ) $ — $ (20,865 ) Loss from continuing operations $ (179,187 ) $ 313 $ (178,874 ) (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due to an $8,535 adjustment to increase benefit for income taxes and a $4,261 adjustment to decrease equity in earnings of unconsolidated subsidiaries, net of tax with an overall impact of a $4,274 adjustment to decrease loss from continuing operations within the issuer financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. Year Ended December 31, 2015 Restated Consolidating Statement of Operations-Guarantor As Previously Restatement As Restated Net revenue $ 1,345,763 $ — $ 1,345,763 Cost of net revenue $ 816,961 $ — $ 816,961 Sales and marketing $ 219,566 $ — $ 219,566 General and administrative $ 147,539 $ 86 $ 147,625 Income (loss) from continuing operations before provision (benefit) for income taxes $ 112,416 $ — $ 112,416 Provision (benefit) for income taxes $ 33,447 $ — $ 33,447 Income (loss) from continuing operations $ 78,969 $ — $ 78,969 Year Ended December 31, 2014 Restated Consolidating Statement of Operations-Guarantor As Previously Restatement As Restated Net revenue $ 1,333,195 $ — $ 1,333,195 Cost of net revenue $ 761,563 $ — $ 761,563 Sales and marketing $ 232,406 $ — $ 232,406 General and administrative $ 155,795 $ 348 $ 156,143 Income (loss) from continuing operations before provision (benefit) for income taxes $ 111,324 $ — $ 111,324 Provision (benefit) for income taxes $ 44,155 $ — 44,155 Income (loss) from continuing operations $ 67,169 $ — $ 67,169 Year Ended December 31, 2015 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 1,397,647 $ (7,701 ) $ 1,389,946 Cost of net revenue $ 808,905 $ (3,457 ) $ 805,448 Sales and marketing $ 209,664 $ (692 ) $ 208,972 General and administrative $ 102,511 $ — $ 102,511 Income from continuing operations before provision for income taxes $ 241,689 $ (3,552 ) $ 238,137 Provision for income taxes $ 64,947 $ (860 ) $ 64,087 Income from continuing operations $ 190,807 $ (2,692 ) $ 188,115 As of December 31, 2015 Restated Consolidating Balance Sheet-Non-Guarantor As Previously Restatement As Restated Total current assets $ 959,592 $ (42,680 ) $ 916,912 Total assets $ 2,763,898 $ (4,961 ) $ 2,758,937 Total current liabilities $ 446,931 $ (1,828 ) $ 445,103 Total long-term liabilities $ 1,112,885 $ — $ 1,112,885 Total equity $ 1,204,082 $ (3,133 ) $ 1,200,949 Total liabilities and equity $ 2,763,898 $ (4,961 ) $ 2,758,937 (1) The figures presented in this column represent the amounts that were presented originally in the Annual Report on Form 10-K for 2015 as adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $184 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the non-guarantor subsidiaries financial statements as of December 31, 2015. (2) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K for 2015 due to a $23,244 adjustment to decrease current deferred tax assets, a $23,244 adjustment to increase non-current deferred tax assets, a $92,350 adjustment to decrease current liabilities and a $92,350 adjustment to increase current intercompany payable within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Quarterly Report on Form 10-Q for the period ended September 30, 2016. Year Ended December 31, 2014 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 1,491,422 $ 1,723 $ 1,493,145 Cost of net revenue $ 847,984 $ 501 $ 848,485 Sales and marketing $ 272,957 $ 88 $ 273,045 General and administrative $ 203,881 $ 673 $ 204,554 Income from continuing operations before provision for income taxes $ 94,509 $ 413 $ 94,922 Provision for income taxes $ 46,618 $ 100 $ 46,718 Income from continuing operations $ 63,819 $ 313 $ 64,132 (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due most significantly to a $15,805 adjustment to decrease revenue, a $7,237 adjustment to decrease cost of revenue, a $1,201 adjustment to decrease operating expenses and a $2,729 adjustment to decrease the provision for income taxes with an overall impact of a $4,638 adjustment to decrease income from continuing operations within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. Year Ended December 31, 2015 Restated Consolidating Statement of Operations-Eliminations As Previously Restatement As Restated Net revenue $ (280,094 ) $ — $ (280,094 ) Cost of net revenue $ (278,373 ) $ — $ (278,373 ) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Loss from continuing operations before provision for income taxes $ (4,921 ) $ — $ (4,921 ) Provision for income taxes $ 308 $ — $ 308 Loss from continuing operations $ (267,864 ) $ 2,692 $ (265,172 ) As of December 31, 2015 Restated Consolidating Balance Sheet-Eliminations As Previously Restatement As Restated Total current assets $ (2,115,095 ) $ — $ (2,115,095 ) Total assets $ (8,331,552 ) $ 3,133 $ (8,328,419 ) Total current liabilities $ (2,098,884 ) $ — $ (2,098,884 ) Total long-term liabilities $ (2,710,922 ) $ — $ (2,710,922 ) Total equity $ (3,521,746 ) $ 3,133 $ (3,518,613 ) Total liabilities and equity $ (8,331,552 ) $ 3,133 $ (8,328,419 ) (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K for 2015 due to a $2,120 adjustment to increase current deferred tax assets, a $616,637 adjustment to decrease current intercompany receivable, a $128,556 adjustment to decrease non-current deferred tax assets, a $616,637 adjustment to decrease current intercompany payable and a $126,436 adjustment to decrease deferred tax liabilities within the eliminations financial statements, which were identified during the preparation of the Quarterly Report on Form 10-Q for the period ended September 30, 2016. Year Ended December 31, 2014 Restated Consolidating Statement of Operations-Eliminations As Previously Restatement As Restated Net revenue $ (249,339 ) $ — $ (249,339 ) Cost of net revenue $ (252,137 ) $ — $ (252,137 ) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Income from continuing operations before provision for income taxes $ 2,733 $ — $ 2,733 Provision for income taxes $ 1,022 $ — $ 1,022 Loss from continuing operations $ (123,555 ) $ (313 ) $ (123,868 ) (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due to a $4,261 adjustment to increase equity in earnings of unconsolidated subsidiaries, net of tax with an overall impact of a $4,261 adjustment to decrease loss from continuing operations within the eliminations financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. The following schedules reconcile the amounts as previously reported in guarantor financial information, quarterly consolidating financial statements to the corresponding revised amounts and is unaudited: Three Months Ended September 30, 2016 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 853 $ — $ 853 Sales and marketing $ 1,867 $ — $ 1,867 General and administrative $ 75,261 $ 12,853 $ 88,114 Loss from continuing operations before benefit for income taxes $ (135,558 ) $ — $ (135,558) Benefit for income taxes $ (227,263 ) $ — $ (227,263) Loss from continuing operations $ 22,027 $ (6,364 ) $ 15,663 Three Months Ended June 30, 2016 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 324 $ — $ 324 Sales and marketing $ 1,568 $ — $ 1,568 General and administrative $ 57,740 $ 10,200 $ 67,940 Loss from continuing operations before provision for income taxes $ (112,630 ) $ — $ (112,630) Provision for income taxes $ 19,765 $ — $ 19,765 Loss from continuing operations $ (34,891 ) $ 2,084 $ (32,807) Three Months Ended March 31, 2016 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Net revenue $ — $ — $ — Cost of net revenue $ 114 $ — $ 114 Sales and marketing $ 1,336 $ — $ 1,336 General and administrative $ 44,615 $ — $ 44,615 Loss from continuing operations before benefit for income taxes $ (89,298 ) $ — $ (89,298) Benefit for income taxes $ (54 ) $ — $ (54) Loss from continuing operations $ (9,977 ) $ 4,005 $ (5,972) As of September 30, 2016 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,265,329 $ — $ 1,265,329 Total assets $ 6,657,371 $ (3,408) $ 6,653,963 Total current liabilities $ 1,248,718 $ — $ 1,248,718 Total long-term liabilities $ 3,362,971 $ — $ 3,362,971 Total equity $ 2,045,682 $ (3,408) $ 2,042,274 Total liabilities and equity $ 6,657,371 $ (3,408) $ 6,653,963 As of June 30, 2016 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 423,167 $ 455 $ 423,622 Total assets $ 5,749,848 $ 69,445 $ 5,819,293 Total current liabilities $ 514,279 $ — $ 514,279 Total long-term liabilities $ 3,227,915 $ 66,489 $ 3,294,404 Total equity $ 2,007,654 $ 2,956 $ 2,010,610 Total liabilities and equity $ 5,749,848 $ 69,445 $ 5,819,293 As of March 31, 2016 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 241,997 $ 52,409 $ 294,406 Total assets $ 5,556,092 $ 67,359 $ 5,623,451 Total current liabilities $ 345,110 $ — $ 345,110 Total long-term liabilities $ 3,130,559 $ 66,488 $ 3,197,047 Total equity $ 2,080,423 $ 871 $ 2,081,294 Total liabilities and equity $ 5,556,092 $ 67,359 $ 5,623,451 Three Months Ended September 30, 2015 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Net revenue $ — $ — $ — Cost of net revenue $ 2,146 $ — $ 2,146 Sales and marketing $ 1,335 $ — $ 1,335 General and administrative $ 22,960 $ — $ 22,960 Loss from continuing operations before provision for income taxes $ (79,741 ) $ — $ (79,741) Provision for income taxes $ 78,040 $ — $ 78,040 Loss from continuing operations $ (2,381 ) $ 913 $ (1,468) Three Months Ended June 30, 2015 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 516 $ — $ 516 Sales and marketing $ 1,570 $ — $ 1,570 General and administrative $ 24,390 $ — $ 24,390 Loss from continuing operations before benefit for income taxes $ (129,585 ) $ — $ (129,585) Benefit for income taxes $ (16,306 ) $ — $ (16,306) Income from continuing operations $ 14,770 $ (272) $ 14,498 Three Months Ended March 31, 2015 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 426 $ — $ 426 Sales and marketing $ 1,260 $ — $ 1,260 General and administrative $ 20,523 $ — $ 20,523 Loss from continuing operations before benefit for income taxes $ (103,485 ) $ — $ (103,485) Benefit for income taxes $ (20,667 ) $ — $ (20,667) Loss from continuing operations $ (8,261 ) $ (315) $ (8,576) As of September 30, 2015 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 1,667,256 $ — $ 1,667,256 Total assets $ 7,159,852 $ 2,137 $ 7,161,989 Total current liabilities $ 1,725,939 $ — $ 1,725,939 Total long-term liabilities $ 3,341,859 $ 2,252 $ 3,344,111 Total equity $ 2,092,054 $ (115) $ 2,091,939 Total liabilities and equity $ 7,159,852 $ 2,137 $ 7,161,989 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended September 30, 2015 due most significantly to a $15,348 adjustment to increase current deferred tax assets, a $472,009 adjustment to increase current intercompany receivables, a $25,760 adjustment to decrease investments in subsidiaries, a $461,815 adjustment to increase accrued expenses, a $16,257 adjustment to increase deferred tax liabilities and a $13,344 adjustment to decrease long-term liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015. These figures were also adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $43,431 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the issuer financial statements as of September 30, 2015. As of June 30, 2015 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 1,036,046 $ — $ 1,036,046 Total assets $ 6,484,050 $ 1,224 $ 6,485,274 Total current liabilities $ 943,570 $ — $ 943,570 Total long-term liabilities $ 3,379,396 $ 2,252 $ 3,381,648 Total equity $ 2,161,084 $ (1,028) $ 2,160,056 Total liabilities and equity $ 6,484,050 $ 1,224 $ 6,485,274 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended June 30, 2015 due most significantly to a $15,347 adjustment to increase current deferred tax assets, a $17,876 adjustment to decrease investments in subsidiaries, a $9,944 adjustment to decrease accrued expenses, a $17,323 adjustment to increase deferred tax liabilities and a decrease of $14,662 in long-term liabilities within the issuer financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. These figures were also adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $45,889 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the issuer financial statements as of June 30, 2015. As of March 31, 2015 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 632,999 $ — $ 632,999 Total assets $ 5,945,568 $ 1,496 $ 5,947,064 Total current liabilities $ 385,171 $ — $ 385,171 Total long-term liabilities $ 3,485,056 $ 2,252 $ 3,487,308 Total equity $ 2,075,341 $ (756) $ 2,074,585 Total liabilities and equity $ 5,945,568 $ 1,496 $ 5,947,064 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q Three Months Ended September 30, 2016 Restated Consolidating Statement of Operations-Guarantor Subsidiaries As Previously Restatement As Restated Net revenue $ 336,679 $ — $ 336,679 Cost of net revenue $ 203,620 $ — $ 203,620 Sales and marketing $ 52,928 $ — $ 52,928 General and administrative $ 18,319 $ 4,700 $ 23,019 Income from continuing operations before provision for income taxes $ 42,335 $ (4,400) $ 37,935 Provision for income taxes $ 75,980 $ (2,631) $ 73,349 Loss from continuing operations $ (33,645 ) $ (1,769 ) $ (35,414) As of September 30, 2016 Restated Consolidating Balance Sheet-Guarantor Subsidiaries (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,309,196 $ — $ 1,309,196 Total assets $ 4,792,740 $ — $ 4,792,740 Total current liabilities $ 996,624 $ (2,631 ) $ 993,993 Total long-term liabilities $ 1,427,397 $ 4,400 $ 1,431,797 Total equity $ 2,368,719 $ (1,769 ) $ 2,366,950 Total liabilities and equity $ 4,792,740 $ — $ 4,792,740 As of June 30, 2016 Restated Consolidating Balance Sheet-Guarantor Subsidiaries (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,233,735 $ (6,513 ) $ 1,227,222 Total assets $ 4,764,565 $ — $ 4,764,565 Total current liabilities $ 892,933 $ — $ 892,933 Total long-term liabilities $ 1,471,124 $ — $ 1,471,124 Total equity $ 2,400,508 $ — $ 2,400,508 Total liabilities and equity $ 4,764,565 $ — $ 4,764,565 As of March 31, 2016 Restated Consolidating Balance Sheet-Guarantor Subsidiaries (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,199,926 $ (31,285 ) $ 1,168,641 Total assets $ 4,737,809 $ — $ 4,737,809 Total current liabilities $ 905,144 $ — $ 905,144 Total long-term liabilities $ 1,476,576 $ — $ 1,476,576 Total equity $ 2,356,089 $ — $ 2,356,089 Total liabilities and equity $ 4,737,809 $ — $ 4,737,809 Three Months Ended September 30, 2016 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 323,246 $ (72 ) $ 323,174 Cost of net revenue $ 187,776 $ 113 $ 187,889 Sales and marketing $ 47,184 $ (13 ) $ 47,171 General and administrative $ 36,196 $ 1,700 $ 37,896 Income from continuing operations before provision for income taxes $ 39,271 $ (1,872 ) $ 37,399 Provision for income taxes $ 100,395 $ 2,723 $ 103,118 Loss from continuing operations $ (54,447 ) $ (4,595 ) $ (59,042 ) Three Months Ended June 30, 2016 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 349,659 $ (784 ) $ 348,875 Cost of net revenue $ 199,704 $ (561 ) $ 199,143 Sales and marketing $ 47,793 $ (72 ) $ 47,721 General and administrative $ 40,154 $ (1,700 ) $ 38,454 Income from continuing operations before benefit for income taxes $ 44,434 $ 1,549 $ 45,983 Benefit for income taxes $ (9,889 ) $ (535 ) $ (10,424 ) Income from continuing operations $ 55,880 $ 2,084 $ 57,964 Three Months Ended March 31, 2016 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 310,620 $ 8,731 $ 319,351 Cost of net revenue $ 178,145 $ 3,863 $ 182,008 Sales and marketing $ 44,012 $ 827 $ 44,839 General and administrative $ 37,155 $ — $ 37,155 Income from continuing operations before benefit for income taxes $ 42,443 $ 4,041 $ 46,484 Benefit for income taxes $ (404 ) $ 36 $ (368 ) Income from continuing operations $ 47,428 $ 4,005 $ 51,433 As of September 30, 2016 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,124,858 $ (39,944 ) $ 1,084,914 Total assets $ 2,871,239 $ (3,989 ) $ 2,867,250 Total current liabilities $ 629,612 $ (2,350 ) $ 627,262 Total long-term liabilities $ 998,037 $ — $ 998,037 Total equity $ 1,243,590 $ (1,639 ) $ 1,241,951 Total liabilities and equity $ 2,871,239 $ (3,989 ) $ 2,867,250 As of June 30, 2016 Restated Consolidating Balance Sheet-Non-Guarantor As Previously Restatement As Restated Total current assets $ 1,142,219 $ (30,019 ) $ 1,112,200 Total assets $ 2,905,690 $ 7,964 $ 2,913,654 Total current liabilities $ 499,901 $ (1,050 ) $ 498,851 Total long-term liabilities $ 1,117,516 $ 6,058 $ 1,123,574 Total equity $ 1,288,273 $ 2,956 $ 1,291,229 Total liabilities and equity $ 2,905,690 $ 7,964 $ 2,913,654 As of March 31, 2016 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,112,355 $ (61,077 ) $ 1,051,278 Total assets $ 2,902,509 $ (135 ) $ 2,902,374 Total current liabilities $ 508,599 $ (1,006 ) $ 507,593 Total long-term liabilities $ 1,118,354 $ — $ 1,118,354 Total equity $ 1,275,556 $ 871 $ 1,276,427 Total liabilities and equity $ 2,902,509 $ (135 ) $ 2,902,374 Three Months Ended September 30, 2015 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 327,731 $ 831 $ 328,562 Cost of net revenue $ 187,690 $ (385 ) $ 187,305 Sales and marketing $ 51,296 $ 231 $ 51,527 General and administrative $ 43,529 $ — $ 43,529 Income from continuing operations before benefit for income taxes $ 26,636 $ 985 $ 27,621 Benefit for income taxes $ (59,605 ) $ 72 $ (59,533 ) Income from continuing operations $ 91,589 $ 913 $ 92,502 Three Months Ended June 30, 2015 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 362,644 $ 603 $ 363,247 Cost of net revenue $ 205,281 $ 894 $ 206,175 Sales and marketing $ 54,353 $ (118 ) $ 54,235 General and administrative $ (14,505 ) $ — $ (14,505 ) Income from continuing operations before provision for income taxes $ 105,715 $ (173 ) $ 105,542 Provision for income taxes $ 21,203 $ 99 $ 21,302 Income from continuing operations $ 84,936 $ (272 ) $ 84,664 Three Months Ended March 31, 2015 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 350,268 $ (2,986 ) $ 347,282 Cost of net revenue $ 194,890 $ (2,296 ) $ 192,594 Sales and marketing $ 54,592 $ (161 ) $ 54,431 General and administrative $ 34,398 $ — $ 34,398 Income from continuing operations before provision for income taxes $ 81,668 $ (529 ) $ 81,139 Provision for income taxes $ 11,717 $ (214 ) $ 11,503 Income from continuing operations $ 73,519 $ (315 ) $ 73,204 As of September 30, 2015 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As of Restatement Adjustment As Restated Total current assets $ 1,003,288 $ (482 ) $ 1,002,806 Total assets $ 2,912,305 $ (482 ) $ 2,911,823 Total current liabilities $ 424,994 $ (367 ) $ 424,627 Total long-term liabilities $ 1,208,211 $ — $ 1,208,211 Total equity $ 1,279,100 $ (115 ) $ 1,278,985 Total liabilities and equity $ 2,912,305 $ (482 ) $ 2,911,823 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended September 30, 2015 due most significantly to a $10,764 adjustment to decrease accounts receivable, a $10,866 adjustment to increase inventory, a $25,228 adjustment to increase current intercompany receivables, a $43,907 adjustment to increase accrued expenses and a $19,096 adjustment to decrease equity within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. These figures were also adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $213 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the non-guarantor subsidiaries financial statements as of September 30, 2015. As of June 30, 2015 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 1,049,149 $ (1,697) $ 1,047,452 Total assets $ 3,016,055 $ (1,697) $ 3,014,358 Total current liabilities $ 561,971 $ (669) $ 561,302 Total long-term liabilities $ 1,181,371 $ — $ 1,181,371 Total equity $ 1,272,713 $ (1,028) $ 1,271,685 Total liabilities and equity $ 3,016,055 $ (1,697) $ 3,014,358 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended June 30, 2015 due most significantly to an $11,082 adjustment to decrease accounts receivable, a $10,371 adjustment to increase inventory, a $15,130 adjustment to increase accrued expenses and a $16,314 adjustment to decrease equity within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. As of March 31, 2015 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 978,225 $ (1,407) $ 976,818 Total assets $ 2,962,300 $ (1,407) $ 2,960,893 Total current liabilities $ 611,673 $ (651) $ 611,022 Total long-term liabilities $ 1,174,407 $ — $ 1,174,407 Total equity $ 1,176,220 $ (756) $ 1,175,464 Total liabilities and equity $ 2,962,300 $ (1,407) $ 2,960,893 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended March 31, 2015 due most significantly to a $7,769 adjustment to decrease accounts receivable, a $9,765 adjustment to increase inventory, a $14,035 adjustment to increase accrued expenses and a $12,463 adjustment to decrease equity within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. Three Months Ended September 30, 2016 Restated Consolidating Statement of Operations-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ (77,571 ) $ — $ (77,571) Cost of net revenue $ (76,023 ) $ — $ (76,023) Sales and marketing $ — $ — $ — General and administrative $ (489 ) $ — $ (489) Loss from continuing operations before provision for income taxes $ (1,058 ) $ — $ (1,058) Provision for income taxes $ — $ — $ — Income from continuing operations $ 88,092 $ 6,364 $ 94,456 Three Months Ended June 30, 2016 Restated Consolidating Statement of Operations-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ (77,671 ) $ — $ (77,671) Cost of net revenue $ (76,792 ) $ — $ (76,792) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Loss from continuing operations before provision for income taxes $ (880 ) $ — $ (880) Provision for income taxes $ — $ — $ — Loss from continuing operations $ (97,819 ) $ (2,084) $ (99,903) Three Months Ended March 31, 2016 Restated Consolidating Statement of Operations-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ (64,195 ) $ — $ (64,195) Cost of net revenue $ (63,577 ) $ — $ (63,577) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Loss from continuing operations before provision for income taxes $ (618 ) $ — $ (618) Provision f

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	(30) Subsequent Events April 2017 Amendment to Credit Facility On April 24, 2017, we entered into a Third Amendment to the Credit Agreement for our secured credit facility, dated as of June 18, 2015, among the Company, the several lenders from time to time party thereto, the Administrative Agents (as defined in the Credit Agreement) and certain other agents and arrangers. Pursuant to the Third Amendment, the lenders under the Credit Agreement have agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or may hereafter occur, resulting from, among other things, (x) our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and the related deliverables for the fiscal year ended December 31, 2016 by the applicable deadline under the Credit Agreement, (y) any restatement, revision or other adjustment of certain financial statements as a result of our review described in our Current Report on Form 8-K as filed with the SEC on April 17, 2017, or the April 8-K, as a result of our incorrect recognition of revenue transactions at our Korean and Japanese locations for certain fiscal periods set forth in the Third Amendment and (z) any breach of any representation or affirmative covenant as a result of certain deliverables being incorrect when delivered, which breach is discovered as part of the review described in the April 8-K, to the extent that such breach is due to our incorrect recognition of revenue transactions at our Korean and Japanese locations for certain fiscal periods set forth in the Third Amendment and (ii) extend the deadlines for delivery of the financial statements for the fiscal year ended December 31, 2016, and certain related deliverables, or the Financial Reports, as described below. In connection with the Third Amendment, we agreed to pay, among other fees and expenses, to each lender that approved the Third Amendment a consent fee of 0.125% of the sum of (i) the aggregate principal amount of such lender’s Term Loans (as defined in the Credit Agreement) outstanding on the effective date of the Third Amendment and (ii) such lender’s Revolving Credit Commitment (as defined in the Credit Agreement) in effect in the effective date of the Third Amendment. We incurred approximately $3.3 million in fees and expenses associated with this Third Amendment. May 2017 Consent Solicitation for Notes On May 1, 2017, we commenced consent solicitations relating to the Notes. On May 4, 2017, we made certain modifications to the consent solicitations, which are reflected herein. We solicited consents from holders of each series of Notes to extend the deadline for delivery of certain financial information and to waive through and until 5:00 p.m., New York City time, on June 15, 2017, any default or event of default that occurred, is continuing or may occur under the indentures under which the Notes were issued (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, or the Fiscal Year 2016 Failure to File. If we did not file this Annual Report on Form 10-K for 2016 and if we had failed to obtain the waivers requested pursuant to the consent solicitations, in each case on or before (i) May 16, 2017, with respect to the 7.25% Senior Notes, (ii) May 19, 2017, with respect to the 6.5% Senior Subordinated Notes, and (iii) June 2, 2017, with respect to the 6.375% Subordinated Notes, an event of default would have arisen under the respective series of Notes and, among the remedies available to the noteholders, would have been the right to accelerate the payment of our obligations upon notice from the relevant trustees or holders of 25% of the applicable Notes. Subject to the terms and conditions of the consent solicitations set forth in the consent solicitation statement, dated May 1, 2017, as supplemented, we offered to pay to each holder of Notes, as of April 28, 2017, a cash payment equal to $17.50 for each $1,000 principal amount of such holder’s Notes, or the Consent Fee, in respect of which the holder validly delivered (and did not validly revoke) a consent prior to 5:00 p.m. New York City time, on May 5, 2017 (such time and date, the Expiration Date), provided that we received and accepted the requisite consents for all series of Notes. If, at any time prior to 9:30 a.m., New York City time, on May 8, 2017, we filed with the SEC this Annual Report on Form 10-K and we terminated the consent solicitations, we would pay to each holder of each series of Notes who delivered (and did not revoke) a valid and duly executed consent prior to the Expiration Date a cash payment, in lieu of the Consent Fee, equal to $10.00 for each $1,000 principal amount of Notes for which such Holder delivered its Consent, or the Consent Termination Fee. On May 8, 2017 we successfully completed this solicitation and, in connection with the completion, we paid the Consent Fee to the consenting holders in an aggregate amount of approximately $23 million. May 2017 Amendment to Credit Facility On May 30, 2017, we entered into a fourth amendment to the Credit Agreement pursuant to which the lenders under the Credit Agreement agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or hereafter occur, resulting from, among other things, (x) failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and the related deliverables for the fiscal year ended December 31, 2016 and the fiscal quarter ended March 31, 2017, in each case, by the applicable deadlines under the Credit Agreement, (y) any restatement, revision or other adjustment of certain financial statements as a result of the Company’s review described our Current Report on Form 8-K (as filed with the SEC on May 22, 2017), or the May 8-K, as a result of our incorrect recognition of revenue transactions for certain fiscal periods set forth in the amendment and (z) any breach of any representation or affirmative covenant as a result of certain deliverables being incorrect when delivered that is discovered as part of the review described in the May 8-K, to the extent that such breach is due to our incorrect recognition of revenue transactions for certain fiscal periods set forth in the amendment, (ii) extend the deadlines for delivery of the financial statements and the related deliverables for the fiscal year ended December 31, 2016, to the earlier of (A) July 15, 2017, and (B) the date that is three business days prior to the earliest date (after giving effect to any applicable cure periods or any waivers or other types of extensions) that an event of default would arise under the indentures for our 6.5% senior subordinated notes, 6.375% senior subordinated notes and 7.25% senior notes as a result of the failure to timely deliver such financial statements and (iii) extend the deadlines for delivery of the financial statements and the related deliverables for the fiscal quarter ended March 31, 2017 to the earliest of (A) the date that is ten business days after delivery of the financial statements for the fiscal year ended December 31, 2016, (B) the date that is three business days prior to the earliest date (after giving effect to any applicable cure periods or any waivers or other types of extensions) that an event of default would arise under the indentures for our 6.5% senior subordinated notes, 6.375% senior subordinated notes and 7.25% senior notes as a result of the failure to timely deliver the financial statements for the fiscal quarter ended March 31, 2017 and (C) July 28, 2017. In connection with this amendment, we agreed to pay, among other fees and expenses, to the lenders that approved the amendment a consent fee of 0.25% of the sum of such lender’s (i) aggregate principal amount of its Term Loans outstanding and (ii) Revolving Credit Commitment (each as defined in the Credit Agreement). We delivered the financial statements for the fiscal year ended December 31, 2016 and certain related deliverables prior to the deadline as set forth in this amendment. June 2017 Consent Solicitation for Notes On June 1, 2017, we commenced consent solicitations relating to each series of our Notes. We solicited consents from holders of each series of Notes to further extend the deadline for delivery of certain financial information and to waive, in each case (i) through and until 5:00 p.m., New York City time, on August 4, 2017 (such time and date, the “First Waiver Date”), (ii) through and until 5:00 p.m., New York City time, on September 5, 2017 (such time and date, the “Second Waiver Date”) if uncured immediately prior to the First Waiver Date, and (iii) through and until 5:00 p.m., New York City time, on October 4, 2017 (such time and date, the “Third Waiver Date”) if uncured immediately prior to the Second Waiver Date, any default or event of default that occurred, is continuing or may occur under the indentures (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, the 2016 Form 10-K (the “Fiscal Year 2016 Failure to File”) and the 2017 First Quarter Form 10-Q (the “First Quarter 2017 Failure to File” and, together with the Fiscal Year 2016 Failure to File, the “Failures to File”). If we did not file this Annual Report on Form 10-K for 2016 by June 15, 2017, an event of default would have arisen under the respective series of Notes and, among the remedies available to the noteholders, would have been the right to accelerate the payment of our obligations upon notice from the relevant trustee or holders of 25% of the applicable Notes. Subject to the terms and conditions of the consent solicitations set forth in the consent solicitation statement, dated as of June 1, 2017, and provided that we receive and accept the requisite consents for all series of Notes, we are offering to pay to each holder of Notes as of 5:00 p.m., New York City time, on May 31, 2017, (1) a cash payment promptly following the Expiration Date (as defined below) equal to: $20.00 for each $1,000 principal amount of 6.375% Notes for which such holder delivered its consent (the “6.375% Notes First Consent Fee”), $15.00 for each $1,000 principal amount of 6.500% Notes for which such holder delivered its consent (the “6.500% Notes First Consent Fee”) and $12.50 for each $1,000 principal amount of 7.250% Notes for which such holder delivered its consent (the “7.250% Notes First Consent Fee” and, together with the 6.375% Notes First Consent Fee and the 6.500% Notes First Consent Fee, the “First Consent Fees” and each a “First Consent Fee”) and (2), if any default or event of default remains uncured immediately prior to the First Waiver Date in connection with the Failures to File, an additional cash payment on or prior to the First Waiver Date (with respect to each series of Notes, the “Second Consent Fee”), equal to $5.00 for each $1,000 principal amount of Notes and (3), if any default or event of default remains uncured immediately prior to the Second Waiver Date in connection with the Failures to File, an additional cash payment on or prior to the Second Waiver Date (with respect to each series of Notes, the “Third Consent Fee”), equal to $7.50 for each $1,000 principal amount of Notes, in each case in respect of which the holder validly delivers (and does not validly revoke) a consent prior to 5:00 p.m. New York City time, on June 7, 2017 (such time and date, as amended, extended or otherwise modified, the “Expiration Date”), provided that we received and accepted the requisite consents for all series of Notes.

Description of Business and B37

Description of Business and Basis of Presentation of Financial Information (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Description of Business and Basis of Presentation of Financial Information	Alere delivers reliable and actionable health information through rapid diagnostic tests, resulting in better clinical and economic healthcare outcomes globally. Our high-performance diagnostics for infectious disease, cardiometabolic disease and toxicology are designed to meet the growing global demand for accurate, easy-to-use Our operating segments are currently (i) professional diagnostics; (ii) consumer diagnostics; and (iii) other non-reportable. In January 2015, we sold our condition management, case management, wellbeing, wellness, and women’s and children’s health businesses, which we refer to collectively as our health management business. As a result of the sale of our health management business, which was the largest component of our former patient self-testing reporting segment, as well as certain other transactions in 2015, the only component of the patient self-testing reporting segment that was retained by Alere was the Alere Home Monitoring business. Therefore, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, we reported our financial information in two reportable operating segments: (i) professional diagnostics and (ii) consumer diagnostics, and Alere Home Monitoring was reported as a component of the professional diagnostics segment. Due to the nature of the operations of Alere Home Monitoring and the manner in which this business is conducted, in this Annual Report on Form 10-K, we will now report our Alere Home Monitoring business as a separate segment under the heading “other non-reportable segment.” Alere Home Monitoring distributes PT/INR coagulation monitors and facilitates the distribution of equipment and supplies to power and control customers’ implanted ventricular assist devices, or VADs, as well as telemonitoring services that allows VAD coordinators to monitor patients soon after discharge and receive alerts when critical patient values fall outside pre-established ranges. The consolidated financial statements include the accounts of Alere Inc. and its subsidiaries. Intercompany transactions and balances are eliminated and net earnings are reduced by the portion of the net earnings of subsidiaries applicable to non-controlling [TO COME] Certain amounts presented may not recalculate directly, due to rounding.
Use of Estimates	(a) Use of Estimates To prepare our financial statements in conformity with accounting principles generally accepted in the United States of America, our management must make estimates, judgments and assumptions that may affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from such estimates under different assumptions or conditions.
Foreign Currencies	(b) Foreign Currencies In general, the functional currencies of our foreign subsidiaries are the local currencies. For the purpose of consolidating the financial statements of our foreign subsidiaries, all assets and liabilities of the foreign subsidiaries are translated into U.S. dollars using the exchange rate at each balance sheet date, while the stockholders’ equity accounts are translated at historical exchange rates. Translation gains and losses that result from the conversion of the balance sheets of the foreign subsidiaries into U.S. dollars are recorded to cumulative translation adjustment, which is a component of accumulated other comprehensive loss (Note 17) within stockholders’ equity. The revenue and expenses of our foreign subsidiaries are translated using the average of the rates of exchange in effect during each fiscal month. Net realized and unrealized foreign currency exchange transaction losses of $4.5 million, $4.8 million and $2.2 million during 2016, 2015 and 2014, respectively, are included as a component of other income (expense), net in the consolidated statements of operations.
Cash and Cash Equivalents	(c) Cash and Cash Equivalents We consider all highly-liquid investments purchased with original maturities of three months or less at the date of acquisition to be cash equivalents. Cash equivalents consisted of money market funds at December 31, 2016 and 2015.
Restricted Cash	(d) Restricted Cash We had restricted cash of $53.7 million and $48.9 million as of December 31, 2016 and 2015, respectively. Of the $48.9 million restricted cash as of December 31, 2015, $43.2 million was classified as non-current non-current
Marketable Securities	(e) Marketable Securities Securities classified as available-for-sale available-for-sale,
Inventories	(f) Inventories Inventories are stated at the lower of cost (first-in, first-out) work-in-process work-in-process
Property, Plant and Equipment	(g) Property, Plant and Equipment We record property, plant and equipment at historical cost or, in the case of a business combination, at fair value on the date of the business combination. Depreciation is computed using the straight-line method based on the following estimated useful lives of the related assets: machinery, laboratory equipment and tooling, 1-15 4- 50 1-10 2-16
Goodwill	(h) Goodwill Goodwill relates to amounts that arose in connection with our various business combinations and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the acquisition method of accounting. Goodwill is not amortized, but is subject to periodic review for impairment. We test goodwill and other intangible assets with indefinite lives at the reporting unit level for impairment on an annual basis and between annual tests, if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that would indicate potential impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business and an adverse action or assessment by a regulator. In performing the annual goodwill impairment test, we utilize the two-step after-tax after-tax If the carrying value of a reporting unit exceeds its estimated fair value, we are required to perform the second step, or Step 2, of the annual goodwill impairment test to measure the amount of impairment loss, if any. Step 2 of the goodwill impairment test compares the implied fair value of a reporting unit’s goodwill to its carrying value. The implied fair value of goodwill is calculated as the difference between the fair value of the reporting unit and the estimated fair value of its assets and liabilities. To the extent this amount is below the carrying value of goodwill, an impairment charge is recorded to write down the carrying value to its implied value. Impairment charges related to goodwill have no impact on our cash balances or on compliance with financial covenants under our Credit Agreement. 2016 Annual Goodwill Impairment Test We conducted our 2016 annual impairment test for our reporting units during the fourth quarter of 2016. Key assumptions (which vary by reporting unit) used in determining fair value under the DCF approach included discount rates ranging from 10.0% to 14.5%, projected compound average revenue growth rates of 3.4% to 5.6%, and terminal value growth rates of 3.0% to 4.0%. In determining the appropriate discount rate, we considered the WACC for each reporting unit, which among other factors considers the cost of common equity capital and the marginal cost of debt of market participants. Key assumptions (which again vary by reporting unit) used in determining fair value under the market approaches were based on observed market multiples of enterprise value to revenue and EBITDA for both comparable publicly-traded companies and recent merger and acquisition transactions involving similar companies to estimate appropriate controlling basis multiples to apply to each of the reporting units. Based on the multiples implied by this market data, we selected multiples of revenue of 0.6 to 3.1 times and multiples of EBITDA of 8.3 to 12.3 times. In assessing the reasonableness of our estimated fair values of the reporting units, management compared the results of the valuation analyses against our then-current market capitalization to imply a control premium. Based on this analysis, the implied control premium was within the range of comparable industry transactions. The Step 1 impairment test indicated the estimated fair value of the professional diagnostics, consumer diagnostics, and other non-reportable
Impairment of Other Long-lived Tangible and Intangible Assets	(i) Impairment of Other Long-lived Tangible and Intangible Assets Our intangible assets consist primarily of core technology, in-process non-competition The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. We amortize the majority of our intangible assets on a straight-line basis, as this methodology most closely approximates the pattern of economic benefits for these assets. We evaluate long-lived tangible and intangible assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment are present with respect to long-lived tangible and intangible assets used in operations and undiscounted future cash flows are not expected to be sufficient to recover the assets’ carrying amount, additional analysis is performed as appropriate and the carrying value of the long-lived assets is reduced to the estimated fair value, if this is lower, and an impairment loss is charged to expense in the period the impairment is identified. Factors we generally consider important which could trigger an impairment review on the carrying value of other long-lived tangible and intangible assets include the following: (1) significant underperformance relative to expected historical or projected future operating results, (2) significant changes in the manner of our use of acquired assets or the strategy for our overall business, (3) underutilization of our tangible assets, (4) discontinuance of product lines by ourselves or our customers, (5) significant negative industry or economic trends, (6) significant decline in our stock price for a sustained period, (7) significant decline in our market capitalization relative to net book value and (8) goodwill impairment identified during an impairment review.
Acquired In-process Research and Development (IPR&D)	(j) Acquired In-process Acquired IPR&D represents the fair value assigned to research and development assets that we acquire as part of business combinations, and which have not been completed at the date of acquisition. The acquired IPR&D is capitalized as an intangible asset and tested for impairment at least annually until commercialization, after which time the IPR&D is amortized over its estimated useful life. We utilize a discounted probable future cash flow model on a project-by-project
Business Acquisitions	(k) Business Acquisitions Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. Significant judgment is required in estimating the fair value of intangible assets and in assigning their respective useful lives. The fair value estimates are based on available historical information and on future expectations and assumptions deemed reasonable by management, but are inherently uncertain. We generally employ the income method to estimate the fair value of intangible assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants, and include the amount and timing of future cash flows (including expected growth rates and profitability), the underlying product life cycles, economic barriers to entry, a brand’s relative market position and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions. Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. During 2016, 2015 and 2014, we expensed acquisition-related costs of $1.0 million, $0.5 million and $0.9 million, respectively, in general and administrative expense.
Income Taxes	(l) Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our income tax provision in the period of enactment We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversal of existing taxable temporary differences, projected future taxable income, tax-planning We account for uncertain tax positions using a “more-likely-than-not” During November 2015, the FASB issued Accounting Standards Update No. 2015-17, 2015-17, 2015-17 non-current 2015-17
Revenue Recognition	(m) Revenue Recognition We primarily recognize revenue when the following four basic criteria have been met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the fee is fixed or determinable and (4) collection is reasonably assured. The majority of our revenue is derived from product sales. We recognize revenue upon transfer of the title and risk of loss of the products to third-party customers, less a reserve for estimated product returns and other incentive arrangements including rebates. Determination of the reserve for estimated product returns and allowances is based on our management’s analyses and judgments regarding certain conditions. For products that include installation, if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For sales that include customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of our products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered and accepted by the customer. Some of our sales transactions qualify as multiple-element arrangements which require us to identify separate units of accounting within the arrangement and allocate the transaction consideration across these separate accounting units. For arrangements that include non-software For software and software-related products, we use the relative fair value method to allocate transaction consideration to each unit of accounting, whereby the evidence used in the determination of fair value estimates are based solely on vendor specific objective evidence. To the extent that vendor specific objective evidence does not exist for delivered elements of the transaction, we apply the residual method. Additionally, with respect to our health management business (which was included in discontinued operations for all periods presented in our financial statements included in this Annual Report on Form 10-K fee-based fee-based at-risk We also receive license and royalty revenue from agreements with third-party licensees. Revenue from fixed fee license and royalty agreements is recognized on a straight-line basis over the obligation period of the related license agreements, or at the time when we have no further obligations. License and royalty fees that the licensees calculate based on their sales, which we have the right to audit under most of our agreements, are generally recognized upon receipt of the license or royalty payments unless we are able to reasonably estimate the fees as they are earned. License and royalty fees that are determinable prior to the receipt thereof are recognized in the period they are earned.
Employee Stock-based Compensation Arrangements	(n) Employee Stock-based Compensation Arrangements We account for share-based payments in accordance with ASC 718, Compensation — Stock Compensation Our stock option plans provide for grants of options to employees to purchase common stock at or above the fair market value of such shares on the grant date of the award. The options generally vest over a four-year period, beginning on the date of grant, with a graded vesting schedule of 25% at the end of each of the four years. The fair value of each option grant is estimated on the date of grant primarily using a Black-Scholes option-pricing method. We use historical data to estimate the expected price volatility and the expected forfeiture rate. The contractual term of our stock option awards is tenyears. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant with a remaining term equal to the expected term of the option. We have not made any dividend payments to common shareholders nor do we have plans to pay dividends in the foreseeable future.
Net Income (Loss) per Common Share	(o) Net Income (Loss) per Common Share Net income (loss) per common share is based upon the weighted-average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year (Note 14).
Other Operating Expenses	(p) Other Operating Expenses We expense advertising costs, other than for direct-response advertising, as incurred. In 2016, 2015 and 2014, advertising costs amounted to $5.6 million, $9.0 million and $8.0 million, respectively, and are included in sales and marketing expenses in the accompanying consolidated statements of operations. Shipping and handling costs are included in cost of net revenue in the accompanying consolidated statements of operations. When we charge our customers for shipping and handling costs, these costs are recorded along with product revenues. Legal fees incurred by us are included in general and administrative expenses and are expensed in the period such costs are incurred. Payments to third parties in connection with the resolution of legal disputes, investigations or other contingencies are included in general and administrative expenses and are expensed when an unfavorable outcome is probable and the amount of loss can be reasonably estimated in accordance with ASC 450 — Contingencies.
Direct-response Advertising	(q) Direct-response Advertising In connection with our mail order diabetes business, we incurred direct-response advertising and associated costs in connection with the placement of advertisements. Direct-response advertising and associated costs payable to third parties for the period presented are capitalized and amortized to selling, general and administrative expenses on an accelerated basis in the month following the broadcast month. Management assesses the realizability of the amounts of direct-response advertising costs reported as assets at each balance sheet date by comparing the net carrying value of capitalized advertising to the net present value of estimated future orders expected to result directly from such advertising. Advertising that does not meet the capitalization requirements is expensed in the current period. Any change in existing accounting rules or a business change that impacts expected future orders or that shortens the period over which such net future benefits are estimated to be realized could result in accelerated charges against our earnings. Whether there is an impairment loss or not is determined by comparing the net carrying value of direct-response advertising costs capitalized as assets at each balance sheet date to the probable remaining future orders expected to result directly from such advertising. If the net carrying value of the assets exceeds the probable remaining future orders expected to result directly from such assets, an impairment loss is recognized in an amount equal to that excess. Future benefits are determined by calculating the net present value of estimated future orders per cost pool. Net present value is calculated based upon the value of an order multiplied by the estimated future orders. Estimate of future orders is determined based on historical customer reorder rates. We perform the impairment test of our direct-response advertising asset in the quarter following the advertising broadcast quarter.
Concentration of Credit Risk, Off-Balance Sheet Risks and Other Risks and Uncertainties	(r) Concentration of Credit Risk, Off-Balance Financial instruments that potentially subject us to concentration of credit risk primarily consist of cash and cash equivalents and accounts receivable. We invest our excess cash primarily in high quality securities and limit the amount of our credit exposure to any one financial institution. We do not require collateral or other securities to support customer receivables; however, we perform on-going At December 31, 2016 and 2015, no individual customer’s accounts receivable balance was more than 10% of our aggregate accounts receivable. During 2016, 2015 and 2014, no one customer represented more than 10% of our net revenue.
Financial Instruments and Fair Value of Financial Instruments	(s) Financial Instruments and Fair Value of Financial Instruments Our primary financial instruments at December 31, 2016 and 2015 consisted of cash equivalents, restricted cash, marketable securities, accounts receivable, accounts payable and debt. We apply fair value measurement accounting to either record or disclose the value of our financial assets and liabilities in our financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Described below are the three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3
Software for Internal Use or for Resale	(t) Software for Internal Use or for Resale We may capitalize certain costs associated with the development of internal-use We also develop software for resale or lease to external parties and expense the costs of developing software for resale or lease incurred before establishment of technological feasibility of the underlying software. The costs incurred from establishment of technological feasibility until general release of the software are capitalized, and the capitalized software is amortized over its estimated useful life. Capitalized software for resale or lease is included in computer software and equipment within property, plant and equipment.
Research and Development	(u) Research and Development Our research and development programs focus on the development of cardiometabolic, infectious disease and toxicology products. Research and development costs are expensed as incurred. Payments received from external parties to fund our research and development activities reduce the recorded research and development expenses.
Leases	(v) Leases We lease certain facilities and equipment from external parties under operating leases. Rent expense related to operating leases is recorded in the income statement as incurred or on a straight-line basis if there are material escalation clauses. We also lease machinery, laboratory equipment, tooling and other equipment under capital leases. In determining whether a lease is a capital or an operating lease, we estimate the expected term of the lease, which includes certain renewable options as required by lease accounting guidance. Rent deferrals, landlord incentives and rent escalations are included in calculation of minimum lease payments when performing the capital lease tests and when calculating the rent expense for operating leases. Leased property, plant and equipment that meet the capital lease criteria are capitalized at the lower of the present value of the minimum lease payments or the fair value of the underlying asset at the inception date of the lease. Assets under capital leases are depreciated on a straight-line basis over the lease term. Leasehold improvements are capitalized and amortized over the shorter of their estimated useful lives or the remainder of the expected term of the lease.
Recent Accounting Pronouncements	(w) Recent Accounting Pronouncements Recently Issued Standards In March 2017, the FASB issued ASU No. 2017-07, 2017-07. 2017-07 2017-07 2017-07 In January 2017, the FASB issued ASU No. 2017-04, 2017-04. 2017-04 2017-04 2017-04 In January 2017, the FASB issued ASU No. 2017-01, 2017-01. 2017-01 2017-01 2017-01 In December 2016, the FASB issued ASU No. 2016-20, 2016-20. 2016-20 2014-09, 2016-20 2016-20 In December 2016, the FASB issued ASU No. 2016-19, 2016-19. 2016-19 2016-19 2016-19 In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, 2016-18. 2016-18 beginning-of-period end-of-period 2016-18 2016-18 In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory, 2016-16. 2016-16 2016-16 2016-16 In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, 2016-15. 2016-15 zero-coupon 2016-15 2016-15 In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, 2016-12. 2016-12: 606-10-25-7; non-cash 2016-12 2016-12 In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, 2016-10. 2016-10 2016-10 2016-10 In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting 2016-09. 2016-09 2016-09 2016-09 In March 2016, the FASB issued ASU No. 2016-07, Investments — Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, 2016-07. 2016-07 step-by-step 2016-07 2016-07 available-for-sale 2016-07 2016-07 In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), 2016-02. 2016-02 right-of-use 2016-02 2016-02 In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, 2015-11. 2015-11 in-scope 2015-11 2015-11 2015-11 In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers 2014-09, 2014-09 one-year 2014-09 We believe that there were no other accounting standards recently issued that had or are expected to have a material impact on our consolidated financial statements. Recently Adopted Standards In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, 2015-16. 2015-16 2015-16 2015-16. In July 2015, the FASB issued ASU No. 2015-12, Plan Accounting: Defined Benefit Pension Plans (Topic 960), Defined Contribution Pension Plans (Topic 962), and Health and Welfare Benefit Plans (Topic 965) — I. Fully Benefit-Responsive Investment Contracts, II. Plan Investment Disclosures, and III. Measurement Date Practical Expedient 2015-12. 2015-12 month-end year-end, month-end. 2015-12 2015-12 In April 2015, the FASB issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30): 2015-03. 2015-03 2015-03 No. 2015-15, Interest — Imputation of Interest (Subtopic 835-30) Line-of-Credit 18, 2015 EITF Meeting) 2015-15. 2015-15 line-of-credit 2015-03. ASU 2015-03 2015-15, non-current In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): 2014-15. 2014-15 2014-15 2014-15. 2014-15 In June 2014, the FASB issued ASU No. 2014-12, Compensation — Stock Compensation (Topic 718) — Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period 2014-12. 2014-12 2014-12 2014-12. 2014-12

Restatement of Previously Iss38

Restatement of Previously Issued Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Restated Consolidated Statements of Operations	ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Year Ended December 31, 2015 As Previously Restatement Adjustment(1) As Restated Net product sales $ 1,954,031 $ (7,701 ) $ 1,946,330 Services revenue 492,308 — 492,308 Net product sales and services revenue 2,446,339 (7,701 ) 2,438,638 License and royalty revenue 16,977 — 16,977 Net revenue 2,463,316 (7,701 ) 2,455,615 Cost of net product sales 1,042,603 (3,457 ) 1,039,146 Cost of services revenue 304,388 — 304,388 Cost of net product sales and services revenue 1,346,991 (3,457 ) 1,343,534 Cost of license and royalty revenue 3,781 — 3,781 Cost of net revenue 1,350,772 (3,457 ) 1,347,315 Gross profit 1,112,544 (4,244 ) 1,108,300 Operating expenses: Research and development 119,453 — 119,453 Sales and marketing 435,131 (692 ) 434,439 General and administrative 369,570 4,586 374,156 Impairment and loss on dispositions, net 50,540 — 50,540 Operating income 137,850 (8,138 ) 129,712 Interest expense, including amortization of original issue discounts and deferred financing costs (216,997 ) — (216,997 ) Other income (expense), net (1,843 ) 4,586 2,743 Loss from continuing operations before provision (benefit) for income taxes (80,990 ) (3,552 ) (84,542 ) Provision (benefit) for income taxes (52,704 ) (860 ) (53,564 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (28,286 ) (2,692 ) (30,978 ) Equity earnings of unconsolidated entities, net of tax 15,530 — 15,530 Income (loss) from continuing operations (12,756 ) (2,692 ) (15,448 ) Income (loss) from discontinued operations, net of tax 219,513 — 219,513 Net income (loss) 206,757 (2,692 ) 204,065 Less: Net income attributable to non-controlling 381 — 381 Net income (loss) attributable to Alere Inc. and Subsidiaries 206,376 (2,692 ) 203,684 Preferred stock dividends (21,293 ) — (21,293 ) Net income (loss) available to common stockholders $ 185,083 $ (2,692 ) $ 182,391 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.40 ) $ (0.03 ) $ (0.43 ) Income (loss) from discontinued operations 2.57 — 2.57 Net income (loss) per common share $ 2.17 $ (0.03 ) $ 2.14 Weighted-average shares — basic and diluted 85,420 — 85,420 (1) All adjustments are related to the Standard Diagnostics revenue recognition matter, except for the $4,586 adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Year Ended December 31, 2014 As Previously Restatement Adjustment(2) As Net product sales $ 2,022,240 $ 1,723 $ 2,023,963 Services revenue 531,988 — 531,988 Net product sales and services revenue 2,554,228 1,723 2,555,951 License and royalty revenue 21,050 — 21,050 Net revenue 2,575,278 1,723 2,577,001 Cost of net product sales 1,062,499 501 1,063,000 Cost of services revenue 294,949 — 294,949 Cost of net product sales and services revenue 1,357,448 501 1,357,949 Cost of license and royalty revenue 5,592 — 5,592 Cost of net revenue 1,363,040 501 1,363,541 Gross profit 1,212,238 1,222 1,213,460 Operating expenses: Research and development 144,828 — 144,828 Sales and marketing 512,961 88 513,049 General and administrative 453,628 (465 ) 453,163 Impairment and loss on dispositions, net 7,742 — 7,742 Operating income 93,079 1,599 94,678 Interest expense, including amortization of original issue discounts and deferred financing costs (209,191 ) — (209,191 ) Other income (expense), net (2,221 ) (1,186 ) (3,407 ) Loss from continuing operations before provision (benefit) for income taxes (118,333 ) 413 (117,920 ) Provision (benefit) for income taxes 70,930 100 71,030 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (189,263 ) 313 (188,950 ) Equity earnings of unconsolidated entities, net of tax 17,509 — 17,509 Income (loss) from continuing operations (171,754 ) 313 (171,441 ) Income (loss) from discontinued operations, net of tax 138,318 — 138,318 Net income (loss) (33,436 ) 313 (33,123 ) Less: Net income attributable to non-controlling 30 — 30 Net income (loss) attributable to Alere Inc. and Subsidiaries (33,466 ) 313 (33,153 ) Preferred stock dividends (21,293 ) — (21,293 ) Net income (loss) available to common stockholders $ (54,759 ) $ 313 $ (54,446 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (2.33 ) $ — $ (2.33 ) Income (loss) from discontinued operations 1.67 — 1.67 Net income (loss) per common share $ (0.66 ) $ — $ (0.66 ) Weighted-average shares — basic and diluted 82,938 — 82,938 (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K 10-K/A 10-K (2) All adjustments are related to the Standard Diagnostics revenue recognition matter; except for the $(1,186) adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended September 30, 2016 As Previously Restatement As Restated Net product sales $ 456,096 $ (72 ) $ 456,024 Services revenue 123,778 — 123,778 Net product sales and services revenue 579,874 (72 ) 579,802 License and royalty revenue 2,480 — 2,480 Net revenue 582,354 (72 ) 582,282 Cost of net product sales 238,946 113 239,059 Cost of services revenue 76,639 — 76,639 Cost of net product sales and services revenue 315,585 113 315,698 Cost of license and royalty revenue 641 — 641 Cost of net revenue 316,226 113 316,339 Gross profit 266,128 (185 ) 265,943 Operating expenses: — Research and development 31,430 — 31,430 Sales and marketing 101,979 (13 ) 101,966 General and administrative 129,287 19,253 148,540 Impairment and (gain) loss on dispositions, net — — — Operating income 3,432 (19,425 ) (15,993 ) Interest expense, including amortization of original issue discounts and deferred financing costs (44,130 ) — (44,130 ) Other income (expense), net (14,312 ) 13,153 (1,159 ) Loss from continuing operations before provision (benefit) for income taxes (55,010 ) (6,272 ) (61,282 ) Provision (benefit) for income taxes (50,888 ) 92 (50,796 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (4,122 ) (6,364 ) (10,486 ) Equity earnings of unconsolidated entities, net of tax 26,149 — 26,149 Income (loss) from continuing operations 22,027 (6,364 ) 15,663 Income (loss) from discontinued operations, net of tax — — — Net income (loss) 22,027 (6,364 ) 15,663 Less: Net income attributable to non-controlling 207 — 207 Net income (loss) attributable to Alere Inc. and Subsidiaries 21,820 (6,364 ) 15,456 Preferred stock dividends (5,366 ) — (5,366 ) Net income (loss) available to common stockholders $ 16,454 $ (6,364 ) $ 10,090 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ 0.19 $ (0.07 ) $ 0.12 Income (loss) from discontinued operations — — — Net income (loss) per common share $ 0.19 $ (0.07 ) $ 0.12 Weighted-average shares—basic 86,753 — 86,753 Weighted-average shares—diluted 87,885 — 87,885 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 30,768 $ (6,364 ) $ 24,404 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $1,700 adjustment to increase bad debt expense, (b) a $4,400 adjustment of additional expense related to a correction in the measurement of an acquisition-related contingent consideration obligation and (c) a $13,153 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses at September 30, 2016. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Nine Months Ended September 30, 2016 As Previously Restatement As Net product sales $ 1,399,613 $ 7,875 $ 1,407,488 Services revenue 364,296 — 364,296 Net product sales and services revenue 1,763,909 7,875 1,771,784 License and royalty revenue 7,742 — 7,742 Net revenue 1,771,651 7,875 1,779,526 Cost of net product sales 726,805 3,415 730,220 Cost of services revenue 228,033 — 228,033 Cost of net product sales and services revenue 954,838 3,415 958,253 Cost of license and royalty revenue 2,567 — 2,567 Cost of net revenue 957,405 3,415 960,820 Gross profit 814,246 4,460 818,706 Operating expenses: — — — Research and development 86,938 — 86,938 Sales and marketing 304,308 742 305,050 General and administrative 372,597 27,753 400,350 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 54,213 (24,035 ) 30,178 Interest expense, including amortization of original issue discounts and deferred financing costs (128,565 ) — (128,565 ) Other income (expense), net (29,773 ) 23,353 (6,420 ) Loss from continuing operations before provision (benefit) for income taxes (104,125 ) (682 ) (104,807 ) Provision (benefit) for income taxes (47,979 ) (407 ) (48,386 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (56,146 ) (275 ) (56,421 ) Equity earnings of unconsolidated entities, net of tax 33,305 — 33,305 Income (loss) from continuing operations (22,841 ) (275 ) (23,116 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (22,841 ) (275 ) (23,116 ) Less: Net income attributable to non-controlling 453 — 453 Net income (loss) attributable to Alere Inc. and Subsidiaries (23,294 ) (275 ) (23,569 ) Preferred stock dividends (15,983 ) — (15,983 ) Net income (loss) available to common stockholders $ (39,277 ) $ (275 ) $ (39,552 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.45 ) $ (0.00 ) $ (0.45 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.45 ) $ (0.00 ) $ (0.45 ) Weighted-average shares—basic and diluted 86,708 — 86,708 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (35,602 ) $ (275 ) $ (35,877 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $4,400 adjustment of additional expense related to the correction in the measurement of an acquisition-related contingent consideration obligation and (b) a $23,353 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses at September 30, 2016. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, 2016 As Previously Restatement As Restated Net product sales $ 483,746 $ (784 ) $ 482,962 Services revenue 124,809 — 124,809 Net product sales and services revenue 608,555 (784 ) 607,771 License and royalty revenue 2,533 — 2,533 Net revenue 611,088 (784 ) 610,304 Cost of net product sales 250,398 (561 ) 249,837 Cost of services revenue 78,294 — 78,294 Cost of net product sales and services revenue 328,692 (561 ) 328,131 Cost of license and royalty revenue 535 — 535 Cost of net revenue 329,227 (561 ) 328,666 Gross profit 281,861 (223 ) 281,638 Operating expenses: — Research and development 28,446 — 28,446 Sales and marketing 102,516 (72 ) 102,444 General and administrative 128,354 8,500 136,854 Impairment and (gain) loss on dispositions, net — — — Operating income 22,545 (8,651 ) 13,894 Interest expense, including amortization of original issue discounts and deferred financing costs (42,329 ) — (42,329 ) Other income (expense), net (14,112 ) 10,200 (3,912 ) Loss from continuing operations before provision (benefit) for income taxes (33,896 ) 1,549 (32,347 ) Provision (benefit) for income taxes 3,117 (535 ) 2,582 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (37,013 ) 2,084 (34,929 ) Equity earnings of unconsolidated entities, net of tax 2,122 — 2,122 Income (loss) from continuing operations (34,891 ) 2,084 (32,807 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (34,891 ) 2,084 (32,807 ) Less: Net income attributable to non-controlling 143 — 143 Net income (loss) attributable to Alere Inc. and Subsidiaries (35,034 ) 2,084 (32,950 ) Preferred stock dividends (5,308 ) — (5,308 ) Net income (loss) available to common stockholders $ (40,342 ) $ 2,084 $ (38,258 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.46 ) $ 0.02 $ (0.44 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.46 ) $ 0.02 $ (0.44 ) Weighted-average shares—basic and diluted 86,737 — 86,737 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (78,638 ) $ 2,084 $ (76,554 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) due to a $1,700 adjustment to decrease bad debt expense and (b) a $10,200 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses at June 30, 2016. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Six Months Ended June 30, 2016 As Previously Reported Restatement As Restated Net product sales $ 943,517 $ 7,947 $ 951,464 Services revenue 240,518 — 240,518 Net product sales and services revenue 1,184,035 7,947 1,191,982 License and royalty revenue 5,262 — 5,262 Net revenue 1,189,297 7,947 1,197,244 Cost of net product sales 487,859 3,302 491,161 Cost of services revenue 151,394 — 151,394 Cost of net product sales and services revenue 639,253 3,302 642,555 Cost of license and royalty revenue 1,926 — 1,926 Cost of net revenue 641,179 3,302 644,481 Gross profit 548,118 4,645 552,763 Operating expenses: — — — Research and development 55,508 — 55,508 Sales and marketing 202,329 755 203,084 General and administrative 243,310 8,500 251,810 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 50,781 (4,610 ) 46,171 Interest expense, including amortization of original issue discounts and deferred financing costs (84,435 ) — (84,435 ) Other income (expense), net (15,461 ) 10,200 (5,261 ) Loss from continuing operations before provision (benefit) for income taxes (49,115 ) 5,590 (43,525 ) Provision (benefit) for income taxes 2,909 (499 ) 2,410 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (52,024 ) 6,089 (45,935 ) Equity earnings of unconsolidated entities, net of tax 7,156 — 7,156 Income (loss) from continuing operations (44,868 ) 6,089 (38,779 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (44,868 ) 6,089 (38,779 ) Less: Net income attributable to non-controlling 246 — 246 Net income (loss) attributable to Alere Inc. and Subsidiaries (45,114 ) 6,089 (39,025 ) Preferred stock dividends (10,617 ) — (10,617 ) Net income (loss) available to common stockholders $ (55,731 ) $ 6,089 $ (49,642 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.64 ) $ 0.07 $ (0.57 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.64 ) $ 0.07 $ (0.57 ) Weighted-average shares—basic and diluted 86,692 — 86,692 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (66,370 ) $ 6,089 $ (60,281 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $1,700 adjustment to decrease bad debt expense and (b) a $10,200 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses at June 30, 2016. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2016 As Previously Restatement As Restated Net product sales $ 459,771 $ 8,731 $ 468,502 Services revenue 115,709 — 115,709 Net product sales and services revenue 575,480 8,731 584,211 License and royalty revenue 2,729 — 2,729 Net revenue 578,209 8,731 586,940 Cost of net product sales 237,461 3,863 241,324 Cost of services revenue 73,100 — 73,100 Cost of net product sales and services revenue 310,561 3,863 314,424 Cost of license and royalty revenue 1,391 — 1,391 Cost of net revenue 311,952 3,863 315,815 Gross profit 266,257 4,868 271,125 Operating expenses: — Research and development 27,062 — 27,062 Sales and marketing 99,813 827 100,640 General and administrative 114,956 — 114,956 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 28,236 4,041 32,277 Interest expense, including amortization of original issue discounts and deferred financing costs (42,106 ) — (42,106 ) Other income (expense), net (1,349 ) — (1,349 ) Loss from continuing operations before provision (benefit) for income taxes (15,219 ) 4,041 (11,178 ) Provision (benefit) for income taxes (208 ) 36 (172 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (15,011 ) 4,005 (11,006 ) Equity earnings of unconsolidated entities, net of tax 5,034 — 5,034 Income (loss) from continuing operations (9,977 ) 4,005 (5,972 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (9,977 ) 4,005 (5,972 ) Less: Net income attributable to non-controlling 103 — 103 Net income (loss) attributable to Alere Inc. and Subsidiaries (10,080 ) 4,005 (6,075 ) Preferred stock dividends (5,309 ) — (5,309 ) Net income (loss) available to common stockholders $ (15,389 ) $ 4,005 $ (11,384 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.18 ) $ 0.05 $ (0.13 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.18 ) $ 0.05 $ (0.13 ) Weighted-average shares—basic and diluted 86,646 — 86,646 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 12,268 $ 4,005 $ 16,273 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended December 31, 2015 As Previously Restatement As Net product sales $ 506,516 $ (6,149 ) $ 500,367 Services revenue 113,483 — 113,483 Net product sales and services revenue 619,999 (6,149 ) 613,850 License and royalty revenue 3,286 — 3,286 Net revenue 623,285 (6,149 ) 617,136 Cost of net product sales 298,795 (1,670 ) 297,125 Cost of services revenue 72,111 — 72,111 Cost of net product sales and services revenue 370,906 (1,670 ) 369,236 Cost of license and royalty revenue (650 ) — (650 ) Cost of net revenue 370,256 (1,670 ) 368,586 Gross profit 253,029 (4,479 ) 248,550 Operating expenses: Research and development 28,228 — 28,228 Sales and marketing 111,535 (644 ) 110,891 General and administrative 114,400 4,586 118,986 Impairment and (gain) loss on dispositions, net 8,132 — 8,132 Operating income (9,266 ) (8,421 ) (17,687 ) Interest expense, including amortization of original issue discounts and deferred financing costs (58,739 ) — (58,739 ) Other income (expense), net (6,329 ) 4,586 (1,743 ) Loss from continuing operations before provision (benefit) for income taxes (74,334 ) (3,835 ) (78,169 ) Provision (benefit) for income taxes (50,329 ) (817 ) (51,146 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (24,005 ) (3,018 ) (27,023 ) Equity earnings of unconsolidated entities, net of tax 5,210 — 5,210 Income (loss) from continuing operations (18,795 ) (3,018 ) (21,813 ) Income (loss) from discontinued operations, net of tax 2,736 — 2,736 Net income (loss) (16,059 ) (3,018 ) (19,077 ) Less: Net income attributable to non-controlling (5 ) — (5 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (16,054 ) (3,018 ) (19,072 ) Preferred stock dividends (5,367 ) — (5,367 ) Net income (loss) available to common stockholders $ (21,421 ) $ (3,018 ) $ (24,439 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.28 ) $ (0.03 ) $ (0.31 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.28 ) $ (0.03 ) $ (0.31 ) Weighted-average shares—basic and diluted 85,953 — 85,953 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (39,957 ) $ (3,018 ) $ (42,975 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustment to increase general and administrative expenses due to a $4,586 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses at December 31, 2015. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended September 30, 2015 As Previously Restatement As Restated Net product sales $ 472,128 $ 831 $ 472,959 Services revenue 128,341 — 128,341 Net product sales and services revenue 600,469 831 601,300 License and royalty revenue 3,299 — 3,299 Net revenue 603,768 831 604,599 Cost of net product sales 245,814 (385 ) 245,429 Cost of services revenue 79,851 — 79,851 Cost of net product sales and services revenue 325,665 (385 ) 325,280 Cost of license and royalty revenue 1,137 — 1,137 Cost of net revenue 326,802 (385 ) 326,417 Gross profit 276,966 1,216 278,182 Operating expenses: Research and development 36,011 — 36,011 Sales and marketing 106,493 231 106,724 General and administrative 101,306 — 101,306 Impairment and (gain) loss on dispositions, net 2,074 — 2,074 Operating income 31,082 985 32,067 Interest expense, including amortization of original issue discounts and deferred financing costs (52,333 ) — (52,333 ) Other income (expense), net 3,658 — 3,658 Loss from continuing operations before provision (benefit) for income taxes (17,593 ) 985 (16,608 ) Provision (benefit) for income taxes (10,212 ) 72 (10,140 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (7,381 ) 913 (6,468 ) Equity earnings of unconsolidated entities, net of tax 5,000 — 5,000 Income (loss) from continuing operations (2,381 ) 913 (1,468 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (2,381 ) 913 (1,468 ) Less: Net income attributable to non-controlling (61 ) — (61 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (2,320 ) 913 (1,407 ) Preferred stock dividends (5,369 ) — (5,369 ) Net income (loss) available to common stockholders $ (7,689 ) $ 913 $ (6,776 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.09 ) $ 0.01 $ (0.08 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.09 ) $ 0.01 $ (0.08 ) Weighted-average shares—basic and diluted 85,895 — 85,895 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (90,713 ) $ 913 $ (89,800 ) (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Quarterly Report on Form 10-Q for the period ended September 30, 2015 due most significantly to a $1,724 adjustment to increase revenue, a $1,087 adjustment to decrease other income and a $8,712 adjustment to decrease benefit for income taxes, with an overall impact of a $7,882 adjustment to decrease net income, which were identified during the preparation of the Annual Report on Form 10-K for 2015. (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Nine Months Ended September 30, 2015 As Previously Restatement As Restated Net product sales $ 1,447,515 $ (1,552 ) $ 1,445,963 Services revenue 378,825 — 378,825 Net product sales and services revenue 1,826,340 (1,552 ) 1,824,788 License and royalty revenue 13,691 — 13,691 Net revenue 1,840,031 (1,552 ) 1,838,479 Cost of net product sales 743,808 (1,787 ) 742,021 Cost of services revenue 232,277 — 232,277 Cost of net product sales and services revenue 976,085 (1,787 ) 974,298 Cost of license and royalty revenue 4,431 — 4,431 Cost of net revenue 980,516 (1,787 ) 978,729 Gross profit 859,515 235 859,750 Operating expenses: Research and development 91,225 — 91,225 Sales and marketing 323,596 (48 ) 323,548 General and administrative 255,170 — 255,170 Impairment and (gain) loss on dispositions, net 42,408 — 42,408 Operating income 147,116 283 147,399 Interest expense, including amortization of original issue discounts and deferred financing costs (158,258 ) — (158,258 ) Other income (expense), net 4,486 — 4,486 Loss from continuing operations before provision (benefit) for income taxes (6,656 ) 283 (6,373 ) Provision (benefit) for income taxes (2,376 ) (43 ) (2,419 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (4,280 ) 326 (3,954 ) Equity earnings of unconsolidated entities, net of tax 10,320 — 10,320 Income (loss) from continuing operations 6,040 326 6,366 Income (loss) from discontinued operations, net of tax 216,777 — 216,777 Net income (loss) 222,817 326 223,143 Less: Net income attributable to non-controlling 386 — 386 Net income (loss) attributable to Alere Inc. and Subsidiaries 222,431 326 222,757 Preferred stock dividends (15,927 ) — (15,927 ) Net income (loss) available to common stockholders $ 206,504 $ 326 $ 206,830 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.12 ) $ 0.00 $ (0.12 ) Income (loss) from discontinued operations 2.57 — 2.57 Net income (loss) per common share $ 2.45 $ 0.00 $ 2.45 Weighted-average shares—basic and diluted 85,141 — 85,141 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 98,666 $ 326 $ 98,992 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended September 30, 2015 due to a $678 adjustment to increase revenue, a $1,971 adjustment to increase cost of revenue and operating expenses, a $3,249 adjustment to decrease other income and a $7,633 adjustment to decrease benefit for income taxes with an overall impact of a $12,175 adjustment to decrease net income, which were identified during the preparation of the Annual Report on Form 10-K (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, 2015 As Previously Restatement As Net product sales $ 491,049 $ 603 $ 491,652 Services revenue 126,628 — 126,628 Net product sales and services revenue 617,677 603 618,280 License and royalty revenue 5,694 — 5,694 Net revenue 623,371 603 623,974 Cost of net product sales 257,893 894 258,787 Cost of services revenue 76,800 — 76,800 Cost of net product sales and services revenue 334,693 894 335,587 Cost of license and royalty revenue 1,344 — 1,344 Cost of net revenue 336,037 894 336,931 Gross profit 287,334 (291 ) 287,043 Operating expenses: Research and development 27,198 — 27,198 Sales and marketing 108,024 (118 ) 107,906 General and administrative 61,173 — 61,173 Impairment and (gain) loss on dispositions, net 5,542 — 5,542 Operating income 85,397 (173 ) 85,224 Interest expense, including amortization of original issue discounts and deferred financing costs (59,494 ) — (59,494 ) Other income (expense), net 3,195 — 3,195 Loss from continuing operations before provision (benefit) for income taxes 29,098 (173 ) 28,925 Provision (benefit) for income taxes 15,689 99 15,788 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax 13,409 (272 ) 13,137 Equity earnings of unconsolidated entities, net of tax 1,361 — 1,361 Income (loss) from continuing operations 14,770 (272 ) 14,498 Income (loss) from discontinued operations, net of tax — — — Net income (loss) 14,770 (272 ) 14,498 Less: Net income attributable to non-controlling 359 — 359 Net income (loss) attributable to Alere Inc. and Subsidiaries 14,411 (272 ) 14,139 Preferred stock dividends (5,308 ) — (5,308 ) Net income (loss) available to common stockholders $ 9,103 $ (272 ) $ 8,831 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ 0.11 $ (0.01 ) $ 0.10 Income (loss) from discontinued operations — — — Net income (loss) per common share $ 0.11 $ (0.01 ) $ 0.10 Weighted-average shares — basic 85,173 — 85,173 Weighted-average shares — diluted 86,635 — 86,635 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 60,763 $ (272 ) $ 60,491 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended June 30, 2016 and in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Quarterly Report on Form 10-Q for the period ended June 30, 2015 due to a $5,785 adjustment to decrease revenue, a $545 adjustment to decrease cost of revenue, a $1,200 adjustment to increase operating expenses, a $1,065 adjustment to decrease other income and a $2,012 adjustment to decrease provision for income taxes with an overall impact of a $5,493 adjustment to decrease net income, which were identified during the preparation of the Annual Report on Form 10-K (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Six Months Ended June 30, 2015 As Previously Restatement As Net product sales $ 975,387 $ (2,383 ) $ 973,004 Services revenue 250,484 — 250,484 Net product sales and services revenue 1,225,871 (2,383 ) 1,223,488 License and royalty revenue 10,392 — 10,392 Net revenue 1,236,263 (2,383 ) 1,233,880 Cost of net product sales 497,994 (1,402 ) 496,592 Cost of services revenue 152,426 — 152,426 Cost of net product sales and services revenue 650,420 (1,402 ) 649,018 Cost of license and royalty revenue 3,294 — 3,294 Cost of net revenue 653,714 (1,402 ) 652,312 Gross profit 582,549 (981 ) 581,568 Operating expenses: Research and development 55,214 — 55,214 Sales and marketing 217,103 (279 ) 216,824 General and administrative 153,864 — 153,864 Impairment and (gain) loss on dispositions, net 40,334 — 40,334 Operating income 116,034 (702 ) 115,332 Interest expense, including amortization of original issue discounts and deferred financing costs (105,925 ) — (105,925 ) Other income (expense), net 828 — 828 Loss from continuing operations before provision (benefit) for income taxes 10,937 (702 ) 10,235 Provision (benefit) for income taxes 7,836 (115 ) 7,721 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax 3,101 (587 ) 2,514 Equity earnings of unconsolidated entities, net of tax 5,320 — 5,320 Income (loss) from continuing operations 8,421 (587 ) 7,834 Income (loss) from disco
Restated and Revised Consolidated Statement of Comprehensive Income (Loss)	Year Ended December 31, 2015 As Previously Restatement Adjustment(1) As Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 58,709 $ (2,692 ) $ 56,017 (1) The restatement adjustment to total comprehensive income (loss) attributable to Alere Inc. and Subsidiaries is comprised solely of the restatement adjustment to net income (loss) for the period. Year Ended December 31, 2014 As Previously Restatement Adjustment(2) As Restated Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (199,889 ) $ 313 $ (199,576 ) (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K 10-K/A (2) The restatement adjustment to total comprehensive income (loss) attributable to Alere Inc. and Subsidiaries is comprised solely of the restatement adjustment to net income (loss) for the period.
Restated Consolidated Balance Sheets	ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except par value) As of December 31, 2015 As Restatement Adjustment(2) As ASSETS Current assets: Cash and cash equivalents $ 502,200 $ — $ 502,200 Restricted cash 5,694 — 5,694 Marketable securities 164 — 164 Accounts receivable, net of allowances of $89,701 at December 31, 2015 445,833 (8,909 ) 436,924 Inventories, net 347,001 3,948 350,949 Prepaid expenses and other current assets 152,233 (37,719 ) 114,514 Assets held for sale — current 4,165 — 4,165 Total current assets 1,457,290 (42,680 ) 1,414,610 Property, plant and equipment, net 446,039 — 446,039 Goodwill 2,836,915 — 2,836,915 Other intangible assets with indefinite lives 28,110 — 28,110 Finite-lived intangible assets, net 997,281 — 997,281 Restricted cash 43,228 — 43,228 Other non-current 18,078 — 18,078 Investments in unconsolidated entities 65,333 — 65,333 Deferred tax assets 13,993 — 13,993 Non-current 3,517 37,719 41,236 Assets held for sale — non-current 13,337 — 13,337 Total assets $ 5,923,121 $ (4,961 ) $ 5,918,160 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 199,992 $ — $ 199,992 Current portion of capital lease obligations 3,962 — 3,962 Accounts payable 195,752 — 195,752 Accrued expenses and other current liabilities 324,465 (1,828 ) 322,637 Liabilities related to assets held for sale — current 363 — 363 Total current liabilities 724,534 (1,828 ) 722,706 Long-term liabilities: Long-term debt, net of current portion 2,831,166 — 2,831,166 Capital lease obligations, net of current portion 7,181 — 7,181 Deferred tax liabilities 147,618 — 147,618 Other long-term liabilities 154,193 — 154,193 Total long-term liabilities 3,140,158 — 3,140,158 Commitments and contingencies Stockholders’ equity: Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at December 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares at December 31, 20154; Outstanding: 1,774 shares at December 31, 2015 606,468 — 606,468 Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,043 shares at December 31, 2015, Outstanding: 86,364 shares at December 31, 2015 94 — 94 Additional paid-in 3,438,732 — 3,438,732 Accumulated deficit (1,466,381 ) (3,133 ) (1,469,514 ) Treasury stock, at cost, 7,679 shares at December 31, 2015 (184,971 ) — (184,971 ) Accumulated other comprehensive loss (339,777 ) — (339,777 ) Total stockholders’ equity 2,054,165 (3,133 ) 2,051,032 Non-controlling 4,264 — 4,264 Total equity 2,058,429 (3,133 ) 2,055,296 Total liabilities and equity $ 5,923,121 $ (4,961 ) $ 5,918,160 (1) The figures presented in this column represent the amounts that were presented originally in the Annual Report on Form 10-K 2015-03 2015-15 non-current (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities, except for the $37,719 classification adjustment between current assets and non-current ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (in thousands, except par value) (unaudited) As of September 30, 2016 As Previously Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 566,213 $ — $ 566,213 Restricted cash 4,999 — 4,999 Marketable securities 75 — 75 Accounts receivable, net of allowance 427,241 (1,034 ) 426,207 Inventories, net 348,845 533 349,378 Prepaid expenses and other current assets 163,833 (39,443 ) 124,390 Total current assets 1,511,206 (39,944 ) 1,471,262 Property, plant and equipment, net 446,313 — 446,313 Goodwill 2,805,682 — 2,805,682 Other intangible assets with indefinite lives 27,991 — 27,991 Finite-lived intangible assets, net 864,785 — 864,785 Restricted cash 42,438 — 42,438 Other non-current 16,219 — 16,219 Investments in unconsolidated entities 80,885 — 80,885 Deferred tax assets 56,638 — 56,638 Non-current 3,517 35,955 39,472 Total assets $ 5,855,674 $ (3,989 ) $ 5,851,685 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 41,424 $ — $ 41,424 Current portion of capital lease obligations 3,713 — 3,713 Accounts payable 211,476 — 211,476 Accrued expenses and other current liabilities 449,897 (4,981 ) 444,916 Total current liabilities 706,510 (4,981 ) 701,529 Long-term liabilities: Long-term debt, net of current portion 2,905,067 — 2,905,067 Capital lease obligations, net of current portion 8,033 — 8,033 Deferred tax liabilities 52,513 — 52,513 Other long-term liabilities 133,182 4,400 137,582 Total long-term liabilities 3,098,795 4,400 3,103,195 Commitments and contingencies Stockholders’ equity: Series B preferred stock, $0.001 par value (liquidation preference: $709,701 at September 30, 2016); Authorized: 2,300 shares; Issued: 2,065 shares; Outstanding: 1,774 shares at September 30, 2016 606,406 — 606,406 Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,613 shares; Outstanding: 86,934 shares at September 30, 2016 95 — 95 Additional paid-in 3,465,898 — 3,465,898 Accumulated deficit (1,489,661 ) (3,408 ) (1,493,069 ) Treasury stock, at cost, 7,679 shares at September 30, 2016 (184,971 ) — (184,971 ) Accumulated other comprehensive loss (352,085 ) — (352,085 ) Total stockholders’ equity 2,045,682 (3,408 ) 2,042,274 Non-controlling 4,687 — 4,687 Total equity 2,050,369 (3,408 ) 2,046,961 Total liabilities and equity $ 5,855,674 $ (3,989 ) $ 5,851,685 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities, except for the $39,443 classification adjustment between non-current assets, current assets and current liabilities and the $4,400 adjustment to long-term liabilities. These adjustments relate to the correction of a classification related to a prepaid income tax balance and an increase in the liability related to a correction in the measurement of an acquisition-related contingent consideration obligation at September 30, 2016, respectively. ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (in thousands, except par value) (unaudited) As of June 30, 2016 As Previously Reported Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 506,164 $ — $ 506,164 Restricted cash 5,662 — 5,662 Marketable securities 74 — 74 Accounts receivable, net of allowance 427,222 739 427,961 Inventories, net 333,846 646 334,492 Prepaid expenses and other current assets 162,339 (37,462 ) 124,877 Total current assets 1,435,307 (36,077 ) 1,399,230 Property, plant and equipment, net 438,787 — 438,787 Goodwill 2,811,545 — 2,811,545 Other intangible assets with indefinite lives 28,279 — 28,279 Finite-lived intangible assets, net 909,208 — 909,208 Restricted cash 42,589 — 42,589 Other non-current 16,290 — 16,290 Investments in unconsolidated entities 74,511 — 74,511 Deferred tax assets 18,638 — 18,638 Non-current 3,517 37,983 41,500 Asset held for sale — non-current 12,223 — 12,223 Total assets $ 5,790,894 $ 1,906 $ 5,792,800 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 43,681 $ — $ 43,681 Current portion of capital lease obligations 3,500 — 3,500 Accounts payable 194,235 — 194,235 Accrued expenses and other current liabilities 320,526 (1,050 ) 319,476 Total current liabilities 561,942 (1,050 ) 560,892 Long-term liabilities: Long-term debt, net of current portion 2,920,789 — 2,920,789 Capital lease obligations, net of current portion 6,972 — 6,972 Deferred tax liabilities 140,864 — 140,864 Other long-term liabilities 148,165 — 148,165 Total long-term liabilities 3,216,790 — 3,216,790 Commitments and contingencies Stockholders’ equity: Series B preferred stock, $0.001 par value (liquidation preference: $709,701 at June 30, 2016); Authorized: 2,300 shares; Issued: 2,065 shares; Outstanding: 1,774 shares at June 30, 2016 606,406 — 606,406 Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,419 shares; Outstanding: 86,740 shares at June 30, 2016 94 — 94 Additional paid-in 3,458,639 — 3,458,639 Accumulated deficit (1,511,481 ) 2,956 (1,508,525 ) Treasury stock, at cost, 7,679 shares at June 30, 2016 (184,971 ) — (184,971 ) Accumulated other comprehensive loss (361,033 ) — (361,033 ) Total stockholders’ equity 2,007,654 2,956 2,010,610 Non-controlling 4,508 — 4,508 Total equity 2,012,162 2,956 2,015,118 Total liabilities and equity $ 5,790,894 $ 1,906 $ 5,792,800 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities, except for the $37,983 classification adjustment between non-current assets, current assets and current liabilities. That adjustment relates to the correction of a classification related to a prepaid income tax balance. ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (in thousands, except par value) (unaudited) As of March 31, 2016 As Previously Reported Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 490,663 $ — $ 490,663 Restricted cash 6,166 — 6,166 Marketable securities 71 — 71 Accounts receivable, net of allowance 459,292 (177 ) 459,115 Inventories, net 350,931 84 351,015 Prepaid expenses and other current assets 144,369 (37,740 ) 106,629 Total current assets 1,451,492 (37,833 ) 1,413,659 Property, plant and equipment, net 445,218 — 445,218 Goodwill 2,839,692 — 2,839,692 Other intangible assets with indefinite lives 28,760 — 28,760 Finite-lived intangible assets, net 962,633 — 962,633 Restricted cash 43,388 — 43,388 Other non-current 17,927 — 17,927 Investments in unconsolidated entities 74,744 — 74,744 Deferred tax assets 16,124 — 16,124 Non-current 3,517 37,698 41,215 Asset held for sale — non-current 11,813 — 11,813 Total assets $ 5,895,308 $ (135 ) $ 5,895,173 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 193,044 $ — $ 193,044 Current portion of capital lease obligations 4,048 — 4,048 Accounts payable 165,800 — 165,800 Accrued expenses and other current liabilities 315,995 (1,006 ) 314,989 Total current liabilities 678,887 (1,006 ) 677,881 Long-term liabilities: Long-term debt, net of current portion 2,823,654 — 2,823,654 Capital lease obligations, net of current portion 7,654 — 7,654 Deferred tax liabilities 144,483 — 144,483 Other long-term liabilities 155,842 — 155,842 Total long-term liabilities 3,131,633 — 3,131,633 Commitments and contingencies Stockholders’ equity: Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at March 31, 2016); Authorized: 2,300 shares; Issued: 2,065 shares; Outstanding: 1,774 shares at March 31, 2016 606,468 — 606,468 Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,415 shares; Outstanding: 86,736 shares at March 31, 2016 94 — 94 Additional paid-in 3,452,722 — 3,452,722 Accumulated deficit (1,476,461 ) 871 (1,475,590 ) Treasury stock, at cost, 7,679 shares at March 31, 2016 (184,971 ) — (184,971 ) Accumulated other comprehensive loss (317,429 ) — (317,429 ) Total stockholders’ equity 2,080,423 871 2,081,294 Non-controlling 4,365 — 4,365 Total equity 2,084,788 871 2,085,659 Total liabilities and equity $ 5,895,308 $ (135 ) $ 5,895,173 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities, except for the $37,740 classification adjustment between non-current assets, current assets and current liabilities. That adjustment relates to the correction of a classification related to a prepaid income tax balance. ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (in thousands, except par value) (unaudited) As of September 30, 2015 As of September 30, Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 479,381 $ — $ 479,381 Restricted cash 430,821 — 430,821 Marketable securities 157 — 157 Accounts receivable, net of allowance 439,250 (2,760 ) 436,490 Inventories, net 373,779 2,278 376,057 Deferred tax assets 30,771 — 30,771 Prepaid expenses and other current assets 121,023 — 121,023 Assets held for sale — current 25,312 — 25,312 Total current assets 1,900,494 (482 ) 1,900,012 Property, plant and equipment, net 445,872 — 445,872 Goodwill 2,842,921 — 2,842,921 Other intangible assets with indefinite lives 28,744 — 28,744 Finite-lived intangible assets, net 1,052,949 — 1,052,949 Restricted cash 44,148 — 44,148 Other non-current 19,635 — 19,635 Investments in unconsolidated entities 73,882 — 73,882 Deferred tax assets 5,380 — 5,380 Non-current 2,537 — 2,537 Assets held for sale — non-current 126,048 — 126,048 Total assets $ 6,542,610 $ (482 ) $ 6,542,128 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 604,092 $ — $ 604,092 Current portion of capital lease obligations 3,505 — 3,505 Accounts payable 194,246 — 194,246 Accrued expenses and other current liabilities 325,551 (367 ) 325,184 Liabilities related to assets held for sale — current 8,836 — 8,836 Total current liabilities 1,136,230 (367 ) 1,135,863 Long-term liabilities: Long-term debt, net of current portion 2,944,014 — 2,944,014 Capital lease obligations, net of current portion 7,346 — 7,346 Deferred tax liabilities 226,976 — 226,976 Other long-term liabilities 121,855 — 121,855 Liabilities related to assets held for sale — non-current 9,603 — 9,603 Total long-term liabilities 3,309,794 — 3,309,794 Commitments and contingencies Stockholders’ equity: Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at September 30, 2015); Authorized: 2,300 shares; Issued: 2,065 shares; Outstanding: 1,774 shares at September 30, 2015 606,468 — 606,468 Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 93,868 shares; Outstanding: 86,189 shares at September 30, 2015 94 — 94 Additional paid-in 3,436,666 — 3,436,666 Accumulated deficit (1,450,328 ) (115 ) (1,450,443 ) Treasury stock, at cost, 7,679 shares at September 30, 2015 (184,971 ) — (184,971 ) Accumulated other comprehensive loss (315,875 ) — (315,875 ) Total stockholders’ equity 2,092,054 (115 ) 2,091,939 Non-controlling 4,532 — 4,532 Total equity 2,096,586 (115 ) 2,096,471 Total liabilities and equity $ 6,542,610 $ (482 ) $ 6,542,128 (1) Adjusted retrospectively for the impact of the adoption of ASU 2015-03 2015-15 non-current (2) The amounts presented in this column have been revised from the figures presented earlier in the Quarterly Report on Form 10-Q for the period ended September 30, 2015 due most significantly to a decrease of $13,116 in accounts receivable, an increase of $11,553 in inventory, an increase of $13,095 in deferred tax assets, an increase of $10,215 in accrued expenses, an increase of $19,525 in deferred tax liabilities and a decrease of $13,345 in long-term liabilities, which were identified during the preparation of the Annual Report on Form 10-K (3) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities. ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (in thousands, except par value) (unaudited) As of June 30, 2015 As of June 30, 2015(1)(2) Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 464,871 $ — $ 464,871 Restricted cash 461,636 — 461,636 Marketable securities 175 — 175 Accounts receivable, net of allowance 458,227 (3,591 ) 454,636 Inventories, net 377,651 1,894 379,545 Deferred tax assets 33,732 — 33,732 Prepaid expenses and other current assets 125,559 — 125,559 Assets held for sale — current 28,631 — 28,631 Total current assets 1,950,482 (1,697 ) 1,948,785 Property, plant and equipment, net 448,891 — 448,891 Goodwill 2,853,551 — 2,853,551 Other intangible assets with indefinite lives 41,306 — 41,306 Finite-lived intangible assets, net 1,093,186 — 1,093,186 Other non-current 21,845 — 21,845 Investments in unconsolidated entities 69,594 — 69,594 Deferred tax assets 5,381 — 5,381 Non-current 2,611 — 2,611 Assets held for sale — non-current 129,194 — 129,194 Total assets $ 6,616,041 $ (1,697 ) $ 6,614,344 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 629,371 $ — $ 629,371 Current portion of capital lease obligations 4,643 — 4,643 Accounts payable 186,941 — 186,941 Accrued expenses and other current liabilities 315,222 (669 ) 314,553 Liabilities related to assets held for sale — current 7,663 — 7,663 Total current liabilities 1,143,840 (669 ) 1,143,171 Long-term liabilities: Long-term debt, net of current portion 2,912,147 — 2,912,147 Capital lease obligations, net of current portion 7,974 — 7,974 Deferred tax liabilities 243,298 — 243,298 Other long-term liabilities 131,578 — 131,578 Liabilities related to assets held for sale — non-current 11,527 — 11,527 Total long-term liabilities 3,306,524 — 3,306,524 Commitments and contingencies Stockholders’ equity: Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at June 30, 2015); Authorized: 2,300 shares; Issued: 2,065 shares; Outstanding: 1,774 shares at June 30, 2015 606,468 — 606,468 Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 93,224 shares; Outstanding: 85,545 shares at June 30, 2015 93 — 93 Additional paid-in 3,414,981 — 3,414,981 Accumulated deficit (1,448,006 ) (1,028 ) (1,449,034 ) Treasury stock, at cost, 7,679 shares at June 30, 2015 (184,971 ) — (184,971 ) Accumulated other comprehensive loss (227,481 ) — (227,481 ) Total stockholders’ equity 2,161,084 (1,028 ) 2,160,056 Non-controlling 4,593 — 4,593 Total equity 2,165,677 (1,028 ) 2,164,649 Total liabilities and equity $ 6,616,041 $ (1,697 ) $ 6,614,344 (1) Adjusted retrospectively for the impact of the adoption of ASU 2015-03 2015-15 non-current (2) The amounts presented in this column have been revised from the figures presented earlier in the Quarterly Report on Form 10-Q for the period ended June 30, 2015 due most significantly to a decrease of $14,459 in accounts receivable, an increase of $11,311 in inventory, an increase of $13,095 in deferred tax assets, an increase of $5,828 in accrued expenses, an increase of $15,807 in deferred tax liabilities and a decrease of $14,662 in long-term liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015. (3) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities. ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (in thousands, except par value) (unaudited) As of March 31, 2015 As of March 31, Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 414,495 $ — $ 414,495 Restricted cash 37,406 — 37,406 Marketable securities 173 — 173 Accounts receivable, net of allowance 461,528 (4,195 ) 457,333 Inventories, net 385,693 2,788 388,481 Deferred tax assets 37,961 — 37,961 Prepaid expenses and other current assets 117,924 — 117,924 Total current assets 1,455,180 (1,407 ) 1,453,773 Property, plant and equipment, net 447,326 — 447,326 Goodwill 2,880,164 — 2,880,164 Other intangible assets with indefinite lives 40,203 — 40,203 Finite-lived intangible assets, net 1,173,866 — 1,173,866 Other non-current 25,052 — 25,052 Investments in unconsolidated entities 95,551 — 95,551 Deferred tax assets 6,360 — 6,360 Non-current 2,545 — 2,545 Total assets $ 6,126,247 $ (1,407 ) $ 6,124,840 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 95,299 $ — $ 95,299 Current portion of capital lease obligations 5,072 — 5,072 Accounts payable 195,980 — 195,980 Accrued expenses and other current liabilities 368,560 (651 ) 367,909 Total current liabilities 664,911 (651 ) 664,260 Long-term liabilities: Long-term debt, net of current portion 2,987,422 — 2,987,422 Capital lease obligations, net of current portion 8,794 — 8,794 Deferred tax liabilities 262,117 — 262,117 Other long-term liabilities 123,428 — 123,428 Total long-term liabilities 3,381,761 — 3,381,761 Commitments and contingencies Stockholders’ equity: Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at March 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares; Outstanding: 1,774 shares at March 31, 2015 606,468 — 606,468 Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 92,561 shares; Outstanding: 84,882 shares at March 31, 2015 93 — 93 Additional paid-in 3,390,002 — 3,390,002 Accumulated deficit (1,462,417 ) (756 ) (1,463,173 ) Treasury stock, at cost, 7,679 shares at March 31, 2015 (184,971 ) — (184,971 ) Accumulated other comprehensive loss (273,834 ) — (273,834 ) Total stockholders’ equity 2,075,341 (756 ) 2,074,585 Non-controlling 4,234 — 4,234 Total equity 2,079,575 (756 ) 2,078,819 Total liabilities and equity $ 6,126,247 $ (1,407 ) $ 6,124,840 (1) Adjusted retrospectively for the impact of the adoption of ASU 2015-03 2015-15 non-current (2) The amounts presented in this column have been revised from the figures presented earlier in the Quarterly Report on Form 10-Q for the period ended March 31, 2015 due most significantly to a decrease of $10,135 in accounts receivable, an increase of $10,720 in inventory, an increase of $13,095 in deferred tax assets, an increase of $3,668 in accrued expenses, an increase of $16,254 in deferred tax liabilities and a decrease of $14,662 in long-term liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015. (3) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities.
Restated Consolidated Statements of Cash Flows	ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Year Ended December 31, 2015 As Restatement Adjustment(1) As Cash Flows from Operating Activities: Net income (loss) $ 206,757 $ (2,692 ) $ 204,065 Income (loss) from discontinued operations, net of tax 219,513 — 219,513 Income (loss) from continuing operations (12,756 ) (2,692 ) (15,448 ) Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities: Non-cash 12,831 — 12,831 Depreciation and amortization 309,264 — 309,264 Non-cash 26,391 — 26,391 Impairment of inventory 15,597 — 15,597 Impairment of intangible and long-lived assets 3,708 — 3,708 Loss on sale of fixed assets 3,925 — 3,925 Equity earnings of unconsolidated entities, net of tax (15,530 ) — (15,530 ) Deferred income taxes (99,389 ) — (99,389 ) Loss on extinguishment of debt 19,886 — 19,886 Loss related to impairment and net loss on disposition 50,540 — 50,540 Other non-cash 28,782 — 28,782 Non-cash (59,871 ) — (59,871 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net (14,380 ) 7,700 (6,680 ) Inventories, net (60,478 ) (3,457 ) (63,935 ) Prepaid expenses and other current assets (43,014 ) 37,719 (5,295 ) Accounts payable (10,783 ) — (10,783 ) Accrued expenses and other current liabilities 24,194 (1,551 ) 22,643 Other non-current 34,362 (37,719 ) (3,357 ) Cash paid for contingent consideration (6,315 ) — (6,315 ) Net cash provided by continuing operations 206,964 — 206,964 Net cash provided by discontinued operations 318 — 318 Net cash provided by operating activities 207,282 — 207,282 Cash Flows from Investing Activities: Increase in restricted cash (13,715 ) — (13,715 ) Purchases of property, plant and equipment (90,778 ) — (90,778 ) Proceeds from sale of property, plant and equipment 2,099 — 2,099 Cash received from business dispositions, net of cash divested 675,823 — 675,823 Cash paid for business acquisitions, net of cash acquired (60,135 ) — (60,135 ) Cash received from sales of marketable securities 92 — 92 Cash received from equity method investments 26,136 — 26,136 (Increase) decrease in other assets (1,794 ) — (1,794 ) Net cash provided by (used in) continuing operations 537,728 — 537,728 Net cash used in discontinued operations (209 ) — (209 ) Net cash provided by (used in) investing activities 537,519 — 537,519 Cash Flows from Financing Activities: Cash paid for financing costs (16,188 ) — (16,188 ) Cash paid for contingent purchase price consideration (14,223 ) — (14,223 ) Cash paid for dividends (21,293 ) — (21,293 ) Proceeds from issuance of common stock, net of issuance costs 79,185 — 79,185 Proceeds from issuance of short-term debt 1,511 — 1,511 Proceeds from issuance of long-term debt 2,162,162 — 2,162,162 Payments on short-term debt (25,584 ) — (25,584 ) Payments on long-term debt (2,656,386 ) — (2,656,386 ) Net (payments) proceeds under revolving credit facilities (127,536 ) — (127,536 ) Principal payments on capital lease obligations (5,618 ) — (5,618 ) Other (8,937 ) — (8,937 ) Net cash provided by (used in) continuing operations (632,907 ) — (632,907 ) Net cash used in discontinued operations (76 ) — (76 ) Net cash provided by (used in) financing activities (632,983 ) — (632,983 ) Foreign exchange effect on cash and cash equivalents (11,379 ) — (11,379 ) Net increase in cash and cash equivalents 100,439 — 100,439 Cash and cash equivalents, beginning of period — continuing operations 378,461 — 378,461 Cash and cash equivalents, beginning of period — discontinued operations 23,300 — 23,300 Cash and cash equivalents, end of period 502,200 — 502,200 Less: Cash and cash equivalents of discontinued operations, end of period — — — Cash and cash equivalents of continuing operations, end of period $ 502,200 $ — $ 502,200 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities, except for the $37,719 classification adjustment between current assets and non-current ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Year Ended December 31, 2014 As Previously Restatement Adjustment(2) As Cash Flows from Operating Activities: Net income (loss) $ (33,436 ) $ 313 $ (33,123 ) Income (loss) from discontinued operations, net of tax 138,318 — 138,318 Income (loss) from continuing operations (171,754 ) 313 (171,441 ) Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities: Non-cash 16,233 — 16,233 Depreciation and amortization 336,029 — 336,029 Non-cash 12,452 — 12,452 Tax benefit related to discontinued operations retained by Alere Inc. 9,845 — 9,845 Impairment of inventory 3,124 — 3,124 Impairment of intangible and long-lived assets 7,019 — 7,019 Loss on sale of fixed assets 6,545 — 6,545 Equity earnings of unconsolidated entities, net of tax (17,509 ) — (17,509 ) Deferred income taxes 12,254 — 12,254 Loss related to impairment and net loss on disposition 7,742 — 7,742 Other non-cash 4,965 — 4,965 Non-cash 7,677 — 7,677 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net (3,262 ) (1,002 ) (4,264 ) Inventories, net (68,033 ) 501 (67,532 ) Prepaid expenses and other current assets (51,998 ) — (51,998 ) Accounts payable 47,851 — 47,851 Accrued expenses and other current liabilities 37,698 188 37,886 Other non-current 13,254 — 13,254 Cash paid for contingent consideration (22,077 ) — (22,077 ) Net cash provided by continuing operations 188,055 — 188,055 Net cash provided by discontinued operations 43,468 — 43,468 Net cash provided by operating activities 231,523 — 231,523 Cash Flows from Investing Activities: Increase in restricted cash (5,446 ) — (5,446 ) Purchases of property, plant and equipment (100,562 ) — (100,562 ) Proceeds from sale of property, plant and equipment 1,486 — 1,486 Cash received from business dispositions, net of cash divested 45,076 — 45,076 Cash paid for business acquisitions, net of cash acquired (75 ) — (75 ) Cash received from investments 198 — 198 Proceeds from sale of equity investment 8,546 — 8,546 Cash received from sales of marketable securities 580 — 580 Cash received from equity method investments 980 — 980 (Increase) decrease in other assets 986 — 986 Net cash provided by (used in) continuing operations (48,231 ) — (48,231 ) Net cash used in discontinued operations (8,972 ) — (8,972 ) Net cash provided by (used in) investing activities (57,203 ) — (57,203 ) Cash Flows from Financing Activities: Cash paid for financing costs (1,528 ) — (1,528 ) Cash paid for contingent purchase price consideration (32,902 ) — (32,902 ) Cash paid for dividends (21,293 ) — (21,293 ) Proceeds from issuance of common stock, net of issuance costs 51,555 — 51,555 Proceeds from issuance of short-term debt 806 — 806 Proceeds from issuance of long-term debt 58 — 58 Payments on long-term debt (65,122 ) — (65,122 ) Net (payments) proceeds under revolving credit facilities (42,522 ) — (42,522 ) Excess tax benefits on exercised stock options 972 — 972 Principal payments on capital lease obligations (6,085 ) — (6,085 ) Purchase of non-controlling (623 ) — (623 ) Net cash provided by (used in) continuing operations (116,684 ) — (116,684 ) Net cash used in discontinued operations (1,471 ) — (1,471 ) Net cash provided by (used in) financing activities (118,155 ) — (118,155 ) Foreign exchange effect on cash and cash equivalents (16,312 ) — (16,312 ) Net increase in cash and cash equivalents 39,853 — 39,853 Cash and cash equivalents, beginning of period – continuing operations 355,431 — 355,431 Cash and cash equivalents, beginning of period – discontinued operations 6,477 — 6,477 Cash and cash equivalents, end of period 401,761 — 401,761 Less: Cash and cash equivalents of discontinued operations, end of period 23,300 — 23,300 Cash and cash equivalents of continuing operations, end of period $ 378,461 $ — $ 378,461 (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K 10-K/A non-current 10-K (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter and the consequential impact on inventory, accounts receivable and accrued liabilities.

Assets Held for Sale (Tables)

Assets Held for Sale (Tables)	12 Months Ended
	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Summarized Financial Information Related to ACS Companies and Health Management Business	The following summarized financial information related to the businesses of the ACS Companies and the health management business has been segregated from continuing operations and has been reported as discontinued operations in our consolidated statements of operations for the applicable periods. The results of the health management business are included in the 2014 and 2015 periods presented, given our January 9, 2015 divestiture of this business. The results of the ACS Companies, other than Wellogic, are included in 2014, given our October 31, 2014 divestiture of this business. Neither the health management business nor the ACS Companies are reported in 2016. The results are as follows (in thousands): For The Years Ended December 31, 2015 2014 Net revenue $ 7,373 $ 359,496 Cost of net revenue (4,413 ) (203,115 ) Research and development — — Sales and marketing (996 ) (56,808 ) General and administrative (5,001 ) (99,383 ) Interest expense (9 ) (506 ) Other income (expense), net 160 (1,799 ) Gain on disposal 364,850 — Income (loss) from discontinued operations before provision (benefit) for income taxes 361,964 (2,115 ) Provision (benefit) for income taxes 142,451 (140,433 ) Income (loss) from discontinued operations, net of tax $ 219,513 $ 138,318

Other Balance Sheet Informati40

Other Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Components of Selected Captions in Consolidated Balance Sheets	Components of selected captions in the consolidated balance sheets consist of (in thousands): December 31, 2016 2015 (As Inventories, net: Raw materials $ 97,652 $ 130,171 Work-in-process 69,086 69,178 Finished goods 142,182 151,600 $ 308,920 $ 350,949 December 31, 2016 2015 (As Prepaid expenses and other current assets: Prepaid expenses $ 28,685 $ 28,041 Prepaid income tax 10,248 12,482 Income taxes receivable 21,445 199 Royalty receivable 7,908 7,757 Other taxes receivable 19,478 15,333 Cash advances 4,097 3,902 Pension receivable 1,347 1,373 Grant receivable 182 651 Employee loans 73 123 Security deposits 3,232 7,014 Other receivable — 15,938 Other 21,912 21,701 $ 118,607 $ 114,514 December 31, 2016 2015 Property, plant and equipment, net: Machinery, laboratory equipment and tooling $ 507,355 $ 469,413 Land and buildings 166,852 169,226 Leasehold improvements 60,119 55,999 Computer software and equipment 176,609 161,192 Furniture and fixtures 29,544 27,325 940,479 883,155 Less: Accumulated depreciation (499,289 ) (437,116 ) $ 441,190 $ 446,039 December 31, 2016 2015 (As Accrued expenses and other current liabilities: Compensation and compensation-related $ 76,556 $ 80,468 Litigation settlements 42,910 4,856 Royalty obligations 20,339 18,912 Deferred revenue 24,309 40,998 Income taxes payable 23,278 14,245 Other taxes payable 30,937 28,320 Acquisition-related obligations 2,382 5,705 Other 174,132 129,133 $ 394,843 $ 322,637

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Summary of Aggregate Purchase Price Allocation	A summary of the fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,060 Intangible assets 4,220 Total assets acquired $ 7,766 Current liabilities $ 368 Non-current 928 Total liabilities assumed $ 1,296 Net assets acquired $ 6,470 Cash paid $ 6,470 A summary of the fair values of the net assets acquired from USD is as follows (in thousands): Total Current assets $ 4,698 Property, plant and equipment 182 Goodwill 29,365 Intangible assets 27,100 Total assets acquired $ 61,345 Current liabilities $ 1,210 Total liabilities assumed $ 1,210 Net assets acquired $ 60,135 Cash paid $ 60,135
Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives	The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- average Useful Life Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete 570 3.0 years Total intangible assets $ 4,220 The following are the intangible assets acquired in connection with the USD acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Total Weighted- average Useful Life Trademarks $ 1,600 10.0 years Customer relationships 24,800 13.0 years Non-compete 700 2.0 years Total intangible assets $ 27,100

Goodwill and Other Intangible42

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Goodwill and Other Intangible Assets	The following is a summary of goodwill and other intangible assets as of December 31, 2016 (dollars in thousands): Gross Carrying Amount Accumulated Amortization and Impairment Losses Net Carrying Weighted- average Useful Life Amortized intangible assets: Core technology and patents $ 899,878 $ 519,698 $ 380,180 15.1 years Other intangible assets: Supplier relationships 17,027 16,090 937 9.1 years Trademarks and trade names 239,714 191,707 48,007 10.7 years License agreements 10,885 10,885 — 7.0 years Customer relationships 1,415,919 1,066,001 349,918 16.6 years Manufacturing know-how 19,600 18,369 1,231 7.6 years Other 106,373 81,069 25,304 7.6 years Total other intangible assets 1,809,518 1,384,121 425,397 Total intangible assets with finite lives $ 2,709,396 $ 1,903,819 $ 805,577 Intangible assets with indefinite lives: Goodwill $ 2,759,366 Other intangible assets(1) 27,164 Total intangible assets with indefinite lives $ 2,786,530 (1) Primarily includes in-process The following is a summary of goodwill and other intangible assets as of December 31, 2015 (dollars in thousands): Gross Accumulated Net Weighted- Amortized intangible assets: Core technology and patents $ 907,629 $ 468,497 $ 439,132 15.1 years Other intangible assets: Supplier relationships 17,599 16,218 1,381 9.2 years Trademarks and trade names 242,473 176,325 66,148 10.7 years License agreements 10,963 10,944 19 7.0 years Customer relationships 1,441,386 985,844 455,542 16.6 years Manufacturing know-how 19,181 16,744 2,437 7.7 years Other 108,217 75,595 32,622 7.7 years Total other intangible assets 1,839,819 1,281,670 558,149 Total intangible assets with finite lives $ 2,747,448 $ 1,750,167 $ 997,281 Intangible assets with indefinite lives: Goodwill $ 2,836,915 Other intangible assets(1) 28,110 Total intangible assets with indefinite lives $ 2,865,025 (1) Primarily includes in-process
Summary of Estimated Amortization Expense of Intangible Assets	The following is a summary of estimated aggregate amortization expense of intangible assets for each of the five succeeding fiscal years as of December 31, 2016 (in thousands): 2017 $ 139,827 2018 $ 116,326 2019 $ 102,824 2020 $ 84,893 2021 $ 68,762
Summary of Goodwill Amounts Allocated to Other Non-Reportable and Reporting Segments	Goodwill amounts for our professional diagnostics, consumer diagnostics and other non-reportable reporting segments are summarized as follows (in thousands): Professional Consumer Other non- Total Goodwill at December 31, 2014 $ 2,847,406 $ 54,991 $ 24,269 $ 2,926,666 Acquisitions(1) 32,970 — — 32,970 Dispositions(2) (58,612 ) — — (58,612 ) Other(3) (53,080 ) (11,029 ) — (64,109 ) Goodwill at December 31, 2015 $ 2,768,684 $ 43,962 $ 24,269 $ 2,836,915 Acquisitions(1) 2,060 — — 2,060 Other(3) (70,910 ) (8,699 ) — (79,609 ) Goodwill at December 31, 2016 $ 2,699,834 $ 35,263 $ 24,269 $ 2,759,366 (1) Includes initial purchase price allocation and purchase accounting adjustments. (2) Reflects write-off (3) These amounts relate primarily to adjustments resulting from fluctuations in foreign currency exchange rates.

Long-term Debt (Tables)

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt Balances Outstanding	We had the following long-term debt balances outstanding (in thousands) as of December 31, 2016 and 2015, respectively: December 31, 2016 December 31, 2015 A term loans(1)(2)(3) $ 544,745 $ 575,746 B term loans(1)(2)(3) 952,664 965,740 Revolving loans(1)(2)(3) 125,000 — 7.25% Senior notes(2)(3) 442,709 446,320 6.5% Senior subordinated notes(2)(3) 415,102 419,209 6.375% Senior subordinated notes(2)(3) 412,831 418,133 3% Convertible senior subordinated notes(4) — 149,839 Other lines of credit 1,124 136 Other 46,400 56,035 2,940,575 3,031,158 Less: Short-term debt and current portion of long-term debt (82,370 ) (199,992 ) Long-term debt $ 2,858,205 $ 2,831,166 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully below in this Note 9, (i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes due 2018, or the 7.25% senior notes, our 6.5% senior subordinated notes due 2020, or the 6.5% senior subordinated notes, our 6.375% senior subordinated notes due 2023, or the 6.375% senior subordinated notes, and our 3% convertible senior subordinated notes due 2016, or the 3% convertible senior subordinated notes, as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K 10-Q 10-Q 10-Q 10-Q (3) See Note 30, Subsequent Events, for information regarding the April 2017 and May 2017 amendments to the Credit Agreement and the May 2017 and June 2017 consent solicitations to the holders of our 7.25% senior notes, our 6.5% senior subordinated notes and our 6.375% senior subordinated notes as a result of, among other things, our failure to timely furnish to the holders of such debt our financial statements for the year ended December 31, 2016 and the quarter ended March 31, 2017. (4) The principal amount of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheets as of December 31, 2015, as these notes matured (and were fully paid and discharged) in May 2016.
Long-Term Debt Interest Expense	In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for 2016, 2015 and 2014, respectively, as follows (in thousands): 2016 2015 2014 Secured credit facility(1)(4) $ 72,543 $ 38,335 $ — Prior credit facility(2)(3) — 49,437 99,399 7.25% Senior notes(4) 36,172 34,103 34,098 6.375% Senior subordinated notes(4) 28,599 14,549 — 6.5% Senior subordinated notes(4) 29,717 28,987 29,057 8.625% Senior subordinated notes(4) — 44,219 37,092 3% Convertible senior subordinated notes 1,847 4,984 4,984 Other 2,773 2,383 4,561 $ 171,651 $ 216,997 $ 209,191 (1) Includes “A” term loans, “B” term loans, and revolving loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” B-2” (3) For 2015, the amount includes a $3.5 million loss on extinguishment of debt associated with our prior credit facility. (4) For 2016, 2015 and 2014, the amounts include $4.5 million, $1.1 million and $1.5 million, respectively, related to the amortization of fees paid for certain debt modifications.
Summary of Maturities of Long-Term Debt Outstanding Including Current Portion	The following is a summary of the maturities of long-term debt, including the current portions thereof, outstanding on December 31, 2016 (in thousands): 2017 $ 82,447 2018 491,275 2019 41,275 2020 1,030,441 2021 10,988 Thereafter 1,340,335 2,996,761 Less: Debt issuance costs (51,886 ) Less: Original issue discounts (4,300 ) $ 2,940,575

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques	The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2016 and 2015, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description December 31, 2016 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Marketable securities $ 76 $ 76 $ — $ — Total assets $ 76 $ 76 $ — $ — Liabilities: Contingent consideration obligations(1) $ 43,200 $ — $ — $ 43,200 Total liabilities $ 43,200 $ — $ — $ 43,200 Description December 31, 2015 Quoted Prices in Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Marketable securities $ 164 $ 164 $ — $ — Total assets $ 164 $ 164 $ — $ — Liabilities: Contingent consideration obligations(1) $ 57,744 $ — $ — $ 57,744 Total liabilities $ 57,744 $ — $ — $ 57,744 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out earn-out
Changes in Fair Value of Contingent Consideration Obligations	Changes in the fair value of our Level 3 contingent consideration obligations during the years ended December 31, 2016 and 2015 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2014 $ 139,671 Payments (22,073 ) Fair value adjustments (59,871 ) Foreign currency adjustments 17 Fair value of contingent consideration obligations, December 31, 2015 $ 57,744 Payments (1,236 ) Fair value adjustments (13,309 ) Foreign currency adjustments 1 Fair value of contingent consideration obligations, December 31, 2016 $ 43,200

Capital Leases (Tables)

Capital Leases (Tables)	12 Months Ended
	Dec. 31, 2016
Leases [Abstract]
Schedule of Future Minimum Lease Payments with Present Value	The following is a schedule of the future minimum lease payments under capital leases as of December 31, 2016 (in thousands): 2017 $ 3,064 2018 2,583 2019 2,869 2020 790 2021 457 Thereafter 522 Total future minimum lease payments 10,285 Less: Current portion (3,064 ) $ 7,221
Capitalized Amounts of Building, Machinery and Equipment and Computer Equipment	At December 31, 2016 and 2015, the capitalized amounts of the building, machinery and equipment and computer equipment under capital leases were as follows (in thousands): December 31, December 31, Machinery, laboratory equipment and tooling $ 26,794 $ 24,258 Computer equipment 208 888 Furniture and fixtures 1,106 606 Vehicles 206 197 Leasehold improvements — 927 28,314 26,876 Less: Accumulated amortization (10,165 ) (9,214 ) $ 18,149 $ 17,662

Postretirement Benefit Plans (T

Postretirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Changes in Benefit Obligations, Plan Assets, Funded Status and Amounts Recognized	Changes in benefit obligations, plan assets, funded status and amounts recognized on the accompanying balance sheet as of and for the years ended December 31, 2016 and 2015, for our Defined Benefit Plan were as follows (in thousands): 2016 2015 Change in projected benefit obligation Benefit obligation at beginning of year $ 21,499 $ 22,560 Interest cost 721 784 Actuarial loss (gain) 5,426 (638 ) Benefits paid (324 ) (179 ) Foreign exchange impact (4,308 ) (1,028 ) Benefit obligation at end of year $ 23,014 $ 21,499 Change in plan assets Fair value of plan assets at beginning of year $ 18,485 $ 18,120 Actual return on plan assets 3,297 491 Employer contribution 814 917 Benefits paid (324 ) (179 ) Foreign exchange impact (3,652 ) (864 ) Fair value of plan assets at end of year $ 18,620 $ 18,485 Funded status $ (4,394 ) $ (3,014 ) Accumulated benefit obligation $ 23,014 $ 21,499
Amounts Recognized in Other Comprehensive Loss	The following represents the amounts recognized in other comprehensive loss, related to our Unipath Defined Benefit Pension Plan for the years ended December 31, 2016 and 2015 (in thousands): 2016 2015 Amortization of net loss $ (279 ) $ (332 ) Amortization of prior service cost (275 ) (310 ) New actuarial loss (3,247 ) (55 ) Foreign exchange impact 4,991 (1,134 ) Total $ 1,190 $ (1,831 )
Amounts Recognized in Accumulated Other Comprehensive Loss	Amounts recognized in accumulated other comprehensive loss at December 31, 2016 and 2015 are as follows: 2016 2015 Net actuarial loss $ 6,967 $ 5,109 Prior service cost 1,744 2,412 Net amount recognized $ 8,711 $ 7,521
Weighted-Average Actuarial Assumptions	The following table provides the weighted-average actuarial assumptions: 2016 2015 Assumptions used to determine benefit obligations(1): Discount rate 2.70 % 3.70 % Rate of compensation increase 4.05 % 3.95 % Assumptions used to determine net periodic benefit cost(2): Discount rate 3.70 % 3.55 % Expected long-term return on plan assets 6.55 % 6.50 % Rate of compensation increase 3.95 % 3.85 % (1) The actuarial assumptions used to compute the unfunded status for the plan are based upon information available as of December 31, 2016 and 2015. (2) The actuarial assumptions used to compute the net periodic pension benefit cost are based upon the information available as of the beginning of the presented year.
Net Periodic Benefit Costs	The annual net periodic benefit costs of the Defined Benefit Plan are as follows (in thousands): 2016 2015 2014 Service cost $ — $ — $ — Interest cost 721 784 938 Expected return on plan assets (1,119 ) (1,183 ) (1,022 ) Amortization of net loss 279 332 267 Amortization of prior service cost 275 310 438 Net periodic benefit cost $ 156 $ 243 $ 621
Fair Values of Pension Plan Assets	The fair values of our pension plan assets at December 31, 2016 and 2015 by asset category are presented in the following table (Level 2 in the fair value hierarchy). Plan Assets at December 31, Asset Category 2016 2015 Equity securities: U.K. equities $ 5,965 $ 6,096 Overseas equities 3,005 3,119 U.S. equities 4,379 3,781 Debt securities — corporate bonds 5,194 4,984 Other — cash 77 505 Total plan assets $ 18,620 $ 18,485

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Annual Rental Payments Under Operating Leases	We have operating lease commitments for certain of our facilities and equipment that expire on various dates through 2028. The following schedule outlines future minimum annual rental payments under these leases at December 31, 2016 (in thousands): 2017 $ 37,801 2018 30,852 2019 24,894 2020 21,492 2021 16,830 Thereafter 38,600 $ 170,469
Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions	The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions (in thousands): Acquisition Acquisition Date Acquisition Date Fair Value Maximum Remaining Earn-out as of December 31, 2016 Remaining Earn-out Period as of December 31, 2016 Estimated Fair Value as Estimated Fair Value as Payments Made During 2016 TwistDx, Inc.(1) March 11, 2010 $ 35,600 $ 102,694 2017 — 2025 (3) $ 35,700 $ 47,800 $ 553 Epocal(2) February 1, 2013 $ 75,000 $ 19,600 2017 — 2018 3,000 4,700 — Other Various $ 30,373 $ — 4,500 5,244 683 $ 43,200 $ 57,744 $ 1,236 (1) The terms of the acquisition agreement require us to pay earn-outs upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out

Net Income (Loss) Per Common 48

Net Income (Loss) Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Income (Loss) Per Common Share	The following tables set forth the computation of basic and diluted net income (loss) per common share (in thousands, except per share amounts): 2016 2015 (As 2014 (As Restated) Basic and diluted net income (loss) per common share: Numerator: Loss from continuing operations $ (137,269 ) $ (15,448 ) $ (171,441 ) Preferred stock dividends (21,350 ) (21,293 ) (21,293 ) Loss from continuing operations attributable to common shares (158,619 ) (36,741 ) (192,734 ) Less: Net income attributable to non-controlling 350 381 30 Loss from continuing operations attributable to Alere Inc. and Subsidiaries (158,969 ) (37,122 ) (192,764 ) Income from discontinued operations — 219,513 138,318 Net income (loss) available to common stockholders $ (158,969 ) $ 182,391 $ (54,446 ) Denominator: Weighted-average common shares outstanding — basic and diluted 86,796 85,420 82,938 Basic and diluted net income (loss) per common share: Loss from continuing operations attributable to Alere Inc. and Subsidiaries $ (1.83 ) $ (0.43 ) $ (2.33 ) Income from discontinued operations — 2.57 1.67 Basic and diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries $ (1.83 ) $ 2.14 $ (0.66 )
Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share	The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share for our continuing operations because the inclusion thereof would be antidilutive (in thousands): 2016 2015 2014 Denominator: Options to purchase shares of common stock and RSUs 6,774 6,793 7,140 Warrants — 4 4 Conversion shares related to 3% convertible senior subordinated notes 1,267 3,411 3,411 Conversion shares related to subordinated convertible promissory notes — — 27 Conversion shares related to Series B convertible preferred stock 10,238 10,239 10,239 Common stock equivalents related to the settlement of a contingent consideration obligation — 14 — Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 18,279 20,461 20,821

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Summary of Stock Option Activity	The following summarizes all stock option activity during the year ended December 31, 2016 (in thousands, except exercise price): Stock Options Weighted- average Exercise Price Weighted (in years) Aggregate (in millions) Outstanding at January 1, 2014 11,441 $ 37.66 Granted 1,287 $ 36.84 Exercised (1,512 ) $ 28.29 Canceled/expired/forfeited (3,852 ) $ 46.66 Outstanding at December 31, 2014 7,364 $ 34.68 Granted 2,399 $ 46.47 Exercised (2,168 ) $ 34.26 Canceled/expired/forfeited (1,454 $ 38.91 Outstanding at December 31, 2015 6,141 $ 38.43 Granted 6 $ 35.80 Exercised (437 ) $ 34.68 Canceled/expired/forfeited (369 ) $ 45.33 Outstanding at December 31, 2016 5,341 $ 38.25 6.30 $ 26.1 Exercisable at December 31, 2016 3,351 $ 34.81 5.28 $ 24.0 Total vested and expected to vest as of December 31, 2016 5,211 $ 38.06 6.26 $ 26.1
Summary of Restricted Stock Unit Activity	The following summarizes all restricted stock unit activity during the year ended December 31, 2016 (in thousands, except grant date fair value): Restricted Stock Units Weighted- average Fair Value Nonvested at January 1, 2016 650 $ 31.00 Granted 1,069 $ 52.03 Vested (261 ) $ 31.84 Forfeited (46 ) $ 45.39 Nonvested at December 31, 2016 1,412 $ 46.29
Summary of Stock Appreciation Rights	The following summarizes all stock appreciation rights, or SARs, activity during the year ended December 31, 2016 (in thousands): Stock Appreciation Rights Nonvested at January 1, 2016 188 Granted 22 Exercised (41 ) Forfeited. (24 ) Nonvested at December 31, 2016 145

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Expense	We recorded stock-based compensation expense in our consolidated statements of operations for the years ended December 31, 2016, 2015 and 2014, respectively, as follows (in thousands): 2016 2015 2014 Cost of net revenue $ 2,054 $ 1,198 $ 1,180 Research and development 1,905 1,195 (41 ) Sales and marketing 8,991 4,794 3,940 General and administrative 28,846 19,204 7,373 41,796 26,391 12,452 Benefit for income taxes (520 ) (8,815 ) (2,891 ) Stock-based compensation, net of tax $ 41,276 $ 17,576 $ 9,561
Fair Value Assumptions for Stock Options on the Date of Grant	The following assumptions were used to estimate the fair value of options granted during the years ended December 31, 2016, 2015 and 2014, using a Black-Scholes option-pricing model: 2016 2015 2014 Risk-free interest rate 1.27 % 1.62 % 1.77 % Expected dividend yield — — — Expected life 5.44 years 5.59 years 5.78 years Expected volatility 35 % 33 % 36 %

Accumulated Other Comprehensi51

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Summary of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consisted of the following (in thousands): Cumulative Translation Adjustment Pension Liability Adjustment Other(1) Accumulated Other Comprehensive Loss Balance at December 31, 2013 $ (18,649 ) $ (7,017 ) $ (21 ) $ (25,687 ) Period change (166,448 ) 4 21 (166,423 ) Balance at December 31, 2014 (185,097 ) (7,013 ) — (192,110 ) Period change (146,438 ) (1,229 ) — (147,667 ) Balance at December 31, 2015 (331,535 ) (8,242 ) — (339,777 ) Period change (122,287 ) (334 ) — (122,621 ) Balance at December 31, 2016 $ (453,822 ) $ (8,576 ) $ — $ (462,398 ) (1) Other represents unrealized gains (losses) on available-for-sale

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Summary of Income (Loss) Before Provision (Benefit) for Income Taxes, Continuing Operations, Excluding Equity Earnings of Unconsolidated Entities	Income (loss) before provision (benefit) for income taxes consists of the following (in thousands): Continuing operations, excluding equity earnings of unconsolidated entities: 2016 2015 (As Restated) 2014 (As Restated) United States $ (339,940 ) $ (226,051 ) $ (184,936 ) Foreign 187,542 141,509 67,016 $ (152,398 ) $ (84,542 ) $ (117,920 )
Components of Deferred Tax Assets and Liabilities	The income tax effects of these temporary differences, are as follows (in thousands): 2016 2015 (As Restated)(1) Deferred tax assets: NOL and capital loss carryforwards $ 274,796 $ 207,812 Tax credit carryforwards 123,216 107,750 Nondeductible reserves 40,936 45,053 Accrued liabilities 48,423 26,490 Difference between book and tax bases of tangible assets 4,388 1,735 Difference between book and tax bases of intangible assets 17,735 19,678 Deferred revenue 7,190 7,426 All other 9,765 16,477 Gross deferred tax assets 526,449 432,421 Less: Valuation allowance (323,272 ) (248,307 ) Total deferred tax assets 203,177 184,114 Deferred tax liabilities: Difference between book and tax bases of tangible assets 18,104 20,990 Difference between book and tax bases of intangible assets 233,646 277,871 Debt 7,075 2,344 Difference between book and tax bases of investment in subsidiaries 29,625 — Other 13,342 16,534 Total deferred tax liabilities 301,792 317,739 Net deferred tax liabilities $ (98,615 ) $ (133,625 ) (1) In addition to the impact from the Restatement, we have also corrected in this table the reported amounts for deferred tax assets for NOL and capital loss carryforwards and the valuation allowance to correct an error. We have previously reported deferred tax assets for NOL and capital loss carryforwards of $221,728 and a total valuation allowance of $262,223. These amounts were each reduced by $13,916 to correct the error. This adjustment has no impact on the consolidated balance sheet or results of operations for any period presented. 2016 2015 (As Restated) Net non-current $ 20,483 $ 13,993 Net non-current (119,098 ) (147,618 ) Net deferred tax liabilities $ (98,615 ) $ (133,625 )
Components of Provision (Benefit) for Income Taxes	The following table presents the components of our provision (benefit) for income taxes (in thousands) for continuing operations: 2016 2015 (As Restated) 2014 (As Restated) Current: Federal $ 5,168 $ (12,027 ) $ 3,949 State 1,606 2,331 487 Foreign 64,612 55,519 54,340 71,386 45,823 58,776 Deferred: Federal (49,569 ) (71,748 ) 25,629 State 8,059 (8,572 ) (4,142 ) Foreign 5,500 (19,067 ) (9,233 ) (36,010 ) (99,387 ) 12,254 Total provision (benefit) for income taxes $ 35,376 $ (53,564 ) $ 71,030
Reconciliation from U.S. Statutory Tax Rate to Effective Tax Rate, Continuing Operations, Excluding Equity Earnings of Unconsolidated Subsidiaries	The following table presents a reconciliation from the U.S. statutory tax rate to our effective tax rate, for continuing operations, excluding equity earnings of unconsolidated subsidiaries: 2016 2015 (As Restated) 2014 (As Restated) Statutory rate 35 % 35 % 35 % Stock-based compensation (3 ) (1 ) (1 ) Rate differential on foreign earnings 18 18 4 Impact of foreign inclusion — — (2 ) U.S. federal research and development credit 2 2 1 State income taxes, net of federal benefit (3 ) 6 3 Contingent consideration 3 25 (3 ) Rate changes 1 1 (3 ) Return to provision (2 ) 4 19 Other permanent items (2 ) (1 ) 3 Change in valuation allowance (40 ) (8 ) (73 ) Foreign dividends, net (11 ) (12 ) (19 ) Uncertain tax positions (5 ) (5 ) (19 ) Withholding taxes — (2 ) (6 ) Sale of business (3 ) — — Non-deductible (4 ) — — Gain on sale of equity investments (9 ) — — Effective tax rate (23 )% 62 % (61 )%
Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for uncertain tax positions excluding interest and penalties is as follows (in thousands): Amount Balance as of January 1, 2014 $ 30,394 Additions for tax positions related to prior years 20,797 Additions for tax positions related to current year 3,217 Reductions for tax positions related to prior years (4,477 ) Balance as of December 31, 2014 49,931 Additions for tax positions related to prior years 823 Additions for tax positions related to current year 71,505 Reductions for tax positions related to prior years (1,552 ) Balance as of December 31, 2015 $ 120,707 Additions for tax positions related to prior years 3,296 Additions for tax positions related to current year 11,062 Reductions for tax positions related to prior years (3,711 ) Balance as of December 31, 2016 $ 131,354

Financial Information by Segm53

Financial Information by Segment (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Performance of Our Operating Segments Based on Revenue and Operating Income (Loss)	Segment information for 2016, 2015 and 2014 and as of December 31, 2016 and 2015 is as follows (in thousands): 2016 Professional Diagnostics Consumer Diagnostics Other Non- Reportable Corporate and Other Total Net revenue $ 2,159,680 $ 74,152 $ 142,503 $ — $ 2,376,335 Operating income (loss) $ 302,759 $ 475 $ 25,250 $ (313,760 ) $ 14,724 Depreciation and amortization $ 253,853 $ 5,266 $ 17,651 $ 8,838 $ 285,608 Restructuring charge $ 15,890 $ — $ — $ 21,995 $ 37,885 Stock-based compensation $ — $ — $ — $ 41,796 $ 41,796 Assets $ 5,199,806 $ 175,362 $ 87,193 $ 185,918 $ 5,648,279 Expenditures for property, plant and equipment $ 58,151 $ 1,508 $ 4,169 $ 3,866 $ 67,694 2015 Professional Diagnostics Consumer Diagnostics Other Non- Reportable Corporate and Other Total Net revenue, as restated $ 2,241,391 $ 85,128 $ 129,096 $ — $ 2,455,615 Operating income (loss) , as restated $ 330,664 $ 2,872 $ 13,000 $ (216,824 ) $ 129,712 Depreciation and amortization $ 282,411 $ 2,836 $ 16,912 $ 7,105 $ 309,264 Restructuring charge $ 14,305 $ — $ — $ 1,362 $ 15,667 Stock-based compensation $ — $ — $ — $ 26,391 $ 26,391 Assets $ 5,515,576 $ 172,551 $ 99,364 $ 130,669 $ 5,918,160 Expenditures for property, plant and equipment $ 73,490 $ 1,403 $ 3,175 $ 12,710 $ 90,778 2014 Professional Diagnostics Consumer Diagnostics Other Non- Reportable Segment Corporate and Other Total Net revenue, as restated $ 2,369,885 $ 89,087 $ 118,029 $ — $ 2,577,001 Operating income (loss) , as restated $ 160,805 $ 11,921 $ 12,233 $ (90,281 ) $ 94,678 Depreciation and amortization $ 318,051 $ 692 $ 13,831 $ 3,455 $ 336,029 Restructuring charge $ 44,503 $ — $ — $ 14,235 $ 58,738 Stock-based compensation $ — $ — $ — $ 12,452 $ 12,452 Expenditures for property, plant and equipment $ 76,111 $ 3,360 $ 3,023 $ 18,068 $ 100,562
Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services	The following tables summarize our net revenue from the professional diagnostics reporting segment by groups of similar products and services for 2016, 2015 and 2014 (in thousands): 2016 2015 (As Restated) 2014 (As Restated) Cardiometabolic $ 622,468 $ 703,553 $ 725,423 Infectious disease 776,153 710,178 723,715 Toxicology 608,635 618,362 644,621 Other 140,426 192,321 255,076 Professional diagnostics net product sales and services revenue 2,147,682 2,224,414 2,348,835 License and royalty revenue 11,998 16,977 21,050 Professional diagnostics net revenue $ 2,159,680 $ 2,241,391 $ 2,369,885
Summary of Revenue and Long-lived Tangible Assets for Segments by Geographic Area	The following tables summarize our net revenue for all segments by geographic area for 2016, 2015 and 2014, respectively, and our long-lived tangible assets by geographic area as of December 31, 2016 and 2015, respectively (in thousands): 2016 2015 (As 2014 (As Revenue by Geographic Area: United States $ 1,294,013 $ 1,372,039 $ 1,366,739 Europe 401,692 437,653 533,116 Elsewhere(1) 680,630 645,923 677,146 $ 2,376,335 $ 2,455,615 $ 2,577,001 (1) Includes, among many others, the following countries: China, India, Japan, South Korea, Brazil, Canada, Uganda and Nigeria. December 31, 2016 2015 Long-lived Tangible Assets by Geographic Area: United States $ 267,519 $ 261,385 United Kingdom 21,342 26,512 China 30,161 28,705 Elsewhere(1) 122,168 129,437 $ 441,190 $ 446,039 (1) Includes, among many others, the following countries: South Korea, Germany, Norway, Canada and Brazil.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Balances with SPD within Consolidated Balance Sheets	The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption As of December 31, 2016 2015 Accounts receivable, net of allowances $ 7,855 $ 9,873 Prepaid expenses and other current assets $ 7,486 $ 6,602 Other non-current $ 6,122 $ 8,895 Accounts payable $ 34,216 $ 24,887

Valuation and Qualifying Acco55

Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2016
Allowance for Doubtful Accounts [Member]
Sets Forth Activities in Accounts Receivable Reserve Accounts	The following table sets forth activities in our accounts receivable reserve accounts (in thousands): Balance at Beginning of Period Provision Amounts Charged Against Reserves Balance at End of Period Year ended December 31, 2014 $ 69,146 $ 42,477 $ (35,460 ) $ 76,163 Year ended December 31, 2015 $ 76,163 $ 45,279 $ (31,741 ) $ 89,701 Year ended December 31, 2016 $ 89,701 $ 48,748 $ (62,651 ) $ 75,798
Inventory Valuation Reserve [Member]
Sets Forth Activities in Accounts Receivable Reserve Accounts	The following table sets forth activities in our inventory reserve accounts (in thousands): Balance at Provision Amounts Balance at Year ended December 31, 2014 $ 21,437 $ 12,818 $ (6,907 ) $ 27,348 Year ended December 31, 2015 $ 27,348 $ 21,592 $ (11,165 ) $ 37,775 Year ended December 31, 2016 $ 37,775 $ 10,640 $ (19,977 ) $ 28,438
Valuation Allowance of Deferred Tax Assets [Member]
Sets Forth Activities in Accounts Receivable Reserve Accounts	The following table sets forth activities in our deferred tax accounts (in thousands): Balance at Additions Amounts Balance at Year ended December 31, 2014 $ 84,315 $ 143,454 $ 864 $ 228,633 Year ended December 31, 2015, As Restated $ 228,633 $ 19,674 $ — $ 248,307 Year ended December 31, 2016 $ 248,307 $ 74,965 $ — $ 323,272

Restructuring Activities (Table

Restructuring Activities (Tables)	12 Months Ended
	Dec. 31, 2016
Restructuring and Related Activities [Abstract]
Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income	The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the years ended December 31, 2016, 2015 and 2014 (in thousands): Statement of Operations Caption 2016 2015 2014 Cost of net revenue $ 5,991 $ 3,816 $ 11,760 Research and development 4,052 2,752 9,800 Sales and marketing 1,798 3,004 11,350 General and administrative 26,033 6,071 25,786 Total operating expenses 37,874 15,643 58,696 Interest expense, including amortization of original issue discounts and deferred financing costs 11 24 42 Total charges $ 37,885 $ 15,667 $ 58,738
Restructuring Activities Related to Restructuring Plans	The following table summarizes the restructuring activities related to the 2016 restructuring plans for the year ended December 31, 2016 (in thousands): Professional Diagnostics 2016 Severance-related costs $ 6,217 Facility and transition costs 3,010 Cash charges 9,227 Fixed asset and inventory impairments 443 Total charges $ 9,670 Corporate and Other 2016 Severance-related costs $ 346 Facility and transition costs 21,649 Total cash charges $ 21,995 The following table summarizes the restructuring activities related to our active restructuring plans prior to 2016 for the years ended December 31, 2016, 2015 and 2014 and since inception of these restructuring plans (in thousands): Professional Diagnostics 2016 2015 2014 Since Severance-related costs $ 3,219 $ 7,143 $ 29,071 $ 65,094 Facility and transition costs 1,257 4,542 4,399 19,738 Other exit costs 11 24 42 833 Cash charges 4,487 11,709 33,512 85,665 Fixed asset and inventory impairments 1,555 678 10,991 19,961 Intangible asset impairments — — — 686 Other non-cash 178 1,918 — 2,160 Total charges $ 6,220 $ 14,305 $ 44,503 $ 108,472 Corporate and Other 2016 2015 2014 Since Severance-related costs $ — $ 1,376 $ 2,901 $ 4,277 Facility and transition costs — (14 ) 11,334 11,322 Cash charges $ — $ 1,362 $ 14,235 $ 15,599
Cash Activity for Restructuring Reserves	The following table summarizes our restructuring reserves related to the plans described above, of which $10.6 million is included in accrued expenses and other current liabilities and $0.3 million is included in other long-term liabilities on our consolidated balance sheets (in thousands): Severance- related Costs Facility and Transition Costs Other Exit Costs Total Balance, December 31, 2013 992 1,781 367 3,140 Cash charges 31,972 15,733 42 47,747 Payments (27,394 ) (7,345 ) (119 ) (34,858 ) Currency adjustments (980 ) (301 ) — (1,281 ) Balance, December 31, 2014 4,590 9,868 290 14,748 Cash charges 8,519 4,528 24 13,071 Payments (11,145 ) (12,222 ) (134 ) (23,501 ) Currency adjustments (331 ) (208 ) — (539 ) Balance, December 31, 2015 $ 1,633 $ 1,966 $ 180 $ 3,779 Cash charges 9,782 25,916 11 35,709 Payments (7,890 ) (20,331 ) (152 ) (28,373 ) Currency adjustments (186 ) (39 ) — (225 ) Balance, December 31, 2016 $ 3,339 $ 7,512 $ 39 $ 10,890

Equity Investments (Tables)

Equity Investments (Tables)	12 Months Ended
	Dec. 31, 2016
Financial Information Combined Condensed Results of Operations	CONSOLIDATING STATEMENT OF OPERATIONS For the Year Ended December 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 907,104 $ 1,291,830 $ (315,358 ) $ 1,883,576 Services revenue — 433,526 47,235 — 480,761 Net product sales and services revenue — 1,340,630 1,339,065 (315,358 ) 2,364,337 License and royalty revenue — 19,626 6,766 (14,394 ) 11,998 Net revenue — 1,360,256 1,345,831 (329,752 ) 2,376,335 Cost of net product sales 610 533,989 719,218 (275,470 ) 978,347 Cost of services revenue 1,776 306,331 31,276 (34,512 ) 304,871 Cost of net product sales and services revenue 2,386 840,320 750,494 (309,982 ) 1,283,218 Cost of license and royalty revenue — 19 17,625 (14,394 ) 3,250 Cost of net revenue 2,386 840,339 768,119 (324,376 ) 1,286,468 Gross profit (loss) (2,386 ) 519,917 577,712 (5,376 ) 1,089,867 Operating expenses: Research and development 1,465 68,627 42,030 — 112,122 Sales and marketing 6,614 212,348 184,093 — 403,055 General and administrative 289,933 119,417 155,172 (746 ) 563,776 Impairment and (gain) loss on dispositions, net — — (3,810 ) — (3,810 ) Operating income (loss) (300,398 ) 119,525 200,227 (4,630 ) 14,724 Interest expense, including amortization of original issue discounts and deferred financing costs (168,904 ) (7,482 ) (11,175 ) 15,910 (171,651 ) Other income (expense), net 10,799 8,551 1,089 (15,910 ) 4,529 Income (loss) before provision (benefit) for income taxes (458,503 ) 120,594 190,141 (4,630 ) (152,398 ) Provision (benefit) for income taxes (64,345 ) 41,896 57,825 — 35,376 Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (394,158 ) 78,698 132,316 (4,630 ) (187,774 ) Equity in earnings of subsidiaries, net of tax 225,588 — — (225,588 ) — Equity earnings of unconsolidated entities, net of tax 31,301 — 18,863 341 50,505 Income (loss) from continuing operations (137,269 ) 78,698 151,179 (229,877 ) (137,269 ) Income (loss) from discontinued operations, net of tax — — — — — Net income (loss) (137,269 ) 78,698 151,179 (229,877 ) (137,269 ) Less: Net income attributable to non- — — 350 — 350 Net income (loss) attributable to Alere Inc. and Subsidiaries (137,269 ) 78,698 150,829 (229,877 ) (137,619 ) Preferred stock dividends (21,350 ) — — — (21,350 ) Net income (loss) available to common stockholders $ (158,619 ) $ 78,698 $ 150,829 $ (229,877 ) $ (158,969 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Year Ended December 31, 2015 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 892,086 $ 1,318,753 $ (264,509 ) $ 1,946,330 Services revenue — 440,709 51,599 — 492,308 Net product sales and services revenue — 1,332,795 1,370,352 (264,509 ) 2,438,638 License and royalty revenue — 12,968 19,594 (15,585 ) 16,977 Net revenue — 1,345,763 1,389,946 (280,094 ) 2,455,615 Cost of net product sales 3,114 510,918 755,954 (230,840 ) 1,039,146 Cost of services revenue 205 305,813 30,319 (31,949 ) 304,388 Cost of net product sales and services revenue 3,319 816,731 786,273 (262,789 ) 1,343,534 Cost of license and royalty revenue (40 ) 230 19,175 (15,584 ) 3,781 Cost of net revenue 3,279 816,961 805,448 (278,373 ) 1,347,315 Gross profit (loss) (3,279 ) 528,802 584,498 (1,721 ) 1,108,300 Operating expenses: Research and development 16,461 60,787 42,205 — 119,453 Sales and marketing 5,901 219,566 208,972 — 434,439 General and administrative 124,020 147,625 102,511 — 374,156 Impairment and (gain) loss on dispositions, net 79,951 (8,747 ) (20,664 ) — 50,540 Operating income (loss) (229,612 ) 109,571 251,474 (1,721 ) 129,712 Interest expense, including amortization of original issue discounts and deferred financing costs (215,070 ) (11,517 ) (18,227 ) 27,817 (216,997 ) Other income (expense), net 14,508 14,362 4,890 (31,017 ) 2,743 Income (loss) from continuing operations before provision (benefit) for income taxes (430,174 ) 112,416 238,137 (4,921 ) (84,542 ) Provision (benefit) for income taxes (151,406 ) 33,447 64,087 308 (53,564 ) Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (278,768 ) 78,969 174,050 (5,229 ) (30,978 ) Equity in earnings of subsidiaries, net of tax 259,924 — — (259,924 ) — Equity earnings of unconsolidated entities, net of tax 1,484 — 14,065 (19 ) 15,530 Income (loss) from continuing operations (17,360 ) 78,969 188,115 (265,172 ) (15,448 ) Income (loss) from discontinued operations, net of tax 221,425 (1,912 ) — — 219,513 Net income 204,065 77,057 188,115 (265,172 ) 204,065 Less: Net income attributable to non-controlling — — 381 — 381 Net income attributable to Alere Inc. and Subsidiaries 204,065 77,057 187,734 (265,172 ) 203,684 Preferred stock dividends (21,293 ) — — — (21,293 ) Net income available to common stockholders $ 182,772 $ 77,057 $ 187,734 $ (265,172 ) $ 182,391 CONSOLIDATING STATEMENT OF OPERATIONS For the Year Ended December 31, 2014 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 855,435 $ 1,405,594 $ (237,066 ) $ 2,023,963 Services revenue — 464,283 67,705 — 531,988 Net product sales and services revenue — 1,319,718 1,473,299 (237,066 ) 2,555,951 License and royalty revenue — 13,477 19,846 (12,273 ) 21,050 Net revenue — 1,333,195 1,493,145 (249,339 ) 2,577,001 Cost of net product sales 5,329 473,076 797,276 (212,681 ) 1,063,000 Cost of services revenue 261 288,288 33,584 (27,184 ) 294,949 Cost of net product sales and services revenue 5,590 761,364 830,860 (239,865 ) 1,357,949 Cost of license and royalty revenue 40 199 17,625 (12,272 ) 5,592 Cost of net revenue 5,630 761,563 848,485 (252,137 ) 1,363,541 Gross profit (loss) (5,630 ) 571,632 644,660 2,798 1,213,460 Operating expenses: Research and development 23,190 61,862 59,776 — 144,828 Sales and marketing 7,598 232,406 273,045 — 513,049 General and administrative 92,466 156,143 204,554 — 453,163 Impairment and gain (loss) on dispositions, net 4,236 11,393 (7,887 ) — 7,742 Operating income (loss) (133,120 ) 109,828 115,172 2,798 94,678 Interest expense, including amortization of original issue discounts and deferred financing costs (205,919 ) (18,995 ) (18,629 ) 34,352 (209,191 ) Other income (expense), net 12,140 20,491 (1,621 ) (34,417 ) (3,407 ) Income (loss) from continuing operations before provision (benefit) for income taxes (326,899 ) 111,324 94,922 2,733 (117,920 ) Provision (benefit) for income taxes (20,865 ) 44,155 46,718 1,022 71,030 Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (306,034 ) 67,169 48,204 1,711 (188,950 ) Equity in earnings of subsidiaries, net of tax 125,443 — — (125,443 ) — Equity earnings of unconsolidated entities, net of tax 1,717 — 15,928 (136 ) 17,509 Income (loss) from continuing operations (178,874 ) 67,169 64,132 (123,868 ) (171,441 ) Income (loss) from discontinued operations, net of tax 145,751 (27,839 ) 20,400 6 138,318 Net income (loss) (33,123 ) 39,330 84,532 (123,862 ) (33,123 ) Less: Net income attributable to non-controlling — — 30 — 30 Net income (loss) attributable to Alere Inc. and Subsidiaries (33,123 ) 39,330 84,502 (123,862 ) (33,153 ) Preferred stock dividends (21,293 ) — — — (21,293 ) Net income (loss) available to common stockholders $ (54,416 ) $ 39,330 $ 84,502 $ (123,862 ) $ (54,446 )
Financial Information Combined Condensed Balance Sheet	CONSOLIDATING BALANCE SHEET December 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 167,639 $ 3,161 $ 396,415 $ — $ 567,215 Restricted cash 1,337 — 50,213 — 51,550 Marketable securities — 76 — — 76 Accounts receivable, net of allowances — 186,067 227,468 — 413,535 Inventories, net — 168,736 163,967 (23,783 ) 308,920 Prepaid expenses and other current assets 15,983 22,318 68,748 11,558 118,607 Intercompany receivables 390,328 1,008,767 204,587 (1,603,682 ) — Total current assets 575,287 1,389,125 1,111,398 (1,615,907 ) 1,459,903 Property, plant and equipment, net 25,525 243,755 176,618 (4,708 ) 441,190 Goodwill — 1,822,290 937,076 — 2,759,366 Other intangible assets with indefinite lives — 7,457 19,765 (58 ) 27,164 Finite-lived intangible assets, net 2,490 507,060 299,227 (3,200 ) 805,577 Restricted cash — — 2,171 — 2,171 Other non-current 509 2,267 13,060 (870 ) 14,966 Investments in subsidiaries 3,409,001 158,195 57,650 (3,624,846 ) — Investments in unconsolidated entities 684 14,765 42,523 14,253 72,225 Deferred tax assets — — 57,819 (37,336 ) 20,483 Non-current 4,580 — 40,654 — 45,234 Intercompany notes receivables 1,757,723 709,965 744 (2,468,432 ) — Total assets $ 5,775,799 $ 4,854,879 $ 2,758,705 $ (7,741,104 ) $ 5,648,279 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 40,072 $ — $ 42,298 $ — $ 82,370 Current portion of capital lease obligations — 1,560 1,504 — 3,064 Accounts payable 35,591 78,981 81,307 — 195,879 Accrued expenses and other current liabilities 65,582 133,506 223,778 (28,023 ) 394,843 Intercompany payables 485,573 859,924 258,154 (1,603,651 ) — Total current liabilities 626,818 1,073,971 607,041 (1,631,674 ) 676,156 Long-term liabilities: Long-term debt, net of current portion 2,852,978 — 5,227 — 2,858,205 Capital lease obligations, net of current portion — 2,029 5,192 — 7,221 Deferred tax liabilities — 51,314 67,702 82 119,098 Other long-term liabilities 91,042 44,563 21,257 (870 ) 155,992 Intercompany notes payables 377,969 1,274,419 816,044 (2,468,432 ) — Total long-term liabilities 3,321,989 1,372,325 915,422 (2,469,220 ) 3,140,516 Total stockholders’ equity 1,826,992 2,408,583 1,231,627 (3,640,210 ) 1,826,992 Non-controlling — — 4,615 — 4,615 Total equity 1,826,992 2,408,583 1,236,242 (3,640,210 ) 1,831,607 Total liabilities and equity $ 5,775,799 $ 4,854,879 $ 2,758,705 $ (7,741,104 ) $ 5,648,279 CONSOLIDATING BALANCE SHEET December 31, 2015 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 139,153 $ 21,150 $ 341,897 $ — $ 502,200 Restricted cash 1,250 — 4,444 — 5,694 Marketable securities — 164 — — 164 Accounts receivable, net of allowances — 192,591 244,333 — 436,924 Inventories, net — 173,383 198,140 (20,574 ) 350,949 Prepaid expenses and other current assets 7,576 27,095 73,242 6,601 114,514 Assets held for sale — current — — 4,165 — 4,165 Intercompany receivables 1,237,474 812,957 50,691 (2,101,122 ) — Total current assets 1,385,453 1,227,340 916,912 (2,115,095 ) 1,414,610 Property, plant and equipment, net 31,384 228,065 188,084 (1,494 ) 446,039 Goodwill — 1,823,919 1,012,996 — 2,836,915 Other intangible assets with indefinite lives — 7,638 20,531 (59 ) 28,110 Finite-lived intangible assets, net 2,951 627,269 370,261 (3,200 ) 997,281 Restricted cash — — 43,228 — 43,228 Other non-current 804 2,340 15,380 (446 ) 18,078 Investments in subsidiaries 3,291,724 158,195 57,650 (3,507,569 ) — Investments in unconsolidated entities 502 14,764 37,947 12,120 65,333 Deferred tax assets 91,220 — 51,329 (128,556 ) 13,993 Non-current 3,517 — 37,719 — 41,236 Assets held for sale — non-current 13,337 — — — 13,337 Intercompany notes receivables 1,905,188 672,032 6,900 (2,584,120 ) — Total assets $ 6,726,080 $ 4,761,562 $ 2,758,937 $ (8,328,419 ) $ 5,918,160 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 197,084 $ — $ 2,908 $ — $ 199,992 Current portion of capital lease obligations — 2,018 1,944 — 3,962 Accounts payable 15,981 76,890 102,881 — 195,752 Accrued expenses and other current liabilities 62,287 126,346 131,766 2,238 322,637 Liabilities related to assets held for sale — current — — 363 — 363 Intercompany payables 1,122,042 773,839 205,241 (2,101,122 ) — Total current liabilities 1,397,394 979,093 445,103 (2,098,884 ) 722,706 Long-term liabilities: Long-term debt, net of current portion 2,784,913 — 46,253 — 2,831,166 Capital lease obligations, net of current portion — 840 6,341 — 7,181 Deferred tax liabilities — 219,224 54,749 (126,355 ) 147,618 Other long-term liabilities 14,962 59,309 80,369 (447 ) 154,193 Intercompany notes payables 477,779 1,181,168 925,173 (2,584,120 ) — Total long-term liabilities 3,277,654 1,460,541 1,112,885 (2,710,922 ) 3,140,158 Total stockholders’ equity 2,051,032 2,321,928 1,196,685 (3,518,613 ) 2,051,032 Non-controlling — — 4,264 — 4,264 Total equity 2,051,032 2,321,928 1,200,949 (3,518,613 ) 2,055,296 Total liabilities and equity $ 6,726,080 $ 4,761,562 $ 2,758,937 $ (8,328,419 ) $ 5,918,160
Swiss Precision Diagnostics And TechLab [Member]
Financial Information Combined Condensed Results of Operations	Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Combined Condensed Results of Operations For The Years Ended December 31, 2016 2015 2014 Net revenue $ 209,239 $ 202,611 $ 211,370 Gross profit $ 151,912 $ 147,386 $ 160,192 Net income after taxes $ 41,616 $ 32,457 $ 35,646
Financial Information Combined Condensed Balance Sheet	Combined Condensed Balance Sheets As of December 31, 2016 2015 Current assets $ 75,248 $ 71,542 Non-current 20,578 30,802 Total assets $ 95,826 $ 102,344 Current liabilities $ 44,234 $ 37,609 Non-current 3,875 5,157 Total liabilities $ 48,109 $ 42,766

Restated Quarterly Financial 58

Restated Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Schedule of Restated Quarterly Financial Information	The information set forth below for the first three quarters and year-to-date periods in fiscal year 2016 and for all quarters and year-to-date periods in fiscal year 2015 has been restated to correct the misstatements described in Note 2. In addition, we have also made adjustments related to (a) misstatements in the classification of certain amounts between current assets, noncurrent assets and current liabilities, (b) misstatements in the classification of certain legal-related charges between non-operating expenses and operating expenses, and (c) misstatements to general and administrative expenses to correct the timing of bad debt expenses and fair value adjustments related to contingent consideration liabilities from acquisitions. The operating results for any given quarter are not necessarily indicative of results for any future periods. Amounts are computed independently each quarter, therefore, the sum of the quarterly amounts may not equal the total amount for the respective year due to rounding. The following tables reconcile the amounts as previously reported in the applicable financial statement to the corresponding restated amounts. All financial statements are unaudited. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended September 30, 2016 As Previously Restatement As Restated Net product sales $ 456,096 $ (72 ) $ 456,024 Services revenue 123,778 — 123,778 Net product sales and services revenue 579,874 (72 ) 579,802 License and royalty revenue 2,480 — 2,480 Net revenue 582,354 (72 ) 582,282 Cost of net product sales 238,946 113 239,059 Cost of services revenue 76,639 — 76,639 Cost of net product sales and services revenue 315,585 113 315,698 Cost of license and royalty revenue 641 — 641 Cost of net revenue 316,226 113 316,339 Gross profit 266,128 (185 ) 265,943 Operating expenses: — Research and development 31,430 — 31,430 Sales and marketing 101,979 (13 ) 101,966 General and administrative 129,287 19,253 148,540 Impairment and (gain) loss on dispositions, net — — — Operating income 3,432 (19,425 ) (15,993 ) Interest expense, including amortization of original issue discounts and deferred financing costs (44,130 ) — (44,130 ) Other income (expense), net (14,312 ) 13,153 (1,159 ) Loss from continuing operations before provision (benefit) for income taxes (55,010 ) (6,272 ) (61,282 ) Provision (benefit) for income taxes (50,888 ) 92 (50,796 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (4,122 ) (6,364 ) (10,486 ) Equity earnings of unconsolidated entities, net of tax 26,149 — 26,149 Income (loss) from continuing operations 22,027 (6,364 ) 15,663 Income (loss) from discontinued operations, net of tax — — — Net income (loss) 22,027 (6,364 ) 15,663 Less: Net income attributable to non-controlling 207 — 207 Net income (loss) attributable to Alere Inc. and Subsidiaries 21,820 (6,364 ) 15,456 Preferred stock dividends (5,366 ) — (5,366 ) Net income (loss) available to common stockholders $ 16,454 $ (6,364 ) $ 10,090 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ 0.19 $ (0.07 ) $ 0.12 Income (loss) from discontinued operations — — — Net income (loss) per common share $ 0.19 $ (0.07 ) $ 0.12 Weighted-average shares—basic 86,753 — 86,753 Weighted-average shares—diluted 87,885 — 87,885 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 30,768 $ (6,364 ) $ 24,404 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $1,700 adjustment to increase bad debt expense, (b) a $4,400 adjustment of additional expense related to a correction in the measurement of an acquisition-related contingent consideration obligation and (c) a $13,153 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Nine Months Ended September 30, 2016 As Previously Restatement As Net product sales $ 1,399,613 $ 7,875 $ 1,407,488 Services revenue 364,296 — 364,296 Net product sales and services revenue 1,763,909 7,875 1,771,784 License and royalty revenue 7,742 — 7,742 Net revenue 1,771,651 7,875 1,779,526 Cost of net product sales 726,805 3,415 730,220 Cost of services revenue 228,033 — 228,033 Cost of net product sales and services revenue 954,838 3,415 958,253 Cost of license and royalty revenue 2,567 — 2,567 Cost of net revenue 957,405 3,415 960,820 Gross profit 814,246 4,460 818,706 Operating expenses: — — — Research and development 86,938 — 86,938 Sales and marketing 304,308 742 305,050 General and administrative 372,597 27,753 400,350 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 54,213 (24,035 ) 30,178 Interest expense, including amortization of original issue discounts and deferred financing costs (128,565 ) — (128,565 ) Other income (expense), net (29,773 ) 23,353 (6,420 ) Loss from continuing operations before provision (benefit) for income taxes (104,125 ) (682 ) (104,807 ) Provision (benefit) for income taxes (47,979 ) (407 ) (48,386 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (56,146 ) (275 ) (56,421 ) Equity earnings of unconsolidated entities, net of tax 33,305 — 33,305 Income (loss) from continuing operations (22,841 ) (275 ) (23,116 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (22,841 ) (275 ) (23,116 ) Less: Net income attributable to non-controlling 453 — 453 Net income (loss) attributable to Alere Inc. and Subsidiaries (23,294 ) (275 ) (23,569 ) Preferred stock dividends (15,983 ) — (15,983 ) Net income (loss) available to common stockholders $ (39,277 ) $ (275 ) $ (39,552 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.45 ) $ (0.00 ) $ (0.45 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.45 ) $ (0.00 ) $ (0.45 ) Weighted-average shares—basic and diluted 86,708 — 86,708 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (35,602 ) $ (275 ) $ (35,877 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $4,400 adjustment of additional expense related to the correction in the measurement of an acquisition-related contingent consideration obligation and (b) a $23,353 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, 2016 As Previously Restatement As Restated Net product sales $ 483,746 $ (784 ) $ 482,962 Services revenue 124,809 — 124,809 Net product sales and services revenue 608,555 (784 ) 607,771 License and royalty revenue 2,533 — 2,533 Net revenue 611,088 (784 ) 610,304 Cost of net product sales 250,398 (561 ) 249,837 Cost of services revenue 78,294 — 78,294 Cost of net product sales and services revenue 328,692 (561 ) 328,131 Cost of license and royalty revenue 535 — 535 Cost of net revenue 329,227 (561 ) 328,666 Gross profit 281,861 (223 ) 281,638 Operating expenses: — Research and development 28,446 — 28,446 Sales and marketing 102,516 (72 ) 102,444 General and administrative 128,354 8,500 136,854 Impairment and (gain) loss on dispositions, net — — — Operating income 22,545 (8,651 ) 13,894 Interest expense, including amortization of original issue discounts and deferred financing costs (42,329 ) — (42,329 ) Other income (expense), net (14,112 ) 10,200 (3,912 ) Loss from continuing operations before provision (benefit) for income taxes (33,896 ) 1,549 (32,347 ) Provision (benefit) for income taxes 3,117 (535 ) 2,582 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (37,013 ) 2,084 (34,929 ) Equity earnings of unconsolidated entities, net of tax 2,122 — 2,122 Income (loss) from continuing operations (34,891 ) 2,084 (32,807 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (34,891 ) 2,084 (32,807 ) Less: Net income attributable to non-controlling 143 — 143 Net income (loss) attributable to Alere Inc. and Subsidiaries (35,034 ) 2,084 (32,950 ) Preferred stock dividends (5,308 ) — (5,308 ) Net income (loss) available to common stockholders $ (40,342 ) $ 2,084 $ (38,258 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.46 ) $ 0.02 $ (0.44 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.46 ) $ 0.02 $ (0.44 ) Weighted-average shares—basic and diluted 86,737 — 86,737 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (78,638 ) $ 2,084 $ (76,554 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $1,700 adjustment to decrease bad debt expense and (b) a $10,200 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Six Months Ended June 30, 2016 As Previously Reported Restatement As Restated Net product sales $ 943,517 $ 7,947 $ 951,464 Services revenue 240,518 — 240,518 Net product sales and services revenue 1,184,035 7,947 1,191,982 License and royalty revenue 5,262 — 5,262 Net revenue 1,189,297 7,947 1,197,244 Cost of net product sales 487,859 3,302 491,161 Cost of services revenue 151,394 — 151,394 Cost of net product sales and services revenue 639,253 3,302 642,555 Cost of license and royalty revenue 1,926 — 1,926 Cost of net revenue 641,179 3,302 644,481 Gross profit 548,118 4,645 552,763 Operating expenses: — — — Research and development 55,508 — 55,508 Sales and marketing 202,329 755 203,084 General and administrative 243,310 8,500 251,810 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 50,781 (4,610 ) 46,171 Interest expense, including amortization of original issue discounts and deferred financing costs (84,435 ) — (84,435 ) Other income (expense), net (15,461 ) 10,200 (5,261 ) Loss from continuing operations before provision (benefit) for income taxes (49,115 ) 5,590 (43,525 ) Provision (benefit) for income taxes 2,909 (499 ) 2,410 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (52,024 ) 6,089 (45,935 ) Equity earnings of unconsolidated entities, net of tax 7,156 — 7,156 Income (loss) from continuing operations (44,868 ) 6,089 (38,779 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (44,868 ) 6,089 (38,779 ) Less: Net income attributable to non-controlling 246 — 246 Net income (loss) attributable to Alere Inc. and Subsidiaries (45,114 ) 6,089 (39,025 ) Preferred stock dividends (10,617 ) — (10,617 ) Net income (loss) available to common stockholders $ (55,731 ) $ 6,089 $ (49,642 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.64 ) $ 0.07 $ (0.57 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.64 ) $ 0.07 $ (0.57 ) Weighted-average shares—basic and diluted 86,692 — 86,692 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (66,370 ) $ 6,089 $ (60,281 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustments to increase general and administrative expenses, which is comprised of (a) a $1,700 adjustment to decrease bad debt expense and (b) a $10,200 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2016 As Previously Restatement As Restated Net product sales $ 459,771 $ 8,731 $ 468,502 Services revenue 115,709 — 115,709 Net product sales and services revenue 575,480 8,731 584,211 License and royalty revenue 2,729 — 2,729 Net revenue 578,209 8,731 586,940 Cost of net product sales 237,461 3,863 241,324 Cost of services revenue 73,100 — 73,100 Cost of net product sales and services revenue 310,561 3,863 314,424 Cost of license and royalty revenue 1,391 — 1,391 Cost of net revenue 311,952 3,863 315,815 Gross profit 266,257 4,868 271,125 Operating expenses: — Research and development 27,062 — 27,062 Sales and marketing 99,813 827 100,640 General and administrative 114,956 — 114,956 Impairment and (gain) loss on dispositions, net (3,810 ) — (3,810 ) Operating income 28,236 4,041 32,277 Interest expense, including amortization of original issue discounts and deferred financing costs (42,106 ) — (42,106 ) Other income (expense), net (1,349 ) — (1,349 ) Loss from continuing operations before provision (benefit) for income taxes (15,219 ) 4,041 (11,178 ) Provision (benefit) for income taxes (208 ) 36 (172 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (15,011 ) 4,005 (11,006 ) Equity earnings of unconsolidated entities, net of tax 5,034 — 5,034 Income (loss) from continuing operations (9,977 ) 4,005 (5,972 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (9,977 ) 4,005 (5,972 ) Less: Net income attributable to non-controlling 103 — 103 Net income (loss) attributable to Alere Inc. and Subsidiaries (10,080 ) 4,005 (6,075 ) Preferred stock dividends (5,309 ) — (5,309 ) Net income (loss) available to common stockholders $ (15,389 ) $ 4,005 $ (11,384 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.18 ) $ 0.05 $ (0.13 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.18 ) $ 0.05 $ (0.13 ) Weighted-average shares—basic and diluted 86,646 — 86,646 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 12,268 $ 4,005 $ 16,273 (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended December 31, 2015 As Previously Restatement As Net product sales $ 506,516 $ (6,149 ) $ 500,367 Services revenue 113,483 — 113,483 Net product sales and services revenue 619,999 (6,149 ) 613,850 License and royalty revenue 3,286 — 3,286 Net revenue 623,285 (6,149 ) 617,136 Cost of net product sales 298,795 (1,670 ) 297,125 Cost of services revenue 72,111 — 72,111 Cost of net product sales and services revenue 370,906 (1,670 ) 369,236 Cost of license and royalty revenue (650 ) — (650 ) Cost of net revenue 370,256 (1,670 ) 368,586 Gross profit 253,029 (4,479 ) 248,550 Operating expenses: Research and development 28,228 — 28,228 Sales and marketing 111,535 (644 ) 110,891 General and administrative 114,400 4,586 118,986 Impairment and (gain) loss on dispositions, net 8,132 — 8,132 Operating income (9,266 ) (8,421 ) (17,687 ) Interest expense, including amortization of original issue discounts and deferred financing costs (58,739 ) — (58,739 ) Other income (expense), net (6,329 ) 4,586 (1,743 ) Loss from continuing operations before provision (benefit) for income taxes (74,334 ) (3,835 ) (78,169 ) Provision (benefit) for income taxes (50,329 ) (817 ) (51,146 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (24,005 ) (3,018 ) (27,023 ) Equity earnings of unconsolidated entities, net of tax 5,210 — 5,210 Income (loss) from continuing operations (18,795 ) (3,018 ) (21,813 ) Income (loss) from discontinued operations, net of tax 2,736 — 2,736 Net income (loss) (16,059 ) (3,018 ) (19,077 ) Less: Net income attributable to non-controlling (5 ) — (5 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (16,054 ) (3,018 ) (19,072 ) Preferred stock dividends (5,367 ) — (5,367 ) Net income (loss) available to common stockholders $ (21,421 ) $ (3,018 ) $ (24,439 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.28 ) $ (0.03 ) $ (0.31 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.28 ) $ (0.03 ) $ (0.31 ) Weighted-average shares—basic and diluted 85,953 — 85,953 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (39,957 ) $ (3,018 ) $ (42,975 ) (1) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter, except for the adjustment to increase general and administrative expenses due to a $4,586 reclassification adjustment to reclassify certain legal-related charges from other income (expense), net to general and administrative expenses. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended September 30, 2015 As Previously Restatement As Restated Net product sales $ 472,128 $ 831 $ 472,959 Services revenue 128,341 — 128,341 Net product sales and services revenue 600,469 831 601,300 License and royalty revenue 3,299 — 3,299 Net revenue 603,768 831 604,599 Cost of net product sales 245,814 (385 ) 245,429 Cost of services revenue 79,851 — 79,851 Cost of net product sales and services revenue 325,665 (385 ) 325,280 Cost of license and royalty revenue 1,137 — 1,137 Cost of net revenue 326,802 (385 ) 326,417 Gross profit 276,966 1,216 278,182 Operating expenses: Research and development 36,011 — 36,011 Sales and marketing 106,493 231 106,724 General and administrative 101,306 — 101,306 Impairment and (gain) loss on dispositions, net 2,074 — 2,074 Operating income 31,082 985 32,067 Interest expense, including amortization of original issue discounts and deferred financing costs (52,333 ) — (52,333 ) Other income (expense), net 3,658 — 3,658 Loss from continuing operations before provision (benefit) for income taxes (17,593 ) 985 (16,608 ) Provision (benefit) for income taxes (10,212 ) 72 (10,140 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (7,381 ) 913 (6,468 ) Equity earnings of unconsolidated entities, net of tax 5,000 — 5,000 Income (loss) from continuing operations (2,381 ) 913 (1,468 ) Income (loss) from discontinued operations, net of tax — — — Net income (loss) (2,381 ) 913 (1,468 ) Less: Net income attributable to non-controlling (61 ) — (61 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (2,320 ) 913 (1,407 ) Preferred stock dividends (5,369 ) — (5,369 ) Net income (loss) available to common stockholders $ (7,689 ) $ 913 $ (6,776 ) Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.09 ) $ 0.01 $ (0.08 ) Income (loss) from discontinued operations — — — Net income (loss) per common share $ (0.09 ) $ 0.01 $ (0.08 ) Weighted-average shares—basic and diluted 85,895 — 85,895 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (90,713 ) $ 913 $ (89,800 ) (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Quarterly Report on Form 10-Q for the period ended September 30, 2015 due most significantly to a $1,724 adjustment to increase revenue, a $1,087 adjustment to decrease other income and an $8,712 adjustment to decrease benefit for income taxes, with an overall impact of a $7,882 adjustment to decrease net income, which were identified during the preparation of the Annual Report on Form 10-K for 2015. (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Nine Months Ended September 30, 2015 As Previously Restatement As Restated Net product sales $ 1,447,515 $ (1,552 ) $ 1,445,963 Services revenue 378,825 — 378,825 Net product sales and services revenue 1,826,340 (1,552 ) 1,824,788 License and royalty revenue 13,691 — 13,691 Net revenue 1,840,031 (1,552 ) 1,838,479 Cost of net product sales 743,808 (1,787 ) 742,021 Cost of services revenue 232,277 — 232,277 Cost of net product sales and services revenue 976,085 (1,787 ) 974,298 Cost of license and royalty revenue 4,431 — 4,431 Cost of net revenue 980,516 (1,787 ) 978,729 Gross profit 859,515 235 859,750 Operating expenses: Research and development 91,225 — 91,225 Sales and marketing 323,596 (48 ) 323,548 General and administrative 255,170 — 255,170 Impairment and (gain) loss on dispositions, net 42,408 — 42,408 Operating income 147,116 283 147,399 Interest expense, including amortization of original issue discounts and deferred financing costs (158,258 ) — (158,258 ) Other income (expense), net 4,486 — 4,486 Loss from continuing operations before provision (benefit) for income taxes (6,656 ) 283 (6,373 ) Provision (benefit) for income taxes (2,376 ) (43 ) (2,419 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (4,280 ) 326 (3,954 ) Equity earnings of unconsolidated entities, net of tax 10,320 — 10,320 Income (loss) from continuing operations 6,040 326 6,366 Income (loss) from discontinued operations, net of tax 216,777 — 216,777 Net income (loss) 222,817 326 223,143 Less: Net income attributable to non-controlling 386 — 386 Net income (loss) attributable to Alere Inc. and Subsidiaries 222,431 326 222,757 Preferred stock dividends (15,927 ) — (15,927 ) Net income (loss) available to common stockholders $ 206,504 $ 326 $ 206,830 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.12 ) $ 0.00 $ (0.12 ) Income (loss) from discontinued operations 2.57 — 2.57 Net income (loss) per common share $ 2.45 $ 0.00 $ 2.45 Weighted-average shares—basic and diluted 85,141 — 85,141 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 98,666 $ 326 $ 98,992 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, Form 10-K (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, 2015 As Previously Restatement As Net product sales $ 491,049 $ 603 $ 491,652 Services revenue 126,628 — 126,628 Net product sales and services revenue 617,677 603 618,280 License and royalty revenue 5,694 — 5,694 Net revenue 623,371 603 623,974 Cost of net product sales 257,893 894 258,787 Cost of services revenue 76,800 — 76,800 Cost of net product sales and services revenue 334,693 894 335,587 Cost of license and royalty revenue 1,344 — 1,344 Cost of net revenue 336,037 894 336,931 Gross profit 287,334 (291 ) 287,043 Operating expenses: Research and development 27,198 — 27,198 Sales and marketing 108,024 (118 ) 107,906 General and administrative 61,173 — 61,173 Impairment and (gain) loss on dispositions, net 5,542 — 5,542 Operating income 85,397 (173 ) 85,224 Interest expense, including amortization of original issue discounts and deferred financing costs (59,494 ) — (59,494 ) Other income (expense), net 3,195 — 3,195 Loss from continuing operations before provision (benefit) for income taxes 29,098 (173 ) 28,925 Provision (benefit) for income taxes 15,689 99 15,788 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax 13,409 (272 ) 13,137 Equity earnings of unconsolidated entities, net of tax 1,361 — 1,361 Income (loss) from continuing operations 14,770 (272 ) 14,498 Income (loss) from discontinued operations, net of tax — — — Net income (loss) 14,770 (272 ) 14,498 Less: Net income attributable to non-controlling 359 — 359 Net income (loss) attributable to Alere Inc. and Subsidiaries 14,411 (272 ) 14,139 Preferred stock dividends (5,308 ) — (5,308 ) Net income (loss) available to common stockholders $ 9,103 $ (272 ) $ 8,831 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ 0.11 $ (0.01 ) $ 0.10 Income (loss) from discontinued operations — — — Net income (loss) per common share $ 0.11 $ (0.01 ) $ 0.10 Weighted-average shares — basic 85,173 — 85,173 Weighted-average shares — diluted 86,635 — 86,635 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 60,763 $ (272 ) $ 60,491 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended June 30, 2016 and, in connection with the presentation in such Form 10-Q, Form 10-K (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Six Months Ended June 30, 2015 As Previously Restatement As Net product sales $ 975,387 $ (2,383 ) $ 973,004 Services revenue 250,484 — 250,484 Net product sales and services revenue 1,225,871 (2,383 ) 1,223,488 License and royalty revenue 10,392 — 10,392 Net revenue 1,236,263 (2,383 ) 1,233,880 Cost of net product sales 497,994 (1,402 ) 496,592 Cost of services revenue 152,426 — 152,426 Cost of net product sales and services revenue 650,420 (1,402 ) 649,018 Cost of license and royalty revenue 3,294 — 3,294 Cost of net revenue 653,714 (1,402 ) 652,312 Gross profit 582,549 (981 ) 581,568 Operating expenses: Research and development 55,214 — 55,214 Sales and marketing 217,103 (279 ) 216,824 General and administrative 153,864 — 153,864 Impairment and (gain) loss on dispositions, net 40,334 — 40,334 Operating income 116,034 (702 ) 115,332 Interest expense, including amortization of original issue discounts and deferred financing costs (105,925 ) — (105,925 ) Other income (expense), net 828 — 828 Loss from continuing operations before provision (benefit) for income taxes 10,937 (702 ) 10,235 Provision (benefit) for income taxes 7,836 (115 ) 7,721 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax 3,101 (587 ) 2,514 Equity earnings of unconsolidated entities, net of tax 5,320 — 5,320 Income (loss) from continuing operations 8,421 (587 ) 7,834 Income (loss) from discontinued operations, net of tax 216,777 — 216,777 Net income (loss) 225,198 (587 ) 224,611 Less: Net income attributable to non-controlling 447 — 447 Net income (loss) attributable to Alere Inc. and Subsidiaries 224,751 (587 ) 224,164 Preferred stock dividends (10,558 ) — (10,558 ) Net income (loss) available to common stockholders $ 214,193 $ (587 ) $ 213,606 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.03 ) $ (0.01 ) $ (0.04 ) Income (loss) from discontinued operations 2.57 — 2.57 Net income (loss) per common share $ 2.54 $ (0.01 ) $ 2.53 Weighted-average shares — basic and diluted 84,758 — 84,758 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 189,379 $ (587 ) $ 188,792 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2015 As Previously Restatement As Net product sales $ 484,338 $ (2,986 ) $ 481,352 Services revenue 123,856 — 123,856 Net product sales and services revenue 608,194 (2,986 ) 605,208 License and royalty revenue 4,698 — 4,698 Net revenue 612,892 (2,986 ) 609,906 Cost of net product sales 240,101 (2,296 ) 237,805 Cost of services revenue 75,626 — 75,626 Cost of net product sales and services revenue 315,727 (2,296 ) 313,431 Cost of license and royalty revenue 1,950 — 1,950 Cost of net revenue 317,677 (2,296 ) 315,381 Gross profit 295,215 (690 ) 294,525 Operating expenses: — Research and development 28,016 — 28,016 Sales and marketing 109,079 (161 ) 108,918 General and administrative 92,691 — 92,691 Impairment and (gain) loss on dispositions, net 34,792 — 34,792 Operating income 30,637 (529 ) 30,108 Interest expense, including amortization of original issue discounts and deferred financing costs (46,431 ) — (46,431 ) Other income (expense), net (2,367 ) — (2,367 ) Loss from continuing operations before provision (benefit) for income taxes (18,161 ) (529 ) (18,690 ) Provision (benefit) for income taxes (7,853 ) (214 ) (8,067 ) Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax (10,308 ) (315 ) (10,623 ) Equity earnings of unconsolidated entities, net of tax 3,959 — 3,959 Income (loss) from continuing operations (6,349 ) (315 ) (6,664 ) Income (loss) from discontinued operations, net of tax 216,777 — 216,777 Net income (loss) 210,428 (315 ) 210,113 Less: Net income attributable to non-controlling 88 — 88 Net income (loss) attributable to Alere Inc. and Subsidiaries 210,340 (315 ) 210,025 Preferred stock dividends (5,250 ) — (5,250 ) Net income (loss) available to common stockholders $ 205,090 $ (315 ) $ 204,775 Basic and Diluted net income (loss) per common share: Loss from continuing operations $ (0.14 ) $ (0.00 ) $ (0.14 ) Income (loss) from discontinued operations 2.57 — 2.57 Net income (loss) per common share $ 2.43 $ (0.00 ) $ 2.43 Weighted-average shares—basic and diluted 84,338 — 84,338 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 128,616 $ (315 ) $ 128,301 (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended March 31, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Quarterly Report on Form 10-Q for the period ended March 31, 2015 due to a $4,739 adjustment to increase revenue, a $1,509 adjustment to increase cost of revenue, a $1,097 adjustment to increase other expense and a $933 adjustment to decrease benefit for income taxes with an overall impact of a $1,200 adjustment to increase net income, which were identified during the preparation of the Annual Report on Form 10-K for 2015. (2) All adjustments in this column relate to the misstatements associated with the Standard Diagnostics revenue recognition matter. ALERE INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (in thousands, except par value) (unaudited) As of September 30, 2016 As Previously Restatement As Restated ASSETS Current assets: Cash and cash equivalents $ 566,213 $ — $ 566,213 Restricted cash 4,999 — 4,999 Marketable securities 75 — 75 Accounts receivable, net of allowance 427,241 (1,034 ) 426,207 Inventories, net 348,845 533 349,378 Prepaid expenses and other current assets 163,833 (39,443 ) 124,390 Total current assets 1,511,206 (39,944 ) 1,471,262 Property, plant and equipment, net 446,313 — 446,313 Goodwill 2,805,682 — 2,805,682 Other intangible assets with indefinite lives 27,991 — 27,991 Finite-lived intangible assets, net 864,785 — 864,785 Restricted cash 42,438 — 42,438 Other non-current 16,219 — 16,219 Investments in unconsolidated entities 80,885 — 80,885 Deferred tax assets 56,638 — 56,638

Guarantor Financial Informati59

Guarantor Financial Information (Tables)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Reconciliation of Previously Reported and Restated Consolidating Financial Statements	The following schedules reconcile the amounts as previously reported in guarantor financial information, consolidating financial statements to the corresponding restated amounts: Year Ended December 31, 2015 Restated Consolidating Statement of Operations-Issuer (in thousands) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 3,279 $ — $ 3,279 Sales and marketing $ 5,901 $ — $ 5,901 General and administrative $ 119,520 $ 4,500 $ 124,020 Loss from continuing operations before benefit for income taxes $ (430,174 ) $ — $ (430,174 ) Benefit for income taxes $ (151,406 ) $ — $ (151,406 ) Loss from continuing operations $ (14,668 ) $ (2,692 ) $ (17,360 ) As of December 31, 2015 Restated Consolidating Balance Sheet-Issuer As Previously Restatement Adjustment As Restated Total current assets $ 1,385,453 $ — $ 1,385,453 Total assets $ 6,729,213 $ (3,133 ) $ 6,726,080 Total current liabilities $ 1,397,394 $ — $ 1,397,394 Total long-term liabilities $ 3,277,654 $ — $ 3,277,654 Total equity $ 2,054,165 $ (3,133 ) $ 2,051,032 Total liabilities and equity $ 6,729,213 $ (3,133 ) $ 6,726,080 (1) The figures presented in this column represent the amounts that were presented originally in the 2015 Annual Report on Form 10-K, as adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $33,866 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the issuer financial statements as of December 31, 2015. (2) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K for 2015 due to a $52,410 adjustment to increase current deferred tax assets, a $616,637 adjustment to increase current intercompany receivable, a $105,298 adjustment to increase non-current deferred tax assets, a $616,637 adjustment to increase current liabilities and a $157,708 adjustment to increase deferred tax liabilities, which were identified during the preparation of the Quarterly Report on Form 10-Q for the period ended September 30, 2016. Year Ended December 31, 2014 Restated Consolidating Statement of Operations-Issuer As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 5,630 $ — $ 5,630 Sales and marketing $ 7,598 $ — $ 7,598 General and administrative $ 93,952 $ (1,486 ) $ 92,466 Loss from continuing operations before benefit for income taxes $ (326,899 ) $ — $ (326,899 ) Benefit for income taxes $ (20,865 ) $ — $ (20,865 ) Loss from continuing operations $ (179,187 ) $ 313 $ (178,874 ) (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due to an $8,535 adjustment to increase benefit for income taxes and a $4,261 adjustment to decrease equity in earnings of unconsolidated subsidiaries, net of tax with an overall impact of a $4,274 adjustment to decrease loss from continuing operations within the issuer financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. Year Ended December 31, 2015 Restated Consolidating Statement of Operations-Guarantor As Previously Restatement As Restated Net revenue $ 1,345,763 $ — $ 1,345,763 Cost of net revenue $ 816,961 $ — $ 816,961 Sales and marketing $ 219,566 $ — $ 219,566 General and administrative $ 147,539 $ 86 $ 147,625 Income (loss) from continuing operations before provision (benefit) for income taxes $ 112,416 $ — $ 112,416 Provision (benefit) for income taxes $ 33,447 $ — $ 33,447 Income (loss) from continuing operations $ 78,969 $ — $ 78,969 Year Ended December 31, 2014 Restated Consolidating Statement of Operations-Guarantor As Previously Restatement As Restated Net revenue $ 1,333,195 $ — $ 1,333,195 Cost of net revenue $ 761,563 $ — $ 761,563 Sales and marketing $ 232,406 $ — $ 232,406 General and administrative $ 155,795 $ 348 $ 156,143 Income (loss) from continuing operations before provision (benefit) for income taxes $ 111,324 $ — $ 111,324 Provision (benefit) for income taxes $ 44,155 $ — 44,155 Income (loss) from continuing operations $ 67,169 $ — $ 67,169 Year Ended December 31, 2015 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 1,397,647 $ (7,701 ) $ 1,389,946 Cost of net revenue $ 808,905 $ (3,457 ) $ 805,448 Sales and marketing $ 209,664 $ (692 ) $ 208,972 General and administrative $ 102,511 $ — $ 102,511 Income from continuing operations before provision for income taxes $ 241,689 $ (3,552 ) $ 238,137 Provision for income taxes $ 64,947 $ (860 ) $ 64,087 Income from continuing operations $ 190,807 $ (2,692 ) $ 188,115 As of December 31, 2015 Restated Consolidating Balance Sheet-Non-Guarantor As Previously Restatement As Restated Total current assets $ 959,592 $ (42,680 ) $ 916,912 Total assets $ 2,763,898 $ (4,961 ) $ 2,758,937 Total current liabilities $ 446,931 $ (1,828 ) $ 445,103 Total long-term liabilities $ 1,112,885 $ — $ 1,112,885 Total equity $ 1,204,082 $ (3,133 ) $ 1,200,949 Total liabilities and equity $ 2,763,898 $ (4,961 ) $ 2,758,937 (1) The figures presented in this column represent the amounts that were presented originally in the Annual Report on Form 10-K for 2015 as adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $184 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the non-guarantor subsidiaries financial statements as of December 31, 2015. (2) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K for 2015 due to a $23,244 adjustment to decrease current deferred tax assets, a $23,244 adjustment to increase non-current deferred tax assets, a $92,350 adjustment to decrease current liabilities and a $92,350 adjustment to increase current intercompany payable within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Quarterly Report on Form 10-Q for the period ended September 30, 2016. Year Ended December 31, 2014 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 1,491,422 $ 1,723 $ 1,493,145 Cost of net revenue $ 847,984 $ 501 $ 848,485 Sales and marketing $ 272,957 $ 88 $ 273,045 General and administrative $ 203,881 $ 673 $ 204,554 Income from continuing operations before provision for income taxes $ 94,509 $ 413 $ 94,922 Provision for income taxes $ 46,618 $ 100 $ 46,718 Income from continuing operations $ 63,819 $ 313 $ 64,132 (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due most significantly to a $15,805 adjustment to decrease revenue, a $7,237 adjustment to decrease cost of revenue, a $1,201 adjustment to decrease operating expenses and a $2,729 adjustment to decrease the provision for income taxes with an overall impact of a $4,638 adjustment to decrease income from continuing operations within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. Year Ended December 31, 2015 Restated Consolidating Statement of Operations-Eliminations As Previously Restatement As Restated Net revenue $ (280,094 ) $ — $ (280,094 ) Cost of net revenue $ (278,373 ) $ — $ (278,373 ) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Loss from continuing operations before provision for income taxes $ (4,921 ) $ — $ (4,921 ) Provision for income taxes $ 308 $ — $ 308 Loss from continuing operations $ (267,864 ) $ 2,692 $ (265,172 ) As of December 31, 2015 Restated Consolidating Balance Sheet-Eliminations As Previously Restatement As Restated Total current assets $ (2,115,095 ) $ — $ (2,115,095 ) Total assets $ (8,331,552 ) $ 3,133 $ (8,328,419 ) Total current liabilities $ (2,098,884 ) $ — $ (2,098,884 ) Total long-term liabilities $ (2,710,922 ) $ — $ (2,710,922 ) Total equity $ (3,521,746 ) $ 3,133 $ (3,518,613 ) Total liabilities and equity $ (8,331,552 ) $ 3,133 $ (8,328,419 ) (1) The figures presented in this column represent the amounts most recently presented in our Quarterly Report on Form 10-Q for the period ended September 30, 2016 and, in connection with the presentation in such Form 10-Q, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K for 2015 due to a $2,120 adjustment to increase current deferred tax assets, a $616,637 adjustment to decrease current intercompany receivable, a $128,556 adjustment to decrease non-current deferred tax assets, a $616,637 adjustment to decrease current intercompany payable and a $126,436 adjustment to decrease deferred tax liabilities within the eliminations financial statements, which were identified during the preparation of the Quarterly Report on Form 10-Q for the period ended September 30, 2016. Year Ended December 31, 2014 Restated Consolidating Statement of Operations-Eliminations As Previously Restatement As Restated Net revenue $ (249,339 ) $ — $ (249,339 ) Cost of net revenue $ (252,137 ) $ — $ (252,137 ) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Income from continuing operations before provision for income taxes $ 2,733 $ — $ 2,733 Provision for income taxes $ 1,022 $ — $ 1,022 Loss from continuing operations $ (123,555 ) $ (313 ) $ (123,868 ) (1) The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due to a $4,261 adjustment to increase equity in earnings of unconsolidated subsidiaries, net of tax with an overall impact of a $4,261 adjustment to decrease loss from continuing operations within the eliminations financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. The following schedules reconcile the amounts as previously reported in guarantor financial information, quarterly consolidating financial statements to the corresponding revised amounts and is unaudited: Three Months Ended September 30, 2016 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 853 $ — $ 853 Sales and marketing $ 1,867 $ — $ 1,867 General and administrative $ 75,261 $ 12,853 $ 88,114 Loss from continuing operations before benefit for income taxes $ (135,558 ) $ — $ (135,558) Benefit for income taxes $ (227,263 ) $ — $ (227,263) Loss from continuing operations $ 22,027 $ (6,364 ) $ 15,663 Three Months Ended June 30, 2016 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 324 $ — $ 324 Sales and marketing $ 1,568 $ — $ 1,568 General and administrative $ 57,740 $ 10,200 $ 67,940 Loss from continuing operations before provision for income taxes $ (112,630 ) $ — $ (112,630) Provision for income taxes $ 19,765 $ — $ 19,765 Loss from continuing operations $ (34,891 ) $ 2,084 $ (32,807) Three Months Ended March 31, 2016 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Net revenue $ — $ — $ — Cost of net revenue $ 114 $ — $ 114 Sales and marketing $ 1,336 $ — $ 1,336 General and administrative $ 44,615 $ — $ 44,615 Loss from continuing operations before benefit for income taxes $ (89,298 ) $ — $ (89,298) Benefit for income taxes $ (54 ) $ — $ (54) Loss from continuing operations $ (9,977 ) $ 4,005 $ (5,972) As of September 30, 2016 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,265,329 $ — $ 1,265,329 Total assets $ 6,657,371 $ (3,408) $ 6,653,963 Total current liabilities $ 1,248,718 $ — $ 1,248,718 Total long-term liabilities $ 3,362,971 $ — $ 3,362,971 Total equity $ 2,045,682 $ (3,408) $ 2,042,274 Total liabilities and equity $ 6,657,371 $ (3,408) $ 6,653,963 As of June 30, 2016 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 423,167 $ 455 $ 423,622 Total assets $ 5,749,848 $ 69,445 $ 5,819,293 Total current liabilities $ 514,279 $ — $ 514,279 Total long-term liabilities $ 3,227,915 $ 66,489 $ 3,294,404 Total equity $ 2,007,654 $ 2,956 $ 2,010,610 Total liabilities and equity $ 5,749,848 $ 69,445 $ 5,819,293 As of March 31, 2016 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 241,997 $ 52,409 $ 294,406 Total assets $ 5,556,092 $ 67,359 $ 5,623,451 Total current liabilities $ 345,110 $ — $ 345,110 Total long-term liabilities $ 3,130,559 $ 66,488 $ 3,197,047 Total equity $ 2,080,423 $ 871 $ 2,081,294 Total liabilities and equity $ 5,556,092 $ 67,359 $ 5,623,451 Three Months Ended September 30, 2015 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Net revenue $ — $ — $ — Cost of net revenue $ 2,146 $ — $ 2,146 Sales and marketing $ 1,335 $ — $ 1,335 General and administrative $ 22,960 $ — $ 22,960 Loss from continuing operations before provision for income taxes $ (79,741 ) $ — $ (79,741) Provision for income taxes $ 78,040 $ — $ 78,040 Loss from continuing operations $ (2,381 ) $ 913 $ (1,468) Three Months Ended June 30, 2015 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 516 $ — $ 516 Sales and marketing $ 1,570 $ — $ 1,570 General and administrative $ 24,390 $ — $ 24,390 Loss from continuing operations before benefit for income taxes $ (129,585 ) $ — $ (129,585) Benefit for income taxes $ (16,306 ) $ — $ (16,306) Income from continuing operations $ 14,770 $ (272) $ 14,498 Three Months Ended March 31, 2015 Restated Consolidating Statement of Operations-Issuer (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ — $ — $ — Cost of net revenue $ 426 $ — $ 426 Sales and marketing $ 1,260 $ — $ 1,260 General and administrative $ 20,523 $ — $ 20,523 Loss from continuing operations before benefit for income taxes $ (103,485 ) $ — $ (103,485) Benefit for income taxes $ (20,667 ) $ — $ (20,667) Loss from continuing operations $ (8,261 ) $ (315) $ (8,576) As of September 30, 2015 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 1,667,256 $ — $ 1,667,256 Total assets $ 7,159,852 $ 2,137 $ 7,161,989 Total current liabilities $ 1,725,939 $ — $ 1,725,939 Total long-term liabilities $ 3,341,859 $ 2,252 $ 3,344,111 Total equity $ 2,092,054 $ (115) $ 2,091,939 Total liabilities and equity $ 7,159,852 $ 2,137 $ 7,161,989 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended September 30, 2015 due most significantly to a $15,348 adjustment to increase current deferred tax assets, a $472,009 adjustment to increase current intercompany receivables, a $25,760 adjustment to decrease investments in subsidiaries, a $461,815 adjustment to increase accrued expenses, a $16,257 adjustment to increase deferred tax liabilities and a $13,344 adjustment to decrease long-term liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015. These figures were also adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $43,431 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the issuer financial statements as of September 30, 2015. As of June 30, 2015 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 1,036,046 $ — $ 1,036,046 Total assets $ 6,484,050 $ 1,224 $ 6,485,274 Total current liabilities $ 943,570 $ — $ 943,570 Total long-term liabilities $ 3,379,396 $ 2,252 $ 3,381,648 Total equity $ 2,161,084 $ (1,028) $ 2,160,056 Total liabilities and equity $ 6,484,050 $ 1,224 $ 6,485,274 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended June 30, 2015 due most significantly to a $15,347 adjustment to increase current deferred tax assets, a $17,876 adjustment to decrease investments in subsidiaries, a $9,944 adjustment to decrease accrued expenses, a $17,323 adjustment to increase deferred tax liabilities and a decrease of $14,662 in long-term liabilities within the issuer financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. These figures were also adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $45,889 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the issuer financial statements as of June 30, 2015. As of March 31, 2015 Restated Consolidating Balance Sheet-Issuer (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 632,999 $ — $ 632,999 Total assets $ 5,945,568 $ 1,496 $ 5,947,064 Total current liabilities $ 385,171 $ — $ 385,171 Total long-term liabilities $ 3,485,056 $ 2,252 $ 3,487,308 Total equity $ 2,075,341 $ (756) $ 2,074,585 Total liabilities and equity $ 5,945,568 $ 1,496 $ 5,947,064 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q Three Months Ended September 30, 2016 Restated Consolidating Statement of Operations-Guarantor Subsidiaries As Previously Restatement As Restated Net revenue $ 336,679 $ — $ 336,679 Cost of net revenue $ 203,620 $ — $ 203,620 Sales and marketing $ 52,928 $ — $ 52,928 General and administrative $ 18,319 $ 4,700 $ 23,019 Income from continuing operations before provision for income taxes $ 42,335 $ (4,400) $ 37,935 Provision for income taxes $ 75,980 $ (2,631) $ 73,349 Loss from continuing operations $ (33,645 ) $ (1,769 ) $ (35,414) As of September 30, 2016 Restated Consolidating Balance Sheet-Guarantor Subsidiaries (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,309,196 $ — $ 1,309,196 Total assets $ 4,792,740 $ — $ 4,792,740 Total current liabilities $ 996,624 $ (2,631 ) $ 993,993 Total long-term liabilities $ 1,427,397 $ 4,400 $ 1,431,797 Total equity $ 2,368,719 $ (1,769 ) $ 2,366,950 Total liabilities and equity $ 4,792,740 $ — $ 4,792,740 As of June 30, 2016 Restated Consolidating Balance Sheet-Guarantor Subsidiaries (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,233,735 $ (6,513 ) $ 1,227,222 Total assets $ 4,764,565 $ — $ 4,764,565 Total current liabilities $ 892,933 $ — $ 892,933 Total long-term liabilities $ 1,471,124 $ — $ 1,471,124 Total equity $ 2,400,508 $ — $ 2,400,508 Total liabilities and equity $ 4,764,565 $ — $ 4,764,565 As of March 31, 2016 Restated Consolidating Balance Sheet-Guarantor Subsidiaries (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,199,926 $ (31,285 ) $ 1,168,641 Total assets $ 4,737,809 $ — $ 4,737,809 Total current liabilities $ 905,144 $ — $ 905,144 Total long-term liabilities $ 1,476,576 $ — $ 1,476,576 Total equity $ 2,356,089 $ — $ 2,356,089 Total liabilities and equity $ 4,737,809 $ — $ 4,737,809 Three Months Ended September 30, 2016 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 323,246 $ (72 ) $ 323,174 Cost of net revenue $ 187,776 $ 113 $ 187,889 Sales and marketing $ 47,184 $ (13 ) $ 47,171 General and administrative $ 36,196 $ 1,700 $ 37,896 Income from continuing operations before provision for income taxes $ 39,271 $ (1,872 ) $ 37,399 Provision for income taxes $ 100,395 $ 2,723 $ 103,118 Loss from continuing operations $ (54,447 ) $ (4,595 ) $ (59,042 ) Three Months Ended June 30, 2016 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 349,659 $ (784 ) $ 348,875 Cost of net revenue $ 199,704 $ (561 ) $ 199,143 Sales and marketing $ 47,793 $ (72 ) $ 47,721 General and administrative $ 40,154 $ (1,700 ) $ 38,454 Income from continuing operations before benefit for income taxes $ 44,434 $ 1,549 $ 45,983 Benefit for income taxes $ (9,889 ) $ (535 ) $ (10,424 ) Income from continuing operations $ 55,880 $ 2,084 $ 57,964 Three Months Ended March 31, 2016 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 310,620 $ 8,731 $ 319,351 Cost of net revenue $ 178,145 $ 3,863 $ 182,008 Sales and marketing $ 44,012 $ 827 $ 44,839 General and administrative $ 37,155 $ — $ 37,155 Income from continuing operations before benefit for income taxes $ 42,443 $ 4,041 $ 46,484 Benefit for income taxes $ (404 ) $ 36 $ (368 ) Income from continuing operations $ 47,428 $ 4,005 $ 51,433 As of September 30, 2016 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,124,858 $ (39,944 ) $ 1,084,914 Total assets $ 2,871,239 $ (3,989 ) $ 2,867,250 Total current liabilities $ 629,612 $ (2,350 ) $ 627,262 Total long-term liabilities $ 998,037 $ — $ 998,037 Total equity $ 1,243,590 $ (1,639 ) $ 1,241,951 Total liabilities and equity $ 2,871,239 $ (3,989 ) $ 2,867,250 As of June 30, 2016 Restated Consolidating Balance Sheet-Non-Guarantor As Previously Restatement As Restated Total current assets $ 1,142,219 $ (30,019 ) $ 1,112,200 Total assets $ 2,905,690 $ 7,964 $ 2,913,654 Total current liabilities $ 499,901 $ (1,050 ) $ 498,851 Total long-term liabilities $ 1,117,516 $ 6,058 $ 1,123,574 Total equity $ 1,288,273 $ 2,956 $ 1,291,229 Total liabilities and equity $ 2,905,690 $ 7,964 $ 2,913,654 As of March 31, 2016 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ 1,112,355 $ (61,077 ) $ 1,051,278 Total assets $ 2,902,509 $ (135 ) $ 2,902,374 Total current liabilities $ 508,599 $ (1,006 ) $ 507,593 Total long-term liabilities $ 1,118,354 $ — $ 1,118,354 Total equity $ 1,275,556 $ 871 $ 1,276,427 Total liabilities and equity $ 2,902,509 $ (135 ) $ 2,902,374 Three Months Ended September 30, 2015 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 327,731 $ 831 $ 328,562 Cost of net revenue $ 187,690 $ (385 ) $ 187,305 Sales and marketing $ 51,296 $ 231 $ 51,527 General and administrative $ 43,529 $ — $ 43,529 Income from continuing operations before benefit for income taxes $ 26,636 $ 985 $ 27,621 Benefit for income taxes $ (59,605 ) $ 72 $ (59,533 ) Income from continuing operations $ 91,589 $ 913 $ 92,502 Three Months Ended June 30, 2015 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 362,644 $ 603 $ 363,247 Cost of net revenue $ 205,281 $ 894 $ 206,175 Sales and marketing $ 54,353 $ (118 ) $ 54,235 General and administrative $ (14,505 ) $ — $ (14,505 ) Income from continuing operations before provision for income taxes $ 105,715 $ (173 ) $ 105,542 Provision for income taxes $ 21,203 $ 99 $ 21,302 Income from continuing operations $ 84,936 $ (272 ) $ 84,664 Three Months Ended March 31, 2015 Restated Consolidating Statement of Operations-Non-Guarantor As Previously Restatement As Restated Net revenue $ 350,268 $ (2,986 ) $ 347,282 Cost of net revenue $ 194,890 $ (2,296 ) $ 192,594 Sales and marketing $ 54,592 $ (161 ) $ 54,431 General and administrative $ 34,398 $ — $ 34,398 Income from continuing operations before provision for income taxes $ 81,668 $ (529 ) $ 81,139 Provision for income taxes $ 11,717 $ (214 ) $ 11,503 Income from continuing operations $ 73,519 $ (315 ) $ 73,204 As of September 30, 2015 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As of Restatement Adjustment As Restated Total current assets $ 1,003,288 $ (482 ) $ 1,002,806 Total assets $ 2,912,305 $ (482 ) $ 2,911,823 Total current liabilities $ 424,994 $ (367 ) $ 424,627 Total long-term liabilities $ 1,208,211 $ — $ 1,208,211 Total equity $ 1,279,100 $ (115 ) $ 1,278,985 Total liabilities and equity $ 2,912,305 $ (482 ) $ 2,911,823 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended September 30, 2015 due most significantly to a $10,764 adjustment to decrease accounts receivable, a $10,866 adjustment to increase inventory, a $25,228 adjustment to increase current intercompany receivables, a $43,907 adjustment to increase accrued expenses and a $19,096 adjustment to decrease equity within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. These figures were also adjusted retrospectively for the impact of the adoption of ASU 2015-03 and ASU 2015-15 in the first quarter of 2016 (as discussed in Note 5(w)), which resulted in the reclassification of $213 of debt issuance costs from other non-current assets to long-term debt, net of current portion within the non-guarantor subsidiaries financial statements as of September 30, 2015. As of June 30, 2015 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 1,049,149 $ (1,697) $ 1,047,452 Total assets $ 3,016,055 $ (1,697) $ 3,014,358 Total current liabilities $ 561,971 $ (669) $ 561,302 Total long-term liabilities $ 1,181,371 $ — $ 1,181,371 Total equity $ 1,272,713 $ (1,028) $ 1,271,685 Total liabilities and equity $ 3,016,055 $ (1,697) $ 3,014,358 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended June 30, 2015 due most significantly to an $11,082 adjustment to decrease accounts receivable, a $10,371 adjustment to increase inventory, a $15,130 adjustment to increase accrued expenses and a $16,314 adjustment to decrease equity within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. As of March 31, 2015 Restated Consolidating Balance Sheet-Non-Guarantor (in thousands) (unaudited) As of Restatement As Restated Total current assets $ 978,225 $ (1,407) $ 976,818 Total assets $ 2,962,300 $ (1,407) $ 2,960,893 Total current liabilities $ 611,673 $ (651) $ 611,022 Total long-term liabilities $ 1,174,407 $ — $ 1,174,407 Total equity $ 1,176,220 $ (756) $ 1,175,464 Total liabilities and equity $ 2,962,300 $ (1,407) $ 2,960,893 (1) The amounts presented in this column have been revised from the figures presented in the Quarterly Report on Form 10-Q for the period ended March 31, 2015 due most significantly to a $7,769 adjustment to decrease accounts receivable, a $9,765 adjustment to increase inventory, a $14,035 adjustment to increase accrued expenses and a $12,463 adjustment to decrease equity within the non-guarantor subsidiaries financial statements, which were identified during the preparation of the Annual Report on Form 10-K for 2015. Three Months Ended September 30, 2016 Restated Consolidating Statement of Operations-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ (77,571 ) $ — $ (77,571) Cost of net revenue $ (76,023 ) $ — $ (76,023) Sales and marketing $ — $ — $ — General and administrative $ (489 ) $ — $ (489) Loss from continuing operations before provision for income taxes $ (1,058 ) $ — $ (1,058) Provision for income taxes $ — $ — $ — Income from continuing operations $ 88,092 $ 6,364 $ 94,456 Three Months Ended June 30, 2016 Restated Consolidating Statement of Operations-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ (77,671 ) $ — $ (77,671) Cost of net revenue $ (76,792 ) $ — $ (76,792) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Loss from continuing operations before provision for income taxes $ (880 ) $ — $ (880) Provision for income taxes $ — $ — $ — Loss from continuing operations $ (97,819 ) $ (2,084) $ (99,903) Three Months Ended March 31, 2016 Restated Consolidating Statement of Operations-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ (64,195 ) $ — $ (64,195) Cost of net revenue $ (63,577 ) $ — $ (63,577) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Loss from continuing operations before provision for income taxes $ (618 ) $ — $ (618) Provision for income taxes $ — $ — $ — Loss from continuing operations $ (79,432 ) $ (4,005) $ (83,437) As of September 30, 2016 Restated Consolidating Balance Sheet-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ (2,188,177 ) $ — $ (2,188,177) Total assets $ (8,465,676 ) $ 3,408 $ (8,462,268) Total current liabilities $ (2,168,444 ) $ — $ (2,168,444) Total long-term liabilities $ (2,689,610 ) $ — $ (2,689,610) Total equity $ (3,607,622 ) $ 3,408 $ (3,604,214) Total liabilities and equity $ (8,465,676 ) $ 3,408 $ (8,462,268) As of June 30, 2016 Restated Consolidating Balance Sheet-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ (1,363,814 ) $ — $ (1,363,814) Total assets $ (7,629,209 ) $ (75,503) $ (7,704,712) Total current liabilities $ (1,345,171 ) $ — $ (1,345,171) Total long-term liabilities $ (2,599,765 ) $ (72,547) $ (2,672,312) Total equity $ (3,684,273 ) $ (2,956) $ (3,687,229) Total liabilities and equity $ (7,629,209 ) $ (75,503) $ (7,704,712) As of March 31, 2016 Restated Consolidating Balance Sheet-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Total current assets $ (1,102,786 ) $ 2,120 $ (1,100,666) Total assets $ (7,301,102 ) $ (67,359) $ (7,368,461) Total current liabilities $ (1,079,966 ) $ — $ (1,079,966) Total long-term liabilities $ (2,593,856 ) $ (66,488) $ (2,660,344) Total equity $ (3,627,280 ) $ (871) $ (3,628,151) Total liabilities and equity $ (7,301,102 ) $ (67,359) $ (7,368,461) Three Months Ended September 30, 2015 Restated Consolidating Statement of Operations-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ (72,001 ) $ — $ (72,001 ) Cost of net revenue $ (70,090 ) $ — $ (70,090 ) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Loss from continuing operations before benefit for income taxes $ (1,911 ) $ — $ (1,911 ) Benefit for income taxes $ (1 ) $ — $ (1 ) Loss from continuing operations $ (157,658 ) $ (913 ) $ (158,571 ) Three Months Ended June 30, 2015 Restated Consolidating Statement of Operations-Eliminations (in thousands) (unaudited) As Previously Restatement As Restated Net revenue $ (69,082 ) $ — $ (69,082) Cost of net revenue $ (69,007 ) $ — $ (69,007) Sales and marketing $ — $ — $ — General and administrative $ — $ — $ — Loss from continuing operations before b
Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss)	CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Year Ended December 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net income (loss) $ (137,269 ) $ 78,698 $ 151,179 $ (229,877 ) $ (137,269 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 2,725 (1,672 ) (123,308 ) (32 ) (122,287 ) Minimum pension liability adjustment — — (207 ) — (207 ) Other comprehensive income (loss), before tax 2,725 (1,672 ) (123,515 ) (32 ) (122,494 ) Income tax provision related to items of other comprehensive loss — — 127 — 127 Other comprehensive income (loss), net of tax 2,725 (1,672 ) (123,642 ) (32 ) (122,621 ) Comprehensive income (loss) (134,544 ) 77,026 27,537 (229,909 ) (259,890 ) Less: Comprehensive income attributable to non-controlling — — 350 — 350 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (134,544 ) $ 77,026 $ 27,187 $ (229,909 ) $ (260,240 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the Year Ended December 31, 2015 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net income $ 204,065 $ 77,057 $ 188,115 $ (265,172 ) $ 204,065 Other comprehensive loss, before tax: Changes in cumulative translation adjustment (1,175 ) (816 ) (144,267 ) (180 ) (146,438 ) Minimum pension liability adjustment — — (1,173 ) — (1,173 ) Other comprehensive loss, before tax (1,175 ) (816 ) (145,440 ) (180 ) (147,611 ) Income tax provision related to items of other comprehensive loss — — 56 — 56 Other comprehensive loss, net of tax (1,175 ) (816 ) (145,496 ) (180 ) (147,667 ) Comprehensive income 202,890 76,241 42,619 (265,352 ) 56,398 Less: Comprehensive income attributable to non-controlling — — 381 — 381 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 202,890 $ 76,241 $ 42,238 $ (265,352 ) $ 56,017 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Year Ended December 31, 2014 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net income (loss) $ (33,123 ) $ 39,330 $ 84,532 $ (123,862 ) $ (33,123 ) Other comprehensive loss, before tax: Changes in cumulative translation adjustment (489 ) (516 ) (165,443 ) — (166,448 ) Unrealized losses on available for sale securities — (17 ) — — (17 ) Unrealized gains on hedging instruments — — 38 — 38 Minimum pension liability adjustment — — (169 ) — (169 ) Other comprehensive loss, before tax (489 ) (533 ) (165,574 ) — (166,596 ) Income tax benefit related to items of other comprehensive loss — — (173 ) — (173 ) Other comprehensive loss, net of tax (489 ) (533 ) (165,401 ) — (166,423 ) Comprehensive income (loss) (33,612 ) 38,797 (80,869 ) (123,862 ) (199,546 ) Less: Comprehensive loss attributable to non-controlling — — 30 — 30 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (33,612 ) $ 38,797 $ (80,899 ) $ (123,862 ) $ (199,576 )
Guarantor Financial Information Consolidating Statement of Cash Flows	CONSOLIDATING STATEMENT OF CASH FLOWS For the Year Ended December 31, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (137,269 ) $ 78,698 $ 151,179 $ (229,877 ) $ (137,269 ) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Equity in earnings of subsidiaries, net of tax (225,588 ) — — 225,588 — Non-cash 13,218 11 140 — 13,369 Depreciation and amortization 9,195 179,672 96,492 249 285,608 Non-cash 22,524 9,629 9,643 — 41,796 Impairment of inventory — (319 ) 2,986 — 2,667 Impairment of long-lived assets — 668 1,124 — 1,792 Loss on sale of fixed assets 114 1,167 2,270 — 3,551 Equity earnings of unconsolidated entities, net of tax (31,301 ) — (18,863 ) (341 ) (50,505 ) Deferred income taxes (12,446 ) (29,063 ) 5,499 — (36,010 ) Net gain on business disposition — — (3,810 ) — (3,810 ) Other non-cash 1,562 408 (2,382 ) (51 ) (463 ) Non-cash (1,700 ) (11,547 ) (62 ) — (13,309 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 4,548 22,150 — 26,698 Inventories, net — (40,886 ) 22,850 4,381 (13,655 ) Prepaid expenses and other current assets (4,887 ) 7,275 (17,354 ) (4,955 ) (19,921 ) Accounts payable 19,087 3,361 (18,086 ) — 4,362 Accrued expenses and other current liabilities (9,342 ) 7,956 83,136 (30,260 ) 51,490 Other non-current 189,853 (141,398 ) (60,342 ) 35,216 23,329 Cash paid for contingent consideration (427 ) — (3 ) — (430 ) Intercompany payable (receivable) 263,255 (54,899 ) (208,406 ) 50 — Net cash provided by operating activities 95,848 15,281 68,161 — 179,290 Cash Flows from Investing Activities: Increase in restricted cash (88 ) — (4,633 ) — (4,721 ) Purchases of property, plant and equipment (3,868 ) (31,317 ) (34,382 ) 1,873 (67,694 ) Proceeds from sale of property, plant and equipment 92 367 2,842 (1,873 ) 1,428 Cash received from (used in) business dispositions, net of cash divested (1,337 ) — 22,807 — 21,470 Cash paid for business acquisitions, net of cash acquired — — (5,958 ) — (5,958 ) Cash paid for equity investments (184 ) — — — (184 ) Proceeds from sale of equity investments 24,525 — 16,226 — 40,751 Cash received from sales of marketable securities — 87 — — 87 Cash received from equity method investments 16,989 — — — 16,989 Decrease (increase) in other assets (49 ) (266 ) 775 — 460 Net cash provided by (used in) investing activities 36,080 (31,129 ) (2,323 ) — 2,628 Cash Flows from Financing Activities: Cash paid for financing costs (29,187 ) — — — (29,187 ) Cash paid for contingent consideration — — (680 ) — (680 ) Cash paid for dividends (21,292 ) — — — (21,292 ) Proceeds from issuance of common stock, net of issuance costs 18,934 — — — 18,934 Proceeds from issuance of long-term debt — — 459 — 459 Payments on short-term debt — — (1,722 ) — (1,722 ) Payments on long-term debt (196,897 ) — (1,419 ) — (198,316 ) Net proceeds (payments) under revolving credit facilities 125,000 — 1,017 — 126,017 Principal payments on capital lease obligations — (2,279 ) (1,753 ) — (4,032 ) Net cash used in financing activities (103,442 ) (2,279 ) (4,098 ) — (109,819 ) Foreign exchange effect on cash and cash equivalents — 138 (7,222 ) — (7,084 ) Net increase (decrease) in cash and cash equivalents 28,486 (17,989 ) 54,518 — 65,015 Cash and cash equivalents, beginning of period 139,153 21,150 341,897 — 502,200 Cash and cash equivalents, end of period $ 167,639 $ 3,161 $ 396,415 $ — $ 567,215 CONSOLIDATING STATEMENT OF CASH FLOWS For the Year Ended December 31, 2015 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Subsidiaries Eliminations Consolidated Cash Flows from Operating Activities: Net income $ 204,065 $ 77,057 $ 188,115 $ (265,172 ) $ 204,065 Income (loss) from discontinued operations, net of tax 221,425 (1,912 ) — — 219,513 Income (loss) from continuing operations (17,360 ) 78,969 188,115 (265,172 ) (15,448 ) Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (259,924 ) — — 259,924 — Non-cash 12,697 25 109 — 12,831 Depreciation and amortization 10,105 175,415 123,921 (177 ) 309,264 Non-cash 14,400 5,869 6,122 — 26,391 Impairment of inventory — 133 15,464 — 15,597 Impairment of long-lived assets — 3,391 317 — 3,708 Loss on sale of fixed assets 121 2,757 1,047 — 3,925 Equity earnings of unconsolidated entities, net of tax (1,484 ) — (14,065 ) 19 (15,530 ) Deferred income taxes (83,208 ) (112 ) (16,508 ) 439 (99,389 ) Loss on extinguishment of debt 19,886 — — — 19,886 Impairment and net (gain) loss on business disposition 79,951 (8,747 ) (20,664 ) — 50,540 Other non-cash 4,809 996 19,777 3,200 28,782 Non-cash (32,975 ) 11,577 (38,473 ) — (59,871 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 1,529 (8,209 ) — (6,680 ) Inventories, net — (22,881 ) (42,951 ) 1,897 (63,935 ) Prepaid expenses and other current assets 3,177 (26,268 ) 21,891 (4,095 ) (5,295 ) Accounts payable (5,467 ) (7,741 ) 2,425 — (10,783 ) Accrued expenses and other current liabilities 2,416 70,776 (52,841 ) 2,292 22,643 Other non-current (4,089 ) 3,034 (4,016 ) 1,714 (3,357 ) Cash paid for contingent consideration (6,302 ) — (13 ) — (6,315 ) Intercompany payable (receivable) 518,055 (320,171 ) (197,877 ) (7 ) — Net cash provided by (used in) continuing operations 254,808 (31,449 ) (16,429 ) 34 206,964 Net cash provided by discontinued operations — 318 — — 318 Net cash provided by (used in) operating activities 254,808 (31,131 ) (16,429 ) 34 207,282 Cash Flows from Investing Activities: (Increase) decrease in restricted cash 3,763 — (17,478 ) — (13,715 ) Purchases of property, plant and equipment (12,710 ) (29,748 ) (49,375 ) 1,055 (90,778 ) Proceeds from sale of property, plant and equipment — 993 2,161 (1,055 ) 2,099 Cash received from (used in) business dispositions, net of cash divested 591,844 (8,723 ) 92,702 — 675,823 Cash paid for business acquisitions, net of cash acquired (60,135 ) — — — (60,135 ) Cash received from sales of marketable securities — 92 — — 92 Cash received from equity method investments 2,695 — 23,441 — 26,136 Decrease (increase) decrease in other assets 301 485 (2,546 ) (34 ) (1,794 ) Net cash provided by (used in) continuing operations 525,758 (36,901 ) 48,905 (34 ) 537,728 Net cash used in discontinued operations — (209 ) — — (209 ) Net cash provided by (used in) investing activities 525,758 (37,110 ) 48,905 (34 ) 537,519 Cash Flows from Financing Activities: Cash paid for financing costs (15,973 ) — (215 ) — (16,188 ) Cash paid for contingent consideration (13,640 ) — (583 ) — (14,223 ) Cash paid for dividends (21,293 ) — — — (21,293 ) Proceeds from issuance of common stock, net of issuance costs 79,185 — — — 79,185 Proceeds from issuance of short-term debt — — 1,511 — 1,511 Proceeds from issuance of long-term debt 2,119,125 — 43,037 — 2,162,162 Payments on short-term debt — — (25,584 ) — (25,584 ) Payments on long-term debt (2,655,343 ) — (1,043 ) — (2,656,386 ) Net payments under revolving credit facilities (127,000 ) — (536 ) — (127,536 ) Principal payments on capital lease obligations — (2,565 ) (3,053 ) — (5,618 ) Other (8,623 ) — (314 ) — (8,937 ) Net cash provided by (used in) continuing operations (643,562 ) (2,565 ) 13,220 — (632,907 ) Net cash used in discontinued operations — (76 ) — — (76 ) Net cash provided by (used in) financing activities (643,562 ) (2,641 ) 13,220 — (632,983 ) Foreign exchange effect on cash and cash equivalents — (422 ) (10,957 ) — (11,379 ) Net increase (decrease) in cash and cash equivalents 137,004 (71,304 ) 34,739 — 100,439 Cash and cash equivalents, beginning of period — continuing operations 2,149 69,154 307,158 — 378,461 Cash and cash equivalents, beginning of period — discontinued operations — 23,300 — — 23,300 Cash and cash equivalents of continuing operations, end of period $ 139,153 $ 21,150 $ 341,897 $ — $ 502,200 CONSOLIDATING STATEMENT OF CASH FLOWS For the Year Ended December 31, 2014 (As Restated) (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (33,123 ) $ 39,330 $ 84,532 $ (123,862 ) $ (33,123 ) Income (loss) from discontinued operations, net of tax 145,751 (27,839 ) 20,400 6 138,318 Income (loss) from continuing operations (178,874 ) 67,169 64,132 (123,868 ) (171,441 ) Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities: Equity in earnings of subsidiaries, net of tax (125,443 ) — — 125,443 — Non-cash 15,780 42 411 — 16,233 Depreciation and amortization 8,783 177,347 149,884 15 336,029 Non-cash 3,446 4,957 4,049 — 12,452 Tax benefit related to discontinued operations retained by Alere Inc — 12,977 (3,132 ) — 9,845 Impairment of inventory — — 3,124 — 3,124 Impairment of long-lived assets 1,019 (712 ) 6,712 — 7,019 Loss on disposition of fixed assets 1 4,807 1,737 — 6,545 Equity earnings of unconsolidated entities, net of tax (1,717 ) — (15,928 ) 136 (17,509 ) Deferred income taxes 59,929 (32,750 ) (15,945 ) 1,020 12,254 Impairment and net gain on business disposition 4,236 11,393 (7,887 ) — 7,742 Other non-cash 1,418 3,726 (179 ) — 4,965 Non-cash (3,414 ) 11,256 (165 ) — 7,677 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (16,345 ) 12,081 — (4,264 ) Inventories, net — (52,670 ) (12,717 ) (2,145 ) (67,532 ) Prepaid expenses and other current assets (4,793 ) (26,445 ) (20,015 ) (745 ) (51,998 ) Accounts payable 8,818 24,776 14,257 — 47,851 Accrued expenses and other current liabilities 1,698 6,734 31,273 (1,819 ) 37,886 Other non-current (594 ) 1,380 9,897 2,571 13,254 Cash paid for contingent consideration (21,867 ) — (210 ) — (22,077 ) Intercompany payable (receivable) 349,314 (184,028 ) (165,293 ) 7 — Net cash provided by continuing operations 117,740 13,614 56,086 615 188,055 Net cash provided by (used in) discontinued operations (671 ) 44,060 79 — 43,468 Net cash provided by operating activities 117,069 57,674 56,165 615 231,523 Cash Flows from Investing Activities: Increase in restricted cash (2,791 ) — (2,655 ) — (5,446 ) Purchases of property, plant and equipment (21,680 ) (40,737 ) (41,862 ) 3,717 (100,562 ) Proceeds from sale of property, plant and equipment 726 845 4,165 (4,250 ) 1,486 Cash received from business disposition, net of cash divested — 1,081 43,995 — 45,076 Cash paid for business acquisitions, net of cash acquired (75 ) — — — (75 ) Cash received (paid) for investments 477 (279 ) — 198 Proceeds from sale of equity investment — — 8,546 — 8,546 Cash received from sales of marketable securities — 576 4 — 580 Cash received from equity method investments — — 980 — 980 Decrease in other assets 96 714 130 46 986 Net cash provided by (used in) continuing operations (23,247 ) (37,800 ) 13,303 (487 ) (48,231 ) Net cash used in discontinued operations — (8,972 ) — — (8,972 ) Net cash provided by (used in) investing activities (23,247 ) (46,772 ) 13,303 (487 ) (57,203 ) Cash Flows from Financing Activities: Cash paid for financing costs (1,528 ) — — — (1,528 ) Cash paid for contingent purchase price consideration (32,467 ) — (435 ) — (32,902 ) Cash paid for dividends (21,293 ) — — — (21,293 ) Proceeds from issuance of common stock, net of issuance costs 51,555 — — — 51,555 Proceeds from issuance of short-term debt — — 806 — 806 Proceeds from issuance of long-term debt — — 58 — 58 Payments on long-term debt (60,000 ) (271 ) (4,851 ) — (65,122 ) Net (payments) proceeds under revolving credit facilities (43,000 ) — 478 — (42,522 ) Excess tax benefits on exercised stock options 460 422 90 — 972 Principal payments on capital lease obligations — (2,885 ) (3,200 ) — (6,085 ) Purchase of non-controlling — — (623 ) — (623 ) Net cash used in continuing operations (106,273 ) (2,734 ) (7,677 ) — (116,684 ) Net cash used in discontinued operations — (893 ) (578 ) — (1,471 ) Net cash used in financing activities (106,273 ) (3,627 ) (8,255 ) — (118,155 ) Foreign exchange effect on cash and cash equivalents (201 ) (273 ) (15,710 ) (128 ) (16,312 ) Net increase (decrease) in cash and cash equivalents (12,652 ) 7,002 45,503 — 39,853 Cash and cash equivalents, beginning of period - continuing operations 14,801 78,976 261,654 — 355,431 Cash and cash equivalents, beginning of period - discontinued operations — 6,476 1 — 6,477 Cash and cash equivalents, end of period 2,149 92,454 307,158 — 401,761 Less: Cash and cash equivalents of discontinued operations, end of period — 23,300 — — 23,300 Cash and cash equivalents of continuing operations, end of period $ 2,149 $ 69,154 $ 307,158 $ — $ 378,461

Description of Business and B60

Description of Business and Basis of Presentation of Financial Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015Segments
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	2

Restatement of Previously Iss61

Restatement of Previously Issued Financial Statements - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2013USD ($)
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase in accumulated deficit	$ 0.8

Restatement of Previously Iss62

Restatement of Previously Issued Financial Statements - Restated Consolidated Statements of Operations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	$ 456,024	$ 482,962	$ 468,502	$ 500,367	$ 472,959	$ 491,652	$ 481,352	$ 951,464	$ 973,004	$ 1,407,488	$ 1,445,963	$ 1,883,576		$ 1,946,330	[1]	$ 2,023,963	[1]
Services revenue	123,778	124,809	115,709	113,483	128,341	126,628	123,856	240,518	250,484	364,296	378,825	480,761		492,308	[1]	531,988	[1]
Net product sales and services revenue	579,802	607,771	584,211	613,850	601,300	618,280	605,208	1,191,982	1,223,488	1,771,784	1,824,788	2,364,337		2,438,638	[1]	2,555,951	[1]
License and royalty revenue	2,480	2,533	2,729	3,286	3,299	5,694	4,698	5,262	10,392	7,742	13,691	11,998		16,977	[1]	21,050	[1]
Net revenue	582,282	610,304	586,940	617,136	604,599	623,974	609,906	1,197,244	1,233,880	1,779,526	1,838,479	2,376,335		2,455,615	[1]	2,577,001	[1]
Cost of net product sales	239,059	249,837	241,324	297,125	245,429	258,787	237,805	491,161	496,592	730,220	742,021	978,347		1,039,146	[1]	1,063,000	[1]
Cost of services revenue	76,639	78,294	73,100	72,111	79,851	76,800	75,626	151,394	152,426	228,033	232,277	304,871		304,388	[1]	294,949	[1]
Cost of net product sales and services revenue	315,698	328,131	314,424	369,236	325,280	335,587	313,431	642,555	649,018	958,253	974,298	1,283,218		1,343,534	[1]	1,357,949	[1]
Cost of license and royalty revenue	641	535	1,391	650	1,137	1,344	1,950	1,926	3,294	2,567	4,431	3,250		3,781	[1]	5,592	[1]
Cost of net revenue	316,339	328,666	315,815	368,586	326,417	336,931	315,381	644,481	652,312	960,820	978,729	1,286,468		1,347,315	[1]	1,363,541	[1]
Gross profit	265,943	281,638	271,125	248,550	278,182	287,043	294,525	552,763	581,568	818,706	859,750	1,089,867		1,108,300	[1]	1,213,460	[1]
Operating expenses:
Research and development	31,430	28,446	27,062	28,228	36,011	27,198	28,016	55,508	55,214	86,938	91,225	112,122		119,453	[1]	144,828	[1]
Sales and marketing	101,966	102,444	100,640	110,891	106,724	107,906	108,918	203,084	216,824	305,050	323,548	403,055		434,439	[1]	513,049	[1]
General and administrative	148,540	136,854	114,956	118,986	101,306	61,173	92,691	251,810	153,864	400,350	255,170	563,776		374,156	[1]	453,163	[1]
Impairment and (gain) loss on dispositions, net	0	0	(3,810)	8,132	2,074	5,542	34,792	(3,810)	40,334	(3,810)	42,408	(3,810)		50,540	[1]	7,742	[1]
Operating income (loss)	(15,993)	13,894	32,277	(17,687)	32,067	85,224	30,108	46,171	115,332	30,178	147,399	14,724		129,712	[1]	94,678	[1]
Interest expense, including amortization of original issue discounts and deferred financing costs	(44,130)	(42,329)	(42,106)	(58,739)	(52,333)	(59,494)	(46,431)	(84,435)	(105,925)	(128,565)	(158,258)	(171,651)		(216,997)	[1]	(209,191)	[1]
Other income (expense), net	(1,159)	(3,912)	(1,349)	(1,743)	3,658	3,195	(2,367)	(5,261)	828	(6,420)	4,486	4,529		2,743	[1]	(3,407)	[1]
Loss from continuing operations before provision (benefit) for income taxes	(61,282)	(32,347)	(11,178)	(78,169)	(16,608)	28,925	(18,690)	(43,525)	10,235	(104,807)	(6,373)	(152,398)		(84,542)	[1]	(117,920)	[1]
Provision (benefit) for income taxes	(50,796)	2,582	(172)	(51,146)	(10,140)	15,788	(8,067)	2,410	7,721	(48,386)	(2,419)	35,376		(53,564)	[1]	71,030	[1]
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(10,486)	(34,929)	(11,006)	(27,023)	(6,468)	13,137	(10,623)	(45,935)	2,514	(56,421)	(3,954)	(187,774)		(30,978)	[1]	(188,950)	[1]
Equity earnings of unconsolidated entities, net of tax	26,149	2,122	5,034	5,210	5,000	1,361	3,959	7,156	5,320	33,305	10,320	50,505		15,530	[1]	17,509	[1]
Income (loss) from continuing operations	15,663	(32,807)	(5,972)	(21,813)	(1,468)	14,498	(6,664)	(38,779)	7,834	(23,116)	6,366	(137,269)		(15,448)	[1]	(171,441)	[1]
Income (loss) from discontinued operations, net of tax	0	0	0	2,736	0	0	216,777	0	216,777	0	216,777	0		219,513	[1]	138,318	[1]
Net (loss) income	15,663	(32,807)	(5,972)	(19,077)	(1,468)	14,498	210,113	(38,779)	224,611	(23,116)	223,143	(137,269)	[1]	204,065	[1]	(33,123)	[1]
Less: Net income attributable to non-controlling interests	207	143	103	(5)	(61)	359	88	246	447	453	386	350		381	[1]	30	[1]
Net (loss) income attributable to Alere Inc. and Subsidiaries	15,456	(32,950)	(6,075)	(19,072)	(1,407)	14,139	210,025	(39,025)	224,164	(23,569)	222,757	(137,619)		203,684	[1]	(33,153)	[1]
Preferred stock dividends	(5,366)	(5,308)	(5,309)	(5,367)	(5,369)	(5,308)	(5,250)	(10,617)	(10,558)	(15,983)	(15,927)	(21,350)		(21,293)	[1]	(21,293)	[1]
Net (loss) income available to common stockholders	$ 10,090	$ (38,258)	$ (11,384)	$ (24,439)	$ (6,776)	$ 8,831	$ 204,775	$ (49,642)	$ 213,606	$ (39,552)	$ 206,830	$ (158,969)		$ 182,391	[1]	$ (54,446)	[1]
Basic and diluted net (loss) income per common share:
Loss from continuing operations	$ 0.12	$ (0.44)	$ (0.13)	$ (0.31)	$ (0.08)	$ 0.10	$ (0.14)	$ (0.57)	$ (0.04)	$ (0.45)	$ (0.12)	$ (1.83)		$ (0.43)	[1]	$ (2.33)	[1]
Income (loss) from discontinued operations	0	0	0		0	0	2.57	0	2.57	0	2.57	0		2.57	[1]	1.67	[1]
Net (loss) income per common share	$ 0.12	$ (0.44)	$ (0.13)	$ (0.31)	$ (0.08)	$ 0.10	$ 2.43	$ (0.57)	$ 2.53	$ (0.45)	$ 2.45	$ (1.83)		$ 2.14	[1]	$ (0.66)	[1]
Weighted-average shares - basic and diluted		86,737	86,646	85,953	85,895		84,338	86,692	84,758	86,708	85,141	86,796		85,420	[1]	82,938	[1]
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	$ 456,096	$ 483,746	$ 459,771	$ 506,516	$ 472,128	$ 491,049	$ 484,338	$ 943,517	$ 975,387	$ 1,399,613	$ 1,447,515			$ 1,954,031		$ 2,022,240
Services revenue	123,778	124,809	115,709	113,483	128,341	126,628	123,856	240,518	250,484	364,296	378,825			492,308		531,988
Net product sales and services revenue	579,874	608,555	575,480	619,999	600,469	617,677	608,194	1,184,035	1,225,871	1,763,909	1,826,340			2,446,339		2,554,228
License and royalty revenue	2,480	2,533	2,729	3,286	3,299	5,694	4,698	5,262	10,392	7,742	13,691			16,977		21,050
Net revenue	582,354	611,088	578,209	623,285	603,768	623,371	612,892	1,189,297	1,236,263	1,771,651	1,840,031			2,463,316		2,575,278
Cost of net product sales	238,946	250,398	237,461	298,795	245,814	257,893	240,101	487,859	497,994	726,805	743,808			1,042,603		1,062,499
Cost of services revenue	76,639	78,294	73,100	72,111	79,851	76,800	75,626	151,394	152,426	228,033	232,277			304,388		294,949
Cost of net product sales and services revenue	315,585	328,692	310,561	370,906	325,665	334,693	315,727	639,253	650,420	954,838	976,085			1,346,991		1,357,448
Cost of license and royalty revenue	641	535	1,391	650	1,137	1,344	1,950	1,926	3,294	2,567	4,431			3,781		5,592
Cost of net revenue	316,226	329,227	311,952	370,256	326,802	336,037	317,677	641,179	653,714	957,405	980,516			1,350,772		1,363,040
Gross profit	266,128	281,861	266,257	253,029	276,966	287,334	295,215	548,118	582,549	814,246	859,515			1,112,544		1,212,238
Operating expenses:
Research and development	31,430	28,446	27,062	28,228	36,011	27,198	28,016	55,508	55,214	86,938	91,225			119,453		144,828
Sales and marketing	101,979	102,516	99,813	111,535	106,493	108,024	109,079	202,329	217,103	304,308	323,596			435,131		512,961
General and administrative	129,287	128,354	114,956	114,400	101,306	61,173	92,691	243,310	153,864	372,597	255,170			369,570		453,628
Impairment and (gain) loss on dispositions, net	0	0	(3,810)	8,132	2,074	5,542	34,792	(3,810)	40,334	(3,810)	42,408			50,540		7,742
Operating income (loss)	3,432	22,545	28,236	(9,266)	31,082	85,397	30,637	50,781	116,034	54,213	147,116			137,850		93,079
Interest expense, including amortization of original issue discounts and deferred financing costs	(44,130)	(42,329)	(42,106)	(58,739)	(52,333)	(59,494)	(46,431)	(84,435)	(105,925)	(128,565)	(158,258)			(216,997)		(209,191)
Other income (expense), net	(14,312)	(14,112)	(1,349)	(6,329)	3,658	3,195	(2,367)	(15,461)	828	(29,773)	4,486			(1,843)		(2,221)
Loss from continuing operations before provision (benefit) for income taxes	(55,010)	(33,896)	(15,219)	(74,334)	(17,593)	29,098	(18,161)	(49,115)	10,937	(104,125)	(6,656)			(80,990)		(118,333)
Provision (benefit) for income taxes	(50,888)	3,117	(208)	(50,329)	(10,212)	15,689	(7,853)	2,909	7,836	(47,979)	(2,376)			(52,704)		70,930
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(4,122)	(37,013)	(15,011)	(24,005)	(7,381)	13,409	(10,308)	(52,024)	3,101	(56,146)	(4,280)			(28,286)		(189,263)
Equity earnings of unconsolidated entities, net of tax	26,149	2,122	5,034	5,210	5,000	1,361	3,959	7,156	5,320	33,305	10,320			15,530		17,509	[2]
Income (loss) from continuing operations	22,027	(34,891)	(9,977)	(18,795)	(2,381)	14,770	(6,349)	(44,868)	8,421	(22,841)	6,040			(12,756)		(171,754)	[2]
Income (loss) from discontinued operations, net of tax	0	0	0	2,736	0	0	216,777	0	216,777	0	216,777			219,513		138,318	[2]
Net (loss) income	22,027	(34,891)	(9,977)	(16,059)	(2,381)	14,770	210,428	(44,868)	225,198	(22,841)	222,817			206,757		(33,436)	[2]
Less: Net income attributable to non-controlling interests	207	143	103	(5)	(61)	359	88	246	447	453	386			381		30
Net (loss) income attributable to Alere Inc. and Subsidiaries	21,820	(35,034)	(10,080)	(16,054)	(2,320)	14,411	210,340	(45,114)	224,751	(23,294)	222,431			206,376		(33,466)
Preferred stock dividends	(5,366)	(5,308)	(5,309)	(5,367)	(5,369)	(5,308)	(5,250)	(10,617)	(10,558)	(15,983)	(15,927)			(21,293)		(21,293)
Net (loss) income available to common stockholders	$ 16,454	$ (40,342)	$ (15,389)	$ (21,421)	$ (7,689)	$ 9,103	$ 205,090	$ (55,731)	$ 214,193	$ (39,277)	$ 206,504			$ 185,083		$ (54,759)
Basic and diluted net (loss) income per common share:
Loss from continuing operations	$ 0.19	$ (0.46)	$ (0.18)	$ (0.28)	$ (0.09)	$ 0.11	$ (0.14)	$ (0.64)	$ (0.03)	$ (0.45)	$ (0.12)			$ (0.40)		$ (2.33)
Income (loss) from discontinued operations	0	0	0		0	0	2.57	0	2.57	0	2.57			2.57		1.67
Net (loss) income per common share	$ 0.19	$ (0.46)	$ (0.18)	$ (0.28)	$ (0.09)	$ 0.11	$ 2.43	$ (0.64)	$ 2.54	$ (0.45)	$ 2.45			$ 2.17		$ (0.66)
Weighted-average shares - basic and diluted		86,737	86,646	85,953	85,895		84,338	86,692	84,758	86,708	85,141			85,420		82,938
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	$ (72)	$ (784)	$ 8,731	$ (6,149)	$ 831	$ 603	$ (2,986)	$ 7,947	$ (2,383)	$ 7,875	$ (1,552)			$ (7,701)		$ 1,723
Services revenue	0	0	0	0	0	0	0	0	0	0	0			0		0
Net product sales and services revenue	(72)	(784)	8,731	(6,149)	831	603	(2,986)	7,947	(2,383)	7,875	(1,552)			(7,701)		1,723
License and royalty revenue	0	0	0	0	0	0	0	0	0	0	0			0		0
Net revenue	(72)	(784)	8,731	(6,149)	831	603	(2,986)	7,947	(2,383)	7,875	(1,552)			(7,701)		1,723
Cost of net product sales	113	(561)	3,863	(1,670)	(385)	894	(2,296)	3,302	(1,402)	3,415	(1,787)			(3,457)		501
Cost of services revenue	0	0	0	0	0	0	0	0	0	0	0			0		0
Cost of net product sales and services revenue	113	(561)	3,863	(1,670)	(385)	894	(2,296)	3,302	(1,402)	3,415	(1,787)			(3,457)		501
Cost of license and royalty revenue	0	0	0	0	0	0	0	0	0	0	0			0		0
Cost of net revenue	113	(561)	3,863	(1,670)	(385)	894	(2,296)	3,302	(1,402)	3,415	(1,787)			(3,457)		501
Gross profit	(185)	(223)	4,868	(4,479)	1,216	(291)	(690)	4,645	(981)	4,460	235			(4,244)		1,222
Operating expenses:
Research and development	0	0	0	0	0	0	0	0	0	0	0			0		0
Sales and marketing	(13)	(72)	827	(644)	231	(118)	(161)	755	(279)	742	(48)			(692)		88
General and administrative	19,253	8,500	0	4,586	0	0	0	8,500	0	27,753	0			4,586		(465)
Impairment and (gain) loss on dispositions, net	0	0	0	0	0	0	0	0	0	0	0			0		0
Operating income (loss)	(19,425)	(8,651)	4,041	(8,421)	985	(173)	(529)	(4,610)	(702)	(24,035)	283			(8,138)		1,599
Interest expense, including amortization of original issue discounts and deferred financing costs	0	0	0	0	0	0	0	0	0	0	0			0		0
Other income (expense), net	13,153	10,200	0	4,586	0	0	0	10,200	0	23,353	0			4,586		(1,186)
Loss from continuing operations before provision (benefit) for income taxes	(6,272)	1,549	4,041	(3,835)	985	(173)	(529)	5,590	(702)	(682)	283			(3,552)		413
Provision (benefit) for income taxes	92	(535)	36	(817)	72	99	(214)	(499)	(115)	(407)	(43)			(860)		100
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(6,364)	2,084	4,005	(3,018)	913	(272)	(315)	6,089	(587)	(275)	326			(2,692)		313
Equity earnings of unconsolidated entities, net of tax	0	0	0	0	0	0	0	0	0	0	0			0		0	[3]
Income (loss) from continuing operations	(6,364)	2,084	4,005	(3,018)	913	(272)	(315)	6,089	(587)	(275)	326			(2,692)		313	[3]
Income (loss) from discontinued operations, net of tax	0	0	0	0	0	0	0	0	0	0	0			0		0	[3]
Net (loss) income	(6,364)	2,084	4,005	(3,018)	913	(272)	(315)	6,089	(587)	(275)	326			(2,692)		313	[3]
Less: Net income attributable to non-controlling interests	0	0	0	0	0	0	0	0	0	0	0			0		0
Net (loss) income attributable to Alere Inc. and Subsidiaries	(6,364)	2,084	4,005	(3,018)	913	(272)	(315)	6,089	(587)	(275)	326			(2,692)		313
Preferred stock dividends	0	0	0	0	0	0	0	0	0	0	0			0		0
Net (loss) income available to common stockholders	$ (6,364)	$ 2,084	$ 4,005	$ (3,018)	$ 913	$ (272)	$ (315)	$ 6,089	$ (587)	$ (275)	$ 326			$ (2,692)		$ 313
Basic and diluted net (loss) income per common share:
Loss from continuing operations	$ (0.07)	$ 0.02	$ 0.05	$ (0.03)	$ 0.01	$ (0.01)	$ 0	$ 0.07	$ (0.01)	$ 0	$ 0			$ (0.03)		$ 0
Income (loss) from discontinued operations	0	0	0	0	0	0	0	0	0	0	0			0		0
Net (loss) income per common share	$ (0.07)	$ 0.02	$ 0.05	$ (0.03)	$ 0.01	$ (0.01)	$ 0	$ 0.07	$ (0.01)	$ 0	$ 0			$ (0.03)		$ 0
Weighted-average shares - basic and diluted		0	0	0	0		0	0	0	0	0			0		0
[1]	Restated Values
[2]	The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been previously revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due principally to a $19,236 increase in operating cash flow related to deferred income taxes and a $15,753 decrease in operating cash flow related to other non-current liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015.
[3]	All adjustments in this column relate to the misstatements associated with the Standard Diagnostics matter and the consequential impact on inventory, accounts receivable and accrued liabilities.

Restatement of Previously Iss63

Restatement of Previously Issued Financial Statements - Restated Consolidated Statements of Operations (Parenthetical) (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		$ 582,282	$ 610,304	$ 586,940	$ 617,136	$ 604,599	$ 623,974	$ 609,906	$ 1,197,244	$ 1,233,880	$ 1,779,526	$ 1,838,479	$ 2,376,335	$ 2,455,615	[1]	$ 2,577,001	[1]
Net income (loss)		15,456	(32,950)	(6,075)	(19,072)	(1,407)	14,139	210,025	(39,025)	224,164	(23,569)	222,757	$ (137,619)	203,684	[1]	(33,153)	[1]
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		(72)	(784)	8,731	(6,149)	831	603	(2,986)	7,947	(2,383)	7,875	(1,552)		(7,701)		1,723
Net income (loss)		(6,364)	2,084	4,005	$ (3,018)	913	(272)	$ (315)	6,089	$ (587)	(275)	$ 326		(2,692)		313
Legal-related charges	$ 4,586	13,153	10,200						$ 10,200		$ 23,353			$ 4,586
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		678	(1,046)	4,739		1,724	(5,785)									(13,426)
Net income (loss)		$ (12,175)	$ (4,293)	$ 1,200		$ (7,882)	$ (5,493)									4,274
Legal-related charges																$ (1,186)
[1]	Restated Values

Restatement of Previously Iss64

Restatement of Previously Issued Financial Statements - Restated and Revised Consolidated Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ 24,404	$ (76,554)	$ 16,273	$ (42,975)	$ (89,800)	$ 60,491	$ 128,301	$ (60,281)	$ 188,792	$ (35,877)	$ 98,992	$ (259,890)	$ 56,398	[1]	$ (199,546)	[1]
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	30,768	(78,638)	12,268	(39,957)	(90,713)	60,763	128,616	(66,370)	189,379	(35,602)	98,666		58,709		(199,889)
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (6,364)	$ 2,084	$ 4,005	$ (3,018)	$ 913	$ (272)	$ (315)	$ 6,089	$ (587)	$ (275)	$ 326		$ (2,692)		$ 313
[1]	Restated Values

Restatement of Previously Iss65

Restatement of Previously Issued Financial Statements - Restated Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012	[1]
Current assets:
Cash and cash equivalents	$ 567,215		$ 566,213	$ 506,164	$ 490,663	$ 502,200	[1]	$ 479,381	$ 464,871	$ 414,495	$ 378,461	[1]	$ 355,431	[1]
Restricted cash	51,550		4,999	5,662	6,166	5,694	[1]	430,821	461,636	37,406
Marketable securities	76		75	74	71	164	[1]	157	175	173
Accounts receivable, net of allowances of $89,701 at December 31, 2015	413,535		426,207	427,961	459,115	436,924	[1]	436,490	454,636	457,333
Inventories, net	308,920		349,378	334,492	351,015	350,949	[1]	376,057	379,545	388,481
Prepaid expenses and other current assets	118,607		124,390	124,877	106,629	114,514	[1]	121,023	125,559	117,924
Assets held for sale - current	0					4,165	[1]	25,312	28,631
Total current assets	1,459,903		1,471,262	1,399,230	1,413,659	1,414,610	[1]	1,900,012	1,948,785	1,453,773
Property, plant and equipment, net	441,190		446,313	438,787	445,218	446,039	[1]	445,872	448,891	447,326
Goodwill	2,759,366		2,805,682	2,811,545	2,839,692	2,836,915	[1]	2,842,921	2,853,551	2,880,164	2,926,666
Other intangible assets with indefinite lives	27,164		27,991	28,279	28,760	28,110	[1]	28,744	41,306	40,203
Finite-lived intangible assets, net	805,577		864,785	909,208	962,633	997,281	[1]	1,052,949	1,093,186	1,173,866
Restricted cash	2,171		42,438	42,589	43,388	43,228	[1]	44,148
Other non-current assets	14,966		16,219	16,290	17,927	18,078	[1]	19,635	21,845	25,052
Investments in unconsolidated entities	72,225		80,885	74,511	74,744	65,333	[1]	73,882	69,594	95,551
Deferred tax assets	20,483		56,638	18,638	16,124	13,993	[1]	5,380	5,381	6,360
Non-current income tax receivable and prepaid	45,234		39,472	41,500	41,215	41,236	[1]	2,537	2,611	2,545
Assets held for sale - non-current	0			12,223	11,813	13,337	[1]	126,048	129,194
Total assets	5,648,279		5,851,685	5,792,800	5,895,173	5,918,160	[1]	6,542,128	6,614,344	6,124,840
Current liabilities:
Short-term debt and current portion of long-term debt	82,370		41,424	43,681	193,044	199,992	[1]	604,092	629,371	95,299
Current portion of capital lease obligations	3,064		3,713	3,500	4,048	3,962	[1]	3,505	4,643	5,072
Accounts payable	195,879		211,476	194,235	165,800	195,752	[1]	194,246	186,941	195,980
Accrued expenses and other current liabilities	394,843		444,916	319,476	314,989	322,637	[1]	325,184	314,553	367,909
Liabilities related to assets held for sale - current	0					363	[1]	8,836	7,663
Total current liabilities	676,156		701,529	560,892	677,881	722,706	[1]	1,135,863	1,143,171	664,260
Long-term liabilities:
Long-term debt, net of current portion	2,858,205		2,905,067	2,920,789	2,823,654	2,831,166	[1]	2,944,014	2,912,147	2,987,422
Capital lease obligations, net of current portion	7,221		8,033	6,972	7,654	7,181	[1]	7,346	7,974	8,794
Deferred tax liabilities	119,098		52,513	140,864	144,483	147,618	[1]	226,976	243,298	262,117
Other long-term liabilities	155,992		137,582	148,165	155,842	154,193	[1]	121,855	131,578	123,428
Total long-term liabilities	3,140,516		3,103,195	3,216,790	3,131,633	3,140,158	[1]	3,309,794	3,306,524	3,381,761
Commitments and contingencies							[1]
Stockholders' equity:
Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at December 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares at December 31, 20154; Outstanding: 1,774 shares at December 31, 2015	606,406		606,406	606,406	606,468	606,468	[1]	606,468	606,468	606,468
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,043 shares at December 31, 2015, Outstanding: 86,364 shares at December 31, 2015	95		95	94	94	94	[1]	94	93	93
Additional paid-in capital	3,474,979		3,465,898	3,458,639	3,452,722	3,438,732	[1]	3,436,666	3,414,981	3,390,002
Accumulated deficit	(1,607,119)		(1,493,069)	(1,508,525)	(1,475,590)	(1,469,514)	[1]	(1,450,443)	(1,449,034)	(1,463,173)
Treasury stock, at cost, 7,679 shares	(184,971)		(184,971)	(184,971)	(184,971)	(184,971)	[1]	(184,971)	(184,971)	(184,971)
Accumulated other comprehensive loss	(462,398)		(352,085)	(361,033)	(317,429)	(339,777)	[1]	(315,875)	(227,481)	(273,834)	(192,110)		(25,687)
Total stockholders' equity	1,826,992		2,042,274	2,010,610	2,081,294	2,051,032	[1]	2,091,939	2,160,056	2,074,585
Non-controlling interests	4,615		4,687	4,508	4,365	4,264	[1]	4,532	4,593	4,234
Total equity	1,831,607	[1]	2,046,961	2,015,118	2,085,659	2,055,296	[1]	2,096,471	2,164,649	2,078,819	1,916,097	[1]	2,079,904	[1]
Total liabilities and equity	$ 5,648,279		5,851,685	5,792,800	5,895,173	5,918,160	[1]	6,542,128	6,614,344	6,124,840
As Previously Reported [Member]
Current assets:
Cash and cash equivalents			566,213	506,164	490,663	502,200		479,381	464,871	414,495	378,461	[2]	355,431	[2]
Restricted cash			4,999	5,662	6,166	5,694		430,821	461,636	37,406
Marketable securities			75	74	71	164		157	175	173
Accounts receivable, net of allowances of $89,701 at December 31, 2015			427,241	427,222	459,292	445,833		439,250	458,227	461,528
Inventories, net			348,845	333,846	350,931	347,001		373,779	377,651	385,693
Prepaid expenses and other current assets			163,833	162,339	144,369	152,233		121,023	125,559	117,924
Assets held for sale - current						4,165		25,312	28,631
Total current assets			1,511,206	1,435,307	1,451,492	1,457,290		1,900,494	1,950,482	1,455,180
Property, plant and equipment, net			446,313	438,787	445,218	446,039		445,872	448,891	447,326
Goodwill			2,805,682	2,811,545	2,839,692	2,836,915		2,842,921	2,853,551	2,880,164
Other intangible assets with indefinite lives			27,991	28,279	28,760	28,110		28,744	41,306	40,203
Finite-lived intangible assets, net			864,785	909,208	962,633	997,281		1,052,949	1,093,186	1,173,866
Restricted cash			42,438	42,589	43,388	43,228		44,148
Other non-current assets			16,219	16,290	17,927	18,078		19,635	21,845	25,052
Investments in unconsolidated entities			80,885	74,511	74,744	65,333		73,882	69,594	95,551
Deferred tax assets			56,638	18,638	16,124	13,993		5,380	5,381	6,360
Non-current income tax receivable and prepaid			3,517	3,517	3,517	3,517		2,537	2,611	2,545
Assets held for sale - non-current				12,223	11,813	13,337		126,048	129,194
Total assets			5,855,674	5,790,894	5,895,308	5,923,121		6,542,610	6,616,041	6,126,247
Current liabilities:
Short-term debt and current portion of long-term debt			41,424	43,681	193,044	199,992		604,092	629,371	95,299
Current portion of capital lease obligations			3,713	3,500	4,048	3,962		3,505	4,643	5,072
Accounts payable			211,476	194,235	165,800	195,752		194,246	186,941	195,980
Accrued expenses and other current liabilities			449,897	320,526	315,995	324,465		325,551	315,222	368,560
Liabilities related to assets held for sale - current						363		8,836	7,663
Total current liabilities			706,510	561,942	678,887	724,534		1,136,230	1,143,840	664,911
Long-term liabilities:
Long-term debt, net of current portion			2,905,067	2,920,789	2,823,654	2,831,166		2,944,014	2,912,147	2,987,422
Capital lease obligations, net of current portion			8,033	6,972	7,654	7,181		7,346	7,974	8,794
Deferred tax liabilities			52,513	140,864	144,483	147,618		226,976	243,298	262,117
Other long-term liabilities			133,182	148,165	155,842	154,193		121,855	131,578	123,428
Total long-term liabilities			3,098,795	3,216,790	3,131,633	3,140,158		3,309,794	3,306,524	3,381,761
Commitments and contingencies
Stockholders' equity:
Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at December 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares at December 31, 20154; Outstanding: 1,774 shares at December 31, 2015			606,406	606,406	606,468	606,468		606,468	606,468	606,468
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,043 shares at December 31, 2015, Outstanding: 86,364 shares at December 31, 2015			95	94	94	94		94	93	93
Additional paid-in capital			3,465,898	3,458,639	3,452,722	3,438,732		3,436,666	3,414,981	3,390,002
Accumulated deficit			(1,489,661)	(1,511,481)	(1,476,461)	(1,466,381)		(1,450,328)	(1,448,006)	(1,462,417)
Treasury stock, at cost, 7,679 shares			(184,971)	(184,971)	(184,971)	(184,971)		(184,971)	(184,971)	(184,971)
Accumulated other comprehensive loss			(352,085)	(361,033)	(317,429)	(339,777)		(315,875)	(227,481)	(273,834)
Total stockholders' equity			2,045,682	2,007,654	2,080,423	2,054,165		2,092,054	2,161,084	2,075,341
Non-controlling interests			4,687	4,508	4,365	4,264		4,532	4,593	4,234
Total equity			2,050,369	2,012,162	2,084,788	2,058,429		2,096,586	2,165,677	2,079,575					$ 2,080,659
Total liabilities and equity			5,855,674	5,790,894	5,895,308	5,923,121		6,542,610	6,616,041	6,126,247
Restatement Adjustment [Member]
Current assets:
Cash and cash equivalents			0	0	0	0		0	0	0	$ 0	[3]	$ 0	[3]
Restricted cash			0	0	0	0		0	0	0
Marketable securities			0	0	0	0		0	0	0
Accounts receivable, net of allowances of $89,701 at December 31, 2015			(1,034)	739	(177)	(8,909)		(2,760)	(3,591)	(4,195)
Inventories, net			533	646	84	3,948		2,278	1,894	2,788
Prepaid expenses and other current assets			(39,443)	(37,462)	(37,740)	(37,719)		0	0	0
Assets held for sale - current						0		0	0
Total current assets			(39,944)	(36,077)	(37,833)	(42,680)		(482)	(1,697)	(1,407)
Property, plant and equipment, net			0	0	0	0		0	0	0
Goodwill			0	0	0	0		0	0	0
Other intangible assets with indefinite lives			0	0	0	0		0	0	0
Finite-lived intangible assets, net			0	0	0	0		0	0	0
Restricted cash			0	0	0	0		0
Other non-current assets			0	0	0	0		0	0	0
Investments in unconsolidated entities			0	0	0	0		0	0	0
Deferred tax assets			0	0	0	0		0	0	0
Non-current income tax receivable and prepaid			35,955	37,983	37,698	37,719		0	0	0
Assets held for sale - non-current				0	0	0		0	0
Total assets			(3,989)	1,906	(135)	(4,961)		(482)	(1,697)	(1,407)
Current liabilities:
Short-term debt and current portion of long-term debt			0	0	0	0		0	0	0
Current portion of capital lease obligations			0	0	0	0		0	0	0
Accounts payable			0	0	0	0		0	0	0
Accrued expenses and other current liabilities			(4,981)	(1,050)	(1,006)	(1,828)		(367)	(669)	(651)
Liabilities related to assets held for sale - current						0		0	0
Total current liabilities			(4,981)	(1,050)	(1,006)	(1,828)		(367)	(669)	(651)
Long-term liabilities:
Long-term debt, net of current portion			0	0	0	0		0	0	0
Capital lease obligations, net of current portion			0	0	0	0		0	0	0
Deferred tax liabilities			0	0	0	0		0	0	0
Other long-term liabilities			4,400	0	0	0		0	0	0
Total long-term liabilities			4,400	0	0	0		0	0	0
Commitments and contingencies
Stockholders' equity:
Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at December 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares at December 31, 20154; Outstanding: 1,774 shares at December 31, 2015			0	0	0	0		0	0	0
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,043 shares at December 31, 2015, Outstanding: 86,364 shares at December 31, 2015			0	0	0	0		0	0	0
Additional paid-in capital			0	0	0	0		0	0	0
Accumulated deficit			(3,408)	2,956	871	(3,133)		(115)	(1,028)	(756)
Treasury stock, at cost, 7,679 shares			0	0	0	0		0	0	0
Accumulated other comprehensive loss			0	0	0	0		0	0	0
Total stockholders' equity			(3,408)	2,956	871	(3,133)		(115)	(1,028)	(756)
Non-controlling interests			0	0	0	0		0	0	0
Total equity			(3,408)	2,956	871	(3,133)		(115)	(1,028)	(756)
Total liabilities and equity			$ (3,989)	$ 1,906	$ (135)	$ (4,961)		$ (482)	$ (1,697)	$ (1,407)
[1]	Restated Values
[2]	The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been previously revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due principally to a $19,236 increase in operating cash flow related to deferred income taxes and a $15,753 decrease in operating cash flow related to other non-current liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015.
[3]	All adjustments in this column relate to the misstatements associated with the Standard Diagnostics matter and the consequential impact on inventory, accounts receivable and accrued liabilities.

Restatement of Previously Iss66

Restatement of Previously Issued Financial Statements - Restated Consolidated Balance Sheets (Parenthetical) (Detail) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, allowances	$ 75,798				$ 89,701	[1]
Series B preferred stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	[1]	$ 0.001	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,701	$ 709,701	$ 709,701	$ 709,763	$ 709,763	[1]	$ 709,763	$ 709,763	$ 709,763
Series B preferred stock, shares authorized	2,300,000	2,300,000	2,300,000	2,300,000	2,300,000	[1]	2,300,000	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000	2,065,000	2,065,000	2,065,000	[1]	2,065,000	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000	1,774,000	1,774,000	1,774,000	[1]	1,774,000	1,774,000	1,774,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	[1]	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000	200,000,000	200,000,000	200,000,000	[1]	200,000,000	200,000,000	200,000,000
Common stock, shares issued	94,770,000	94,613,000	94,419,000	94,415,000	94,043,000	[1]	93,868,000	93,224,000	92,561,000
Common stock, shares outstanding	87,091,000	86,934,000	86,740,000	86,736,000	86,364,000	[1]	86,189,000	85,545,000	84,882,000
Treasury stock, shares	7,679,000	7,679,000	7,679,000	7,679,000	7,679,000	[1]	7,679,000	7,679,000	7,679,000
Debt issuance cost	$ 51,886
Non-current income tax receivable and prepaid	$ 45,234	$ 39,472	$ 41,500	$ 41,215	$ 41,236	[1]	$ 2,537	$ 2,611	$ 2,545
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, allowances					$ 89,701
Series B preferred stock, par value		$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference		$ 709,701	$ 709,701	$ 709,763	$ 709,763		$ 709,763	$ 709,763	$ 709,763
Series B preferred stock, shares authorized		2,300,000	2,300,000	2,300,000	2,300,000		2,300,000	2,300,000	2,300,000
Series B preferred stock, shares issued		2,065,000	2,065,000	2,065,000	2,065,000		2,065,000	2,065,000	2,065,000
Series B preferred stock, shares outstanding		1,774,000	1,774,000	1,774,000	1,774,000		1,774,000	1,774,000	1,774,000
Common stock, par value		$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized		200,000,000	200,000,000	200,000,000	200,000,000		200,000,000	200,000,000	200,000,000
Common stock, shares issued		94,613,000	94,419,000	94,415,000	94,043,000		93,868,000	93,224,000	92,561,000
Common stock, shares outstanding		86,934,000	86,740,000	86,736,000	86,364,000		86,189,000	85,545,000	84,882,000
Treasury stock, shares		7,679,000	7,679,000	7,679,000	7,679,000		7,679,000	7,679,000	7,679,000
Non-current income tax receivable and prepaid		$ 3,517	$ 3,517	$ 3,517	$ 3,517		$ 2,537	$ 2,611	$ 2,545
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, allowances					$ 89,701
Series B preferred stock, par value		$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference		$ 709,701	$ 709,701	$ 709,763	$ 709,763		$ 709,763	$ 709,763	$ 709,763
Series B preferred stock, shares authorized		2,300,000	2,300,000	2,300,000	2,300,000		2,300,000	2,300,000	2,300,000
Series B preferred stock, shares issued		2,065,000	2,065,000	2,065,000	2,065,000		2,065,000	2,065,000	2,065,000
Series B preferred stock, shares outstanding		1,774,000	1,774,000	1,774,000	1,774,000		1,774,000	1,774,000	1,774,000
Common stock, par value		$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized		200,000,000	200,000,000	200,000,000	200,000,000		200,000,000	200,000,000	200,000,000
Common stock, shares issued		94,613,000	94,419,000	94,415,000	94,043,000		93,868,000	93,224,000	92,561,000
Common stock, shares outstanding		86,934,000	86,740,000	86,736,000	86,364,000		86,189,000	85,545,000	84,882,000
Treasury stock, shares		7,679,000	7,679,000	7,679,000	7,679,000		7,679,000	7,679,000	7,679,000
Non-current income tax receivable and prepaid		$ 35,955	$ 37,983	$ 37,698	$ 37,719		$ 0	$ 0	$ 0
Accounting Standards Update 2015-03 [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance cost					$ 34,050		$ 43,644	$ 45,889	$ 36,425
[1]	Restated Values

Restatement of Previously Iss67

Restatement of Previously Issued Financial Statements - Restated Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Thousands		3 Months Ended										6 Months Ended				9 Months Ended				12 Months Ended
		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016		Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015		Jun. 30, 2016		Jun. 30, 2015		Sep. 30, 2016		Sep. 30, 2015		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Cash Flows from Operating Activities:
Net income (loss)		$ 15,663	$ (32,807)	$ (5,972)		$ (19,077)		$ (1,468)	$ 14,498	$ 210,113		$ (38,779)		$ 224,611		$ (23,116)		$ 223,143		$ (137,269)	[1]	$ 204,065	[1]	$ (33,123)	[1]
Income (loss) from discontinued operations, net of tax		0	0	0		2,736		0	0	216,777		0		216,777		0		216,777		0		219,513	[1]	138,318	[1]
Income (loss) from continuing operations		15,663	(32,807)	(5,972)		(21,813)		(1,468)	14,498	(6,664)		(38,779)		7,834		(23,116)		6,366		(137,269)		(15,448)	[1]	(171,441)	[1]
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs																				13,369		12,831	[1]	16,233	[1]
Depreciation and amortization																				285,608		309,264	[1]	336,029	[1]
Non-cash stock-based compensation expense																				41,796		26,391	[1]	12,452	[1]
Tax benefit related to discontinued operations retained by Alere Inc.																				0		0	[1]	9,845	[1]
Impairment of inventory																				2,667		15,597	[1]	3,124	[1]
Impairment of intangible and long-lived assets																				1,792		3,708	[1]	7,019	[1]
Loss on sale of fixed assets																				3,551		3,925	[1]	6,545	[1]
Equity earnings of unconsolidated entities, net of tax		(26,149)	(2,122)	(5,034)		(5,210)		(5,000)	(1,361)	(3,959)		(7,156)		(5,320)		(33,305)		(10,320)		(50,505)		(15,530)	[1]	(17,509)	[1]
Deferred income taxes																				(36,010)		(99,389)	[1]	12,254	[1]
Loss on extinguishment of debt																				0		19,886	[1]	0	[1]
Impairment and net (gain) loss on business disposition																				(3,810)		50,540	[1]	7,742	[1]
Other non-cash items																				(463)		28,782	[1]	4,965	[1]
Non-cash change in fair value of contingent purchase price consideration																				(13,309)		(59,871)	[1]	7,677	[1]
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net																				26,698		(6,680)	[1]	(4,264)	[1]
Inventories, net																				(13,655)		(63,935)	[1]	(67,532)	[1]
Prepaid expenses and other current assets																				(19,921)		(5,295)	[1]	(51,998)	[1]
Accounts payable																				4,362		(10,783)	[1]	47,851	[1]
Accrued expenses and other current liabilities																				51,490		22,643	[1]	37,886	[1]
Other non-current assets and liabilities																				23,329		(3,357)	[1]	13,254	[1]
Cash paid for contingent consideration																				(430)		(6,315)	[1]	(22,077)	[1]
Net cash provided by (used in) continuing operations																				179,290		206,964	[1]	188,055	[1]
Net cash provided by discontinued operations																				0		318	[1]	43,468	[1]
Net cash provided by operating activities																				179,290		207,282	[1]	231,523	[1]
Cash Flows from Investing Activities:
Increase in restricted cash																				(4,721)		(13,715)	[1]	(5,446)	[1]
Purchases of property, plant and equipment																				(67,694)		(90,778)	[1]	(100,562)	[1]
Proceeds from sale of property, plant and equipment																				1,428		2,099	[1]	1,486	[1]
Cash received from business dispositions, net of cash divested																				21,470		675,823	[1]	45,076	[1]
Cash paid for business acquisitions, net of cash acquired																				(5,958)		(60,135)	[1]	(75)	[1]
Cash received from investments																				0		0	[1]	198	[1]
Proceeds from sale of equity investment																				40,751		0	[1]	8,546	[1]
Cash received from sales of marketable securities																				87		92	[1]	580	[1]
Cash received from equity method investments																				16,989		26,136	[1]	980	[1]
(Increase) decrease in other assets																				460		(1,794)	[1]	986	[1]
Net cash provided by (used in) continuing operations																				2,628		537,728	[1]	(48,231)	[1]
Net cash used in discontinued operations																				0		(209)	[1]	(8,972)	[1]
Net cash provided by (used in) investing activities																				2,628		537,519	[1]	(57,203)	[1]
Cash Flows from Financing Activities:
Cash paid for financing costs																				(29,187)		(16,188)	[1]	(1,528)	[1]
Cash paid for contingent purchase price consideration																				(680)		(14,223)	[1]	(32,902)	[1]
Cash paid for dividends																				(21,292)		(21,293)	[1]	(21,293)	[1]
Proceeds from issuance of common stock, net of issuance costs																				18,934		79,185	[1]	51,555	[1]
Proceeds from issuance of short-term debt																				0		1,511	[1]	806	[1]
Proceeds from issuance of long-term debt																				459		2,162,162	[1]	58	[1]
Payments on short-term debt																				(1,722)		(25,584)	[1]	0	[1]
Payments on long-term debt																				(198,316)		(2,656,386)	[1]	(65,122)	[1]
Net (payments) proceeds under revolving credit facilities																				126,017		(127,536)	[1]	(42,522)	[1]
Excess tax benefits on exercised stock options																				0		0	[1]	972	[1]
Principal payments on capital lease obligations																				(4,032)		(5,618)	[1]	(6,085)	[1]
Purchase of non-controlling interest																				0		0	[1]	(623)	[1]
Other																				0		(8,937)	[1]	0	[1]
Net cash provided by (used in) continuing operations																				(109,819)		(632,907)	[1]	(116,684)	[1]
Net cash used in discontinued operations																				0		(76)	[1]	(1,471)	[1]
Net cash provided by (used in) financing activities																				(109,819)		(632,983)	[1]	(118,155)	[1]
Foreign exchange effect on cash and cash equivalents																				(7,084)		(11,379)	[1]	(16,312)	[1]
Net increase in cash and cash equivalents																				65,015		100,439	[1]	39,853	[1]
Cash and cash equivalents, beginning of period - continuing operations		506,164	490,663	502,200	[1]	479,381		464,871	414,495	378,461	[1]	502,200	[1]	378,461	[1]	502,200	[1]	378,461	[1]	502,200	[1]	378,461	[1]	355,431	[1]
Cash and cash equivalents, beginning of period - discontinued operations	[1]			0						23,300		0		23,300		0		23,300		0		23,300		6,477
Cash and cash equivalents, end of period						502,200	[1]													567,215		502,200	[1]	401,761	[1]
Less: Cash and cash equivalents of discontinued operations, end of period						0	[1]													0		0	[1]	23,300	[1]
Cash and cash equivalents of continuing operations, end of period		566,213	506,164	490,663		502,200	[1]	479,381	464,871	414,495		506,164		464,871		566,213		479,381		567,215		502,200	[1]	378,461	[1]
As Previously Reported [Member]
Cash Flows from Operating Activities:
Net income (loss)		22,027	(34,891)	(9,977)		(16,059)		(2,381)	14,770	210,428		(44,868)		225,198		(22,841)		222,817				206,757		(33,436)	[2]
Income (loss) from discontinued operations, net of tax		0	0	0		2,736		0	0	216,777		0		216,777		0		216,777				219,513		138,318	[2]
Income (loss) from continuing operations		22,027	(34,891)	(9,977)		(18,795)		(2,381)	14,770	(6,349)		(44,868)		8,421		(22,841)		6,040				(12,756)		(171,754)	[2]
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs																						12,831		16,233	[2]
Depreciation and amortization																						309,264		336,029	[2]
Non-cash stock-based compensation expense																						26,391		12,452	[2]
Tax benefit related to discontinued operations retained by Alere Inc.	[2]																							9,845
Impairment of inventory																						15,597		3,124	[2]
Impairment of intangible and long-lived assets																						3,708		7,019	[2]
Loss on sale of fixed assets																						3,925		6,545	[2]
Equity earnings of unconsolidated entities, net of tax		(26,149)	(2,122)	(5,034)		(5,210)		(5,000)	(1,361)	(3,959)		(7,156)		(5,320)		(33,305)		(10,320)				(15,530)		(17,509)	[2]
Deferred income taxes																						(99,389)		12,254	[2]
Loss on extinguishment of debt																						19,886
Impairment and net (gain) loss on business disposition																						50,540		7,742	[2]
Other non-cash items																						28,782		4,965	[2]
Non-cash change in fair value of contingent purchase price consideration																						(59,871)		7,677	[2]
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net																						(14,380)		(3,262)	[2]
Inventories, net																						(60,478)		(68,033)	[2]
Prepaid expenses and other current assets																						(43,014)		(51,998)	[2]
Accounts payable																						(10,783)		47,851	[2]
Accrued expenses and other current liabilities																						24,194		37,698	[2]
Other non-current assets and liabilities																						34,362		13,254	[2]
Cash paid for contingent consideration																						(6,315)		(22,077)	[2]
Net cash provided by (used in) continuing operations																						206,964		188,055	[2]
Net cash provided by discontinued operations																						318		43,468	[2]
Net cash provided by operating activities																						207,282		231,523	[2]
Cash Flows from Investing Activities:
Increase in restricted cash																						(13,715)		(5,446)	[2]
Purchases of property, plant and equipment																						(90,778)		(100,562)	[2]
Proceeds from sale of property, plant and equipment																						2,099		1,486	[2]
Cash received from business dispositions, net of cash divested																						675,823		45,076	[2]
Cash paid for business acquisitions, net of cash acquired																						(60,135)		(75)	[2]
Cash received from investments	[2]																							198
Proceeds from sale of equity investment	[2]																							8,546
Cash received from sales of marketable securities																						92		580	[2]
Cash received from equity method investments																						26,136		980	[2]
(Increase) decrease in other assets																						(1,794)		986	[2]
Net cash provided by (used in) continuing operations																						537,728		(48,231)	[2]
Net cash used in discontinued operations																						(209)		(8,972)	[2]
Net cash provided by (used in) investing activities																						537,519		(57,203)	[2]
Cash Flows from Financing Activities:
Cash paid for financing costs																						(16,188)		(1,528)	[2]
Cash paid for contingent purchase price consideration																						(14,223)		(32,902)	[2]
Cash paid for dividends																						(21,293)		(21,293)	[2]
Proceeds from issuance of common stock, net of issuance costs																						79,185		51,555	[2]
Proceeds from issuance of short-term debt																						1,511		806	[2]
Proceeds from issuance of long-term debt																						2,162,162		58	[2]
Payments on short-term debt																						(25,584)
Payments on long-term debt																						(2,656,386)		(65,122)	[2]
Net (payments) proceeds under revolving credit facilities																						(127,536)		(42,522)	[2]
Excess tax benefits on exercised stock options	[2]																							972
Principal payments on capital lease obligations																						(5,618)		(6,085)	[2]
Purchase of non-controlling interest	[2]																							(623)
Other																						(8,937)
Net cash provided by (used in) continuing operations																						(632,907)		(116,684)	[2]
Net cash used in discontinued operations																						(76)		(1,471)	[2]
Net cash provided by (used in) financing activities																						(632,983)		(118,155)	[2]
Foreign exchange effect on cash and cash equivalents																						(11,379)		(16,312)	[2]
Net increase in cash and cash equivalents																						100,439		39,853	[2]
Cash and cash equivalents, beginning of period - continuing operations		506,164	490,663	502,200		479,381		464,871	414,495	378,461	[2]	502,200		378,461	[2]	502,200		378,461	[2]	502,200		378,461	[2]	355,431	[2]
Cash and cash equivalents, beginning of period - discontinued operations				0						23,300	[2]	0		23,300	[2]	0		23,300	[2]	0		23,300	[2]	6,477	[2]
Cash and cash equivalents, end of period						502,200																502,200		401,761	[2]
Less: Cash and cash equivalents of discontinued operations, end of period						0																0		23,300	[2]
Cash and cash equivalents of continuing operations, end of period		566,213	506,164	490,663		502,200		479,381	464,871	414,495		506,164		464,871		566,213		479,381				502,200		378,461	[2]
Restatement Adjustment [Member]
Cash Flows from Operating Activities:
Net income (loss)		(6,364)	2,084	4,005		(3,018)		913	(272)	(315)		6,089		(587)		(275)		326				(2,692)		313	[3]
Income (loss) from discontinued operations, net of tax		0	0	0		0		0	0	0		0		0		0		0				0		0	[3]
Income (loss) from continuing operations		(6,364)	2,084	4,005		(3,018)		913	(272)	(315)		6,089		(587)		(275)		326				(2,692)		313	[3]
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs																						0		0	[3]
Depreciation and amortization																						0		0	[3]
Non-cash stock-based compensation expense																						0		0	[3]
Tax benefit related to discontinued operations retained by Alere Inc.	[3]																							0
Impairment of inventory																						0		0	[3]
Impairment of intangible and long-lived assets																						0		0	[3]
Loss on sale of fixed assets																						0		0	[3]
Equity earnings of unconsolidated entities, net of tax		0	0	0		0		0	0	0		0		0		0		0				0		0	[3]
Deferred income taxes																						0		0	[3]
Loss on extinguishment of debt																						0
Impairment and net (gain) loss on business disposition																						0		0	[3]
Other non-cash items																						0		0	[3]
Non-cash change in fair value of contingent purchase price consideration																						0		0	[3]
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net																						7,700		(1,002)	[3]
Inventories, net																						(3,457)		501	[3]
Prepaid expenses and other current assets																						37,719		0	[3]
Accounts payable																						0		0	[3]
Accrued expenses and other current liabilities																						(1,551)		188	[3]
Other non-current assets and liabilities																						(37,719)		0	[3]
Cash paid for contingent consideration																						0		0	[3]
Net cash provided by (used in) continuing operations																						0		0	[3]
Net cash provided by discontinued operations																						0		0	[3]
Net cash provided by operating activities																						0		0	[3]
Cash Flows from Investing Activities:
Increase in restricted cash																						0		0	[3]
Purchases of property, plant and equipment																						0		0	[3]
Proceeds from sale of property, plant and equipment																						0		0	[3]
Cash received from business dispositions, net of cash divested																						0		0	[3]
Cash paid for business acquisitions, net of cash acquired																						0		0	[3]
Cash received from investments	[3]																							0
Proceeds from sale of equity investment	[3]																							0
Cash received from sales of marketable securities																						0		0	[3]
Cash received from equity method investments																						0		0	[3]
(Increase) decrease in other assets																						0		0	[3]
Net cash provided by (used in) continuing operations																						0		0	[3]
Net cash used in discontinued operations																						0		0	[3]
Net cash provided by (used in) investing activities																						0		0	[3]
Cash Flows from Financing Activities:
Cash paid for financing costs																						0		0	[3]
Cash paid for contingent purchase price consideration																						0		0	[3]
Cash paid for dividends																						0		0	[3]
Proceeds from issuance of common stock, net of issuance costs																						0		0	[3]
Proceeds from issuance of short-term debt																						0		0	[3]
Proceeds from issuance of long-term debt																						0		0	[3]
Payments on short-term debt																						0
Payments on long-term debt																						0		0	[3]
Net (payments) proceeds under revolving credit facilities																						0		0	[3]
Excess tax benefits on exercised stock options	[3]																							0
Principal payments on capital lease obligations																						0		0	[3]
Purchase of non-controlling interest	[3]																							0
Other																						0
Net cash provided by (used in) continuing operations																						0		0	[3]
Net cash used in discontinued operations																						0		0	[3]
Net cash provided by (used in) financing activities																						0		0	[3]
Foreign exchange effect on cash and cash equivalents																						0		0	[3]
Net increase in cash and cash equivalents																						0		0	[3]
Cash and cash equivalents, beginning of period - continuing operations		0	0	0		0		0	0	0	[3]	0		0	[3]	0		0	[3]	0		0	[3]	0	[3]
Cash and cash equivalents, beginning of period - discontinued operations				0						0	[3]	0		0	[3]	0		0	[3]	$ 0		0	[3]	0	[3]
Cash and cash equivalents, end of period						0																0		0	[3]
Less: Cash and cash equivalents of discontinued operations, end of period						0																0		0	[3]
Cash and cash equivalents of continuing operations, end of period		$ 0	$ 0	$ 0		$ 0		$ 0	$ 0	$ 0		$ 0		$ 0		$ 0		$ 0				$ 0		$ 0	[3]
[1]	Restated Values
[2]	The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been previously revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due principally to a $19,236 increase in operating cash flow related to deferred income taxes and a $15,753 decrease in operating cash flow related to other non-current liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015.
[3]	All adjustments in this column relate to the misstatements associated with the Standard Diagnostics matter and the consequential impact on inventory, accounts receivable and accrued liabilities.

Restatement of Previously Iss68

Restatement of Previously Issued Financial Statements - Restated Consolidated Statements of Cash Flows (Parenthetical) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Non-current income tax receivable and prepaid	$ 45,234,000	$ 41,236,000	[1]			$ 39,472,000	$ 41,500,000	$ 41,215,000	$ 2,537,000	$ 2,611,000	$ 2,545,000
Deferred income taxes	$ (36,010,000)	(99,389,000)	[1]	$ 12,254,000	[1]
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Non-current income tax receivable and prepaid		37,719,000				$ 35,955,000	$ 37,983,000	$ 37,698,000	$ 0	$ 0	$ 0
Deferred income taxes		$ 0		0	[2]
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred income taxes				19,236
Other non-current liabilities				$ (15,753)
[1]	Restated Values
[2]	All adjustments in this column relate to the misstatements associated with the Standard Diagnostics matter and the consequential impact on inventory, accounts receivable and accrued liabilities.

Merger Agreement - Additional I

Merger Agreement - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Apr. 13, 2017	Jan. 30, 2016	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	[1]	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Business Acquisition [Line Items]
Preferred Stock, par value			$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Merger Agreement [Member]
Business Acquisition [Line Items]
Right to receive cash by each common stockholder		$ 56
Termination fee of agreement		$ 177	$ 161
Merger Agreement [Member] | Conversion Shares Related to Series B Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred Stock, par value		$ 0.001
Merger Agreement [Member] | Subsequent Events [Member]
Business Acquisition [Line Items]
Right to receive cash by each common stockholder	$ 51
[1]	Restated Values

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - USD ($)	Jan. 09, 2015	Oct. 10, 2014	Dec. 31, 2016
Prior Credit Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayment of senior secured credit facility			$ 1,650,000,000
Alere Accountable Care Solutions, LLC ("ACS") [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of subsidiary		$ 2
Contingent consideration receivable on sale of discontinued operations		7,000,000
Alere Accountable Care Solutions, LLC ("ACS") [Member] | Maximum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Reimbursable expenses payable to purchaser		$ 750,000
Health Management Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of subsidiary	$ 599,900,000
Health Management Business [Member] | Prior Credit Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayment of senior secured credit facility	$ 575,000,000

Discontinued Operations - Summa

Discontinued Operations - Summarized Financial Information Related to ACS Companies and Health Management Business (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations, net of tax	$ 0	$ 0	$ 0	$ 2,736	$ 0	$ 0	$ 216,777	$ 0	$ 216,777	$ 0	$ 216,777	$ 0	$ 219,513	[1]	$ 138,318	[1]
Alere Accountable Care Solutions, LLC ("ACS") and Health Management Business Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue													7,373		359,496
Cost of net revenue													(4,413)		(203,115)
Research and development													0		0
Sales and marketing													(996)		(56,808)
General and administrative													(5,001)		(99,383)
Interest expense													(9)		(506)
Other income (expense), net													160		(1,799)
Gain on disposal													364,850		0
Income (loss) from discontinued operations before provision (benefit) for income taxes													361,964		(2,115)
Provision (benefit) for income taxes													142,451		(140,433)
Income (loss) from discontinued operations, net of tax													$ 219,513		$ 138,318
[1]	Restated Values

Summary of Significant Accoun72

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)InvestmentCustomer	Dec. 31, 2015USD ($)Customer		Dec. 31, 2014USD ($)Customer	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Sep. 30, 2015USD ($)	Jul. 31, 2015	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)
Significant Accounting Policies [Line Items]
Net realized and unrealized foreign currency exchange transaction losses	$ 4,500	$ 4,800		$ 2,200
Restricted cash	53,700	48,900
Securities for loan agreement of restricted cash classified as non-current	$ 2,171	43,228	[1]		$ 42,438	$ 42,589	$ 43,388	$ 44,148
Securities for loan agreement deposit period	2 years
Depreciation expense related to property, plant and equipment	$ 105,100	98,700		97,600
Discount rates, Minimum	10.00%
Discount rates, Maximum	14.50%
Projected compound average revenue growth rates, Minimum	3.40%
Projected compound average revenue growth rates, Maximum	5.60%
Multiples of revenue, Minimum | Investment	0.6
Multiples of revenue, Maximum | Investment	3.1
Multiples of EBITDA, Minimum | Investment	8.3
Multiples of EBITDA, Maximum | Investment	12.3
Acquisition-related costs in general and administrative expense	$ 1,000	500		900
Vesting period	4 years
Granted vesting schedule	25.00%
Contractual term of stock option awards	10 years
Advertising costs	$ 5,600	$ 9,000		$ 8,000
Individual customer's accounts receivable balance in excess of ten percentage | Customer	0	0		0
Individual customer's accounts receivable balance in excess of ten percentage | Customer	0	0
Debt issuance cost	$ 51,886
Accounting Standards Update 2015-03 [Member]
Significant Accounting Policies [Line Items]
Debt issuance cost		$ 34,050						$ 43,644		$ 45,889	$ 36,425
Minimum [Member]
Significant Accounting Policies [Line Items]
Terminal value growth rates	3.00%
Concentration of credit risk	10.00%	10.00%		10.00%
Concentration of credit risk	10.00%	10.00%
Individual investment percent of net assets available for benefits									5.00%
Maximum [Member]
Significant Accounting Policies [Line Items]
Terminal value growth rates	4.00%
2015 Annual Goodwill Impairment Test [Member]
Significant Accounting Policies [Line Items]
Estimated fair value exceeding carrying value of net assets	$ 219,600
Machinery, Laboratory Equipment and Tooling [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	1 year
Machinery, Laboratory Equipment and Tooling [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	15 years
Building [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	4 years
Building [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	50 years
Computer Equipment [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	1 year
Computer Equipment [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	2 years
Furniture and Fixtures [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives	16 years
Professional Diagnostics [Member]
Significant Accounting Policies [Line Items]
Percentage of fair value exceeding carrying value of net assets	50.00%
Professional Diagnostics [Member] | 2015 Annual Goodwill Impairment Test [Member]
Significant Accounting Policies [Line Items]
Estimated fair value exceeding carrying value of net assets	$ 2,600,000
Consumer Diagnostics [Member]
Significant Accounting Policies [Line Items]
Percentage of fair value exceeding carrying value of net assets	36.00%
Consumer Diagnostics [Member] | 2015 Annual Goodwill Impairment Test [Member]
Significant Accounting Policies [Line Items]
Estimated fair value exceeding carrying value of net assets	$ 88,500
Other Non-reportable [Member]
Significant Accounting Policies [Line Items]
Percentage of fair value exceeding carrying value of net assets	194.00%
[1]	Restated Values

Other Balance Sheet Informati73

Other Balance Sheet Information - Components of Selected Captions in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Inventories, net:
Raw materials	$ 97,652				$ 130,171
Work-in-process	69,086				69,178
Finished goods	142,182				151,600
Inventories, net	308,920	$ 349,378	$ 334,492	$ 351,015	350,949	[1]	$ 376,057	$ 379,545	$ 388,481
Prepaid expenses and other current assets:
Prepaid expenses	28,685				28,041
Prepaid income tax	10,248				12,482
Income taxes receivable	21,445				199
Royalty receivable	7,908				7,757
Other taxes receivable	19,478				15,333
Cash advances	4,097				3,902
Pension receivable	1,347				1,373
Grant receivable	182				651
Employee loans	73				123
Security deposits	3,232				7,014
Other receivable	0				15,938
Other	21,912				21,701
Prepaid expenses and other current assets	118,607	124,390	124,877	106,629	114,514	[1]	121,023	125,559	117,924
Property, plant and equipment, net:
Machinery, laboratory equipment and tooling	507,355				469,413
Land and buildings	166,852				169,226
Leasehold improvements	60,119				55,999
Computer software and equipment	176,609				161,192
Furniture and fixtures	29,544				27,325
Property, plant and equipment, gross, Total	940,479				883,155
Less: Accumulated depreciation	(499,289)				(437,116)
Property, plant and equipment, net, Total	441,190	446,313	438,787	445,218	446,039	[1]	445,872	448,891	447,326
Accrued expenses and other current liabilities:
Compensation and compensation-related	76,556				80,468
Litigation settlements	42,910				4,856
Royalty obligations	20,339				18,912
Deferred revenue	24,309				40,998
Income taxes payable	23,278				14,245
Other taxes payable	30,937				28,320
Acquisition-related obligations	2,382				5,705
Other	174,132				129,133
Accrued expenses and other current liabilities, Total	$ 394,843	$ 444,916	$ 319,476	$ 314,989	$ 322,637	[1]	$ 325,184	$ 314,553	$ 367,909
[1]	Restated Values

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Feb. 11, 2016

Sep. 30, 2015

Jul. 10, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Business Acquisition [Line Items]

Goodwill

$ 2,759,366

$ 2,836,915

[1]

$ 2,805,682

$ 2,811,545

$ 2,839,692

$ 2,842,921

$ 2,853,551

$ 2,880,164

$ 2,926,666

EDTS [Member]

Business Acquisition [Line Items]

Preliminary aggregate purchase price

$ 6,500

Total revenue related to acquisition

5,200

Goodwill

2,100

US Diagnostics [Member]

Business Acquisition [Line Items]

Preliminary aggregate purchase price

$ 60,100

Total revenue related to acquisition

21,800

$ 10,700

Goodwill

$ 29,400

[1]

Restated Values

Business Combinations - Summary

Business Combinations - Summary of Aggregate Purchase Price Allocation (Detail) - USD ($) $ in Thousands	Jul. 10, 2015	Dec. 31, 2016	Dec. 31, 2015
Business Combinations [Abstract]
Current assets	$ 4,698	$ 1,371
Property, plant and equipment	182	115
Goodwill	29,365	2,060
Intangible assets	27,100	4,220	$ 27,100
Total assets acquired	61,345	7,766
Current liabilities	1,210	368
Non-current liabilities		928
Total liabilities assumed	1,210	1,296
Net assets acquired	60,135	6,470
Cash paid	$ 60,135	$ 6,470

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jul. 10, 2015
Finite And Infinite Lived Intangible Assets [Line Items]
Total intangible assets	$ 4,220	$ 27,100	$ 27,100
Trademarks [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount		$ 1,600
Weighted-average Useful Life		10 years
Customer Relationships [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 2,800	$ 24,800
Weighted-average Useful Life	14 years	13 years
Non-Compete Agreements [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 570	$ 700
Weighted-average Useful Life	3 years	2 years
Core Technology and Patents [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 540
Weighted-average Useful Life	10 years
Trademarks and Trade Names [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 310
Weighted-average Useful Life	20 years

Goodwill and Other Intangible77

Goodwill and Other Intangible Assets - Summary of Goodwill and Other Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,709,396	$ 2,747,448
Accumulated Amortization and Impairment Losses	1,903,819	1,750,167
Net Carrying Value	805,577	997,281	[1]	$ 864,785	$ 909,208	$ 962,633	$ 1,052,949	$ 1,093,186	$ 1,173,866
Goodwill, Gross Carrying Amount	2,759,366	2,836,915
Other intangible assets, Gross Carrying Amount	27,164	28,110
Total intangible assets with indefinite lives, Gross Carrying Value	2,786,530	2,865,025
Core Technology and Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	899,878	907,629
Accumulated Amortization and Impairment Losses	519,698	468,497
Net Carrying Value	$ 380,180	$ 439,132
Weighted- average Useful Life	15 years 1 month 6 days	15 years 1 month 6 days
Supplier Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 17,027	$ 17,599
Accumulated Amortization and Impairment Losses	16,090	16,218
Net Carrying Value	$ 937	$ 1,381
Weighted- average Useful Life	9 years 1 month 6 days	9 years 2 months 12 days
Trademarks and Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 239,714	$ 242,473
Accumulated Amortization and Impairment Losses	191,707	176,325
Net Carrying Value	$ 48,007	$ 66,148
Weighted- average Useful Life	10 years 8 months 12 days	10 years 8 months 12 days
License Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 10,885	$ 10,963
Accumulated Amortization and Impairment Losses	10,885	10,944
Net Carrying Value	$ 0	$ 19
Weighted- average Useful Life	7 years	7 years
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,415,919	$ 1,441,386
Accumulated Amortization and Impairment Losses	1,066,001	985,844
Net Carrying Value	$ 349,918	$ 455,542
Weighted- average Useful Life	16 years 7 months 6 days	16 years 7 months 6 days
Manufacturing Know-How [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 19,600	$ 19,181
Accumulated Amortization and Impairment Losses	18,369	16,744
Net Carrying Value	$ 1,231	$ 2,437
Weighted- average Useful Life	7 years 7 months 6 days	7 years 8 months 12 days
Other [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 106,373	$ 108,217
Accumulated Amortization and Impairment Losses	81,069	75,595
Net Carrying Value	$ 25,304	$ 32,622
Weighted- average Useful Life	7 years 7 months 6 days	7 years 8 months 12 days
Intangible Assets Other than Core Technology and Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,809,518	$ 1,839,819
Accumulated Amortization and Impairment Losses	1,384,121	1,281,670
Net Carrying Value	$ 425,397	$ 558,149
[1]	Restated Values

Goodwill and Other Intangible78

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Goodwill And Other Intangible Assets [Line Items]
Amortization expense of intangible assets	$ 180,500,000	$ 210,500,000	$ 237,200,000
Cost capitalized, net of amortization	$ 8,700,000	8,900,000
In-Process Research and Development [Member]
Goodwill And Other Intangible Assets [Line Items]
Impairment charge		7,400,000
Estimated fair value		$ 0

Goodwill and Other Intangible79

Goodwill and Other Intangible Assets - Summary of Estimated Amortization Expense of Intangible Assets (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,017	$ 139,827
2,018	116,326
2,019	102,824
2,020	84,893
2,021	$ 68,762

Goodwill and Other Intangible80

Goodwill and Other Intangible Assets - Summary of Goodwill Amounts Allocated to Other Non-Reportable and Reporting Segments (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015
Goodwill [Line Items]
Goodwill beginning balance	$ 2,836,915	[1]	$ 2,926,666
Acquisitions	2,060		32,970
Dispositions			(58,612)
Other	(79,609)		(64,109)
Goodwill ending balance	2,759,366		2,836,915	[1]
Professional Diagnostics [Member]
Goodwill [Line Items]
Goodwill beginning balance	2,768,684		2,847,406
Acquisitions	2,060		32,970
Dispositions			(58,612)
Other	(70,910)		(53,080)
Goodwill ending balance	2,699,834		2,768,684
Consumer Diagnostics [Member]
Goodwill [Line Items]
Goodwill beginning balance	43,962		54,991
Acquisitions	0		0
Dispositions			0
Other	(8,699)		(11,029)
Goodwill ending balance	35,263		43,962
Other Non-reportable [Member]
Goodwill [Line Items]
Goodwill beginning balance	24,269		24,269
Acquisitions	0		0
Dispositions			0
Other	0		0
Goodwill ending balance	$ 24,269		$ 24,269
[1]	Restated Values

Long-Term Debt - Long-Term Debt

Long-Term Debt - Long-Term Debt Balances Outstanding (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	May 31, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Jun. 24, 2015	Mar. 31, 2015	Dec. 11, 2012	May 14, 2007
Debt Instrument [Line Items]
Long-term debt, Total	$ 2,940,575					$ 3,031,158
Less: Short-term debt and current portion of long-term debt	(82,370)					(199,992)
Long-term debt	2,858,205	$ 2,905,067	$ 2,920,789		$ 2,823,654	2,831,166	[1]	$ 2,944,014	$ 2,912,147		$ 2,987,422
Revolver Facility [Member]
Debt Instrument [Line Items]
Long-term debt, Total	125,000					0
A Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	544,745					575,746
B Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	952,664					965,740
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	442,709					446,320						$ 450,000
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	415,102			$ 425,000		419,209
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	412,831					418,133				$ 425,000
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	0					149,839							$ 150,000
Other Lines of Credit [Member]
Debt Instrument [Line Items]
Long-term debt, Total	1,124					136
Other [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 46,400					$ 56,035
[1]	Restated Values

Long-Term Debt - Long-Term De82

Long-Term Debt - Long-Term Debt Balances Outstanding (Parenthetical) (Detail)	Dec. 31, 2016	Jun. 24, 2015	Dec. 31, 2016	May 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 11, 2012	May 14, 2007
Debt Instrument [Line Items]
Description of default under credit agreement			(i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes due 2018, or the 7.25% senior notes, our 6.5% senior subordinated notes due 2020, or the 6.5% senior subordinated notes, our 6.375% senior subordinated notes due 2023, or the 6.375% senior subordinated notes, and our 3% convertible senior subordinated notes due 2016, or the 3% convertible senior subordinated notes, as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K for the year ended December 31, 2015, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing our notes. As discussed more fully below in this Note 9, in August 2016 we entered into a further amendment to the Credit Agreement with respect to our failure to timely file our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.
Maturity date		Oct. 1, 2015	May 15, 2016
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%		7.25%		7.25%	7.25%	7.25%
Maturity date			Jul. 1, 2018
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%		6.50%	6.50%	6.50%	6.50%
Maturity date			Jun. 15, 2020
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%		6.375%	6.375%
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	3.00%		3.00%		3.00%	3.00%		3.00%
Maturity date	May 31, 2016

Long-Term Debt - Long-Term De83

Long-Term Debt - Long-Term Debt Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 44,130	$ 42,329	$ 42,106	$ 58,739	$ 52,333	$ 59,494	$ 46,431	$ 84,435	$ 105,925	$ 128,565	$ 158,258	$ 171,651	$ 216,997	[1]	$ 209,191	[1]
Secured Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost												72,543	38,335		0
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost												0	49,437		99,399
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost												36,172	34,103		34,098
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost												28,599	14,549		0
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost												29,717	28,987		29,057
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost												0	44,219		37,092
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost												1,847	4,984		4,984
Other [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost												$ 2,773	$ 2,383		$ 4,561
[1]	Restated Values

Long-Term Debt - Long-Term De84

Long-Term Debt - Long-Term Debt Interest Expense (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 24, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014		May 31, 2016	Oct. 01, 2015	Dec. 11, 2012	May 14, 2007
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 0	$ 19,886	[1]	$ 0	[1]
Amortization fee		$ 4,500	1,100		$ 1,500
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 3,500
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate		7.25%	7.25%		7.25%				7.25%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%		6.375%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate		6.50%	6.50%		6.50%		6.50%
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate		8.625%	8.625%		8.625%			8.625%
Loss on extinguishment of debt	$ (19,900)
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate		3.00%	3.00%		3.00%					3.00%
[1]	Restated Values

Long-Term Debt - Secured Credit

Long-Term Debt - Secured Credit Facility - Additional Information (Detail) - USD ($)	Jul. 01, 2016	Jun. 18, 2015	Nov. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014	[1]	Aug. 18, 2016	May 30, 2016	Apr. 22, 2016
Debt Instrument [Line Items]
Sublimit for the issuance of letters of credit		$ 250,000,000
Proceeds of term loans under secured credit facility				$ 459,000	$ 2,162,162,000	[1]	$ 58,000
Amount of aggregate consent fee									$ 2,200,000		$ 4,500,000
Increase in applicable interest rate margin for all loans outstanding	0.25%
BBI Business [Member]
Debt Instrument [Line Items]
Net cash proceeds from sale of business			$ 106,400,000
Letter of Credit [Member]
Debt Instrument [Line Items]
Sublimit for the issuance of letters of credit		50,000,000
Secured Credit Facility [Member]
Debt Instrument [Line Items]
Aggregate initial principal term loans amount under secured credit facility		1,700,000,000		1,600,000,000
Proceeds of term loans under secured credit facility		1,680,000,000
Amount outstanding under revolving line of credit				125,000,000
Accrued interest				600,000
A Term Loans [Member]
Debt Instrument [Line Items]
Aggregate initial principal term loans amount under secured credit facility		650,000,000		$ 544,700,000
Number of installments for repayments of term loans				Nineteen consecutive quarterly installments
Term loan installment					7,600,000
Term loan final installment					461,900,000
Consolidated secured leverage ratio Base Rate				2.00%
Consolidated secured leverage ratio Eurodollar Rate				3.00%
Lines of credit interest rate percentage				3.77%
B Term Loans [Member]
Debt Instrument [Line Items]
Aggregate initial principal term loans amount under secured credit facility		$ 1,050,000,000		$ 952,700,000
Number of installments for repayments of term loans				Twenty-seven consecutive quarterly installments
Term loan installment					2,400,000
Term loan final installment					$ 912,500,000
Floor rate applicable to term loans based on Eurodollar rate				1.00%
Percentage of fee on the unused portion of revolving credit facility				0.50%
Lines of credit interest rate percentage				4.25%
B Term Loans [Member] | Minimum [Member]
Debt Instrument [Line Items]
Consolidated secured leverage ratio Base Rate					2.00%
Consolidated secured leverage ratio Eurodollar Rate					3.00%
B Term Loans [Member] | Maximum [Member]
Debt Instrument [Line Items]
Consolidated secured leverage ratio Base Rate					2.25%
Consolidated secured leverage ratio Eurodollar Rate					3.25%
Term Loans And B [Member]
Debt Instrument [Line Items]
Aggregate outstanding principal amount			115,000,000
Term Loans And B [Member] | BBI Business [Member]
Debt Instrument [Line Items]
Net cash proceeds from sale of business			$ 115,000,000
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Amount outstanding under revolving line of credit										$ 125,000,000
[1]	Restated Values

Long-Term Debt - Prior Credit F

Long-Term Debt - Prior Credit Facility - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Aggregate outstanding principal amount	$ 1,650

Long-Term Debt - 6.375% Senior

Long-Term Debt - 6.375% Senior Subordinated Notes - Additional Information (Detail) - USD ($)	Jun. 24, 2015	Jul. 31, 2016	May 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt, Total				$ 2,940,575,000	$ 3,031,158,000
Percentage of aggregate principal amount redeemed				35.00%
Percentage of aggregate principal amount redeemed paid				106.375%
Consent aggregate payments per 1,000 aggregate principal amount		$ 15	$ 15
Aggregate payments to note holders		$ 19,200,000	$ 19,200,000
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 425,000,000			$ 412,831,000	$ 418,133,000
Long-term debt, Interest rate	6.375%			6.375%	6.375%	6.375%
Initial offering price				100.00%
Net proceeds from senior notes offering	$ 417,300,000			$ 417,300,000
Net purchasers discount				$ 7,700,000
Percentage of redemption premium for period one				4.781%
Percentage of redemption premium for period two				3.188%
Percentage of redemption premium for period three				1.594%
Percentage of redemption premium for period four				0.00%
Period of redemption of notes				90 days
Percentage of aggregate principal amount outstanding				65.00%
Percentage of aggregate principal amount to be sold				101.00%
Percentage of purchase price of aggregate principal amount				100.00%
Accrued interest				$ 13,500,000

Long-Term Debt - 7.25% Senior N

Long-Term Debt - 7.25% Senior Notes - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 24, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014		Jul. 01, 2018	Dec. 11, 2012
Debt Instrument [Line Items]
Aggregate borrowings under term loans		$ 2,940,575	$ 3,031,158
Debt instrument, maturity date	Oct. 1, 2015	May 15, 2016
Repayment of long term debt		$ 198,316	2,656,386	[1]	$ 65,122	[1]
Revolver Facility [Member]
Debt Instrument [Line Items]
Aggregate borrowings under term loans		125,000	0
Repayments of revolving line of credit		170,000
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Aggregate borrowings under term loans		$ 442,709	$ 446,320					$ 450,000
Interest rate of debt instrument		7.25%	7.25%		7.25%			7.25%
Initial offering price			100.00%
Net proceeds from senior notes offering			$ 443,200
Net underwriter's commissions			$ 6,800
Net proceeds from sale of senior notes		$ 267,400
Debt instrument, maturity date		Jul. 1, 2018
Percentage of redemption premium for period two		1.813%
Percentage of redemption premium for period three		0.00%
Percentage of aggregate principal amount to be sold		101.00%
Percentage of purchase price of aggregate principal amount		100.00%
Accrued interest		$ 1,400
7.25% Senior Notes [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Repayment of long term debt							$ 450,000
7.875% Senior Notes [Member]
Debt Instrument [Line Items]
Redemption of remaining outstanding principal		$ 248,200
[1]	Restated Values

Long-Term Debt - 6.5% Senior Su

Long-Term Debt - 6.5% Senior Subordinated Notes - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 24, 2015	May 31, 2016	May 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2013
Debt Instrument [Line Items]
Long-term debt, Total				$ 2,940,575	$ 3,031,158
Debt instrument, maturity date	Oct. 1, 2015			May 15, 2016
Percentage of aggregate principal amount redeemed				35.00%
Percentage of aggregate principal amount redeemed paid				106.375%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total		$ 425,000		$ 415,102	$ 419,209
Long-term debt, Interest rate		6.50%		6.50%	6.50%	6.50%
Initial offering price		100.00%
Net proceeds from senior notes offering		$ 417,700
Net underwriters' commissions		$ 7,300
Net proceeds from sale of senior subordinated notes			$ 200,600
Debt instrument, maturity date				Jun. 15, 2020
Percentage of redemption premium				3.25%
Percentage of redemption premium				1.625%
Percentage of redemption premium				0.00%
Percentage of aggregate principal amount redeemed				35.00%
Percentage of aggregate principal amount redeemed paid				106.50%
Percentage of aggregate principal amount outstanding				6.50%
Period of redemption of notes				90 days
Debt instrument redemption period start date				Jun. 15, 2016
Debt instrument redemption description				The premium declines from 3.250% during the twelve months on and after June 15, 2016 to 1.625% during the twelve months on and after June 15, 2017 to zero on and after June 15, 2018.
Percentage of aggregate of principal amount to be sold				101.00%
Percentage of purchase price of aggregate principal amount				100.00%
Accrued interest				$ 1,200
9% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate			9.00%
Redemption of remaining outstanding principal			$ 190,600				$ 209,400

Long-Term Debt - 8.625% Senior

Long-Term Debt - 8.625% Senior Subordinated Notes - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 24, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014		Oct. 01, 2015
Debt Instrument [Line Items]
Long-term debt, Total		$ 2,940,575	$ 3,031,158
Maturity date	Oct. 1, 2015	May 15, 2016
Loss on extinguishment of debt		$ 0	$ (19,886)	[1]	$ 0	[1]
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total							$ 400,000
Long-term debt, Interest rate		8.625%	8.625%		8.625%		8.625%
Debt instrument, redemption price, percentage	102.156%
Maturity date		Oct. 1, 2015
Additional cash allocated to redemption fund	$ 8,600
Loss on extinguishment of debt	19,900
Tender offer consideration and call premium amount	8,600
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 425,000	$ 412,831	$ 418,133
Long-term debt, Interest rate	6.375%	6.375%	6.375%		6.375%
Net proceeds from senior notes offering	$ 417,300	$ 417,300
[1]	Restated Values

Long-Term Debt - 3% Convertible

Long-Term Debt - 3% Convertible Senior Subordinated Notes - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	May 15, 2016	Jun. 24, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014		May 14, 2007
Debt Instrument [Line Items]
Aggregate borrowings under term loans	$ 2,940,575			$ 2,940,575	$ 3,031,158
Maturity date			Oct. 1, 2015	May 15, 2016
Repayment of long term debt				$ 198,316	2,656,386	[1]	$ 65,122	[1]
Revolver Facility [Member]
Debt Instrument [Line Items]
Aggregate borrowings under term loans	$ 125,000			$ 125,000	$ 0
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	3.00%			3.00%	3.00%		3.00%		3.00%
Aggregate borrowings under term loans	$ 0			$ 0	$ 149,839				$ 150,000
Maturity date	May 31, 2016
Repayment of long term debt		$ 152,000
3% Convertible Senior Subordinated Notes [Member] | Cash [Member]
Debt Instrument [Line Items]
Repayment of long term debt		27,000
3% Convertible Senior Subordinated Notes [Member] | Revolver Facility [Member]
Debt Instrument [Line Items]
Repayment of long term debt		$ 125,000
[1]	Restated Values

Long-Term Debt - Lines of Credi

Long-Term Debt - Lines of Credit - Additional Information (Detail) - Long-term Debt [Member] $ in Millions	Dec. 31, 2016USD ($)
Debt Instrument [Line Items]
Lines of credit borrowed	$ 9.8
Aggregate outstanding principal amount	$ 1.1

Long-Term Debt - Other Debt - A

Long-Term Debt - Other Debt - Additional Information (Detail) - USD ($) $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2015

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Jun. 30, 2016

Jun. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Dec. 31, 2016

Dec. 31, 2015

[1]

Dec. 31, 2014

[1]

Debt Instrument [Line Items]

Interest expense

$ 44,130

$ 42,329

$ 42,106

$ 58,739

$ 52,333

$ 59,494

$ 46,431

$ 84,435

$ 105,925

$ 128,565

$ 158,258

$ 171,651

$ 216,997

$ 209,191

Other [Member] | HSBC [Member]

Debt Instrument [Line Items]

Principal amount under secured credit facility

$ 40,000

$ 40,000

$ 40,000

Maturity term

2 years

Interest expense

$ 2,700

Other [Member] | HSBC [Member] | London Interbank Offered Rate (LIBOR) [Member]

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate

0.80%

[1]

Restated Values

Long-Term Debt - Summary of Mat

Long-Term Debt - Summary of Maturities of Long-Term Debt Outstanding Including Current Portion (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
2,017	$ 82,447
2,018	491,275
2,019	41,275
2,020	1,030,441
2,021	10,988
Thereafter	1,340,335
Long-term Debt, Total	2,996,761	$ 3,100,000
Less: Debt issuance costs	(51,886)
Less: Original issue discounts	(4,300)
Total debt after discount	$ 2,940,575	$ 3,031,158

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	$ 76	$ 164
Total assets	76	164
Liabilities:
Contingent consideration obligations	43,200	57,744
Total liabilities	43,200	57,744
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	76	164
Total assets	76	164
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent consideration obligations	43,200	57,744	$ 139,671
Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	43,200	57,744
Total liabilities	$ 43,200	$ 57,744

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Contingent Consideration Obligations (Detail) - Unobservable Inputs (Level 3) [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration obligations, Beginning balance	$ 57,744	$ 139,671
Payments	(1,236)	(22,073)
Fair value adjustments	(13,309)	(59,871)
Foreign currency adjustments	1	17
Fair value of contingent consideration obligations, Ending balance	$ 43,200	$ 57,744

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Estimated fair value of long-term debt	$ 2,900,000	$ 3,000,000
Long-term debt, Total	$ 2,996,761	$ 3,100,000

Capital Leases - Schedule of Fu

Capital Leases - Schedule of Future Minimum Lease Payments with Present Value (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	[1]	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Leases [Abstract]
2,017	$ 3,064
2,018	2,583
2,019	2,869
2,020	790
2,021	457
Thereafter	522
Total future minimum lease payments	10,285
Less: Current portion	(3,064)	$ (3,713)	$ (3,500)	$ (4,048)	$ (3,962)		$ (3,505)	$ (4,643)	$ (5,072)
Net Present value of future minimum lease payments	$ 7,221	$ 8,033	$ 6,972	$ 7,654	$ 7,181		$ 7,346	$ 7,974	$ 8,794
[1]	Restated Values

Capital Leases - Capitalized Am

Capital Leases - Capitalized Amounts of Building, Machinery Equipment Computer Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Capital Leased Assets [Line Items]
Capital leased assets, Gross, Total	$ 28,314	$ 26,876
Less: Accumulated amortization	(10,165)	(9,214)
Capital leased assets, Net, Total	18,149	17,662
Machinery, Laboratory Equipment and Tooling [Member]
Capital Leased Assets [Line Items]
Capital leased assets, Gross, Total	26,794	24,258
Computer Equipment [Member]
Capital Leased Assets [Line Items]
Capital leased assets, Gross, Total	208	888
Furniture and Fixtures [Member]
Capital Leased Assets [Line Items]
Capital leased assets, Gross, Total	1,106	606
Vehicles [Member]
Capital Leased Assets [Line Items]
Capital leased assets, Gross, Total	206	197
Leasehold Improvements [Member]
Capital Leased Assets [Line Items]
Capital leased assets, Gross, Total	$ 0	$ 927

Postretirement Benefit Plans -

Postretirement Benefit Plans - Additional Information (Detail) $ in Thousands, £ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2016GBP (£)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Defined Contribution Plan Disclosure [Line Items]
Net amounts recognized in the accompanying consolidated balance sheets	$ 4,400		$ 3,000
Actuarial loss (gain)	(5,426)		638
Amortization of actuarial gain/loss	500
Amortization of prior service cost	275		310	$ 438
Contribution to defined benefit plan in current fiscal year	814		917
Expected benefits to be paid in next five years, Minimum	200
Expected benefits to be paid in next five years, Maximum	300
Thereafter	$ 400
Defined benefit plans aggregate payment period	5 years	5 years
Equity Securities [Member]
Defined Contribution Plan Disclosure [Line Items]
Contribution of fixed income securities to defined benefit plan	72.00%
Target allocation for the plan assets	70.00%	70.00%
Fixed Income Securities [Member]
Defined Contribution Plan Disclosure [Line Items]
Contribution of fixed income securities to defined benefit plan	28.00%
2017 [Member]
Defined Contribution Plan Disclosure [Line Items]
Amortization of prior service cost	$ 200
Estimated Contribution to defined benefit plan in next fiscal year | £		£ 0.6
Contribution to defined benefit plan in current fiscal year	700
Employee Savings Plans [Member]
Defined Contribution Plan Disclosure [Line Items]
Total matching contributions related to employee savings plans	$ 5,800		$ 5,800	$ 9,200

Postretirement Benefit Plans101

Postretirement Benefit Plans - Changes in Benefit Obligations, Plan Assets, Funded Status and Amounts Recognized (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Change in projected benefit obligation
Benefit obligation at beginning of year	$ 21,499	$ 22,560
Interest cost	721	784	$ 938
Actuarial loss (gain)	5,426	(638)
Benefits paid	(324)	(179)
Foreign exchange impact	(4,308)	(1,028)
Benefit obligation at end of year	23,014	21,499	22,560
Change in plan assets
Fair value of plan assets at beginning of year	18,485	18,120
Actual return on plan assets	3,297	491
Employer contribution	814	917
Benefits paid	(324)	(179)
Foreign exchange impact	(3,652)	(864)
Fair value of plan assets at end of year	18,620	18,485	$ 18,120
Funded status	(4,394)	(3,014)
Accumulated benefit obligation	$ 23,014	$ 21,499

Postretirement Benefit Plans102

Postretirement Benefit Plans - Amounts Recognized in Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Postemployment Benefits [Abstract]
Amortization of net loss	$ (279)	$ (332)	$ (267)
Amortization of prior service cost	(275)	(310)	$ (438)
New actuarial loss	(3,247)	(55)
Foreign exchange impact	4,991	(1,134)
Plan Adjustment Before Tax	$ 1,190	$ (1,831)

Postretirement Benefit Plans103

Postretirement Benefit Plans - Amounts Recognized in Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Net actuarial loss	$ 6,967	$ 5,109
Prior service cost	1,744	2,412
Net amount recognized	$ 8,711	$ 7,521

Postretirement Benefit Plans104

Postretirement Benefit Plans - Weighted-Average Actuarial Assumptions (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Assumptions used to determine benefit obligations:
Discount rate	2.70%	3.70%
Rate of compensation increase	4.05%	3.95%
Assumptions used to determine net periodic benefit cost:
Discount rate	3.70%	3.55%
Expected long-term return on plan assets	6.55%	6.50%
Rate of compensation increase	3.95%	3.85%

Postretirement Benefit Plans105

Postretirement Benefit Plans - Net Periodic Benefit Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Service cost	$ 0	$ 0	$ 0
Interest cost	721	784	938
Expected return on plan assets	(1,119)	(1,183)	(1,022)
Amortization of net loss	279	332	267
Amortization of prior service cost	275	310	438
Net periodic benefit cost	$ 156	$ 243	$ 621

Postretirement Benefit Plans106

Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 18,620	$ 18,485	$ 18,120
Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	18,620	18,485
U.K. Equities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,965	6,096
Overseas Equities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,005	3,119
U.S. Equities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,379	3,781
Debt Securities - Corporate Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,194	4,984
Other - Cash [Member] | Significant Other Observable Inputs (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 77	$ 505

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Annual Rental Payments Under Operating Leases (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 37,801
2,018	30,852
2,019	24,894
2,020	21,492
2,021	16,830
Thereafter	38,600
Future minimum annual rent, total	$ 170,469

Commitments and Contingencie108

Commitments and Contingencies - Additional Information (Detail)	Oct. 12, 2016USD ($)Patient	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Loss Contingencies [Line Items]
Rent expense relating to operating leases		$ 41,600,000	$ 41,800,000	$ 48,400,000
Number of Medicare beneficiaries deceased | Patient	211
Number of Medicare beneficiaries identified in CMS letter | Patient	47
Medicare claims	$ 5,700,000
Number of Medicare beneficiaries | Patient	1,000,000
Number of days required from filing date, to complete process of administrative law judge		180 days
Loss Contingency Accrual		$ 35,000,000
Earn-out payment to shareholders of Ionian Technologies		30,000,000
Original Merger Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Payment to be received upon termination of merger agreement		30,000,000
Original Merger Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Payment to be received upon termination of merger agreement		$ 50,000,000

Commitments and Contingencie109

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition, Contingent Consideration [Line Items]
Estimated Fair Value	$ 43,200,000	$ 57,744,000
Payments Made During 2016	$ 1,236,000
TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Mar. 11, 2010
Acquisition Date Fair Value	$ 35,600,000
Maximum Remaining Earn-out Potential	102,694,000
Estimated Fair Value	35,700,000	47,800,000
Payments Made During 2016	$ 553,000
Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Feb. 1, 2013
Acquisition Date Fair Value	$ 75,000,000
Maximum Remaining Earn-out Potential	19,600,000
Estimated Fair Value	3,000,000	4,700,000
Payments Made During 2016	$ 0
Other [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Various
Acquisition Date Fair Value	$ 30,373,000
Maximum Remaining Earn-out Potential	0
Estimated Fair Value	4,500,000	$ 5,244,000
Payments Made During 2016	$ 683,000
Minimum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,017
Minimum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,017
Maximum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,025
Maximum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,018

Commitments and Contingencie110

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Earn-out period	15 years

Net Income (Loss) Per Common111

Net Income (Loss) Per Common Share - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Numerator:
Loss from continuing operations	$ 15,663	$ (32,807)	$ (5,972)	$ (21,813)	$ (1,468)	$ 14,498	$ (6,664)	$ (38,779)	$ 7,834	$ (23,116)	$ 6,366	$ (137,269)	$ (15,448)	[1]	$ (171,441)	[1]
Preferred stock dividends	(5,366)	(5,308)	(5,309)	(5,367)	(5,369)	(5,308)	(5,250)	(10,617)	(10,558)	(15,983)	(15,927)	(21,350)	(21,293)	[1]	(21,293)	[1]
Loss from continuing operations attributable to common shares												(158,619)	(36,741)		(192,734)
Less: Net income attributable to non-controlling interest	207	143	103	(5)	(61)	359	88	246	447	453	386	350	381	[1]	30	[1]
Loss from continuing operations attributable to Alere Inc. and Subsidiaries												(158,969)	(37,122)		(192,764)
Income from discontinued operations	0	0	0	2,736	0	0	216,777	0	216,777	0	216,777	0	219,513	[1]	138,318	[1]
Net income (loss) available to common stockholders	$ 10,090	$ (38,258)	$ (11,384)	$ (24,439)	$ (6,776)	$ 8,831	$ 204,775	$ (49,642)	$ 213,606	$ (39,552)	$ 206,830	$ (158,969)	$ 182,391	[1]	$ (54,446)	[1]
Denominator:
Weighted-average common shares outstanding - basic and diluted		86,737	86,646	85,953	85,895		84,338	86,692	84,758	86,708	85,141	86,796	85,420	[1]	82,938	[1]
Basic and Diluted net income (loss) per common share:
Loss from continuing operations attributable to Alere Inc. and Subsidiaries	$ 0.12	$ (0.44)	$ (0.13)	$ (0.31)	$ (0.08)	$ 0.10	$ (0.14)	$ (0.57)	$ (0.04)	$ (0.45)	$ (0.12)	$ (1.83)	$ (0.43)	[1]	$ (2.33)	[1]
Income from discontinued operations	0	0	0		0	0	2.57	0	2.57	0	2.57	0	2.57	[1]	1.67	[1]
Basic and diluted net income (loss) per common share attributable to Alere Inc. and Subsidiaries	$ 0.12	$ (0.44)	$ (0.13)	$ (0.31)	$ (0.08)	$ 0.10	$ 2.43	$ (0.57)	$ 2.53	$ (0.45)	$ 2.45	$ (1.83)	$ 2.14	[1]	$ (0.66)	[1]
[1]	Restated Values

Net Income (Loss) Per Common112

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	18,279	20,461	20,821
Options to Purchase Shares of Common Stock and RSUs [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	6,774	6,793	7,140
Warrants [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	4	4
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	1,267	3,411	3,411
Conversion Shares Related to Subordinated Convertible Promissory Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	0	27
Conversion Shares Related to Series B Convertible Preferred Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	10,238	10,239	10,239
Common Stock Equivalents Related to the Settlement of a Contingent Consideration Obligation [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	14	0

Net Income (Loss) Per Common113

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Parenthetical) (Detail)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest rate of debt instrument	3.00%	3.00%	3.00%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Class of Stock [Line Items]
Common stock, shares authorized	200,000,000	200,000,000	200,000,000	200,000,000	200,000,000	[1]	200,000,000	200,000,000	200,000,000	200,000,000	200,000,000	200,000,000	200,000,000	200,000,000	200,000,000	[1]
Common stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	[1]	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	[1]
Treasury stock, shares	7,679,000	7,679,000	7,679,000	7,679,000	7,679,000	[1]	7,679,000	7,679,000	7,679,000	7,679,000	7,679,000	7,679,000	7,679,000	7,679,000	7,679,000	[1]
Common stock, shares outstanding	87,091,000	86,934,000	86,740,000	86,736,000	86,364,000	[1]	86,189,000	85,545,000	84,882,000	86,740,000	85,545,000	86,934,000	86,189,000	87,091,000	86,364,000	[1]
Common stock, shares reserved for future grant	11,500,000													11,500,000
Common stock, shares reserved for issuance under employee stock purchase plan	1,700,000													1,700,000
Aggregate liquidation preference	$ 709,701	$ 709,701	$ 709,701	$ 709,763	$ 709,763	[1]	$ 709,763	$ 709,763	$ 709,763	$ 709,701	$ 709,763	$ 709,701	$ 709,763	$ 709,701	$ 709,763	[1]
Preferred stock, shares authorized	2,300,000	2,300,000	2,300,000	2,300,000	2,300,000	[1]	2,300,000	2,300,000	2,300,000	2,300,000	2,300,000	2,300,000	2,300,000	2,300,000	2,300,000	[1]
Series B preferred stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	[1]	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	[1]
Series B preferred stock, shares outstanding	1,774,000	1,774,000	1,774,000	1,774,000	1,774,000	[1]	1,774,000	1,774,000	1,774,000	1,774,000	1,774,000	1,774,000	1,774,000	1,774,000	1,774,000	[1]
Percentage of conversion price of common stock														130.00%
Preferred stock dividends		$ 5,366	$ 5,308	$ 5,309	$ 5,367		$ 5,369	$ 5,308	$ 5,250	$ 10,617	$ 10,558	$ 15,983	$ 15,927	$ 21,350	$ 21,293	[1]	$ 21,293	[1]
Common stock, shares available for future grant	16,100,000													16,100,000
Common stock, shares for future grant	6,100,000				7,900,000									6,100,000	7,900,000		2,800,000
Aggregate intrinsic value of stock options exercised														$ 5,000	$ 31,400		$ 14,900
Compensation cost not yet recognized, period														1 year 11 days
Aggregate intrinsic value of the RSUs expected to vest, Weighted-average remaining vesting period														4 years
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Weighted-average grant date fair value of RSUs granted														$ 52.03	$ 28.04		$ 35.99
Aggregate intrinsic value of the RSUs	$ 55,000													$ 55,000
Weighted-average remaining contractual term														1 year 15 days
Aggregate intrinsic value of the RSUs expected to vest	51,000													$ 51,000
Aggregate intrinsic value of the RSUs expected to vest, Weighted-average remaining vesting period														1 year 11 days
Stock Appreciation Rights (SARs) [Member]
Class of Stock [Line Items]
Share based liabilities paid														$ 800	$ 1,100		$ 900
Accrual related to SARs	$ 1,900				$ 2,000									$ 1,900	$ 2,000		$ 2,400
Common Stock [Member]
Class of Stock [Line Items]
Common stock, par value	$ 0.001				$ 0.001									$ 0.001	$ 0.001		$ 0.001
Preferred stock convertible into common stock, value														$ 1,800
Senior subordinated convertible notes, convertible into common stock, shares	888													888
Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	5,000,000													5,000,000
Stock Options [Member]
Class of Stock [Line Items]
Compensation cost not yet recognized	$ 35,200													$ 35,200
Compensation cost not yet recognized, period														1 year 2 months 1 day
Two Thousand One Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Common stock, shares available for future grant	5,000,000													5,000,000
Shares issued under ESPP	3,300,000
Purchase price as percentage of market value of common stock														85.00%
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Aggregate liquidation preference	$ 709,800													$ 709,800
Common stock issuable on conversion of preferred stock	10,200,000													10,200,000
Preferred stock, shares authorized	2,300,000													2,300,000
Series B preferred stock, shares outstanding	1,800,000													1,800,000
Series B preferred stock outstanding with fair value	$ 590,600													$ 590,600
Liquidation preference per share	$ 400													$ 400
Initial conversion price	$ 69.32													$ 69.32
Senior subordinated convertible notes, convertible into common stock, shares	5.7703													5.7703
Number of preferred stock converted into common stock	154													154
Stock conversion agreement terms and conditions														Closing sale price of our common stock for each of 20 or more trading days within any period of 30
Series B preferred stock accrues dividends	$ 12													$ 12
Preferred Stock, Dividend Rate, Percentage														3.00%
Preferred stock dividends														$ 21,300	$ 21,300		$ 21,300
Series B Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Aggregate liquidation preference	$ 709,700													$ 709,700
Preferred stock conversion price	$ 69.32													$ 69.32
Common stock issuable on conversion of preferred stock	10,200,000													10,200,000
Stock Options and Awards [Member]
Class of Stock [Line Items]
Compensation cost not yet recognized	$ 49,700													$ 49,700
[1]	Restated Values

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Equity [Abstract]
Beginning balance, shares	6,141	7,364	11,441
Granted, Stock options	6	2,399	1,287
Exercised, Stock options	(437)	(2,168)	(1,512)
Canceled/expired/forfeited, Stock options	(369)	(1,454)	(3,852)
Ending balance, Stock options	5,341	6,141	7,364
Beginning balance, Weighted Average Exercise Price	$ 38.43	$ 34.68	$ 37.66
Exercisable at December 31, Stock options	3,351
Granted, Weighted Average Exercise Price	$ 35.80	46.47	36.84
Total vested and expected to vest as of December 31, 2016	5,211
Exercised, Weighted Average Exercise Price	$ 34.68	34.26	28.29
Canceled/expired/forfeited, Weighted Average Exercise Price	45.33	38.91	46.66
Ending Balance, Weighted Average Exercise Price	38.25	$ 38.43	$ 34.68
Exercisable at December 31, Weighted Average Exercise Price	34.81
Total vested and expected to vest as of December 31, 2016	$ 38.06
Outstanding at December 31, 2016, Weighted Average Remaining Contractual Life	6 years 3 months 18 days
Exercisable at December 31, 2016, Weighted Average Remaining Contractual Life	5 years 3 months 11 days
Total vested and expected to vest as of December 31, 2016, Weighted Average Remaining Contractual Life	6 years 3 months 4 days
Outstanding at December 31, 2016, Aggregate Intrinsic Value	$ 26.1
Exercisable at December 31, 2016, Aggregate Intrinsic Value	24
Total vested and expected to vest as of December 31, 2016, Aggregate Intrinsic Value	$ 26.1

Stockholders' Equity - Summa116

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested, Stock Appreciation Rights, Beginning balance	650
Restricted Stock Units, Granted	1,069
Restricted Stock Units, Vested	(261)
Restricted Stock Units, Forfeited	(46)
Nonvested, Stock Appreciation Rights, Ending balance	1,412	650
Weighted- average Grant Date Fair Value, Nonvested, beginning balance	$ 31
Weighted- average Grant Date Fair Value, Granted	52.03	$ 28.04	$ 35.99
Weighted- average Grant Date Fair Value, Vested	31.84
Weighted- average Grant Date Fair Value, Forfeited	45.39
Weighted- average Grant Date Fair Value, Nonvested, ending balance	$ 46.29	$ 31

Stockholders' Equity - Summa117

Stockholders' Equity - Summary of Stock Appreciation Rights (Detail) - Stock Appreciation Rights (SARs) [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2016shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested, Stock Appreciation Rights, Beginning balance	188
Granted, Stock Appreciation Rights	22
Exercised, Stock Appreciation Rights	(41)
Forfeited, Stock Appreciation Rights	(24)
Nonvested, Stock Appreciation Rights, Ending balance	145

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 41,796	$ 26,391	[1]	$ 12,452	[1]
Benefit for income taxes	(520)	(8,815)		(2,891)
Stock-based compensation, net of tax	41,276	17,576		9,561
Cost of Net Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	2,054	1,198		1,180
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense adjustment	1,905	1,195		(41)
Sales and Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	8,991	4,794		3,940
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 28,846	$ 19,204		$ 7,373
[1]	Restated Values

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reversal of stock-based compensation expense	$ 5,600
Excess tax benefits on exercised stock options and vesting of RSU's		$ 0	$ 0	[1]	$ 972	[1]
Weighted average fair value		$ 11.66	$ 15.01		$ 14.05
Compensation expense		$ 41,796	$ 26,391	[1]	$ 12,452	[1]
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense		$ 1,500	$ 1,900		$ 2,600
Expected volatility		36.00%
Risk-free interest rate		0.49%
Expected life		181 days
Maximum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			30.00%		35.00%
Risk-free interest rate			0.11%		0.09%
Expected life			181 days		181 days
Minimum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			29.00%		32.00%
Risk-free interest rate			0.13%		0.06%
Expected life			184 days		184 days
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reversal of stock-based compensation expense	2,200
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reversal of stock-based compensation expense	$ 3,400
Compensation expense		$ 28,846	$ 19,204		$ 7,373
[1]	Restated Values

Stock-based Compensation - Fair

Stock-based Compensation - Fair Value Assumptions for Stock Options on Date of Grant (Detail) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.27%	1.62%	1.77%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	5 years 5 months 9 days	5 years 7 months 2 days	5 years 9 months 11 days
Expected volatility	35.00%	33.00%	36.00%

Accumulated Other Comprehens121

Accumulated Other Comprehensive Loss - Summary of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Equity [Abstract]
Cumulative Translation Adjustment, beginning balance		$ (331,535)		$ (185,097)		$ (18,649)
Period change, Cumulative Translation Adjustment	[1]	(122,287)		(146,438)		(166,448)
Cumulative Translation Adjustment, ending balance		(453,822)		(331,535)		(185,097)
Pension Liability Adjustment, Beginning balance		(8,242)		(7,013)		(7,017)
Period change, Pension Liability Adjustment	[1]	(334)		(1,229)		4
Pension Liability Adjustment, Ending balance		(8,576)		(8,242)		(7,013)
Other, Beginning balance		0		0		(21)
Period change, Other		0		0		21
Other, Ending balance		0		0		0
Accumulated Other Comprehensive Loss, Beginning Balance		(339,777)	[1]	(192,110)		(25,687)
Period change, accumulated other comprehensive loss		(122,621)		(147,667)	[1]	(166,423)	[1]
Accumulated Other Comprehensive Loss, Ending Balance		$ (462,398)		$ (339,777)	[1]	$ (192,110)
[1]	Restated Values

Income Taxes - Summary of Incom

Income Taxes - Summary of Income (Loss) Before Provision (Benefit) for Income Taxes, Continuing Operations, Excluding Equity Earnings of Unconsolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Income Tax Disclosure [Abstract]
United States												$ (339,940)	$ (226,051)		$ (184,936)
Foreign												187,542	141,509		67,016
Income (loss) from continuing operations before provision (benefit) for income taxes	$ (61,282)	$ (32,347)	$ (11,178)	$ (78,169)	$ (16,608)	$ 28,925	$ (18,690)	$ (43,525)	$ 10,235	$ (104,807)	$ (6,373)	$ (152,398)	$ (84,542)	[1]	$ (117,920)	[1]
[1]	Restated Values

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	[1]	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Deferred tax assets:
NOL and capital loss carryforwards	$ 274,796				$ 207,812
Tax credit carryforwards	123,216				107,750
Nondeductible reserves	40,936				45,053
Accrued liabilities	48,423				26,490
Difference between book and tax bases of tangible assets	4,388				1,735
Difference between book and tax bases of intangible assets	17,735				19,678
Deferred revenue	7,190				7,426
All other	9,765				16,477
Gross deferred tax assets	526,449				432,421
Less: Valuation allowance	(323,272)				(248,307)
Total deferred tax assets	203,177				184,114
Difference between book and tax bases of tangible assets	18,104				20,990
Difference between book and tax bases of intangible assets	233,646				277,871
Debt	7,075				2,344
Difference between book and tax bases of investment in subsidiaries	29,625				0
Other	13,342				16,534
Total deferred tax liabilities	301,792				317,739
Net deferred tax liabilities	(98,615)				(133,625)
Net non-current deferred tax assets	20,483	$ 56,638	$ 18,638	$ 16,124	13,993		$ 5,380	$ 5,381	$ 6,360
Net non-current deferred tax liabilities	(119,098)	$ (52,513)	$ (140,864)	$ (144,483)	(147,618)		$ (226,976)	$ (243,298)	$ (262,117)
Net deferred tax liabilities	$ (98,615)				$ (133,625)
[1]	Restated Values

Income Taxes - Components of124

Income Taxes - Components of Deferred Tax Assets and Liabilities (Parenthetical) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Components Of Deferred Tax Assets And Liabilities [Line Items]
NOL and capital loss carryforwards	$ 274,796	$ 207,812	[1]
Valuation allowance	$ 323,272	248,307	[1]
As Previously Reported [Member]
Components Of Deferred Tax Assets And Liabilities [Line Items]
NOL and capital loss carryforwards		221,728
Valuation allowance		262,223
Revision Adjustment [Member]
Components Of Deferred Tax Assets And Liabilities [Line Items]
NOL and capital loss carryforwards		(13,916)
Valuation allowance		$ (13,916)
[1]	Restated Values

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Income Taxes [Line Items]
US Federal net operating loss carryforwards													$ 173,900,000
US Federal net operating loss carryforwards, after tax effect													60,900,000
State net operating loss carryforwards													1,032,800,000
State net operating loss carryforwards, after tax effect													70,100,000
Foreign net operating loss carryforwards													505,600,000
Foreign net operating loss carryforwards, after tax effect													81,500,000
US Federal capital loss carryforwards													223,300,000
US Federal capital loss carryforwards, after tax effect													78,200,000
Foreign capital loss carryforwards													5,100,000
Foreign capital loss carryforwards, after tax effect													1,100,000
State capital loss carryforwards													223,300,000
State capital loss carryforwards, after tax effect													11,200,000
U.S. federal Alternative Minimum Tax ("AMT") credit carryforwards													$ 7,900,000
U.S. federal loss carryforwards and credits percentage of change in ownership period													3 years
U.S. federal loss carryforwards and credits percentage of cumulative changes in the ownership interest of significant shareholders													50.00%
Valuation allowance				$ 248,307,000	[1]								$ 323,272,000	$ 248,307,000	[1]
Increase of valuation allowance														75,000,000
Undistributed earnings of foreign subsidiaries													550,500,000
Provision for income taxes increased													89,000,000
Provision (benefit) for income taxes	$ (50,796,000)	$ 2,582,000	$ (172,000)	(51,146,000)		$ (10,140,000)	$ 15,788,000	$ (8,067,000)	$ 2,410,000	$ 7,721,000	$ (48,386,000)	$ (2,419,000)	$ 35,376,000	$ (53,564,000)	[1]	$ 71,030,000	[1]
Effective tax rate													(23.00%)	62.00%		(61.00%)
Effective income tax rate reconciliation, change in enacted tax rate, amount														$ 2,100,000
Unrecognized tax benefits, increase in period, due to uncertain tax positions excluding interest and penalties													$ 10,600,000
Tax, total													$ 131,400,000
Unrecognized income tax description													Included in the balance of unrecognized tax benefits as of December 31, 2016 is $73.8 million of tax benefits that, if recognized, would affect the effective tax rate.
Unrecognized tax benefits that would impact effective tax rate													$ 73,800,000
Unrecognized tax benefits excluding interest and penalties, current													9,700,000
Interest and penalties													2,900,000	1,400,000		$ 1,100,000
Accrued interest and penalties				3,700,000									$ 6,600,000	3,700,000		2,300,000
Research and Development Credit [Member]
Income Taxes [Line Items]
Tax credit carryforwards expiration year													2,026
California Franchise Tax Board [Member]
Income Taxes [Line Items]
US Federal and state R&D, tax credit carryforwards													$ 6,800,000
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration year													2,020
Capital loss carryforwards expiration year													2,017
US Federal and state R&D, tax credit carryforwards													$ 6,300,000
Open tax year													2,013
State [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration year													2,017
US Federal and state R&D, tax credit carryforwards													$ 21,600,000
Open tax year													2,011
Foreign [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration year													2,017
Foreign tax credit carryforwards													$ 1,100,000
Tax credit carryforwards expiration year													2,018
Valuation allowance													$ 14,600,000
Open tax year													2,010
Foreign [Member] | Subsidiaries [Member]
Income Taxes [Line Items]
Foreign													$ 2,800,000
United States [Member]
Income Taxes [Line Items]
Foreign tax credit carryforwards													93,900,000
Valuation allowance													$ 60,400,000
Restatement Adjustment [Member]
Income Taxes [Line Items]
Foreign														1,500,000		2,900,000
Provision (benefit) for income taxes	$ 92,000	$ (535,000)	$ 36,000	$ (817,000)		$ 72,000	$ 99,000	$ (214,000)	$ (499,000)	$ (115,000)	$ (407,000)	$ (43,000)		$ (860,000)		$ 100,000
[1]	Restated Values

Income Taxes - Components of Pr

Income Taxes - Components of Provision (Benefit) for Income Taxes - continuing operations (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Components Of Income Tax Expense Benefit [Line Items]
Total deferred												$ (36,010)	$ (99,389)	[1]	$ 12,254	[1]
Total provision (benefit) for income taxes	$ (50,796)	$ 2,582	$ (172)	$ (51,146)	$ (10,140)	$ 15,788	$ (8,067)	$ 2,410	$ 7,721	$ (48,386)	$ (2,419)	35,376	(53,564)	[1]	71,030	[1]
Continuing Operations [Member]
Components Of Income Tax Expense Benefit [Line Items]
Federal												5,168	(12,027)		3,949
State												1,606	2,331		487
Foreign												64,612	55,519		54,340
Total current												71,386	45,823		58,776
Federal												(49,569)	(71,748)		25,629
State												8,059	(8,572)		(4,142)
Foreign												5,500	(19,067)		(9,233)
Total deferred												(36,010)	(99,387)		12,254
Total provision (benefit) for income taxes												$ 35,376	$ (53,564)		$ 71,030
[1]	Restated Values

Income Taxes - Reconciliation f

Income Taxes - Reconciliation from U.S. Statutory Tax Rate to Effective Tax Rate, Continuing Operations, Excluding Equity Earnings of Unconsolidated Subsidiaries (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Statutory rate	35.00%	35.00%	35.00%
Stock-based compensation	(3.00%)	(1.00%)	(1.00%)
Rate differential on foreign earnings	18.00%	18.00%	4.00%
Impact of foreign inclusion	0.00%	0.00%	(2.00%)
U.S. federal research and development credit	2.00%	2.00%	1.00%
State income taxes, net of federal benefit	(3.00%)	6.00%	3.00%
Contingent consideration	3.00%	25.00%	(3.00%)
Rate changes	1.00%	1.00%	(3.00%)
Return to provision	(2.00%)	4.00%	19.00%
Other permanent items	(2.00%)	(1.00%)	3.00%
Change in valuation allowance	(40.00%)	(8.00%)	(73.00%)
Foreign dividends, net	(11.00%)	(12.00%)	(19.00%)
Uncertain tax positions	(5.00%)	(5.00%)	(19.00%)
Withholding taxes	0.00%	(2.00%)	(6.00%)
Sale of business	(3.00%)	0.00%	0.00%
Non-deductible fines and penalties	(4.00%)	0.00%	0.00%
Gain on sale of equity investments	(9.00%)	0.00%	0.00%
Effective tax rate	(23.00%)	62.00%	(61.00%)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Beginning Balance	$ 120,707	$ 49,931	$ 30,394
Additions for tax positions related to prior years	3,296	823	20,797
Additions for tax positions related to current year	11,062	71,505	3,217
Reductions for tax positions related to prior years	(3,711)	(1,552)	(4,477)
Ending Balance	$ 131,354	$ 120,707	$ 49,931

Financial Information by Seg129

Financial Information by Segment - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015Segments
Segment Reporting [Abstract]
Number of operating segments	2

Financial Information by Seg130

Financial Information by Segment - Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Segment Reporting Information [Line Items]
Net revenue	$ 582,282	$ 610,304	$ 586,940	$ 617,136		$ 604,599	$ 623,974	$ 609,906	$ 1,197,244	$ 1,233,880	$ 1,779,526	$ 1,838,479	$ 2,376,335	$ 2,455,615	[1]	$ 2,577,001	[1]
Operating income (loss)	(15,993)	13,894	32,277	(17,687)		32,067	85,224	30,108	46,171	115,332	30,178	147,399	14,724	129,712	[1]	94,678	[1]
Depreciation and amortization													285,608	309,264	[1]	336,029	[1]
Restructuring charge													37,885	15,667		58,738
Stock-based compensation													41,796	26,391	[1]	12,452	[1]
Assets	$ 5,851,685	$ 5,792,800	$ 5,895,173	5,918,160	[1]	$ 6,542,128	$ 6,614,344	$ 6,124,840	$ 5,792,800	$ 6,614,344	$ 5,851,685	$ 6,542,128	5,648,279	5,918,160	[1]
Expenditures for property, plant and equipment													67,694	90,778	[1]	100,562	[1]
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue													2,159,680	2,241,391		2,369,885
Operating income (loss)													302,759	330,664		160,805
Depreciation and amortization													253,853	282,411		318,051
Restructuring charge													15,890	14,305		44,503
Stock-based compensation													0	0		0
Assets				5,515,576									5,199,806	5,515,576
Expenditures for property, plant and equipment													58,151	73,490		76,111
Consumer Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue													74,152	85,128		89,087
Operating income (loss)													475	2,872		11,921
Depreciation and amortization													5,266	2,836		692
Restructuring charge													0	0		0
Stock-based compensation													0	0		0
Assets				172,551									175,362	172,551
Expenditures for property, plant and equipment													1,508	1,403		3,360
Other Non-Reportable Segments [Member]
Segment Reporting Information [Line Items]
Net revenue													142,503	129,096		118,029
Operating income (loss)													25,250	13,000		12,233
Depreciation and amortization													17,651	16,912		13,831
Restructuring charge													0	0		0
Stock-based compensation													0	0		0
Assets				99,364									87,193	99,364
Expenditures for property, plant and equipment													4,169	3,175		3,023
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenue													0	0		0
Operating income (loss)													(313,760)	(216,824)		(90,281)
Depreciation and amortization													8,838	7,105		3,455
Restructuring charge													21,995	1,362		14,235
Stock-based compensation													41,796	26,391		12,452
Assets				$ 130,669									185,918	130,669
Expenditures for property, plant and equipment													$ 3,866	$ 12,710		$ 18,068
[1]	Restated Values

Financial Information by Seg131

Financial Information by Segment - Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Segment Reporting Information [Line Items]
Sales revenue net	$ 579,802	$ 607,771	$ 584,211	$ 613,850	$ 601,300	$ 618,280	$ 605,208	$ 1,191,982	$ 1,223,488	$ 1,771,784	$ 1,824,788	$ 2,364,337	$ 2,438,638	[1]	$ 2,555,951	[1]
Professional diagnostics net product sales and services revenue	123,778	124,809	115,709	113,483	128,341	126,628	123,856	240,518	250,484	364,296	378,825	480,761	492,308	[1]	531,988	[1]
License and royalty revenue	2,480	2,533	2,729	3,286	3,299	5,694	4,698	5,262	10,392	7,742	13,691	11,998	16,977	[1]	21,050	[1]
Net revenue	$ 582,282	$ 610,304	$ 586,940	$ 617,136	$ 604,599	$ 623,974	$ 609,906	$ 1,197,244	$ 1,233,880	$ 1,779,526	$ 1,838,479	2,376,335	2,455,615	[1]	2,577,001	[1]
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue												2,159,680	2,241,391		2,369,885
Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Professional diagnostics net product sales and services revenue												2,147,682	2,224,414		2,348,835
License and royalty revenue												11,998	16,977		21,050
Net revenue												2,159,680	2,241,391		2,369,885
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Cardiometabolic [Member]
Segment Reporting Information [Line Items]
Sales revenue net												622,468	703,553		725,423
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Infectious Disease [Member]
Segment Reporting Information [Line Items]
Sales revenue net												776,153	710,178		723,715
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Toxicology [Member]
Segment Reporting Information [Line Items]
Sales revenue net												608,635	618,362		644,621
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Sales revenue net												$ 140,426	$ 192,321		$ 255,076
[1]	Restated Values

Financial Information by Seg132

Financial Information by Segment - Summary of Revenue and Long-lived Tangible Assets for Segments by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Segment Reporting Information [Line Items]
Net revenue	$ 582,282	$ 610,304	$ 586,940	$ 617,136		$ 604,599	$ 623,974	$ 609,906	$ 1,197,244	$ 1,233,880	$ 1,779,526	$ 1,838,479	$ 2,376,335	$ 2,455,615	[1]	$ 2,577,001	[1]
Long-Lived Tangible Assets	$ 446,313	$ 438,787	$ 445,218	446,039	[1]	$ 445,872	$ 448,891	$ 447,326	$ 438,787	$ 448,891	$ 446,313	$ 445,872	441,190	446,039	[1]
United States [Member]
Segment Reporting Information [Line Items]
Net revenue													1,294,013	1,372,039		1,366,739
Long-Lived Tangible Assets				261,385									267,519	261,385
United Kingdom [Member]
Segment Reporting Information [Line Items]
Long-Lived Tangible Assets				26,512									21,342	26,512
China [Member]
Segment Reporting Information [Line Items]
Long-Lived Tangible Assets				28,705									30,161	28,705
Europe [Member]
Segment Reporting Information [Line Items]
Net revenue													401,692	437,653		533,116
Elsewhere [Member]
Segment Reporting Information [Line Items]
Net revenue													680,630	645,923		$ 677,146
Long-Lived Tangible Assets				$ 129,437									$ 122,168	$ 129,437
[1]	Restated Values

Other Arrangements - Additional

Other Arrangements - Additional Information (Detail) - USD ($)	1 Months Ended			12 Months Ended
	Dec. 31, 2016	Sep. 30, 2014	Feb. 28, 2013	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
The amount provided for development of diagnostic device by BARDA as defined in the agreement		$ 12,900,000
Net expenditure incurred under the contract				$ 4,500,000	$ 3,400,000
The amount of cash reimbursement received from BARDA				3,600,000	2,700,000
Amount of accounts receivables	$ 900,000			900,000	700,000
Restricted cash	51,550,000			51,550,000	5,694,000	[1]		$ 4,999,000	$ 5,662,000	$ 6,166,000	$ 430,821,000	$ 461,636,000	$ 37,406,000
Gates Foundation [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue from grant awarded			$ 21,600,000
Cash received from grant-related funding					19,700,000
Qualified expenditures					3,900,000		$ 9,500,000
Deferred grant funding	0			0	0
Restricted cash	0			0	0
Gates Foundation [Member] | Malaria Program [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue from grant awarded				3,500,000
Cash received from grant-related funding	800,000
Qualified expenditures				1,300,000	$ 500,000
Deferred grant funding	1,200,000			1,200,000
Restricted cash	$ 1,300,000			$ 1,300,000
Gates Loan Agreement [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Aggregate principal amount of subordinated term loan			$ 20,600,000
[1]	Restated Values

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) $ in Thousands	Sep. 16, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)		Dec. 31, 2014USD ($)		Dec. 31, 2016CNY (¥)	May 31, 2007
Related Party Transaction [Line Items]
Restructuring charges		$ 37,885	$ 15,667		$ 58,738
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables		0	15,938
Cash received from SPD as a distribution of earnings		16,989	26,136	[1]	980	[1]
Restricted cash		$ 53,700	48,900
SPD [Member]
Related Party Transaction [Line Items]
Equity method investment ownership percentage		50.00%					50.00%	50.00%
SPD Shanghai [Member]
Related Party Transaction [Line Items]
Restricted cash		$ 3,300
SPD Shanghai [Member] | Alere Shanghai [Member]
Related Party Transaction [Line Items]
Loan arrangement from related party		3,300
SPD Shanghai [Member] | Maximum [Member] | Alere Shanghai [Member]
Related Party Transaction [Line Items]
Loan arrangement from related party | ¥							¥ 23,000,000
TechLab [Member]
Related Party Transaction [Line Items]
Net payable to SPD		1,400	3,200
Percentage of equity method investments sold	49.00%
Purchases from related party		29,900	27,100		24,800
Gain (Loss) on sale of equity method investment, before tax	$ 29,900
Gain (Loss) on sale of equity method investment, tax effect	$ 11,200
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Net payable to SPD		3,700	1,200
Restructuring charges		1,200	1,500
Long-term receivable cost related to restructuring plan		6,100	8,900
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables		7,500	7,800
Trade receivables from SPD		7,900	9,900
Trade payable to SPD		34,200	23,600
Cash received from SPD as a distribution of earnings		13,600	23,400
SPD Joint Venture [Member] | Sales Revenue Goods [Member]
Related Party Transaction [Line Items]
Revenue from joint venture		78,700	77,100		83,200
SPD Joint Venture [Member] | Sales Revenue Services [Member]
Related Party Transaction [Line Items]
Revenue from joint venture		$ 1,000	$ 1,100		$ 1,300
SPD Joint Venture [Member] | TechLab [Member]
Related Party Transaction [Line Items]
Equity method investment ownership percentage			49.00%
[1]	Restated Values

Related Party Transactions - Re

Related Party Transactions - Related Party Balances with SPD within Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	$ 413,535	$ 426,207	$ 427,961	$ 459,115	$ 436,924	[1]	$ 436,490	$ 454,636	$ 457,333
Prepaid expenses and other current assets	118,607	124,390	124,877	106,629	114,514	[1]	121,023	125,559	117,924
Other non-current assets	14,966	16,219	16,290	17,927	18,078	[1]	19,635	21,845	25,052
Accounts payable	195,879	$ 211,476	$ 194,235	$ 165,800	195,752	[1]	$ 194,246	$ 186,941	$ 195,980
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	7,855				9,873
Prepaid expenses and other current assets	7,486				6,602
Other non-current assets	6,122				8,895
Accounts payable	$ 34,216				$ 24,887
[1]	Restated Values

Valuation and Qualifying Acc136

Valuation and Qualifying Accounts - Sets Forth Activities in Accounts Receivable Reserve Accounts (Detail) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 89,701	$ 76,163	$ 69,146
Provision	48,748	45,279	42,477
Amounts Charged Against Reserves	(62,651)	(31,741)	(35,460)
Ending balance	$ 75,798	$ 89,701	$ 76,163

Valuation and Qualifying Acc137

Valuation and Qualifying Accounts - Sets Forth Activities in Inventory Reserve Accounts (Detail) - Inventory Valuation Reserve [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 37,775	$ 27,348	$ 21,437
Provision	10,640	21,592	12,818
Amounts Charged Against Reserves	(19,977)	(11,165)	(6,907)
Ending balance	$ 28,438	$ 37,775	$ 27,348

Valuation and Qualifying Acc138

Valuation and Qualifying Accounts - Sets Forth Activities in Deferred Tax Accounts (Detail) - Valuation Allowance of Deferred Tax Assets [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 248,307	$ 228,633	$ 84,315
Additions	74,965	19,674	143,454
Amounts Charged Against Other Accounts	0	0	864
Ending balance	$ 323,272	$ 248,307	$ 228,633

Restructuring Activities - Aggr

Restructuring Activities - Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 37,885	$ 15,667	$ 58,738
Restructuring charges	37,885	15,667	58,738
Interest Expense, Including Amortization of Original Issue Discounts and Deferred Financing Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	11	24	42
Cost of Net Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5,991	3,816	11,760
Research and Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,052	2,752	9,800
Sales and Marketing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,798	3,004	11,350
General and Administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	26,033	6,071	25,786
Total Operating Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 37,874	$ 15,643	$ 58,696

Restructuring Activities - Rest

Restructuring Activities - Restructuring Activities Related to Restructuring Plans (Detail) - USD ($) $ in Thousands	12 Months Ended			108 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 37,885	$ 15,667	$ 58,738
Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	15,890	14,305	44,503
Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	21,995	1,362	14,235
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	9,670
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	6,217
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,010
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Cash Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	9,227
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	443
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	21,995
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	346
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	21,649
Restructuring Plans Prior to 2016 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$ 15,599
Restructuring Plans Prior to 2016 [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				4,277
Restructuring Plans Prior to 2016 [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				11,322
Restructuring Plans Prior to 2016 [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Other non-cash charges	178	1,918	0	2,160
Restructuring charges	6,220	14,305	44,503	108,472
Restructuring Plans Prior to 2016 [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,219	7,143	29,071	65,094
Restructuring Plans Prior to 2016 [Member] | Professional Diagnostics [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,257	4,542	4,399	19,738
Restructuring Plans Prior to 2016 [Member] | Professional Diagnostics [Member] | Cash Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	4,487	11,709	33,512	85,665
Restructuring Plans Prior to 2016 [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,555	678	10,991	19,961
Restructuring Plans Prior to 2016 [Member] | Professional Diagnostics [Member] | Other Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	11	24	42	833
Restructuring Plans Prior to 2016 [Member] | Professional Diagnostics [Member] | Intangible Asset Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	0	0	$ 686
Restructuring Plans Prior to 2016 [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	1,362	14,235
Restructuring Plans Prior to 2016 [Member] | Corporate and Other [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	1,376	2,901
Restructuring Plans Prior to 2016 [Member] | Corporate and Other [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 0	$ (14)	$ 11,334

Restructuring Activities - Addi

Restructuring Activities - Additional Information (Detail) $ in Millions	Dec. 31, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring reserves included in accrued expenses and other current liabilities	$ 10.6
Restructuring reserves included in other long-term liabilities	0.3
2016 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Cash charges remain unpaid	7.6
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	1.7
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	2.7
Restructuring Plans Prior to 2016 [Member]
Restructuring Cost and Reserve [Line Items]
Cash charges remain unpaid	3.3
Restructuring Plans Prior to 2016 [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	$ 2.1

Restructuring Activities - Cash

Restructuring Activities - Cash Activity for Restructuring Reserves (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]
Cash charges	$ 37,885	$ 15,667	$ 58,738
Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	10,890	3,779	14,748	$ 3,140
Cash charges		35,709	13,071	47,747
Payments		(28,373)	(23,501)	(34,858)
Currency adjustments		(225)	(539)	(1,281)
Restructuring Reserve, Ending Balance		10,890	3,779	14,748
Severance-Related Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	3,339	1,633	4,590	992
Cash charges		9,782	8,519	31,972
Payments		(7,890)	(11,145)	(27,394)
Currency adjustments		(186)	(331)	(980)
Restructuring Reserve, Ending Balance		3,339	1,633	4,590
Facility and Transition Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	7,512	1,966	9,868	1,781
Cash charges		25,916	4,528	15,733
Payments		(20,331)	(12,222)	(7,345)
Currency adjustments		(39)	(208)	(301)
Restructuring Reserve, Ending Balance		7,512	1,966	9,868
Other Exit Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	$ 39	180	290	367
Cash charges		11	24	42
Payments		(152)	(134)	(119)
Currency adjustments		0	0	0
Restructuring Reserve, Ending Balance		$ 39	$ 180	$ 290

Equity Investments - Additional

Equity Investments - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 16, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014		May 31, 2007
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax		$ 26,149	$ 2,122	$ 5,034	$ 5,210	$ 5,000	$ 1,361	$ 3,959	$ 7,156	$ 5,320	$ 33,305	$ 10,320	$ 50,505	$ 15,530	[1]	$ 17,509	[1]
Dividends received													13,600
SPD [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax													$ 19,000	14,300		16,200
Equity method investment ownership percentage													50.00%					50.00%
TechLab [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax													$ 1,800	$ 1,500		$ 1,600
Percentage of equity method investments sold	49.00%
Gain (Loss) on sale of equity method investment, before tax	$ 29,900
[1]	Restated Values

Equity Investments - Financial

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Results of Operations (Detail) - TechLab [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]
Net revenue	$ 209,239	$ 202,611	$ 211,370
Gross profit	151,912	147,386	160,192
Net income after taxes	$ 41,616	$ 32,457	$ 35,646

Equity Investments - Financi145

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Balance Sheet (Detail) - Equity Method Investee [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Current assets	$ 75,248	$ 71,542
Non-current assets	20,578	30,802
Total assets	95,826	102,344
Current liabilities	44,234	37,609
Non-current liabilities	3,875	5,157
Total liabilities	$ 48,109	$ 42,766

Assets Held For Sale - Addition

Assets Held For Sale - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 16, 2016	Jan. 31, 2016	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Assets Held For Sale [Line Items]
Assets held for sale - current			$ 0				$ 4,165	[1]	$ 25,312	$ 28,631
Goodwill			2,759,366	$ 2,805,682	$ 2,811,545	$ 2,839,692	2,836,915	[1]	2,842,921	2,853,551	$ 2,880,164	$ 2,926,666
Liabilities related to assets held for sale - current			0				363	[1]	8,836	7,663
Assets held for sale - non-current			0		$ 12,223	$ 11,813	13,337	[1]	$ 126,048	$ 129,194
TechLab [Member]
Assets Held For Sale [Line Items]
Assets held for sale - non-current							$ 13,300
Percentage of equity method investments sold	49.00%
Gain (Loss) on sale of equity method investment, before tax	$ 29,900
TechLab [Member] | SPD Joint Venture [Member]
Assets Held For Sale [Line Items]
Joint venture ownership percentage							49.00%
Alere E-Sante [Member]
Assets Held For Sale [Line Items]
Assets held for sale - current							$ 4,200
Goodwill							3,200
Liabilities related to assets held for sale - current							$ 400
Sale of business, purchase price		$ 8,100
Sale of business, contingent consideration		1,500
Sale of business, working capital adjustment		$ 200
Gain (Loss) on sale of disposal of group			$ 3,800
[1]	Restated Values

Impairment and (Gain) Loss on D

Impairment and (Gain) Loss on Dispositions, Net - Additional Information (Detail) € in Millions, AUD in Millions, $ in Millions, ₩ in Billions

1 Months Ended

12 Months Ended

Jan. 31, 2016USD ($)

Nov. 30, 2015USD ($)

Mar. 31, 2015USD ($)

Mar. 31, 2015EUR (€)

Nov. 30, 2014USD ($)

Oct. 31, 2014USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Jul. 31, 2015USD ($)

Jul. 31, 2015AUD

May 31, 2015USD ($)

Nov. 30, 2014KRW (₩)

Alere E-Sante [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Sale of business, cash received

$ 8.1

Sale of business, working capital adjustment

0.2

Sale of business, contingent consideration

1.5

Gain (Loss) on sale of disposal group

$ 3.8

Cash consideration received at date of disposition

$ 8.1

AdnaGen GmbH [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain (loss) from sale of assets

$ (0.3)

Proceeds from sale of assets

$ 4.6

BBI Business [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Sale of business, cash received

$ 106.4

Sale of business, contingent consideration

$ 46.6

Gain (Loss) on sale of disposal group

(9.3)

Net assets disposed

66.5

Sale of business, Goodwill

49.2

Alere Analytics [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Impairment charges

26.7

Write-off of intangible assets

26.2

Write-off of fixed assets

0.5

Contribution to working capital

$ 2.7

Gain (loss) from sale of assets

(3.6)

Alere Analytics [Member] | Cash [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Contribution to working capital

2.4

Alere Analytics [Member] | Escrow [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Contribution to working capital

$ 0.3

Gesellschaft Fur Patientenhilfe DGP GmbH [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain (Loss) on sale of disposal group

(7.5)

Cash proceeds from sale of business

$ 8.2

€ 7.6

Alere Connect LLC [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Impairment charges

1.1

$ 10.8

Bio Note Inc [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain (Loss) on sale of disposal group

$ 6.5

Cash consideration received at date of disposition

$ 43.2

₩ 48

Mologic Ltd [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain (Loss) on sale of disposal group

$ (2.8)

Inverness Medical Innovations Australia Pty Ltd business [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain (Loss) on sale of disposal group

(1.2)

Cash consideration received at date of disposition

$ 0.1

AUD 0.2

Additional charges recorded in connection with certain other business closures or divestitures

$ 0.8

Supplemental Cash Flow Infor148

Supplemental Cash Flow Information - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 157.7	$ 167.6	$ 192.1
Cash paid for income taxes	$ 70.9	$ 55.2	$ 58.8

Restated Quarterly Financial149

Restated Quarterly Financial Information (Unaudited) - Restated Consolidated Statements of Operations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	$ 456,024	$ 482,962	$ 468,502	$ 500,367	$ 472,959	$ 491,652	$ 481,352	$ 951,464	$ 973,004	$ 1,407,488	$ 1,445,963	$ 1,883,576		$ 1,946,330	[1]	$ 2,023,963	[1]
Services revenue	123,778	124,809	115,709	113,483	128,341	126,628	123,856	240,518	250,484	364,296	378,825	480,761		492,308	[1]	531,988	[1]
Net product sales and services revenue	579,802	607,771	584,211	613,850	601,300	618,280	605,208	1,191,982	1,223,488	1,771,784	1,824,788	2,364,337		2,438,638	[1]	2,555,951	[1]
License and royalty revenue	2,480	2,533	2,729	3,286	3,299	5,694	4,698	5,262	10,392	7,742	13,691	11,998		16,977	[1]	21,050	[1]
Net revenue	582,282	610,304	586,940	617,136	604,599	623,974	609,906	1,197,244	1,233,880	1,779,526	1,838,479	2,376,335		2,455,615	[1]	2,577,001	[1]
Cost of net product sales	239,059	249,837	241,324	297,125	245,429	258,787	237,805	491,161	496,592	730,220	742,021	978,347		1,039,146	[1]	1,063,000	[1]
Cost of services revenue	76,639	78,294	73,100	72,111	79,851	76,800	75,626	151,394	152,426	228,033	232,277	304,871		304,388	[1]	294,949	[1]
Cost of net product sales and services revenue	315,698	328,131	314,424	369,236	325,280	335,587	313,431	642,555	649,018	958,253	974,298	1,283,218		1,343,534	[1]	1,357,949	[1]
Cost of license and royalty revenue	641	535	1,391	650	1,137	1,344	1,950	1,926	3,294	2,567	4,431	3,250		3,781	[1]	5,592	[1]
Cost of net revenue	316,339	328,666	315,815	368,586	326,417	336,931	315,381	644,481	652,312	960,820	978,729	1,286,468		1,347,315	[1]	1,363,541	[1]
Gross profit	265,943	281,638	271,125	248,550	278,182	287,043	294,525	552,763	581,568	818,706	859,750	1,089,867		1,108,300	[1]	1,213,460	[1]
Operating expenses:
Research and development	31,430	28,446	27,062	28,228	36,011	27,198	28,016	55,508	55,214	86,938	91,225	112,122		119,453	[1]	144,828	[1]
Sales and marketing	101,966	102,444	100,640	110,891	106,724	107,906	108,918	203,084	216,824	305,050	323,548	403,055		434,439	[1]	513,049	[1]
General and administrative	148,540	136,854	114,956	118,986	101,306	61,173	92,691	251,810	153,864	400,350	255,170	563,776		374,156	[1]	453,163	[1]
Impairment and (gain) loss on dispositions, net	0	0	(3,810)	8,132	2,074	5,542	34,792	(3,810)	40,334	(3,810)	42,408	(3,810)		50,540	[1]	7,742	[1]
Operating income (loss)	(15,993)	13,894	32,277	(17,687)	32,067	85,224	30,108	46,171	115,332	30,178	147,399	14,724		129,712	[1]	94,678	[1]
Interest expense, including amortization of original issue discounts and deferred financing costs	(44,130)	(42,329)	(42,106)	(58,739)	(52,333)	(59,494)	(46,431)	(84,435)	(105,925)	(128,565)	(158,258)	(171,651)		(216,997)	[1]	(209,191)	[1]
Other income (expense), net	(1,159)	(3,912)	(1,349)	(1,743)	3,658	3,195	(2,367)	(5,261)	828	(6,420)	4,486	4,529		2,743	[1]	(3,407)	[1]
Loss from continuing operations before provision (benefit) for income taxes	(61,282)	(32,347)	(11,178)	(78,169)	(16,608)	28,925	(18,690)	(43,525)	10,235	(104,807)	(6,373)	(152,398)		(84,542)	[1]	(117,920)	[1]
Provision (benefit) for income taxes	(50,796)	2,582	(172)	(51,146)	(10,140)	15,788	(8,067)	2,410	7,721	(48,386)	(2,419)	35,376		(53,564)	[1]	71,030	[1]
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(10,486)	(34,929)	(11,006)	(27,023)	(6,468)	13,137	(10,623)	(45,935)	2,514	(56,421)	(3,954)	(187,774)		(30,978)	[1]	(188,950)	[1]
Equity earnings of unconsolidated entities, net of tax	26,149	2,122	5,034	5,210	5,000	1,361	3,959	7,156	5,320	33,305	10,320	50,505		15,530	[1]	17,509	[1]
Income (loss) from continuing operations	15,663	(32,807)	(5,972)	(21,813)	(1,468)	14,498	(6,664)	(38,779)	7,834	(23,116)	6,366	(137,269)		(15,448)	[1]	(171,441)	[1]
Income (loss) from discontinued operations, net of tax	0	0	0	2,736	0	0	216,777	0	216,777	0	216,777	0		219,513	[1]	138,318	[1]
Net income (loss)	15,663	(32,807)	(5,972)	(19,077)	(1,468)	14,498	210,113	(38,779)	224,611	(23,116)	223,143	(137,269)	[1]	204,065	[1]	(33,123)	[1]
Less: Net income attributable to non-controlling interests	207	143	103	(5)	(61)	359	88	246	447	453	386	350		381	[1]	30	[1]
Net income (loss) attributable to Alere Inc. and Subsidiaries	15,456	(32,950)	(6,075)	(19,072)	(1,407)	14,139	210,025	(39,025)	224,164	(23,569)	222,757	(137,619)		203,684	[1]	(33,153)	[1]
Preferred stock dividends	(5,366)	(5,308)	(5,309)	(5,367)	(5,369)	(5,308)	(5,250)	(10,617)	(10,558)	(15,983)	(15,927)	(21,350)		(21,293)	[1]	(21,293)	[1]
Net income (loss) available to common stockholders	$ 10,090	$ (38,258)	$ (11,384)	$ (24,439)	$ (6,776)	$ 8,831	$ 204,775	$ (49,642)	$ 213,606	$ (39,552)	$ 206,830	$ (158,969)		$ 182,391	[1]	$ (54,446)	[1]
Basic and Diluted net income (loss) per common share:
Loss from continuing operations	$ 0.12	$ (0.44)	$ (0.13)	$ (0.31)	$ (0.08)	$ 0.10	$ (0.14)	$ (0.57)	$ (0.04)	$ (0.45)	$ (0.12)	$ (1.83)		$ (0.43)	[1]	$ (2.33)	[1]
Income (loss) from discontinued operations	0	0	0		0	0	2.57	0	2.57	0	2.57	0		2.57	[1]	1.67	[1]
Net income (loss) per common share	$ 0.12	$ (0.44)	$ (0.13)	$ (0.31)	$ (0.08)	$ 0.10	$ 2.43	$ (0.57)	$ 2.53	$ (0.45)	$ 2.45	$ (1.83)		$ 2.14	[1]	$ (0.66)	[1]
Weighted-average shares - basic	86,753					85,173
Weighted-average shares - basic and diluted		86,737	86,646	85,953	85,895		84,338	86,692	84,758	86,708	85,141	86,796		85,420	[1]	82,938	[1]
Weighted-average shares - diluted	87,885					86,635			86,070		86,279
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ 24,404	$ (76,554)	$ 16,273	$ (42,975)	$ (89,800)	$ 60,491	$ 128,301	$ (60,281)	$ 188,792	$ (35,877)	$ 98,992	$ (259,890)		$ 56,398	[1]	$ (199,546)	[1]
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	456,096	483,746	459,771	506,516	472,128	491,049	484,338	943,517	975,387	1,399,613	1,447,515			1,954,031		2,022,240
Services revenue	123,778	124,809	115,709	113,483	128,341	126,628	123,856	240,518	250,484	364,296	378,825			492,308		531,988
Net product sales and services revenue	579,874	608,555	575,480	619,999	600,469	617,677	608,194	1,184,035	1,225,871	1,763,909	1,826,340			2,446,339		2,554,228
License and royalty revenue	2,480	2,533	2,729	3,286	3,299	5,694	4,698	5,262	10,392	7,742	13,691			16,977		21,050
Net revenue	582,354	611,088	578,209	623,285	603,768	623,371	612,892	1,189,297	1,236,263	1,771,651	1,840,031			2,463,316		2,575,278
Cost of net product sales	238,946	250,398	237,461	298,795	245,814	257,893	240,101	487,859	497,994	726,805	743,808			1,042,603		1,062,499
Cost of services revenue	76,639	78,294	73,100	72,111	79,851	76,800	75,626	151,394	152,426	228,033	232,277			304,388		294,949
Cost of net product sales and services revenue	315,585	328,692	310,561	370,906	325,665	334,693	315,727	639,253	650,420	954,838	976,085			1,346,991		1,357,448
Cost of license and royalty revenue	641	535	1,391	650	1,137	1,344	1,950	1,926	3,294	2,567	4,431			3,781		5,592
Cost of net revenue	316,226	329,227	311,952	370,256	326,802	336,037	317,677	641,179	653,714	957,405	980,516			1,350,772		1,363,040
Gross profit	266,128	281,861	266,257	253,029	276,966	287,334	295,215	548,118	582,549	814,246	859,515			1,112,544		1,212,238
Operating expenses:
Research and development	31,430	28,446	27,062	28,228	36,011	27,198	28,016	55,508	55,214	86,938	91,225			119,453		144,828
Sales and marketing	101,979	102,516	99,813	111,535	106,493	108,024	109,079	202,329	217,103	304,308	323,596			435,131		512,961
General and administrative	129,287	128,354	114,956	114,400	101,306	61,173	92,691	243,310	153,864	372,597	255,170			369,570		453,628
Impairment and (gain) loss on dispositions, net	0	0	(3,810)	8,132	2,074	5,542	34,792	(3,810)	40,334	(3,810)	42,408			50,540		7,742
Operating income (loss)	3,432	22,545	28,236	(9,266)	31,082	85,397	30,637	50,781	116,034	54,213	147,116			137,850		93,079
Interest expense, including amortization of original issue discounts and deferred financing costs	(44,130)	(42,329)	(42,106)	(58,739)	(52,333)	(59,494)	(46,431)	(84,435)	(105,925)	(128,565)	(158,258)			(216,997)		(209,191)
Other income (expense), net	(14,312)	(14,112)	(1,349)	(6,329)	3,658	3,195	(2,367)	(15,461)	828	(29,773)	4,486			(1,843)		(2,221)
Loss from continuing operations before provision (benefit) for income taxes	(55,010)	(33,896)	(15,219)	(74,334)	(17,593)	29,098	(18,161)	(49,115)	10,937	(104,125)	(6,656)			(80,990)		(118,333)
Provision (benefit) for income taxes	(50,888)	3,117	(208)	(50,329)	(10,212)	15,689	(7,853)	2,909	7,836	(47,979)	(2,376)			(52,704)		70,930
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(4,122)	(37,013)	(15,011)	(24,005)	(7,381)	13,409	(10,308)	(52,024)	3,101	(56,146)	(4,280)			(28,286)		(189,263)
Equity earnings of unconsolidated entities, net of tax	26,149	2,122	5,034	5,210	5,000	1,361	3,959	7,156	5,320	33,305	10,320			15,530		17,509	[2]
Income (loss) from continuing operations	22,027	(34,891)	(9,977)	(18,795)	(2,381)	14,770	(6,349)	(44,868)	8,421	(22,841)	6,040			(12,756)		(171,754)	[2]
Income (loss) from discontinued operations, net of tax	0	0	0	2,736	0	0	216,777	0	216,777	0	216,777			219,513		138,318	[2]
Net income (loss)	22,027	(34,891)	(9,977)	(16,059)	(2,381)	14,770	210,428	(44,868)	225,198	(22,841)	222,817			206,757		(33,436)	[2]
Less: Net income attributable to non-controlling interests	207	143	103	(5)	(61)	359	88	246	447	453	386			381		30
Net income (loss) attributable to Alere Inc. and Subsidiaries	21,820	(35,034)	(10,080)	(16,054)	(2,320)	14,411	210,340	(45,114)	224,751	(23,294)	222,431			206,376		(33,466)
Preferred stock dividends	(5,366)	(5,308)	(5,309)	(5,367)	(5,369)	(5,308)	(5,250)	(10,617)	(10,558)	(15,983)	(15,927)			(21,293)		(21,293)
Net income (loss) available to common stockholders	$ 16,454	$ (40,342)	$ (15,389)	$ (21,421)	$ (7,689)	$ 9,103	$ 205,090	$ (55,731)	$ 214,193	$ (39,277)	$ 206,504			$ 185,083		$ (54,759)
Basic and Diluted net income (loss) per common share:
Loss from continuing operations	$ 0.19	$ (0.46)	$ (0.18)	$ (0.28)	$ (0.09)	$ 0.11	$ (0.14)	$ (0.64)	$ (0.03)	$ (0.45)	$ (0.12)			$ (0.40)		$ (2.33)
Income (loss) from discontinued operations	0	0	0		0	0	2.57	0	2.57	0	2.57			2.57		1.67
Net income (loss) per common share	$ 0.19	$ (0.46)	$ (0.18)	$ (0.28)	$ (0.09)	$ 0.11	$ 2.43	$ (0.64)	$ 2.54	$ (0.45)	$ 2.45			$ 2.17		$ (0.66)
Weighted-average shares - basic	86,753					85,173
Weighted-average shares - basic and diluted		86,737	86,646	85,953	85,895		84,338	86,692	84,758	86,708	85,141			85,420		82,938
Weighted-average shares - diluted	87,885					86,635			86,070		86,279
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ 30,768	$ (78,638)	$ 12,268	$ (39,957)	$ (90,713)	$ 60,763	$ 128,616	$ (66,370)	$ 189,379	$ (35,602)	$ 98,666			$ 58,709		$ (199,889)
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	(72)	(784)	8,731	(6,149)	831	603	(2,986)	7,947	(2,383)	7,875	(1,552)			(7,701)		1,723
Services revenue	0	0	0	0	0	0	0	0	0	0	0			0		0
Net product sales and services revenue	(72)	(784)	8,731	(6,149)	831	603	(2,986)	7,947	(2,383)	7,875	(1,552)			(7,701)		1,723
License and royalty revenue	0	0	0	0	0	0	0	0	0	0	0			0		0
Net revenue	(72)	(784)	8,731	(6,149)	831	603	(2,986)	7,947	(2,383)	7,875	(1,552)			(7,701)		1,723
Cost of net product sales	113	(561)	3,863	(1,670)	(385)	894	(2,296)	3,302	(1,402)	3,415	(1,787)			(3,457)		501
Cost of services revenue	0	0	0	0	0	0	0	0	0	0	0			0		0
Cost of net product sales and services revenue	113	(561)	3,863	(1,670)	(385)	894	(2,296)	3,302	(1,402)	3,415	(1,787)			(3,457)		501
Cost of license and royalty revenue	0	0	0	0	0	0	0	0	0	0	0			0		0
Cost of net revenue	113	(561)	3,863	(1,670)	(385)	894	(2,296)	3,302	(1,402)	3,415	(1,787)			(3,457)		501
Gross profit	(185)	(223)	4,868	(4,479)	1,216	(291)	(690)	4,645	(981)	4,460	235			(4,244)		1,222
Operating expenses:
Research and development	0	0	0	0	0	0	0	0	0	0	0			0		0
Sales and marketing	(13)	(72)	827	(644)	231	(118)	(161)	755	(279)	742	(48)			(692)		88
General and administrative	19,253	8,500	0	4,586	0	0	0	8,500	0	27,753	0			4,586		(465)
Impairment and (gain) loss on dispositions, net	0	0	0	0	0	0	0	0	0	0	0			0		0
Operating income (loss)	(19,425)	(8,651)	4,041	(8,421)	985	(173)	(529)	(4,610)	(702)	(24,035)	283			(8,138)		1,599
Interest expense, including amortization of original issue discounts and deferred financing costs	0	0	0	0	0	0	0	0	0	0	0			0		0
Other income (expense), net	13,153	10,200	0	4,586	0	0	0	10,200	0	23,353	0			4,586		(1,186)
Loss from continuing operations before provision (benefit) for income taxes	(6,272)	1,549	4,041	(3,835)	985	(173)	(529)	5,590	(702)	(682)	283			(3,552)		413
Provision (benefit) for income taxes	92	(535)	36	(817)	72	99	(214)	(499)	(115)	(407)	(43)			(860)		100
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(6,364)	2,084	4,005	(3,018)	913	(272)	(315)	6,089	(587)	(275)	326			(2,692)		313
Equity earnings of unconsolidated entities, net of tax	0	0	0	0	0	0	0	0	0	0	0			0		0	[3]
Income (loss) from continuing operations	(6,364)	2,084	4,005	(3,018)	913	(272)	(315)	6,089	(587)	(275)	326			(2,692)		313	[3]
Income (loss) from discontinued operations, net of tax	0	0	0	0	0	0	0	0	0	0	0			0		0	[3]
Net income (loss)	(6,364)	2,084	4,005	(3,018)	913	(272)	(315)	6,089	(587)	(275)	326			(2,692)		313	[3]
Less: Net income attributable to non-controlling interests	0	0	0	0	0	0	0	0	0	0	0			0		0
Net income (loss) attributable to Alere Inc. and Subsidiaries	(6,364)	2,084	4,005	(3,018)	913	(272)	(315)	6,089	(587)	(275)	326			(2,692)		313
Preferred stock dividends	0	0	0	0	0	0	0	0	0	0	0			0		0
Net income (loss) available to common stockholders	$ (6,364)	$ 2,084	$ 4,005	$ (3,018)	$ 913	$ (272)	$ (315)	$ 6,089	$ (587)	$ (275)	$ 326			$ (2,692)		$ 313
Basic and Diluted net income (loss) per common share:
Loss from continuing operations	$ (0.07)	$ 0.02	$ 0.05	$ (0.03)	$ 0.01	$ (0.01)	$ 0	$ 0.07	$ (0.01)	$ 0	$ 0			$ (0.03)		$ 0
Income (loss) from discontinued operations	0	0	0	0	0	0	0	0	0	0	0			0		0
Net income (loss) per common share	$ (0.07)	$ 0.02	$ 0.05	$ (0.03)	$ 0.01	$ (0.01)	$ 0	$ 0.07	$ (0.01)	$ 0	$ 0			$ (0.03)		$ 0
Weighted-average shares - basic	0					0
Weighted-average shares - basic and diluted		0	0	0	0		0	0	0	0	0			0		0
Weighted-average shares - diluted	0					0			0		0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (6,364)	$ 2,084	$ 4,005	$ (3,018)	$ 913	$ (272)	$ (315)	$ 6,089	$ (587)	$ (275)	$ 326			$ (2,692)		$ 313
[1]	Restated Values
[2]	The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been previously revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due principally to a $19,236 increase in operating cash flow related to deferred income taxes and a $15,753 decrease in operating cash flow related to other non-current liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015.
[3]	All adjustments in this column relate to the misstatements associated with the Standard Diagnostics matter and the consequential impact on inventory, accounts receivable and accrued liabilities.

Restated Quarterly Financial150

Restated Quarterly Financial Information (Unaudited) - Restated Consolidated Statements of Operations (Parenthetical) (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues			$ 582,282	$ 610,304	$ 586,940	$ 617,136	$ 604,599	$ 623,974	$ 609,906	$ 1,197,244	$ 1,233,880	$ 1,779,526	$ 1,838,479	$ 2,376,335	$ 2,455,615	[1]	$ 2,577,001	[1]
Cost of revenue			316,339	328,666	315,815	368,586	326,417	336,931	315,381	644,481	652,312	960,820	978,729	1,286,468	1,347,315	[1]	1,363,541	[1]
Income taxes benefit			(50,796)	2,582	(172)	(51,146)	(10,140)	15,788	(8,067)	2,410	7,721	(48,386)	(2,419)	35,376	(53,564)	[1]	71,030	[1]
Net income (loss)			15,456	(32,950)	(6,075)	(19,072)	(1,407)	14,139	210,025	(39,025)	224,164	(23,569)	222,757	$ (137,619)	203,684	[1]	(33,153)	[1]
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase general and administrative expenses	$ 1,700			1,700						1,700
Adjustment to increase bad debt expense	$ 4,400
Legal-related charges		$ 4,586	13,153	10,200						10,200		23,353			4,586
Revenues			(72)	(784)	8,731	(6,149)	831	603	(2,986)	7,947	(2,383)	7,875	(1,552)		(7,701)		1,723
Cost of revenue			113	(561)	3,863	(1,670)	(385)	894	(2,296)	3,302	(1,402)	3,415	(1,787)		(3,457)		501
Income taxes benefit			92	(535)	36	(817)	72	99	(214)	(499)	(115)	(407)	(43)		(860)		100
Net income (loss)			(6,364)	2,084	4,005	$ (3,018)	913	(272)	$ (315)	$ 6,089	$ (587)	$ (275)	$ 326		$ (2,692)		313
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Legal-related charges																	(1,186)
Revenues			678	(1,046)	4,739		1,724	(5,785)									(13,426)
Cost of revenue				2,164	1,509			(545)
Other income			(3,249)	2,162			(1,087)	(1,065)
Income taxes benefit			(7,633)	(1,079)	933		(8,712)	(2,012)
Operating expenses								1,200
Cost of revenue and operating expenses			1,971
Other Expenses					1,097
Net income (loss)			$ (12,175)	$ (4,293)	$ 1,200		$ (7,882)	$ (5,493)									$ 4,274
[1]	Restated Values

Restated Quarterly Financial151

Restated Quarterly Financial Information (Unaudited) - Restated Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2016		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012	[1]
Current assets:
Cash and cash equivalents	$ 567,215		$ 566,213	$ 506,164	$ 490,663	$ 502,200	[1]	$ 479,381	$ 464,871	$ 414,495	$ 378,461	[1]	$ 355,431	[1]
Restricted cash	51,550		4,999	5,662	6,166	5,694	[1]	430,821	461,636	37,406
Marketable securities	76		75	74	71	164	[1]	157	175	173
Accounts receivable, net of allowance	413,535		426,207	427,961	459,115	436,924	[1]	436,490	454,636	457,333
Inventories, net	308,920		349,378	334,492	351,015	350,949	[1]	376,057	379,545	388,481
Deferred tax assets								30,771	33,732	37,961
Prepaid expenses and other current assets	118,607		124,390	124,877	106,629	114,514	[1]	121,023	125,559	117,924
Assets held for sale - current	0					4,165	[1]	25,312	28,631
Total current assets	1,459,903		1,471,262	1,399,230	1,413,659	1,414,610	[1]	1,900,012	1,948,785	1,453,773
Property, plant and equipment, net	441,190		446,313	438,787	445,218	446,039	[1]	445,872	448,891	447,326
Goodwill	2,759,366		2,805,682	2,811,545	2,839,692	2,836,915	[1]	2,842,921	2,853,551	2,880,164	2,926,666
Other intangible assets with indefinite lives	27,164		27,991	28,279	28,760	28,110	[1]	28,744	41,306	40,203
Finite-lived intangible assets, net	805,577		864,785	909,208	962,633	997,281	[1]	1,052,949	1,093,186	1,173,866
Restricted cash	2,171		42,438	42,589	43,388	43,228	[1]	44,148
Other non-current assets	14,966		16,219	16,290	17,927	18,078	[1]	19,635	21,845	25,052
Investments in unconsolidated entities	72,225		80,885	74,511	74,744	65,333	[1]	73,882	69,594	95,551
Deferred tax assets	20,483		56,638	18,638	16,124	13,993	[1]	5,380	5,381	6,360
Non-current income tax receivable and prepaid	45,234		39,472	41,500	41,215	41,236	[1]	2,537	2,611	2,545
Asset held for sale - non-current	0			12,223	11,813	13,337	[1]	126,048	129,194
Total assets	5,648,279		5,851,685	5,792,800	5,895,173	5,918,160	[1]	6,542,128	6,614,344	6,124,840
Current liabilities:
Short-term debt and current portion of long-term debt	82,370		41,424	43,681	193,044	199,992	[1]	604,092	629,371	95,299
Current portion of capital lease obligations	3,064		3,713	3,500	4,048	3,962	[1]	3,505	4,643	5,072
Accounts payable	195,879		211,476	194,235	165,800	195,752	[1]	194,246	186,941	195,980
Accrued expenses and other current liabilities	394,843		444,916	319,476	314,989	322,637	[1]	325,184	314,553	367,909
Liabilities related to assets held for sale - current	0					363	[1]	8,836	7,663
Total current liabilities	676,156		701,529	560,892	677,881	722,706	[1]	1,135,863	1,143,171	664,260
Long-term liabilities:
Long-term debt, net of current portion	2,858,205		2,905,067	2,920,789	2,823,654	2,831,166	[1]	2,944,014	2,912,147	2,987,422
Capital lease obligations, net of current portion	7,221		8,033	6,972	7,654	7,181	[1]	7,346	7,974	8,794
Deferred tax liabilities	119,098		52,513	140,864	144,483	147,618	[1]	226,976	243,298	262,117
Other long-term liabilities	155,992		137,582	148,165	155,842	154,193	[1]	121,855	131,578	123,428
Liabilities related to assets held for sale - non-current								9,603	11,527
Total long-term liabilities	3,140,516		3,103,195	3,216,790	3,131,633	3,140,158	[1]	3,309,794	3,306,524	3,381,761
Commitments and contingencies							[1]
Stockholders' equity:
Series B preferred stock	606,406		606,406	606,406	606,468	606,468	[1]	606,468	606,468	606,468
Common stock	95		95	94	94	94	[1]	94	93	93
Additional paid-in capital	3,474,979		3,465,898	3,458,639	3,452,722	3,438,732	[1]	3,436,666	3,414,981	3,390,002
Accumulated deficit	(1,607,119)		(1,493,069)	(1,508,525)	(1,475,590)	(1,469,514)	[1]	(1,450,443)	(1,449,034)	(1,463,173)
Treasury stock, at cost, 7,679 shares	(184,971)		(184,971)	(184,971)	(184,971)	(184,971)	[1]	(184,971)	(184,971)	(184,971)
Accumulated other comprehensive loss	(462,398)		(352,085)	(361,033)	(317,429)	(339,777)	[1]	(315,875)	(227,481)	(273,834)	(192,110)		(25,687)
Total stockholders' equity	1,826,992		2,042,274	2,010,610	2,081,294	2,051,032	[1]	2,091,939	2,160,056	2,074,585
Non-controlling interests	4,615		4,687	4,508	4,365	4,264	[1]	4,532	4,593	4,234
Total equity	1,831,607	[1]	2,046,961	2,015,118	2,085,659	2,055,296	[1]	2,096,471	2,164,649	2,078,819	1,916,097	[1]	2,079,904	[1]
Total liabilities and equity	$ 5,648,279		5,851,685	5,792,800	5,895,173	5,918,160	[1]	6,542,128	6,614,344	6,124,840
As Previously Reported [Member]
Current assets:
Cash and cash equivalents			566,213	506,164	490,663	502,200		479,381	464,871	414,495	378,461	[2]	355,431	[2]
Restricted cash			4,999	5,662	6,166	5,694		430,821	461,636	37,406
Marketable securities			75	74	71	164		157	175	173
Accounts receivable, net of allowance			427,241	427,222	459,292	445,833		439,250	458,227	461,528
Inventories, net			348,845	333,846	350,931	347,001		373,779	377,651	385,693
Deferred tax assets								30,771	33,732	37,961
Prepaid expenses and other current assets			163,833	162,339	144,369	152,233		121,023	125,559	117,924
Assets held for sale - current						4,165		25,312	28,631
Total current assets			1,511,206	1,435,307	1,451,492	1,457,290		1,900,494	1,950,482	1,455,180
Property, plant and equipment, net			446,313	438,787	445,218	446,039		445,872	448,891	447,326
Goodwill			2,805,682	2,811,545	2,839,692	2,836,915		2,842,921	2,853,551	2,880,164
Other intangible assets with indefinite lives			27,991	28,279	28,760	28,110		28,744	41,306	40,203
Finite-lived intangible assets, net			864,785	909,208	962,633	997,281		1,052,949	1,093,186	1,173,866
Restricted cash			42,438	42,589	43,388	43,228		44,148
Other non-current assets			16,219	16,290	17,927	18,078		19,635	21,845	25,052
Investments in unconsolidated entities			80,885	74,511	74,744	65,333		73,882	69,594	95,551
Deferred tax assets			56,638	18,638	16,124	13,993		5,380	5,381	6,360
Non-current income tax receivable and prepaid			3,517	3,517	3,517	3,517		2,537	2,611	2,545
Asset held for sale - non-current				12,223	11,813	13,337		126,048	129,194
Total assets			5,855,674	5,790,894	5,895,308	5,923,121		6,542,610	6,616,041	6,126,247
Current liabilities:
Short-term debt and current portion of long-term debt			41,424	43,681	193,044	199,992		604,092	629,371	95,299
Current portion of capital lease obligations			3,713	3,500	4,048	3,962		3,505	4,643	5,072
Accounts payable			211,476	194,235	165,800	195,752		194,246	186,941	195,980
Accrued expenses and other current liabilities			449,897	320,526	315,995	324,465		325,551	315,222	368,560
Liabilities related to assets held for sale - current						363		8,836	7,663
Total current liabilities			706,510	561,942	678,887	724,534		1,136,230	1,143,840	664,911
Long-term liabilities:
Long-term debt, net of current portion			2,905,067	2,920,789	2,823,654	2,831,166		2,944,014	2,912,147	2,987,422
Capital lease obligations, net of current portion			8,033	6,972	7,654	7,181		7,346	7,974	8,794
Deferred tax liabilities			52,513	140,864	144,483	147,618		226,976	243,298	262,117
Other long-term liabilities			133,182	148,165	155,842	154,193		121,855	131,578	123,428
Liabilities related to assets held for sale - non-current								9,603	11,527
Total long-term liabilities			3,098,795	3,216,790	3,131,633	3,140,158		3,309,794	3,306,524	3,381,761
Commitments and contingencies
Stockholders' equity:
Series B preferred stock			606,406	606,406	606,468	606,468		606,468	606,468	606,468
Common stock			95	94	94	94		94	93	93
Additional paid-in capital			3,465,898	3,458,639	3,452,722	3,438,732		3,436,666	3,414,981	3,390,002
Accumulated deficit			(1,489,661)	(1,511,481)	(1,476,461)	(1,466,381)		(1,450,328)	(1,448,006)	(1,462,417)
Treasury stock, at cost, 7,679 shares			(184,971)	(184,971)	(184,971)	(184,971)		(184,971)	(184,971)	(184,971)
Accumulated other comprehensive loss			(352,085)	(361,033)	(317,429)	(339,777)		(315,875)	(227,481)	(273,834)
Total stockholders' equity			2,045,682	2,007,654	2,080,423	2,054,165		2,092,054	2,161,084	2,075,341
Non-controlling interests			4,687	4,508	4,365	4,264		4,532	4,593	4,234
Total equity			2,050,369	2,012,162	2,084,788	2,058,429		2,096,586	2,165,677	2,079,575					$ 2,080,659
Total liabilities and equity			5,855,674	5,790,894	5,895,308	5,923,121		6,542,610	6,616,041	6,126,247
Restatement Adjustment [Member]
Current assets:
Cash and cash equivalents			0	0	0	0		0	0	0	$ 0	[3]	$ 0	[3]
Restricted cash			0	0	0	0		0	0	0
Marketable securities			0	0	0	0		0	0	0
Accounts receivable, net of allowance			(1,034)	739	(177)	(8,909)		(2,760)	(3,591)	(4,195)
Inventories, net			533	646	84	3,948		2,278	1,894	2,788
Deferred tax assets								0	0	0
Prepaid expenses and other current assets			(39,443)	(37,462)	(37,740)	(37,719)		0	0	0
Assets held for sale - current						0		0	0
Total current assets			(39,944)	(36,077)	(37,833)	(42,680)		(482)	(1,697)	(1,407)
Property, plant and equipment, net			0	0	0	0		0	0	0
Goodwill			0	0	0	0		0	0	0
Other intangible assets with indefinite lives			0	0	0	0		0	0	0
Finite-lived intangible assets, net			0	0	0	0		0	0	0
Restricted cash			0	0	0	0		0
Other non-current assets			0	0	0	0		0	0	0
Investments in unconsolidated entities			0	0	0	0		0	0	0
Deferred tax assets			0	0	0	0		0	0	0
Non-current income tax receivable and prepaid			35,955	37,983	37,698	37,719		0	0	0
Asset held for sale - non-current				0	0	0		0	0
Total assets			(3,989)	1,906	(135)	(4,961)		(482)	(1,697)	(1,407)
Current liabilities:
Short-term debt and current portion of long-term debt			0	0	0	0		0	0	0
Current portion of capital lease obligations			0	0	0	0		0	0	0
Accounts payable			0	0	0	0		0	0	0
Accrued expenses and other current liabilities			(4,981)	(1,050)	(1,006)	(1,828)		(367)	(669)	(651)
Liabilities related to assets held for sale - current						0		0	0
Total current liabilities			(4,981)	(1,050)	(1,006)	(1,828)		(367)	(669)	(651)
Long-term liabilities:
Long-term debt, net of current portion			0	0	0	0		0	0	0
Capital lease obligations, net of current portion			0	0	0	0		0	0	0
Deferred tax liabilities			0	0	0	0		0	0	0
Other long-term liabilities			4,400	0	0	0		0	0	0
Liabilities related to assets held for sale - non-current								0	0
Total long-term liabilities			4,400	0	0	0		0	0	0
Commitments and contingencies
Stockholders' equity:
Series B preferred stock			0	0	0	0		0	0	0
Common stock			0	0	0	0		0	0	0
Additional paid-in capital			0	0	0	0		0	0	0
Accumulated deficit			(3,408)	2,956	871	(3,133)		(115)	(1,028)	(756)
Treasury stock, at cost, 7,679 shares			0	0	0	0		0	0	0
Accumulated other comprehensive loss			0	0	0	0		0	0	0
Total stockholders' equity			(3,408)	2,956	871	(3,133)		(115)	(1,028)	(756)
Non-controlling interests			0	0	0	0		0	0	0
Total equity			(3,408)	2,956	871	(3,133)		(115)	(1,028)	(756)
Total liabilities and equity			$ (3,989)	$ 1,906	$ (135)	$ (4,961)		$ (482)	$ (1,697)	$ (1,407)
[1]	Restated Values
[2]	The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been previously revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due principally to a $19,236 increase in operating cash flow related to deferred income taxes and a $15,753 decrease in operating cash flow related to other non-current liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015.
[3]	All adjustments in this column relate to the misstatements associated with the Standard Diagnostics matter and the consequential impact on inventory, accounts receivable and accrued liabilities.

Restated Quarterly Financial152

Restated Quarterly Financial Information (Unaudited) - Restated Consolidated Balance Sheet (Parenthetical) (Detail) - USD ($)	3 Months Ended			12 Months Ended
	Sep. 30, 2016	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014		Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Series B preferred stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	[1]			$ 0.001	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,701,000	$ 709,763,000	$ 709,763,000	$ 709,701,000	$ 709,763,000	[1]			$ 709,701,000	$ 709,763,000	$ 709,763,000
Series B preferred stock, shares authorized	2,300,000	2,300,000	2,300,000	2,300,000	2,300,000	[1]			2,300,000	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000	2,065,000	2,065,000	2,065,000	[1]			2,065,000	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000	1,774,000	1,774,000	1,774,000	[1]			1,774,000	1,774,000	1,774,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	[1]			$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000	200,000,000	200,000,000	200,000,000	[1]			200,000,000	200,000,000	200,000,000
Common stock, shares issued	94,613,000	93,224,000	92,561,000	94,770,000	94,043,000	[1]			94,419,000	94,415,000	93,868,000
Common stock, shares outstanding	86,934,000	85,545,000	84,882,000	87,091,000	86,364,000	[1]			86,740,000	86,736,000	86,189,000
Treasury stock, shares	7,679,000	7,679,000	7,679,000	7,679,000	7,679,000	[1]			7,679,000	7,679,000	7,679,000
Debt issuance cost				$ 51,886,000
Accounts receivable				(26,698,000)	$ 6,680,000	[1]	$ 4,264,000	[1]
Long-term liabilities	$ 3,103,195,000	$ 3,306,524,000	$ 3,381,761,000	3,140,516,000	3,140,158,000	[1]			$ 3,216,790,000	$ 3,131,633,000	$ 3,309,794,000
Inventories				13,655,000	63,935,000	[1]	67,532,000	[1]
Deferred tax assets				526,449,000	432,421,000	[1]
Deferred tax liabilities				$ 98,615,000	$ 133,625,000	[1]
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Series B preferred stock, par value	$ 0.001	$ 0.001	$ 0.001		$ 0.001				$ 0.001	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,701,000	$ 709,763,000	$ 709,763,000		$ 709,763,000				$ 709,701,000	$ 709,763,000	$ 709,763,000
Series B preferred stock, shares authorized	2,300,000	2,300,000	2,300,000		2,300,000				2,300,000	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000	2,065,000		2,065,000				2,065,000	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000	1,774,000		1,774,000				1,774,000	1,774,000	1,774,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001		$ 0.001				$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000	200,000,000		200,000,000				200,000,000	200,000,000	200,000,000
Common stock, shares issued	94,613,000	93,224,000	92,561,000		94,043,000				94,419,000	94,415,000	93,868,000
Common stock, shares outstanding	86,934,000	85,545,000	84,882,000		86,364,000				86,740,000	86,736,000	86,189,000
Treasury stock, shares	7,679,000	7,679,000	7,679,000		7,679,000				7,679,000	7,679,000	7,679,000
Accounts receivable					$ 14,380,000		3,262,000	[2]
Long-term liabilities	$ 3,098,795,000	$ 3,306,524,000	$ 3,381,761,000		3,140,158,000				$ 3,216,790,000	$ 3,131,633,000	$ 3,309,794,000
Inventories					$ 60,478,000		68,033,000	[2]
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Series B preferred stock, par value	$ 0.001	$ 0.001	$ 0.001		$ 0.001				$ 0.001	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,701,000	$ 709,763,000	$ 709,763,000		$ 709,763,000				$ 709,701,000	$ 709,763,000	$ 709,763,000
Series B preferred stock, shares authorized	2,300,000	2,300,000	2,300,000		2,300,000				2,300,000	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000	2,065,000		2,065,000				2,065,000	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000	1,774,000		1,774,000				1,774,000	1,774,000	1,774,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001		$ 0.001				$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000	200,000,000		200,000,000				200,000,000	200,000,000	200,000,000
Common stock, shares issued	94,613,000	93,224,000	92,561,000		94,043,000				94,419,000	94,415,000	93,868,000
Common stock, shares outstanding	86,934,000	85,545,000	84,882,000		86,364,000				86,740,000	86,736,000	86,189,000
Treasury stock, shares	7,679,000	7,679,000	7,679,000		7,679,000				7,679,000	7,679,000	7,679,000
Accounts receivable					$ (7,700,000)		1,002,000	[3]
Long-term liabilities	$ 4,400,000	$ 0	$ 0		0				$ 0	$ 0	$ 0
Inventories					3,457,000		$ (501,000)	[3]
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable and accrued liabilities	39,443,000								$ 37,983	$ 37,740,000
Accounts receivable	13,116,000	(14,459,000)	10,135,000
Long-term liabilities	4,400,000
Inventories	11,553,000	11,311,000	10,720,000
Deferred tax assets	(13,095,000)	13,095,000	13,095,000
Accrued expenses	19,525,000	5,828,000
Increase in accrued expenses			3,668,000
long-term liabilities	$ (13,345,000)	(14,662,000)	(14,662,000)
Deferred tax liabilities		15,807,000	16,254,000
Accounting Standards Update 2015-03 [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance cost		$ 45,889,000	$ 36,425,000		$ 34,050,000						$ 43,644,000
[1]	Restated Values
[2]	The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been previously revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due principally to a $19,236 increase in operating cash flow related to deferred income taxes and a $15,753 decrease in operating cash flow related to other non-current liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015.
[3]	All adjustments in this column relate to the misstatements associated with the Standard Diagnostics matter and the consequential impact on inventory, accounts receivable and accrued liabilities.

Guarantor Financial Informat153

Guarantor Financial Information - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 24, 2015	Dec. 31, 2016	May 31, 2016	Dec. 31, 2015	Oct. 01, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 11, 2012
Debt Instrument [Line Items]
Maturity date	Oct. 1, 2015	May 15, 2016
Debt issuance cost		$ 51,886
Accounting Standards Update 2015-03 [Member]
Debt Instrument [Line Items]
Debt issuance cost				$ 34,050		$ 43,644	$ 45,889	$ 36,425
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument		7.25%		7.25%					7.25%	7.25%
Maturity date		Jul. 1, 2018
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument		6.50%	6.50%	6.50%					6.50%
Maturity date		Jun. 15, 2020
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.375%	6.375%		6.375%					6.375%
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument		8.625%		8.625%	8.625%				8.625%
Maturity date		Oct. 1, 2015

Guarantor Financial Informat154

Guarantor Financial Information - Restated Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 582,282	$ 610,304	$ 586,940	$ 617,136	$ 604,599	$ 623,974	$ 609,906	$ 1,197,244	$ 1,233,880	$ 1,779,526	$ 1,838,479	$ 2,376,335	$ 2,455,615	[1]	$ 2,577,001	[1]
Cost of net revenue	316,339	328,666	315,815	368,586	326,417	336,931	315,381	644,481	652,312	960,820	978,729	1,286,468	1,347,315	[1]	1,363,541	[1]
Sales and marketing	101,966	102,444	100,640	110,891	106,724	107,906	108,918	203,084	216,824	305,050	323,548	403,055	434,439	[1]	513,049	[1]
General and administrative	148,540	136,854	114,956	118,986	101,306	61,173	92,691	251,810	153,864	400,350	255,170	563,776	374,156	[1]	453,163	[1]
Income (loss) from continuing operations before provision (benefit) for income taxes	(61,282)	(32,347)	(11,178)	(78,169)	(16,608)	28,925	(18,690)	(43,525)	10,235	(104,807)	(6,373)	(152,398)	(84,542)	[1]	(117,920)	[1]
Provision (benefit) for income taxes	(50,796)	2,582	(172)	(51,146)	(10,140)	15,788	(8,067)	2,410	7,721	(48,386)	(2,419)	35,376	(53,564)	[1]	71,030	[1]
Income (loss) from continuing operations	15,663	(32,807)	(5,972)	(21,813)	(1,468)	14,498	(6,664)	(38,779)	7,834	(23,116)	6,366	(137,269)	(15,448)	[1]	(171,441)	[1]
Eliminations [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	(77,571)	(77,671)	(64,195)		(72,001)	(69,082)	(63,668)					(329,752)	(280,094)		(249,339)
Cost of net revenue	(76,023)	(76,792)	(63,577)		(70,090)	(69,007)	(64,779)					(324,376)	(278,373)		(252,137)
Sales and marketing	0	0	0		0	0	0					0	0		0
General and administrative	(489)	0	0		0	0	0					(746)	0		0
Income (loss) from continuing operations before provision (benefit) for income taxes	(1,058)	(880)	(618)		(1,911)	(75)	1,111					(4,630)	(4,921)		2,733
Provision (benefit) for income taxes	0	0	0		(1)	(38)	346					0	308		1,022
Income (loss) from continuing operations	94,456	(99,903)	(83,437)		(158,571)	(126,877)	(73,086)					(229,877)	(265,172)		(123,868)
Issuer [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	0	0	0		0	0	0					0	0		0
Cost of net revenue	853	324	114		2,146	516	426					2,386	3,279		5,630
Sales and marketing	1,867	1,568	1,336		1,335	1,570	1,260					6,614	5,901		7,598
General and administrative	88,114	67,940	44,615		22,960	24,390	20,523					289,933	124,020		92,466
Income (loss) from continuing operations before provision (benefit) for income taxes	(135,558)	(112,630)	(89,298)		(79,741)	(129,585)	(103,485)					(458,503)	(430,174)		(326,899)
Provision (benefit) for income taxes	(227,263)	19,765	(54)		78,040	(16,306)	(20,667)					(64,345)	(151,406)		(20,865)
Income (loss) from continuing operations	15,663	(32,807)	(5,972)		(1,468)	14,498	(8,576)					(137,269)	(17,360)		(178,874)
Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	336,679											1,360,256	1,345,763		1,333,195
Cost of net revenue	203,620											840,339	816,961		761,563
Sales and marketing	52,928											212,348	219,566		232,406
General and administrative	23,019											119,417	147,625		156,143
Income (loss) from continuing operations before provision (benefit) for income taxes	37,935											120,594	112,416		111,324
Provision (benefit) for income taxes	73,349											41,896	33,447		44,155
Income (loss) from continuing operations	(35,414)											78,698	78,969		67,169
Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	323,174	348,875	319,351		328,562	363,247	347,282					1,345,831	1,389,946		1,493,145
Cost of net revenue	187,889	199,143	182,008		187,305	206,175	192,594					768,119	805,448		848,485
Sales and marketing	47,171	47,721	44,839		51,527	54,235	54,431					184,093	208,972		273,045
General and administrative	37,896	38,454	37,155		43,529	(14,505)	34,398					155,172	102,511		204,554
Income (loss) from continuing operations before provision (benefit) for income taxes	37,399	45,983	46,484		27,621	105,542	81,139					190,141	238,137		94,922
Provision (benefit) for income taxes	103,118	(10,424)	(368)		(59,533)	21,302	11,503					57,825	64,087		46,718
Income (loss) from continuing operations	(59,042)	57,964	51,433		92,502	84,664	73,204					$ 151,179	188,115		64,132
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	582,354	611,088	578,209	623,285	603,768	623,371	612,892	1,189,297	1,236,263	1,771,651	1,840,031		2,463,316		2,575,278
Cost of net revenue	316,226	329,227	311,952	370,256	326,802	336,037	317,677	641,179	653,714	957,405	980,516		1,350,772		1,363,040
Sales and marketing	101,979	102,516	99,813	111,535	106,493	108,024	109,079	202,329	217,103	304,308	323,596		435,131		512,961
General and administrative	129,287	128,354	114,956	114,400	101,306	61,173	92,691	243,310	153,864	372,597	255,170		369,570		453,628
Income (loss) from continuing operations before provision (benefit) for income taxes	(55,010)	(33,896)	(15,219)	(74,334)	(17,593)	29,098	(18,161)	(49,115)	10,937	(104,125)	(6,656)		(80,990)		(118,333)
Provision (benefit) for income taxes	(50,888)	3,117	(208)	(50,329)	(10,212)	15,689	(7,853)	2,909	7,836	(47,979)	(2,376)		(52,704)		70,930
Income (loss) from continuing operations	22,027	(34,891)	(9,977)	$ (18,795)	(2,381)	14,770	(6,349)	$ (44,868)	$ 8,421	$ (22,841)	$ 6,040		(12,756)		(171,754)	[2]
As Previously Reported [Member] | Eliminations [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	(77,571)	(77,671)	(64,195)		(72,001)	(69,082)	(63,668)						(280,094)		(249,339)
Cost of net revenue	(76,023)	(76,792)	(63,577)		(70,090)	(69,007)	(64,779)						(278,373)		(252,137)
Sales and marketing	0	0	0		0	0	0						0		0
General and administrative	(489)	0	0		0	0	0						0		0
Income (loss) from continuing operations before provision (benefit) for income taxes	(1,058)	(880)	(618)		(1,911)	(75)	1,111						(4,921)		2,733
Provision (benefit) for income taxes	0	0	0		(1)	(38)	346						308		1,022
Income (loss) from continuing operations	88,092	(97,819)	(79,432)		(157,658)	(127,149)	(73,401)						(267,864)		(123,555)
As Previously Reported [Member] | Issuer [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	0	0	0		0	0	0						0		0
Cost of net revenue	853	324	114		2,146	516	426						3,279		5,630
Sales and marketing	1,867	1,568	1,336		1,335	1,570	1,260						5,901		7,598
General and administrative	75,261	57,740	44,615		22,960	24,390	20,523						119,520		93,952
Income (loss) from continuing operations before provision (benefit) for income taxes	(135,558)	(112,630)	(89,298)		(79,741)	(129,585)	(103,485)						(430,174)		(326,899)
Provision (benefit) for income taxes	(227,263)	19,765	(54)		78,040	(16,306)	(20,667)						(151,406)		(20,865)
Income (loss) from continuing operations	22,027	(34,891)	(9,977)		(2,381)	14,770	(8,261)						(14,668)		(179,187)
As Previously Reported [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	336,679												1,345,763		1,333,195
Cost of net revenue	203,620												816,961		761,563
Sales and marketing	52,928												219,566		232,406
General and administrative	18,319												147,539		155,795
Income (loss) from continuing operations before provision (benefit) for income taxes	42,335												112,416		111,324
Provision (benefit) for income taxes	75,980												33,447		44,155
Income (loss) from continuing operations	(33,645)												78,969		67,169
As Previously Reported [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	323,246	349,659	310,620		327,731	362,644	350,268						1,397,647		1,491,422
Cost of net revenue	187,776	199,704	178,145		187,690	205,281	194,890						808,905		847,984
Sales and marketing	47,184	47,793	44,012		51,296	54,353	54,592						209,664		272,957
General and administrative	36,196	40,154	37,155		43,529	(14,505)	34,398						102,511		203,881
Income (loss) from continuing operations before provision (benefit) for income taxes	39,271	44,434	42,443		26,636	105,715	81,668						241,689		94,509
Provision (benefit) for income taxes	100,395	(9,889)	(404)		(59,605)	21,203	11,717						64,947		46,618
Income (loss) from continuing operations	(54,447)	55,880	47,428		91,589	84,936	73,519						190,807		63,819
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	678	(1,046)	4,739		1,724	(5,785)									(13,426)
Cost of net revenue		2,164	1,509			(545)
Provision (benefit) for income taxes	(7,633)	(1,079)	933		(8,712)	(2,012)
Revision Adjustment [Member] | Eliminations [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	0	0	0		0	0	0						0		0
Cost of net revenue	0	0	0		0	0	0						0		0
Sales and marketing	0	0	0		0	0	0						0		0
General and administrative	0	0	0		0	0	0						0		0
Income (loss) from continuing operations before provision (benefit) for income taxes	0	0	0		0	0	0						0		0
Provision (benefit) for income taxes	0	0	0		0	0	0						0		0
Income (loss) from continuing operations	6,364	(2,084)	(4,005)		(913)	272	315						2,692		(313)
Revision Adjustment [Member] | Issuer [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	0	0	0		0	0	0						0		0
Cost of net revenue	0	0	0		0	0	0						0		0
Sales and marketing	0	0	0		0	0	0						0		0
General and administrative	12,853	10,200	0		0	0	0						4,500		(1,486)
Income (loss) from continuing operations before provision (benefit) for income taxes	0	0	0		0	0	0						0		0
Provision (benefit) for income taxes	0	0	0		0	0	0						0		0
Income (loss) from continuing operations	(6,364)	2,084	4,005		913	(272)	(315)						(2,692)		313
Revision Adjustment [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	0												0		0
Cost of net revenue	0												0		0
Sales and marketing	0												0		0
General and administrative	4,700												86		348
Income (loss) from continuing operations before provision (benefit) for income taxes	(4,400)												0		0
Provision (benefit) for income taxes	(2,631)												0		0
Income (loss) from continuing operations	1,769												0		0
Revision Adjustment [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	(72)	(784)	8,731		831	603	(2,986)						(7,701)		1,723
Cost of net revenue	113	(561)	3,863		(385)	894	(2,296)						(3,457)		501
Sales and marketing	(13)	(72)	827		231	(118)	(161)						(692)		88
General and administrative	1,700	(1,700)	0		0	0	0						0		673
Income (loss) from continuing operations before provision (benefit) for income taxes	(1,872)	1,549	4,041		985	(173)	(529)						(3,552)		413
Provision (benefit) for income taxes	2,723	(535)	36		72	99	(214)						(860)		100
Income (loss) from continuing operations	$ (4,595)	$ 2,084	$ 4,005		$ 913	$ (272)	$ (315)						$ (2,692)		$ 313
[1]	Restated Values
[2]	The figures presented in this column represent the amounts most recently presented in our Annual Report on Form 10-K for 2015 and, in connection with the presentation in such Form 10-K, such amounts had been previously revised from the figures presented earlier in the Annual Report on Form 10-K/A for 2014 due principally to a $19,236 increase in operating cash flow related to deferred income taxes and a $15,753 decrease in operating cash flow related to other non-current liabilities, which were identified during the preparation of the Annual Report on Form 10-K for 2015.

Guarantor Financial Informat155

Guarantor Financial Information - Restated Consolidating Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2016		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	[1]	Dec. 31, 2013	[1]	Dec. 31, 2012	[1]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets	$ 1,459,903		$ 1,471,262	$ 1,399,230	$ 1,413,659	$ 1,414,610	[1]	$ 1,900,012	$ 1,948,785	$ 1,453,773
Total assets	5,648,279		5,851,685	5,792,800	5,895,173	5,918,160	[1]	6,542,128	6,614,344	6,124,840
Total current liabilities	676,156		701,529	560,892	677,881	722,706	[1]	1,135,863	1,143,171	664,260
Total long-term liabilities	3,140,516		3,103,195	3,216,790	3,131,633	3,140,158	[1]	3,309,794	3,306,524	3,381,761
Total equity	1,831,607	[1]	2,046,961	2,015,118	2,085,659	2,055,296	[1]	2,096,471	2,164,649	2,078,819	$ 1,916,097		$ 2,079,904
Total liabilities and equity	5,648,279		5,851,685	5,792,800	5,895,173	5,918,160	[1]	6,542,128	6,614,344	6,124,840
Eliminations [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets	(1,615,907)		(2,188,177)	(1,363,814)	(1,100,666)	(2,115,095)		(2,001,967)	(1,317,329)	(1,304,328)
Total assets	(7,741,104)		(8,462,268)	(7,704,712)	(7,368,461)	(8,328,419)		(8,355,373)	(7,651,674)	(7,553,913)
Total current liabilities	(1,631,674)		(2,168,444)	(1,345,171)	(1,079,966)	(2,098,884)		(1,981,597)	(1,298,126)	(1,286,051)
Total long-term liabilities	(2,469,220)		(2,689,610)	(2,672,312)	(2,660,344)	(2,710,922)		(2,714,032)	(2,760,666)	(2,803,565)
Total equity	(3,640,210)		(3,604,214)	(3,687,229)	(3,628,151)	(3,518,613)		(3,659,744)	(3,592,882)	(3,464,297)
Total liabilities and equity	(7,741,104)		(8,462,268)	(7,704,712)	(7,368,461)	(8,328,419)		(8,355,373)	(7,651,674)	(7,553,913)
Issuer [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets	575,287		1,265,329	423,622	294,406	1,385,453		1,667,256	1,036,046	632,999
Total assets	5,775,799		6,653,963	5,819,293	5,623,451	6,726,080		7,161,989	6,485,274	5,947,064
Total current liabilities	626,818		1,248,718	514,279	345,110	1,397,394		1,725,939	943,570	385,171
Total long-term liabilities	3,321,989		3,362,971	3,294,404	3,197,047	3,277,654		3,344,111	3,381,648	3,487,308
Total equity	1,826,992		2,042,274	2,010,610	2,081,294	2,051,032		2,091,939	2,160,056	2,074,585
Total liabilities and equity	5,775,799		6,653,963	5,819,293	5,623,451	6,726,080		7,161,989	6,485,274	5,947,064
Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets	1,111,398		1,084,914	1,112,200	1,051,278	916,912		1,002,806	1,047,452	976,818
Total assets	2,758,705		2,867,250	2,913,654	2,902,374	2,758,937		2,911,823	3,014,358	2,960,893
Total current liabilities	607,041		627,262	498,851	507,593	445,103		424,627	561,302	611,022
Total long-term liabilities	915,422		998,037	1,123,574	1,118,354	1,112,885		1,208,211	1,181,371	1,174,407
Total equity	1,236,242		1,241,951	1,291,229	1,276,427	1,200,949		1,278,985	1,271,685	1,175,464
Total liabilities and equity	2,758,705		2,867,250	2,913,654	2,902,374	2,758,937		2,911,823	3,014,358	2,960,893
Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets	1,389,125		1,309,196	1,227,222	1,168,641	1,227,340
Total assets	4,854,879		4,792,740	4,764,565	4,737,809	4,761,562
Total current liabilities	1,073,971		993,993	892,933	905,144	979,093
Total long-term liabilities	1,372,325		1,431,797	1,471,124	1,476,576	1,460,541
Total equity	2,408,583		2,366,950	2,400,508	2,356,089	2,321,928
Total liabilities and equity	$ 4,854,879		4,792,740	4,764,565	4,737,809	4,761,562
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets			1,511,206	1,435,307	1,451,492	1,457,290		1,900,494	1,950,482	1,455,180
Total assets			5,855,674	5,790,894	5,895,308	5,923,121		6,542,610	6,616,041	6,126,247
Total current liabilities			706,510	561,942	678,887	724,534		1,136,230	1,143,840	664,911
Total long-term liabilities			3,098,795	3,216,790	3,131,633	3,140,158		3,309,794	3,306,524	3,381,761
Total equity			2,050,369	2,012,162	2,084,788	2,058,429		2,096,586	2,165,677	2,079,575					$ 2,080,659
Total liabilities and equity			5,855,674	5,790,894	5,895,308	5,923,121		6,542,610	6,616,041	6,126,247
As Previously Reported [Member] | Eliminations [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets			(2,188,177)	(1,363,814)	(1,102,786)	(2,115,095)		(2,001,967)	(1,317,329)	(1,304,328)
Total assets			(8,465,676)	(7,629,209)	(7,301,102)	(8,331,552)		(8,353,236)	(7,650,450)	(7,552,417)
Total current liabilities			(2,168,444)	(1,345,171)	(1,079,966)	(2,098,884)		(1,981,597)	(1,298,126)	(1,286,051)
Total long-term liabilities			(2,689,610)	(2,599,765)	(2,593,856)	(2,710,922)		(2,711,780)	(2,758,414)	(2,801,313)
Total equity			(3,607,622)	(3,684,273)	(3,627,280)	(3,521,746)		(3,659,859)	(3,593,910)	(3,465,053)
Total liabilities and equity			(8,465,676)	(7,629,209)	(7,301,102)	(8,331,552)		(8,353,236)	(7,650,450)	(7,552,417)
As Previously Reported [Member] | Issuer [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets			1,265,329	423,167	241,997	1,385,453		1,667,256	1,036,046	632,999
Total assets			6,657,371	5,749,848	5,556,092	6,729,213		7,159,852	6,484,050	5,945,568
Total current liabilities			1,248,718	514,279	345,110	1,397,394		1,725,939	943,570	385,171
Total long-term liabilities			3,362,971	3,227,915	3,130,559	3,277,654		3,341,859	3,379,396	3,485,056
Total equity			2,045,682	2,007,654	2,080,423	2,054,165		2,092,054	2,161,084	2,075,341
Total liabilities and equity			6,657,371	5,749,848	5,556,092	6,729,213		7,159,852	6,484,050	5,945,568
As Previously Reported [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets			1,124,858	1,142,219	1,112,355	959,592		1,003,288	1,049,149	978,225
Total assets			2,871,239	2,905,690	2,902,509	2,763,898		2,912,305	3,016,055	2,962,300
Total current liabilities			629,612	499,901	508,599	446,931		424,994	561,971	611,673
Total long-term liabilities			998,037	1,117,516	1,118,354	1,112,885		1,208,211	1,181,371	1,174,407
Total equity			1,243,590	1,288,273	1,275,556	1,204,082		1,279,100	1,272,713	1,176,220
Total liabilities and equity			2,871,239	2,905,690	2,902,509	2,763,898		2,912,305	3,016,055	2,962,300
As Previously Reported [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets			1,309,196	1,233,735	1,199,926
Total assets			4,792,740	4,764,565	4,737,809
Total current liabilities			996,624	892,933	905,144
Total long-term liabilities			1,427,397	1,471,124	1,476,576
Total equity			2,368,719	2,400,508	2,356,089
Total liabilities and equity			4,792,740	4,764,565	4,737,809
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total long-term liabilities			4,400
Revision Adjustment [Member] | Eliminations [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets			0	0	2,120	0		0	0	0
Total assets			3,408	(75,503)	(67,359)	3,133		(2,137)	(1,224)	(1,496)
Total current liabilities			0	0	0	0		0	0	0
Total long-term liabilities			0	72,547	(66,488)	0		(2,252)	(2,252)	(2,252)
Total equity			3,408	(2,956)	(871)	3,133		115	1,028	756
Total liabilities and equity			3,408	(75,503)	(67,359)	3,133		(2,137)	(1,224)	(1,496)
Revision Adjustment [Member] | Issuer [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets			0	455	52,409	0		0	0	0
Total assets			(3,408)	69,445	67,359	(3,133)		2,137	1,224	1,496
Total current liabilities			(92,350)	0	0	0		0	0	0
Total long-term liabilities			0	66,489	66,488	0		2,252	2,252	2,252
Total equity			(3,408)	2,956	871	(3,133)		(115)	(1,028)	(756)
Total liabilities and equity			(3,408)	69,445	67,359	(3,133)		2,137	1,224	1,496
Revision Adjustment [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets			(39,944)	(30,019)	(61,077)	(42,680)		(482)	(1,697)	(1,407)
Total assets			(3,989)	7,964	(135)	(4,961)		(482)	(1,697)	(1,407)
Total current liabilities			(2,350)	(1,050)	(1,006)	(1,828)		(367)	(669)	(651)
Total long-term liabilities			0	6,058	0	0		0	0	0
Total equity			(1,639)	2,956	871	(3,133)		(115)	(1,028)	(756)
Total liabilities and equity			(3,989)	7,964	(135)	$ (4,961)		$ (482)	$ (1,697)	$ (1,407)
Revision Adjustment [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total current assets			0	(6,513)	(31,285)
Total assets			0	0	0
Total current liabilities			(2,631)	0	0
Total long-term liabilities			4,400	0	0
Total equity			(1,769)	0	0
Total liabilities and equity			$ 0	$ 0	$ 0
[1]	Restated Values

Guarantor Financial Informat156

Guarantor Financial Information - Restated Consolidating Balance Sheet (Parenthetical) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	[1]	Dec. 31, 2013	[1]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance cost	$ 51,886
Intercompany receivable	0					$ 0
Deferred tax assets, Non-current	20,483		$ 56,638	$ 18,638	$ 16,124	13,993	[1]	$ 5,380	$ 5,381	$ 6,360
Liabilities current	676,156		701,529	560,892	677,881	722,706	[1]	1,135,863	1,143,171	664,260
Deferred tax liabilities	98,615					133,625	[1]
Intercompany payable	0					0
Deferred tax liabilities	119,098		52,513	140,864	144,483	147,618	[1]	226,976	243,298	262,117
Long-term liabilities	3,140,516		3,103,195	3,216,790	3,131,633	3,140,158	[1]	3,309,794	3,306,524	3,381,761
Equity	1,831,607	[1]	2,046,961	2,015,118	2,085,659	2,055,296	[1]	2,096,471	2,164,649	2,078,819	$ 1,916,097		$ 2,079,904
Inventory	308,920		349,378	334,492	351,015	350,949	[1]	376,057	379,545	388,481
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred tax liabilities									15,807	16,254
Long-term liabilities			4,400
Issuer [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Intercompany receivable	390,328					1,237,474
Deferred tax assets, Non-current	0					91,220
Liabilities current	626,818		1,248,718	514,279	345,110	1,397,394		1,725,939	943,570	385,171
Intercompany payable	485,573					1,122,042
Deferred tax liabilities	0					0
Long-term liabilities	3,321,989		3,362,971	3,294,404	3,197,047	3,277,654		3,344,111	3,381,648	3,487,308
Equity	1,826,992		2,042,274	2,010,610	2,081,294	2,051,032		2,091,939	2,160,056	2,074,585
Inventory	0					0
Issuer [Member] | Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance cost						33,866
Deferred tax assets, current			52,410			2,120
Intercompany receivable			616,637			616,637
Deferred tax assets, Non-current			105,298			(128,556)
Liabilities current			(92,350)	0	0	0		0	0	0
Deferred tax liabilities			157,708
Intercompany payable						(616,637)
Deferred tax liabilities						(126,436)
Long-term liabilities			0	66,489	66,488	0		2,252	2,252	2,252
Equity			(3,408)	2,956	871	(3,133)		(115)	(1,028)	(756)
Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Intercompany receivable	204,587					50,691
Deferred tax assets, Non-current	57,819					51,329
Liabilities current	607,041		627,262	498,851	507,593	445,103		424,627	561,302	611,022
Intercompany payable	258,154					205,241
Deferred tax liabilities	67,702					54,749
Long-term liabilities	915,422		998,037	1,123,574	1,118,354	1,112,885		1,208,211	1,181,371	1,174,407
Equity	1,236,242		1,241,951	1,291,229	1,276,427	1,200,949		1,278,985	1,271,685	1,175,464
Inventory	163,967					198,140
Non-Guarantor Subsidiaries [Member] | Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance cost						184
Liabilities current			(2,350)	(1,050)	(1,006)	(1,828)		(367)	(669)	(651)
Long-term liabilities			0	6,058	0	0		0	0	0
Equity			(1,639)	2,956	871	(3,133)		(115)	(1,028)	(756)
Non-Guarantor Subsidiaries [Member] | Amended Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred tax assets, current			(23,244)
Deferred tax assets, Non-current			23,244
Liabilities current			(92,350)
Intercompany payable			92,350
Accounting Standards Update 2015-03 [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance cost						34,050		43,644	45,889	36,425
Accounting Standards Update 2015-03 [Member] | Issuer [Member] | Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance cost								43,431	45,889	36,425
Deferred tax assets, current								15,348	15,347	15,347
Intercompany receivable								472,009
Deferred tax liabilities								16,257	17,323	17,324
Investment in subsidiaries								(25,760)	(17,876)	(12,384)
Accrued expenses								461,815	(9,944)	(9,944)
Long-term liabilities								(13,344)	(14,662)	(14,662)
Equity										7,994
Accounting Standards Update 2015-03 [Member] | Non-Guarantor Subsidiaries [Member] | Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt issuance cost								213
Intercompany receivable								25,228
Accrued expenses								43,907	15,130	14,035
Equity								19,096	(16,314)	(12,463)
Accounts receivable								(10,764)	(11,082)	(7,769)
Inventory								10,866	10,371	9,765
Eliminations [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Intercompany receivable	(1,603,682)					(2,101,122)
Deferred tax assets, Non-current	(37,336)					(128,556)
Liabilities current	(1,631,674)		(2,168,444)	(1,345,171)	(1,079,966)	(2,098,884)		(1,981,597)	(1,298,126)	(1,286,051)
Intercompany payable	(1,603,651)					(2,101,122)
Deferred tax liabilities	82					(126,355)
Long-term liabilities	(2,469,220)		(2,689,610)	(2,672,312)	(2,660,344)	(2,710,922)		(2,714,032)	(2,760,666)	(2,803,565)
Equity	(3,640,210)		(3,604,214)	(3,687,229)	(3,628,151)	(3,518,613)		(3,659,744)	(3,592,882)	(3,464,297)
Inventory	$ (23,783)					(20,574)
Eliminations [Member] | Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Liabilities current			0	0	0	0		0	0	0
Long-term liabilities			0	72,547	(66,488)	0		(2,252)	(2,252)	(2,252)
Equity			$ 3,408	$ (2,956)	$ (871)	$ 3,133		115	1,028	756
Eliminations [Member] | Accounting Standards Update 2015-03 [Member] | Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Intercompany receivable								(497,237)
Intercompany payable								(494,784)
Investment in subsidiaries								25,760	17,876	12,384
Equity								$ 25,760	$ 17,876	$ 12,384
[1]	Restated Values

Guarantor Financial Informat157

Guarantor Financial Information - Restated Consolidating Statement of Operations (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes	$ (50,796)	$ 2,582	$ (172)	$ (51,146)	$ (10,140)	$ 15,788	$ (8,067)	$ 2,410	$ 7,721	$ (48,386)	$ (2,419)	$ 35,376	$ (53,564)	[1]	$ 71,030	[1]
Loss from continuing operations before equity earnings of unconsolidated entities, net of tax	(10,486)	(34,929)	(11,006)	(27,023)	(6,468)	13,137	(10,623)	(45,935)	2,514	(56,421)	(3,954)	(187,774)	(30,978)	[1]	(188,950)	[1]
Loss from continuing operations	15,663	(32,807)	(5,972)	(21,813)	(1,468)	14,498	(6,664)	(38,779)	7,834	(23,116)	6,366	(137,269)	(15,448)	[1]	(171,441)	[1]
Cost of revenue	316,339	328,666	315,815	368,586	326,417	336,931	315,381	644,481	652,312	960,820	978,729	1,286,468	1,347,315	[1]	1,363,541	[1]
Net income (loss)	15,456	(32,950)	(6,075)	$ (19,072)	(1,407)	14,139	210,025	$ (39,025)	$ 224,164	$ (23,569)	$ 222,757	(137,619)	203,684	[1]	(33,153)	[1]
Issuer [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes	(227,263)	19,765	(54)		78,040	(16,306)	(20,667)					(64,345)	(151,406)		(20,865)
Loss from continuing operations	15,663	(32,807)	(5,972)		(1,468)	14,498	(8,576)					(137,269)	(17,360)		(178,874)
Cost of revenue	853	324	114		2,146	516	426					2,386	3,279		5,630
Net income (loss)												(137,269)	204,065		(33,123)
Issuer [Member] | Amended Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes													(8,535)
Loss from continuing operations before equity earnings of unconsolidated entities, net of tax													(4,261)
Loss from continuing operations													(2,692)
Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes	103,118	(10,424)	(368)		(59,533)	21,302	11,503					57,825	64,087		46,718
Loss from continuing operations	(59,042)	57,964	51,433		92,502	84,664	73,204					151,179	188,115		64,132
Cost of revenue	187,889	199,143	182,008		187,305	206,175	192,594					768,119	805,448		848,485
Net income (loss)												150,829	187,734		84,502
Non-Guarantor Subsidiaries [Member] | Amended Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes													(2,729)
Loss from continuing operations before equity earnings of unconsolidated entities, net of tax															15,805
Cost of revenue															(7,237)
Operating expense													(1,201)
Net income (loss)													(4,638)
Eliminations [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes	0	0	0		(1)	(38)	346					0	308		1,022
Loss from continuing operations	94,456	(99,903)	(83,437)		(158,571)	(126,877)	(73,086)					(229,877)	(265,172)		(123,868)
Cost of revenue	$ (76,023)	$ (76,792)	$ (63,577)		$ (70,090)	$ (69,007)	$ (64,779)					(324,376)	(278,373)		(252,137)
Net income (loss)												$ (229,877)	$ (265,172)		(123,862)
Eliminations [Member] | Amended Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Loss from continuing operations before equity earnings of unconsolidated entities, net of tax															4,261
Loss from continuing operations															$ 4,261
[1]	Restated Values

Guarantor Financial Informat158

Guarantor Financial Information - Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Net product sales	$ 456,024	$ 482,962	$ 468,502	$ 500,367	$ 472,959	$ 491,652	$ 481,352	$ 951,464	$ 973,004	$ 1,407,488	$ 1,445,963	$ 1,883,576		$ 1,946,330	[1]	$ 2,023,963	[1]
Services revenue	123,778	124,809	115,709	113,483	128,341	126,628	123,856	240,518	250,484	364,296	378,825	480,761		492,308	[1]	531,988	[1]
Net product sales and services revenue	579,802	607,771	584,211	613,850	601,300	618,280	605,208	1,191,982	1,223,488	1,771,784	1,824,788	2,364,337		2,438,638	[1]	2,555,951	[1]
License and royalty revenue	2,480	2,533	2,729	3,286	3,299	5,694	4,698	5,262	10,392	7,742	13,691	11,998		16,977	[1]	21,050	[1]
Net revenue	582,282	610,304	586,940	617,136	604,599	623,974	609,906	1,197,244	1,233,880	1,779,526	1,838,479	2,376,335		2,455,615	[1]	2,577,001	[1]
Cost of net product sales	239,059	249,837	241,324	297,125	245,429	258,787	237,805	491,161	496,592	730,220	742,021	978,347		1,039,146	[1]	1,063,000	[1]
Cost of services revenue	76,639	78,294	73,100	72,111	79,851	76,800	75,626	151,394	152,426	228,033	232,277	304,871		304,388	[1]	294,949	[1]
Cost of net product sales and services revenue	315,698	328,131	314,424	369,236	325,280	335,587	313,431	642,555	649,018	958,253	974,298	1,283,218		1,343,534	[1]	1,357,949	[1]
Cost of license and royalty revenue	641	535	1,391	650	1,137	1,344	1,950	1,926	3,294	2,567	4,431	3,250		3,781	[1]	5,592	[1]
Cost of net revenue	316,339	328,666	315,815	368,586	326,417	336,931	315,381	644,481	652,312	960,820	978,729	1,286,468		1,347,315	[1]	1,363,541	[1]
Gross profit (loss)	265,943	281,638	271,125	248,550	278,182	287,043	294,525	552,763	581,568	818,706	859,750	1,089,867		1,108,300	[1]	1,213,460	[1]
Operating expenses:
Research and development	31,430	28,446	27,062	28,228	36,011	27,198	28,016	55,508	55,214	86,938	91,225	112,122		119,453	[1]	144,828	[1]
Sales and marketing	101,966	102,444	100,640	110,891	106,724	107,906	108,918	203,084	216,824	305,050	323,548	403,055		434,439	[1]	513,049	[1]
General and administrative	148,540	136,854	114,956	118,986	101,306	61,173	92,691	251,810	153,864	400,350	255,170	563,776		374,156	[1]	453,163	[1]
Impairment and (gain) loss on dispositions, net	0	0	(3,810)	8,132	2,074	5,542	34,792	(3,810)	40,334	(3,810)	42,408	(3,810)		50,540	[1]	7,742	[1]
Operating income (loss)	(15,993)	13,894	32,277	(17,687)	32,067	85,224	30,108	46,171	115,332	30,178	147,399	14,724		129,712	[1]	94,678	[1]
Interest expense, including amortization of original issue discounts and deferred financing costs	(44,130)	(42,329)	(42,106)	(58,739)	(52,333)	(59,494)	(46,431)	(84,435)	(105,925)	(128,565)	(158,258)	(171,651)		(216,997)	[1]	(209,191)	[1]
Other income (expense), net	(1,159)	(3,912)	(1,349)	(1,743)	3,658	3,195	(2,367)	(5,261)	828	(6,420)	4,486	4,529		2,743	[1]	(3,407)	[1]
Income (loss) from continuing operations before provision (benefit) for income taxes	(61,282)	(32,347)	(11,178)	(78,169)	(16,608)	28,925	(18,690)	(43,525)	10,235	(104,807)	(6,373)	(152,398)		(84,542)	[1]	(117,920)	[1]
Provision (benefit) for income taxes	(50,796)	2,582	(172)	(51,146)	(10,140)	15,788	(8,067)	2,410	7,721	(48,386)	(2,419)	35,376		(53,564)	[1]	71,030	[1]
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax												(187,774)		(30,978)		(188,950)
Equity in earnings of subsidiaries, net of tax												0		0		0
Equity earnings (losses) of unconsolidated entities, net of tax	26,149	2,122	5,034	5,210	5,000	1,361	3,959	7,156	5,320	33,305	10,320	50,505		15,530	[1]	17,509	[1]
Income (loss) from continuing operations	15,663	(32,807)	(5,972)	(21,813)	(1,468)	14,498	(6,664)	(38,779)	7,834	(23,116)	6,366	(137,269)		(15,448)	[1]	(171,441)	[1]
Income (loss) from discontinued operations, net of tax	0	0	0	2,736	0	0	216,777	0	216,777	0	216,777	0		219,513	[1]	138,318	[1]
Net income (loss)	15,663	(32,807)	(5,972)	(19,077)	(1,468)	14,498	210,113	(38,779)	224,611	(23,116)	223,143	(137,269)	[1]	204,065	[1]	(33,123)	[1]
Less: Net income (loss) attributable to non-controlling interests	207	143	103	(5)	(61)	359	88	246	447	453	386	350		381	[1]	30	[1]
Net income (loss) attributable to Alere Inc. and Subsidiaries	15,456	(32,950)	(6,075)	(19,072)	(1,407)	14,139	210,025	(39,025)	224,164	(23,569)	222,757	(137,619)		203,684	[1]	(33,153)	[1]
Preferred stock dividends	(5,366)	(5,308)	(5,309)	(5,367)	(5,369)	(5,308)	(5,250)	(10,617)	(10,558)	(15,983)	(15,927)	(21,350)		(21,293)	[1]	(21,293)	[1]
Net income (loss) available to common stockholders	10,090	(38,258)	(11,384)	$ (24,439)	(6,776)	8,831	204,775	$ (49,642)	$ 213,606	$ (39,552)	$ 206,830	(158,969)		182,391	[1]	(54,446)	[1]
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales												0		0		0
Services revenue												0		0		0
Net product sales and services revenue												0		0		0
License and royalty revenue												0		0		0
Net revenue	0	0	0		0	0	0					0		0		0
Cost of net product sales												610		3,114		5,329
Cost of services revenue												1,776		205		261
Cost of net product sales and services revenue												2,386		3,319		5,590
Cost of license and royalty revenue												0		(40)		40
Cost of net revenue	853	324	114		2,146	516	426					2,386		3,279		5,630
Gross profit (loss)												(2,386)		(3,279)		(5,630)
Operating expenses:
Research and development												1,465		16,461		23,190
Sales and marketing	1,867	1,568	1,336		1,335	1,570	1,260					6,614		5,901		7,598
General and administrative	88,114	67,940	44,615		22,960	24,390	20,523					289,933		124,020		92,466
Impairment and (gain) loss on dispositions, net												0		79,951		4,236
Operating income (loss)												(300,398)		(229,612)		(133,120)
Interest expense, including amortization of original issue discounts and deferred financing costs												(168,904)		(215,070)		(205,919)
Other income (expense), net												10,799		14,508		12,140
Income (loss) from continuing operations before provision (benefit) for income taxes	(135,558)	(112,630)	(89,298)		(79,741)	(129,585)	(103,485)					(458,503)		(430,174)		(326,899)
Provision (benefit) for income taxes	(227,263)	19,765	(54)		78,040	(16,306)	(20,667)					(64,345)		(151,406)		(20,865)
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax												(394,158)		(278,768)		(306,034)
Equity in earnings of subsidiaries, net of tax												225,588		259,924		125,443
Equity earnings (losses) of unconsolidated entities, net of tax												31,301		1,484		1,717
Income (loss) from continuing operations	15,663	(32,807)	(5,972)		(1,468)	14,498	(8,576)					(137,269)		(17,360)		(178,874)
Income (loss) from discontinued operations, net of tax												0		221,425		145,751
Net income (loss)												(137,269)		204,065		(33,123)
Less: Net income (loss) attributable to non-controlling interests												0		0		0
Net income (loss) attributable to Alere Inc. and Subsidiaries												(137,269)		204,065		(33,123)
Preferred stock dividends												(21,350)		(21,293)		(21,293)
Net income (loss) available to common stockholders												(158,619)		182,772		(54,416)
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales												907,104		892,086		855,435
Services revenue												433,526		440,709		464,283
Net product sales and services revenue												1,340,630		1,332,795		1,319,718
License and royalty revenue												19,626		12,968		13,477
Net revenue	336,679											1,360,256		1,345,763		1,333,195
Cost of net product sales												533,989		510,918		473,076
Cost of services revenue												306,331		305,813		288,288
Cost of net product sales and services revenue												840,320		816,731		761,364
Cost of license and royalty revenue												19		230		199
Cost of net revenue	203,620											840,339		816,961		761,563
Gross profit (loss)												519,917		528,802		571,632
Operating expenses:
Research and development												68,627		60,787		61,862
Sales and marketing	52,928											212,348		219,566		232,406
General and administrative	23,019											119,417		147,625		156,143
Impairment and (gain) loss on dispositions, net												0		(8,747)		11,393
Operating income (loss)												119,525		109,571		109,828
Interest expense, including amortization of original issue discounts and deferred financing costs												(7,482)		(11,517)		(18,995)
Other income (expense), net												8,551		14,362		20,491
Income (loss) from continuing operations before provision (benefit) for income taxes	37,935											120,594		112,416		111,324
Provision (benefit) for income taxes	73,349											41,896		33,447		44,155
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax												78,698		78,969		67,169
Equity in earnings of subsidiaries, net of tax												0		0		0
Equity earnings (losses) of unconsolidated entities, net of tax												0		0		0
Income (loss) from continuing operations	(35,414)											78,698		78,969		67,169
Income (loss) from discontinued operations, net of tax												0		(1,912)		(27,839)
Net income (loss)												78,698		77,057		39,330
Less: Net income (loss) attributable to non-controlling interests												0		0		0
Net income (loss) attributable to Alere Inc. and Subsidiaries												78,698		77,057		39,330
Preferred stock dividends												0		0		0
Net income (loss) available to common stockholders												78,698		77,057		39,330
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales												1,291,830		1,318,753		1,405,594
Services revenue												47,235		51,599		67,705
Net product sales and services revenue												1,339,065		1,370,352		1,473,299
License and royalty revenue												6,766		19,594		19,846
Net revenue	323,174	348,875	319,351		328,562	363,247	347,282					1,345,831		1,389,946		1,493,145
Cost of net product sales												719,218		755,954		797,276
Cost of services revenue												31,276		30,319		33,584
Cost of net product sales and services revenue												750,494		786,273		830,860
Cost of license and royalty revenue												17,625		19,175		17,625
Cost of net revenue	187,889	199,143	182,008		187,305	206,175	192,594					768,119		805,448		848,485
Gross profit (loss)												577,712		584,498		644,660
Operating expenses:
Research and development												42,030		42,205		59,776
Sales and marketing	47,171	47,721	44,839		51,527	54,235	54,431					184,093		208,972		273,045
General and administrative	37,896	38,454	37,155		43,529	(14,505)	34,398					155,172		102,511		204,554
Impairment and (gain) loss on dispositions, net												(3,810)		(20,664)		(7,887)
Operating income (loss)												200,227		251,474		115,172
Interest expense, including amortization of original issue discounts and deferred financing costs												(11,175)		(18,227)		(18,629)
Other income (expense), net												1,089		4,890		(1,621)
Income (loss) from continuing operations before provision (benefit) for income taxes	37,399	45,983	46,484		27,621	105,542	81,139					190,141		238,137		94,922
Provision (benefit) for income taxes	103,118	(10,424)	(368)		(59,533)	21,302	11,503					57,825		64,087		46,718
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax												132,316		174,050		48,204
Equity in earnings of subsidiaries, net of tax												0		0		0
Equity earnings (losses) of unconsolidated entities, net of tax												18,863		14,065		15,928
Income (loss) from continuing operations	(59,042)	57,964	51,433		92,502	84,664	73,204					151,179		188,115		64,132
Income (loss) from discontinued operations, net of tax												0		0		20,400
Net income (loss)												151,179		188,115		84,532
Less: Net income (loss) attributable to non-controlling interests												350		381		30
Net income (loss) attributable to Alere Inc. and Subsidiaries												150,829		187,734		84,502
Preferred stock dividends												0		0		0
Net income (loss) available to common stockholders												150,829		187,734		84,502
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales												(315,358)		(264,509)		(237,066)
Services revenue												0		0		0
Net product sales and services revenue												(315,358)		(264,509)		(237,066)
License and royalty revenue												(14,394)		(15,585)		(12,273)
Net revenue	(77,571)	(77,671)	(64,195)		(72,001)	(69,082)	(63,668)					(329,752)		(280,094)		(249,339)
Cost of net product sales												(275,470)		(230,840)		(212,681)
Cost of services revenue												(34,512)		(31,949)		(27,184)
Cost of net product sales and services revenue												(309,982)		(262,789)		(239,865)
Cost of license and royalty revenue												(14,394)		(15,584)		(12,272)
Cost of net revenue	(76,023)	(76,792)	(63,577)		(70,090)	(69,007)	(64,779)					(324,376)		(278,373)		(252,137)
Gross profit (loss)												(5,376)		(1,721)		2,798
Operating expenses:
Research and development												0		0		0
Sales and marketing	0	0	0		0	0	0					0		0		0
General and administrative	(489)	0	0		0	0	0					(746)		0		0
Impairment and (gain) loss on dispositions, net												0		0		0
Operating income (loss)												(4,630)		(1,721)		2,798
Interest expense, including amortization of original issue discounts and deferred financing costs												15,910		27,817		34,352
Other income (expense), net												(15,910)		(31,017)		(34,417)
Income (loss) from continuing operations before provision (benefit) for income taxes	(1,058)	(880)	(618)		(1,911)	(75)	1,111					(4,630)		(4,921)		2,733
Provision (benefit) for income taxes	0	0	0		(1)	(38)	346					0		308		1,022
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax												(4,630)		(5,229)		1,711
Equity in earnings of subsidiaries, net of tax												(225,588)		(259,924)		(125,443)
Equity earnings (losses) of unconsolidated entities, net of tax												341		(19)		(136)
Income (loss) from continuing operations	$ 94,456	$ (99,903)	$ (83,437)		$ (158,571)	$ (126,877)	$ (73,086)					(229,877)		(265,172)		(123,868)
Income (loss) from discontinued operations, net of tax												0		0		6
Net income (loss)												(229,877)		(265,172)		(123,862)
Less: Net income (loss) attributable to non-controlling interests												0		0		0
Net income (loss) attributable to Alere Inc. and Subsidiaries												(229,877)		(265,172)		(123,862)
Preferred stock dividends												0		0		0
Net income (loss) available to common stockholders												$ (229,877)		$ (265,172)		$ (123,862)
[1]	Restated Values

Guarantor Financial Informat159

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended							6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	$ 15,663	$ (32,807)	$ (5,972)	$ (19,077)	$ (1,468)	$ 14,498	$ 210,113	$ (38,779)	$ 224,611	$ (23,116)	$ 223,143	$ (137,269)	[1]	$ 204,065	[1]	$ (33,123)	[1]
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment												(122,287)		(146,438)	[1]	(166,448)	[1]
Unrealized losses on available for sale securities												0		0	[1]	(17)	[1]
Unrealized gains on hedging instruments												0		0	[1]	38	[1]
Minimum pension liability adjustment												(207)		(1,173)	[1]	(169)	[1]
Other comprehensive income (loss), before tax												(122,494)		(147,611)	[1]	(166,596)	[1]
Income tax provision (benefit) related to items of other comprehensive loss												127		56	[1]	(173)	[1]
Other comprehensive income (loss)												(122,621)		(147,667)	[1]	(166,423)	[1]
Comprehensive income (loss)	$ 24,404	$ (76,554)	$ 16,273	$ (42,975)	$ (89,800)	$ 60,491	$ 128,301	$ (60,281)	$ 188,792	$ (35,877)	$ 98,992	(259,890)		56,398	[1]	(199,546)	[1]
Less: Comprehensive income (loss) attributable to non-controlling interests												350		381	[1]	30	[1]
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries												(260,240)		56,017	[1]	(199,576)	[1]
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)												(137,269)		204,065		(33,123)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment												2,725		(1,175)		(489)
Unrealized losses on available for sale securities																0
Unrealized gains on hedging instruments																0
Minimum pension liability adjustment												0		0		0
Other comprehensive income (loss), before tax												2,725		(1,175)		(489)
Income tax provision (benefit) related to items of other comprehensive loss												0		0		0
Other comprehensive income (loss)												2,725		(1,175)		(489)
Comprehensive income (loss)												(134,544)		202,890		(33,612)
Less: Comprehensive income (loss) attributable to non-controlling interests												0		0		0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries												(134,544)		202,890		(33,612)
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)												78,698		77,057		39,330
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment												(1,672)		(816)		(516)
Unrealized losses on available for sale securities																(17)
Unrealized gains on hedging instruments																0
Minimum pension liability adjustment												0		0		0
Other comprehensive income (loss), before tax												(1,672)		(816)		(533)
Income tax provision (benefit) related to items of other comprehensive loss												0		0		0
Other comprehensive income (loss)												(1,672)		(816)		(533)
Comprehensive income (loss)												77,026		76,241		38,797
Less: Comprehensive income (loss) attributable to non-controlling interests												0		0		0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries												77,026		76,241		38,797
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)												151,179		188,115		84,532
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment												(123,308)		(144,267)		(165,443)
Unrealized losses on available for sale securities																0
Unrealized gains on hedging instruments																38
Minimum pension liability adjustment												(207)		(1,173)		(169)
Other comprehensive income (loss), before tax												(123,515)		(145,440)		(165,574)
Income tax provision (benefit) related to items of other comprehensive loss												127		56		(173)
Other comprehensive income (loss)												(123,642)		(145,496)		(165,401)
Comprehensive income (loss)												27,537		42,619		(80,869)
Less: Comprehensive income (loss) attributable to non-controlling interests												350		381		30
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries												27,187		42,238		(80,899)
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)												(229,877)		(265,172)		(123,862)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment												(32)		(180)		0
Unrealized losses on available for sale securities																0
Unrealized gains on hedging instruments																0
Minimum pension liability adjustment												0		0		0
Other comprehensive income (loss), before tax												(32)		(180)		0
Income tax provision (benefit) related to items of other comprehensive loss												0		0		0
Other comprehensive income (loss)												(32)		(180)		0
Comprehensive income (loss)												(229,909)		(265,352)		(123,862)
Less: Comprehensive income (loss) attributable to non-controlling interests												0		0		0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries												$ (229,909)		$ (265,352)		$ (123,862)
[1]	Restated Values

Guarantor Financial Informat160

Guarantor Financial Information - Consolidating Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2016		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 567,215		$ 566,213	$ 506,164	$ 490,663	$ 502,200	[1]	$ 479,381	$ 464,871	$ 414,495	$ 378,461	[1]	$ 355,431	[1]
Restricted cash	51,550		4,999	5,662	6,166	5,694	[1]	430,821	461,636	37,406
Marketable securities	76		75	74	71	164	[1]	157	175	173
Accounts receivable, net of allowances	413,535		426,207	427,961	459,115	436,924	[1]	436,490	454,636	457,333
Inventories, net	308,920		349,378	334,492	351,015	350,949	[1]	376,057	379,545	388,481
Prepaid expenses and other current assets	118,607		124,390	124,877	106,629	114,514	[1]	121,023	125,559	117,924
Assets held for sale - current	0					4,165	[1]	25,312	28,631
Intercompany receivables	0					0
Total current assets	1,459,903		1,471,262	1,399,230	1,413,659	1,414,610	[1]	1,900,012	1,948,785	1,453,773
Property, plant and equipment, net	441,190		446,313	438,787	445,218	446,039	[1]	445,872	448,891	447,326
Goodwill	2,759,366		2,805,682	2,811,545	2,839,692	2,836,915	[1]	2,842,921	2,853,551	2,880,164	2,926,666
Other intangible assets with indefinite lives	27,164		27,991	28,279	28,760	28,110	[1]	28,744	41,306	40,203
Finite-lived intangible assets, net	805,577		864,785	909,208	962,633	997,281	[1]	1,052,949	1,093,186	1,173,866
Restricted cash	2,171		42,438	42,589	43,388	43,228	[1]	44,148
Other non-current assets	14,966		16,219	16,290	17,927	18,078	[1]	19,635	21,845	25,052
Investments in subsidiaries	0					0
Investments in unconsolidated entities	72,225		80,885	74,511	74,744	65,333	[1]	73,882	69,594	95,551
Deferred tax assets	20,483		56,638	18,638	16,124	13,993	[1]	5,380	5,381	6,360
Non-current income tax receivable	45,234		39,472	41,500	41,215	41,236	[1]	2,537	2,611	2,545
Assets held for sale - non-current	0			12,223	11,813	13,337	[1]	126,048	129,194
Intercompany notes receivables	0					0
Total assets	5,648,279		5,851,685	5,792,800	5,895,173	5,918,160	[1]	6,542,128	6,614,344	6,124,840
Current liabilities:
Short-term debt and current portion of long-term debt	82,370		41,424	43,681	193,044	199,992	[1]	604,092	629,371	95,299
Current portion of capital lease obligations	3,064		3,713	3,500	4,048	3,962	[1]	3,505	4,643	5,072
Accounts payable	195,879		211,476	194,235	165,800	195,752	[1]	194,246	186,941	195,980
Accrued expenses and other current liabilities	394,843		444,916	319,476	314,989	322,637	[1]	325,184	314,553	367,909
Liabilities related to assets held for sale - current	0					363	[1]	8,836	7,663
Intercompany payables	0					0
Total current liabilities	676,156		701,529	560,892	677,881	722,706	[1]	1,135,863	1,143,171	664,260
Long-term liabilities:
Long-term debt, net of current portion	2,858,205		2,905,067	2,920,789	2,823,654	2,831,166	[1]	2,944,014	2,912,147	2,987,422
Capital lease obligations, net of current portion	7,221		8,033	6,972	7,654	7,181	[1]	7,346	7,974	8,794
Deferred tax liabilities	119,098		52,513	140,864	144,483	147,618	[1]	226,976	243,298	262,117
Other long-term liabilities	155,992		137,582	148,165	155,842	154,193	[1]	121,855	131,578	123,428
Intercompany notes payables	0					0
Total long-term liabilities	3,140,516		3,103,195	3,216,790	3,131,633	3,140,158	[1]	3,309,794	3,306,524	3,381,761
Total stockholders' equity	1,826,992		2,042,274	2,010,610	2,081,294	2,051,032	[1]	2,091,939	2,160,056	2,074,585
Non-controlling interests	4,615		4,687	4,508	4,365	4,264	[1]	4,532	4,593	4,234
Total equity	1,831,607	[1]	2,046,961	2,015,118	2,085,659	2,055,296	[1]	2,096,471	2,164,649	2,078,819	1,916,097	[1]	2,079,904	[1]
Total liabilities and equity	5,648,279		5,851,685	5,792,800	5,895,173	5,918,160	[1]	6,542,128	6,614,344	6,124,840
Issuer [Member]
Current assets:
Cash and cash equivalents	167,639					139,153					2,149		14,801
Restricted cash	1,337					1,250
Marketable securities	0					0
Accounts receivable, net of allowances	0					0
Inventories, net	0					0
Prepaid expenses and other current assets	15,983					7,576
Assets held for sale - current						0
Intercompany receivables	390,328					1,237,474
Total current assets	575,287		1,265,329	423,622	294,406	1,385,453		1,667,256	1,036,046	632,999
Property, plant and equipment, net	25,525					31,384
Goodwill	0					0
Other intangible assets with indefinite lives	0					0
Finite-lived intangible assets, net	2,490					2,951
Restricted cash	0					0
Other non-current assets	509					804
Investments in subsidiaries	3,409,001					3,291,724
Investments in unconsolidated entities	684					502
Deferred tax assets	0					91,220
Non-current income tax receivable	4,580					3,517
Assets held for sale - non-current						13,337
Intercompany notes receivables	1,757,723					1,905,188
Total assets	5,775,799		6,653,963	5,819,293	5,623,451	6,726,080		7,161,989	6,485,274	5,947,064
Current liabilities:
Short-term debt and current portion of long-term debt	40,072					197,084
Current portion of capital lease obligations	0					0
Accounts payable	35,591					15,981
Accrued expenses and other current liabilities	65,582					62,287
Liabilities related to assets held for sale - current						0
Intercompany payables	485,573					1,122,042
Total current liabilities	626,818		1,248,718	514,279	345,110	1,397,394		1,725,939	943,570	385,171
Long-term liabilities:
Long-term debt, net of current portion	2,852,978					2,784,913
Capital lease obligations, net of current portion	0					0
Deferred tax liabilities	0					0
Other long-term liabilities	91,042					14,962
Intercompany notes payables	377,969					477,779
Total long-term liabilities	3,321,989		3,362,971	3,294,404	3,197,047	3,277,654		3,344,111	3,381,648	3,487,308
Total stockholders' equity	1,826,992					2,051,032
Non-controlling interests	0					0
Total equity	1,826,992		2,042,274	2,010,610	2,081,294	2,051,032		2,091,939	2,160,056	2,074,585
Total liabilities and equity	5,775,799		6,653,963	5,819,293	5,623,451	6,726,080		7,161,989	6,485,274	5,947,064
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	3,161					21,150					69,154		78,976
Restricted cash	0					0
Marketable securities	76					164
Accounts receivable, net of allowances	186,067					192,591
Inventories, net	168,736					173,383
Prepaid expenses and other current assets	22,318					27,095
Assets held for sale - current						0
Intercompany receivables	1,008,767					812,957
Total current assets	1,389,125		1,309,196	1,227,222	1,168,641	1,227,340
Property, plant and equipment, net	243,755					228,065
Goodwill	1,822,290					1,823,919
Other intangible assets with indefinite lives	7,457					7,638
Finite-lived intangible assets, net	507,060					627,269
Restricted cash	0					0
Other non-current assets	2,267					2,340
Investments in subsidiaries	158,195					158,195
Investments in unconsolidated entities	14,765					14,764
Deferred tax assets	0					0
Non-current income tax receivable	0					0
Assets held for sale - non-current						0
Intercompany notes receivables	709,965					672,032
Total assets	4,854,879		4,792,740	4,764,565	4,737,809	4,761,562
Current liabilities:
Short-term debt and current portion of long-term debt	0					0
Current portion of capital lease obligations	1,560					2,018
Accounts payable	78,981					76,890
Accrued expenses and other current liabilities	133,506					126,346
Liabilities related to assets held for sale - current						0
Intercompany payables	859,924					773,839
Total current liabilities	1,073,971		993,993	892,933	905,144	979,093
Long-term liabilities:
Long-term debt, net of current portion	0					0
Capital lease obligations, net of current portion	2,029					840
Deferred tax liabilities	51,314					219,224
Other long-term liabilities	44,563					59,309
Intercompany notes payables	1,274,419					1,181,168
Total long-term liabilities	1,372,325		1,431,797	1,471,124	1,476,576	1,460,541
Total stockholders' equity	2,408,583					2,321,928
Non-controlling interests	0					0
Total equity	2,408,583		2,366,950	2,400,508	2,356,089	2,321,928
Total liabilities and equity	4,854,879		4,792,740	4,764,565	4,737,809	4,761,562
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	396,415					341,897					307,158		261,654
Restricted cash	50,213					4,444
Marketable securities	0					0
Accounts receivable, net of allowances	227,468					244,333
Inventories, net	163,967					198,140
Prepaid expenses and other current assets	68,748					73,242
Assets held for sale - current						4,165
Intercompany receivables	204,587					50,691
Total current assets	1,111,398		1,084,914	1,112,200	1,051,278	916,912		1,002,806	1,047,452	976,818
Property, plant and equipment, net	176,618					188,084
Goodwill	937,076					1,012,996
Other intangible assets with indefinite lives	19,765					20,531
Finite-lived intangible assets, net	299,227					370,261
Restricted cash	2,171					43,228
Other non-current assets	13,060					15,380
Investments in subsidiaries	57,650					57,650
Investments in unconsolidated entities	42,523					37,947
Deferred tax assets	57,819					51,329
Non-current income tax receivable	40,654					37,719
Assets held for sale - non-current						0
Intercompany notes receivables	744					6,900
Total assets	2,758,705		2,867,250	2,913,654	2,902,374	2,758,937		2,911,823	3,014,358	2,960,893
Current liabilities:
Short-term debt and current portion of long-term debt	42,298					2,908
Current portion of capital lease obligations	1,504					1,944
Accounts payable	81,307					102,881
Accrued expenses and other current liabilities	223,778					131,766
Liabilities related to assets held for sale - current						363
Intercompany payables	258,154					205,241
Total current liabilities	607,041		627,262	498,851	507,593	445,103		424,627	561,302	611,022
Long-term liabilities:
Long-term debt, net of current portion	5,227					46,253
Capital lease obligations, net of current portion	5,192					6,341
Deferred tax liabilities	67,702					54,749
Other long-term liabilities	21,257					80,369
Intercompany notes payables	816,044					925,173
Total long-term liabilities	915,422		998,037	1,123,574	1,118,354	1,112,885		1,208,211	1,181,371	1,174,407
Total stockholders' equity	1,231,627					1,196,685
Non-controlling interests	4,615					4,264
Total equity	1,236,242		1,241,951	1,291,229	1,276,427	1,200,949		1,278,985	1,271,685	1,175,464
Total liabilities and equity	2,758,705		2,867,250	2,913,654	2,902,374	2,758,937		2,911,823	3,014,358	2,960,893
Eliminations [Member]
Current assets:
Cash and cash equivalents	0					0					$ 0		$ 0
Restricted cash	0					0
Marketable securities	0					0
Accounts receivable, net of allowances	0					0
Inventories, net	(23,783)					(20,574)
Prepaid expenses and other current assets	11,558					6,601
Assets held for sale - current						0
Intercompany receivables	(1,603,682)					(2,101,122)
Total current assets	(1,615,907)		(2,188,177)	(1,363,814)	(1,100,666)	(2,115,095)		(2,001,967)	(1,317,329)	(1,304,328)
Property, plant and equipment, net	(4,708)					(1,494)
Goodwill	0					0
Other intangible assets with indefinite lives	(58)					(59)
Finite-lived intangible assets, net	(3,200)					(3,200)
Restricted cash	0					0
Other non-current assets	(870)					(446)
Investments in subsidiaries	(3,624,846)					(3,507,569)
Investments in unconsolidated entities	14,253					12,120
Deferred tax assets	(37,336)					(128,556)
Non-current income tax receivable	0					0
Assets held for sale - non-current						0
Intercompany notes receivables	(2,468,432)					(2,584,120)
Total assets	(7,741,104)		(8,462,268)	(7,704,712)	(7,368,461)	(8,328,419)		(8,355,373)	(7,651,674)	(7,553,913)
Current liabilities:
Short-term debt and current portion of long-term debt	0					0
Current portion of capital lease obligations	0					0
Accounts payable	0					0
Accrued expenses and other current liabilities	(28,023)					2,238
Liabilities related to assets held for sale - current						0
Intercompany payables	(1,603,651)					(2,101,122)
Total current liabilities	(1,631,674)		(2,168,444)	(1,345,171)	(1,079,966)	(2,098,884)		(1,981,597)	(1,298,126)	(1,286,051)
Long-term liabilities:
Long-term debt, net of current portion	0					0
Capital lease obligations, net of current portion	0					0
Deferred tax liabilities	82					(126,355)
Other long-term liabilities	(870)					(447)
Intercompany notes payables	(2,468,432)					(2,584,120)
Total long-term liabilities	(2,469,220)		(2,689,610)	(2,672,312)	(2,660,344)	(2,710,922)		(2,714,032)	(2,760,666)	(2,803,565)
Total stockholders' equity	(3,640,210)					(3,518,613)
Non-controlling interests	0					0
Total equity	(3,640,210)		(3,604,214)	(3,687,229)	(3,628,151)	(3,518,613)		(3,659,744)	(3,592,882)	(3,464,297)
Total liabilities and equity	$ (7,741,104)		$ (8,462,268)	$ (7,704,712)	$ (7,368,461)	$ (8,328,419)		$ (8,355,373)	$ (7,651,674)	$ (7,553,913)
[1]	Restated Values

Guarantor Financial Informat161

Guarantor Financial Information - Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands		3 Months Ended										6 Months Ended				9 Months Ended				12 Months Ended
		Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016		Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015		Jun. 30, 2016		Jun. 30, 2015		Sep. 30, 2016		Sep. 30, 2015		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Cash Flows from Operating Activities:
Net income (loss)		$ 15,663	$ (32,807)	$ (5,972)		$ (19,077)		$ (1,468)	$ 14,498	$ 210,113		$ (38,779)		$ 224,611		$ (23,116)		$ 223,143		$ (137,269)	[1]	$ 204,065	[1]	$ (33,123)	[1]
Income (loss) from discontinued operations, net of tax		0	0	0		2,736		0	0	216,777		0		216,777		0		216,777		0		219,513	[1]	138,318	[1]
Income (loss) from continuing operations		15,663	(32,807)	(5,972)		(21,813)		(1,468)	14,498	(6,664)		(38,779)		7,834		(23,116)		6,366		(137,269)		(15,448)	[1]	(171,441)	[1]
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax																				0		0		0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs																				13,369		12,831	[1]	16,233	[1]
Depreciation and amortization																				285,608		309,264	[1]	336,029	[1]
Non-cash stock-based compensation expense																				41,796		26,391	[1]	12,452	[1]
Tax benefit related to discontinued operations retained by Alere Inc																				0		0	[1]	9,845	[1]
Impairment of inventory																				2,667		15,597	[1]	3,124	[1]
Impairment of long-lived assets																				1,792		3,708	[1]	7,019	[1]
Loss on disposition of fixed assets																				3,551		3,925	[1]	6,545	[1]
Equity earnings of unconsolidated entities, net of tax		(26,149)	(2,122)	(5,034)		(5,210)		(5,000)	(1,361)	(3,959)		(7,156)		(5,320)		(33,305)		(10,320)		(50,505)		(15,530)	[1]	(17,509)	[1]
Deferred income taxes																				(36,010)		(99,389)	[1]	12,254	[1]
Loss on extinguishment of debt																				0		19,886	[1]	0	[1]
Net gain on business disposition																				(3,810)
Impairment and net (gain) loss on business disposition		0	0	(3,810)		8,132		2,074	5,542	34,792		(3,810)		40,334		(3,810)		42,408		(3,810)		50,540	[1]	7,742	[1]
Other non-cash items																				(463)		28,782	[1]	4,965	[1]
Non-cash change in fair value of contingent consideration																				(13,309)		(59,871)	[1]	7,677	[1]
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net																				26,698		(6,680)	[1]	(4,264)	[1]
Inventories, net																				(13,655)		(63,935)	[1]	(67,532)	[1]
Prepaid expenses and other current assets																				(19,921)		(5,295)	[1]	(51,998)	[1]
Accounts payable																				4,362		(10,783)	[1]	47,851	[1]
Accrued expenses and other current liabilities																				51,490		22,643	[1]	37,886	[1]
Other non-current assets and liabilities																				23,329		(3,357)	[1]	13,254	[1]
Cash paid for contingent consideration																				(430)		(6,315)	[1]	(22,077)	[1]
Intercompany payable (receivable)																				0		0		0
Net cash provided by (used in) continuing operations																				179,290		206,964	[1]	188,055	[1]
Net cash provided by (used in) discontinued operations																				0		318	[1]	43,468	[1]
Net cash provided by operating activities																				179,290		207,282	[1]	231,523	[1]
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash																				(4,721)		(13,715)	[1]	(5,446)	[1]
Purchases of property, plant and equipment																				(67,694)		(90,778)	[1]	(100,562)	[1]
Proceeds from sale of property, plant and equipment																				1,428		2,099	[1]	1,486	[1]
Cash received from (used in) business dispositions, net of cash divested																				21,470		675,823		45,076
Cash paid for business acquisitions, net of cash acquired																				(5,958)		(60,135)	[1]	(75)	[1]
Cash received (paid) for investments																								198
Cash paid for equity investments																				(184)		0	[1]	0	[1]
Proceeds from sale of equity investment																				40,751		0	[1]	8,546	[1]
Cash received from sales of marketable securities																				87		92	[1]	580	[1]
Cash received from equity method investments																				16,989		26,136	[1]	980	[1]
(Increase) decrease in other assets																				460		(1,794)	[1]	986	[1]
Net cash provided by (used in) continuing operations																				2,628		537,728	[1]	(48,231)	[1]
Net cash used in discontinued operations																				0		(209)	[1]	(8,972)	[1]
Net cash provided by (used in) investing activities																				2,628		537,519	[1]	(57,203)	[1]
Cash Flows from Financing Activities:
Cash paid for financing costs																				(29,187)		(16,188)	[1]	(1,528)	[1]
Cash paid for contingent consideration																				(680)		(14,223)	[1]	(32,902)	[1]
Cash paid for dividends																				(21,292)		(21,293)	[1]	(21,293)	[1]
Proceeds from issuance of common stock, net of issuance costs																				18,934		79,185	[1]	51,555	[1]
Proceeds from issuance of short-term debt																				0		1,511	[1]	806	[1]
Proceeds from issuance of long-term debt																				459		2,162,162	[1]	58	[1]
Payments on short-term debt																				(1,722)		(25,584)	[1]	0	[1]
Payments on long-term debt																				(198,316)		(2,656,386)	[1]	(65,122)	[1]
Net (payments) proceeds under revolving credit facilities																				126,017		(127,536)	[1]	(42,522)	[1]
Excess tax benefits on exercised stock options																				0		0	[1]	972	[1]
Principal payments on capital lease obligations																				(4,032)		(5,618)	[1]	(6,085)	[1]
Purchase of non-controlling interest																				0		0	[1]	(623)	[1]
Other																				0		(8,937)	[1]	0	[1]
Net cash provided by (used in) continuing operations																				(109,819)		(632,907)	[1]	(116,684)	[1]
Net cash used in discontinued operations																				0		(76)	[1]	(1,471)	[1]
Net cash provided by (used in) financing activities																				(109,819)		(632,983)	[1]	(118,155)	[1]
Foreign exchange effect on cash and cash equivalents																				(7,084)		(11,379)	[1]	(16,312)	[1]
Net increase (decrease) in cash and cash equivalents																				65,015		100,439	[1]	39,853	[1]
Cash and cash equivalents, beginning of period - continuing operations		506,164	490,663	502,200	[1]	479,381		464,871	414,495	378,461	[1]	502,200	[1]	378,461	[1]	502,200	[1]	378,461	[1]	502,200	[1]	378,461	[1]	355,431	[1]
Cash and cash equivalents, beginning of period - discontinued operations	[1]			0						23,300		0		23,300		0		23,300		0		23,300		6,477
Cash and cash equivalents, end of period						502,200	[1]													567,215		502,200	[1]	401,761	[1]
Less: Cash and cash equivalents of discontinued operations, end of period						0	[1]													0		0	[1]	23,300	[1]
Cash and cash equivalents of continuing operations, end of period		566,213	506,164	490,663		502,200	[1]	479,381	464,871	414,495		506,164		464,871		566,213		479,381		567,215		502,200	[1]	378,461	[1]
Issuer [Member]
Cash Flows from Operating Activities:
Net income (loss)																				(137,269)		204,065		(33,123)
Income (loss) from discontinued operations, net of tax																				0		221,425		145,751
Income (loss) from continuing operations		15,663	(32,807)	(5,972)				(1,468)	14,498	(8,576)										(137,269)		(17,360)		(178,874)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax																				(225,588)		(259,924)		(125,443)
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs																				13,218		12,697		15,780
Depreciation and amortization																				9,195		10,105		8,783
Non-cash stock-based compensation expense																				22,524		14,400		3,446
Tax benefit related to discontinued operations retained by Alere Inc																								0
Impairment of inventory																				0		0		0
Impairment of long-lived assets																				0		0		1,019
Loss on disposition of fixed assets																				114		121		1
Equity earnings of unconsolidated entities, net of tax																				(31,301)		(1,484)		(1,717)
Deferred income taxes																				(12,446)		(83,208)		59,929
Loss on extinguishment of debt																						19,886
Net gain on business disposition																				0
Impairment and net (gain) loss on business disposition																				0		79,951		4,236
Other non-cash items																				1,562		4,809		1,418
Non-cash change in fair value of contingent consideration																				(1,700)		(32,975)		(3,414)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net																				0		0		0
Inventories, net																				0		0		0
Prepaid expenses and other current assets																				(4,887)		3,177		(4,793)
Accounts payable																				19,087		(5,467)		8,818
Accrued expenses and other current liabilities																				(9,342)		2,416		1,698
Other non-current assets and liabilities																				189,853		(4,089)		(594)
Cash paid for contingent consideration																				(427)		(6,302)		(21,867)
Intercompany payable (receivable)																				263,255		518,055		349,314
Net cash provided by (used in) continuing operations																						254,808		117,740
Net cash provided by (used in) discontinued operations																						0		(671)
Net cash provided by operating activities																				95,848		254,808		117,069
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash																				(88)		3,763		(2,791)
Purchases of property, plant and equipment																				(3,868)		(12,710)		(21,680)
Proceeds from sale of property, plant and equipment																				92		0		726
Cash received from (used in) business dispositions, net of cash divested																				(1,337)		591,844		0
Cash paid for business acquisitions, net of cash acquired																				0		(60,135)		(75)
Cash received (paid) for investments																								477
Cash paid for equity investments																				(184)
Proceeds from sale of equity investment																				24,525				0
Cash received from sales of marketable securities																				0		0		0
Cash received from equity method investments																				16,989		2,695		0
(Increase) decrease in other assets																				(49)		301		96
Net cash provided by (used in) continuing operations																						525,758		(23,247)
Net cash used in discontinued operations																						0		0
Net cash provided by (used in) investing activities																				36,080		525,758		(23,247)
Cash Flows from Financing Activities:
Cash paid for financing costs																				(29,187)		(15,973)		(1,528)
Cash paid for contingent consideration																				0		(13,640)		(32,467)
Cash paid for dividends																				(21,292)		(21,293)		(21,293)
Proceeds from issuance of common stock, net of issuance costs																				18,934		79,185		51,555
Proceeds from issuance of short-term debt																						0		0
Proceeds from issuance of long-term debt																				0		2,119,125		0
Payments on short-term debt																				0		0
Payments on long-term debt																				(196,897)		(2,655,343)		(60,000)
Net (payments) proceeds under revolving credit facilities																				125,000		(127,000)		(43,000)
Excess tax benefits on exercised stock options																								460
Principal payments on capital lease obligations																				0		0		0
Purchase of non-controlling interest																								0
Other																						(8,623)
Net cash provided by (used in) continuing operations																						(643,562)		(106,273)
Net cash used in discontinued operations																						0		0
Net cash provided by (used in) financing activities																				(103,442)		(643,562)		(106,273)
Foreign exchange effect on cash and cash equivalents																				0		0		(201)
Net increase (decrease) in cash and cash equivalents																				28,486		137,004		(12,652)
Cash and cash equivalents, beginning of period - continuing operations				139,153						2,149		139,153		2,149		139,153		2,149		139,153		2,149		14,801
Cash and cash equivalents, beginning of period - discontinued operations				0						0		0		0		0		0		0		0		0
Cash and cash equivalents, end of period						0														167,639		0		2,149
Less: Cash and cash equivalents of discontinued operations, end of period						0														0		0		0
Cash and cash equivalents of continuing operations, end of period						139,153														167,639		139,153		2,149
Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)																				78,698		77,057		39,330
Income (loss) from discontinued operations, net of tax																				0		(1,912)		(27,839)
Income (loss) from continuing operations		(35,414)																		78,698		78,969		67,169
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax																				0		0		0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs																				11		25		42
Depreciation and amortization																				179,672		175,415		177,347
Non-cash stock-based compensation expense																				9,629		5,869		4,957
Tax benefit related to discontinued operations retained by Alere Inc																								12,977
Impairment of inventory																				(319)		133		0
Impairment of long-lived assets																				668		3,391		(712)
Loss on disposition of fixed assets																				1,167		2,757		4,807
Equity earnings of unconsolidated entities, net of tax																				0		0		0
Deferred income taxes																				(29,063)		(112)		(32,750)
Loss on extinguishment of debt																						0
Net gain on business disposition																				0
Impairment and net (gain) loss on business disposition																				0		(8,747)		11,393
Other non-cash items																				408		996		3,726
Non-cash change in fair value of contingent consideration																				(11,547)		11,577		11,256
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net																				4,548		1,529		(16,345)
Inventories, net																				(40,886)		(22,881)		(52,670)
Prepaid expenses and other current assets																				7,275		(26,268)		(26,445)
Accounts payable																				3,361		(7,741)		24,776
Accrued expenses and other current liabilities																				7,956		70,776		6,734
Other non-current assets and liabilities																				(141,398)		3,034		1,380
Cash paid for contingent consideration																				0		0		0
Intercompany payable (receivable)																				(54,899)		(320,171)		(184,028)
Net cash provided by (used in) continuing operations																						(31,449)		13,614
Net cash provided by (used in) discontinued operations																						318		44,060
Net cash provided by operating activities																				15,281		(31,131)		57,674
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash																				0		0		0
Purchases of property, plant and equipment																				(31,317)		(29,748)		(40,737)
Proceeds from sale of property, plant and equipment																				367		993		845
Cash received from (used in) business dispositions, net of cash divested																				0		(8,723)		1,081
Cash paid for business acquisitions, net of cash acquired																				0		0		0
Cash received (paid) for investments																								(279)
Cash paid for equity investments																				0
Proceeds from sale of equity investment																				0				0
Cash received from sales of marketable securities																				87		92		576
Cash received from equity method investments																				0		0		0
(Increase) decrease in other assets																				(266)		485		714
Net cash provided by (used in) continuing operations																						(36,901)		(37,800)
Net cash used in discontinued operations																						(209)		(8,972)
Net cash provided by (used in) investing activities																				(31,129)		(37,110)		(46,772)
Cash Flows from Financing Activities:
Cash paid for financing costs																				0		0		0
Cash paid for contingent consideration																				0		0		0
Cash paid for dividends																				0		0		0
Proceeds from issuance of common stock, net of issuance costs																				0		0		0
Proceeds from issuance of short-term debt																						0		0
Proceeds from issuance of long-term debt																				0		0		0
Payments on short-term debt																				0		0
Payments on long-term debt																				0		0		(271)
Net (payments) proceeds under revolving credit facilities																				0		0		0
Excess tax benefits on exercised stock options																								422
Principal payments on capital lease obligations																				(2,279)		(2,565)		(2,885)
Purchase of non-controlling interest																								0
Other																						0
Net cash provided by (used in) continuing operations																						(2,565)		(2,734)
Net cash used in discontinued operations																						(76)		(893)
Net cash provided by (used in) financing activities																				(2,279)		(2,641)		(3,627)
Foreign exchange effect on cash and cash equivalents																				138		(422)		(273)
Net increase (decrease) in cash and cash equivalents																				(17,989)		(71,304)		7,002
Cash and cash equivalents, beginning of period - continuing operations				21,150						69,154		21,150		69,154		21,150		69,154		21,150		69,154		78,976
Cash and cash equivalents, beginning of period - discontinued operations				0						23,300		0		23,300		0		23,300		0		23,300		6,476
Cash and cash equivalents, end of period						0														3,161		0		92,454
Less: Cash and cash equivalents of discontinued operations, end of period						0														0		0		23,300
Cash and cash equivalents of continuing operations, end of period						21,150														3,161		21,150		69,154
Non-Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)																				151,179		188,115		84,532
Income (loss) from discontinued operations, net of tax																				0		0		20,400
Income (loss) from continuing operations		(59,042)	57,964	51,433				92,502	84,664	73,204										151,179		188,115		64,132
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax																				0		0		0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs																				140		109		411
Depreciation and amortization																				96,492		123,921		149,884
Non-cash stock-based compensation expense																				9,643		6,122		4,049
Tax benefit related to discontinued operations retained by Alere Inc																								(3,132)
Impairment of inventory																				2,986		15,464		3,124
Impairment of long-lived assets																				1,124		317		6,712
Loss on disposition of fixed assets																				2,270		1,047		1,737
Equity earnings of unconsolidated entities, net of tax																				(18,863)		(14,065)		(15,928)
Deferred income taxes																				5,499		(16,508)		(15,945)
Loss on extinguishment of debt																						0
Net gain on business disposition																				(3,810)
Impairment and net (gain) loss on business disposition																				(3,810)		(20,664)		(7,887)
Other non-cash items																				(2,382)		19,777		(179)
Non-cash change in fair value of contingent consideration																				(62)		(38,473)		(165)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net																				22,150		(8,209)		12,081
Inventories, net																				22,850		(42,951)		(12,717)
Prepaid expenses and other current assets																				(17,354)		21,891		(20,015)
Accounts payable																				(18,086)		2,425		14,257
Accrued expenses and other current liabilities																				83,136		(52,841)		31,273
Other non-current assets and liabilities																				(60,342)		(4,016)		9,897
Cash paid for contingent consideration																				(3)		(13)		(210)
Intercompany payable (receivable)																				(208,406)		(197,877)		(165,293)
Net cash provided by (used in) continuing operations																						(16,429)		56,086
Net cash provided by (used in) discontinued operations																						0		79
Net cash provided by operating activities																				68,161		(16,429)		56,165
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash																				(4,633)		(17,478)		(2,655)
Purchases of property, plant and equipment																				(34,382)		(49,375)		(41,862)
Proceeds from sale of property, plant and equipment																				2,842		2,161		4,165
Cash received from (used in) business dispositions, net of cash divested																				22,807		92,702		43,995
Cash paid for business acquisitions, net of cash acquired																				(5,958)		0		0
Cash paid for equity investments																				0
Proceeds from sale of equity investment																				16,226				8,546
Cash received from sales of marketable securities																				0		0		4
Cash received from equity method investments																				0		23,441		980
(Increase) decrease in other assets																				775		(2,546)		130
Net cash provided by (used in) continuing operations																						48,905		13,303
Net cash used in discontinued operations																						0		0
Net cash provided by (used in) investing activities																				(2,323)		48,905		13,303
Cash Flows from Financing Activities:
Cash paid for financing costs																				0		(215)		0
Cash paid for contingent consideration																				(680)		(583)		(435)
Cash paid for dividends																				0		0		0
Proceeds from issuance of common stock, net of issuance costs																				0		0		0
Proceeds from issuance of short-term debt																						1,511		806
Proceeds from issuance of long-term debt																				459		43,037		58
Payments on short-term debt																				(1,722)		(25,584)
Payments on long-term debt																				(1,419)		(1,043)		(4,851)
Net (payments) proceeds under revolving credit facilities																				1,017		(536)		478
Excess tax benefits on exercised stock options																								90
Principal payments on capital lease obligations																				(1,753)		(3,053)		(3,200)
Purchase of non-controlling interest																								(623)
Other																						(314)
Net cash provided by (used in) continuing operations																						13,220		(7,677)
Net cash used in discontinued operations																						0		(578)
Net cash provided by (used in) financing activities																				(4,098)		13,220		(8,255)
Foreign exchange effect on cash and cash equivalents																				(7,222)		(10,957)		(15,710)
Net increase (decrease) in cash and cash equivalents																				54,518		34,739		45,503
Cash and cash equivalents, beginning of period - continuing operations				341,897						307,158		341,897		307,158		341,897		307,158		341,897		307,158		261,654
Cash and cash equivalents, beginning of period - discontinued operations				0						0		0		0		0		0		0		0		1
Cash and cash equivalents, end of period						0														396,415		0		307,158
Less: Cash and cash equivalents of discontinued operations, end of period						0														0		0		0
Cash and cash equivalents of continuing operations, end of period						341,897														396,415		341,897		307,158
Eliminations [Member]
Cash Flows from Operating Activities:
Net income (loss)																				(229,877)		(265,172)		(123,862)
Income (loss) from discontinued operations, net of tax																				0		0		6
Income (loss) from continuing operations		$ 94,456	$ (99,903)	(83,437)				$ (158,571)	$ (126,877)	(73,086)										(229,877)		(265,172)		(123,868)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax																				225,588		259,924		125,443
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs																				0		0		0
Depreciation and amortization																				249		(177)		15
Non-cash stock-based compensation expense																				0		0		0
Tax benefit related to discontinued operations retained by Alere Inc																								0
Impairment of inventory																				0		0		0
Impairment of long-lived assets																				0		0		0
Loss on disposition of fixed assets																				0		0		0
Equity earnings of unconsolidated entities, net of tax																				(341)		19		136
Deferred income taxes																				0		439		1,020
Loss on extinguishment of debt																						0
Net gain on business disposition																				0
Impairment and net (gain) loss on business disposition																				0		0		0
Other non-cash items																				(51)		3,200		0
Non-cash change in fair value of contingent consideration																				0		0		0
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net																				0		0		0
Inventories, net																				4,381		1,897		(2,145)
Prepaid expenses and other current assets																				(4,955)		(4,095)		(745)
Accounts payable																				0		0		0
Accrued expenses and other current liabilities																				(30,260)		2,292		(1,819)
Other non-current assets and liabilities																				35,216		1,714		2,571
Cash paid for contingent consideration																				0		0		0
Intercompany payable (receivable)																				50		(7)		7
Net cash provided by (used in) continuing operations																						34		615
Net cash provided by (used in) discontinued operations																						0		0
Net cash provided by operating activities																				0		34		615
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash																				0		0		0
Purchases of property, plant and equipment																				1,873		1,055		3,717
Proceeds from sale of property, plant and equipment																				(1,873)		(1,055)		(4,250)
Cash received from (used in) business dispositions, net of cash divested																				0		0		0
Cash paid for business acquisitions, net of cash acquired																				0		0		0
Cash received (paid) for investments																								0
Cash paid for equity investments																				0
Proceeds from sale of equity investment																				0				0
Cash received from sales of marketable securities																				0		0		0
Cash received from equity method investments																				0		0		0
(Increase) decrease in other assets																				0		(34)		46
Net cash provided by (used in) continuing operations																						(34)		(487)
Net cash used in discontinued operations																						0		0
Net cash provided by (used in) investing activities																				0		(34)		(487)
Cash Flows from Financing Activities:
Cash paid for financing costs																				0		0		0
Cash paid for contingent consideration																				0		0		0
Cash paid for dividends																				0		0		0
Proceeds from issuance of common stock, net of issuance costs																				0		0		0
Proceeds from issuance of short-term debt																						0		0
Proceeds from issuance of long-term debt																				0		0		0
Payments on short-term debt																				0		0
Payments on long-term debt																				0		0		0
Net (payments) proceeds under revolving credit facilities																				0		0		0
Excess tax benefits on exercised stock options																								0
Principal payments on capital lease obligations																				0		0		0
Purchase of non-controlling interest																								0
Other																						0
Net cash provided by (used in) continuing operations																						0		0
Net cash used in discontinued operations																						0		0
Net cash provided by (used in) financing activities																				0		0		0
Foreign exchange effect on cash and cash equivalents																				0		0		(128)
Net increase (decrease) in cash and cash equivalents																				0		0		0
Cash and cash equivalents, beginning of period - continuing operations				0						0		0		0		0		0		0		0		0
Cash and cash equivalents, beginning of period - discontinued operations				$ 0						$ 0		$ 0		$ 0		$ 0		$ 0		0		0		0
Cash and cash equivalents, end of period						0														0		0		0
Less: Cash and cash equivalents of discontinued operations, end of period						0														0		0		0
Cash and cash equivalents of continuing operations, end of period						$ 0														$ 0		$ 0		$ 0
[1]	Restated Values

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Jun. 02, 2017	Jun. 01, 2017	May 30, 2017	May 08, 2017	Apr. 28, 2017	Apr. 24, 2017	Jul. 31, 2016	May 31, 2016	Dec. 31, 2016	Aug. 18, 2016	Apr. 22, 2016
Subsequent Event [Line Items]
Third amendment consent fee, percentage of outstanding and credit commitment amount									0.125%
Consent aggregate payments per 1,000 principal amount							$ 15	$ 15
Aggregate amount of consent fee										$ 2,200,000	$ 4,500,000
Amendment agreement description									(i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or hereafter occur, resulting from, among other things, (x) failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and the related deliverables for the fiscal year ended December 31, 2016 and the fiscal quarter ended March 31, 2017, in each case, by the applicable deadlines under the Credit Agreement, (y) any restatement, revision or other adjustment of certain financial statements as a result of the Company’s review described our Current Report on Form 8-K (as filed with the SEC on May 22, 2017), or the May 8-K, as a result of our incorrect recognition of revenue transactions for certain fiscal periods set forth in the amendment and (z) any breach of any representation or affirmative covenant as a result of certain deliverables delivered being incorrect when delivered that is discovered as part of the review described in the May 8-K, to the extent that such breach is due to our incorrect recognition of revenue transactions for certain fiscal periods set forth in the amendment, (ii) extend the deadlines for delivery of the financial statements for the fiscal year ended December 31, 2016, to the earlier of (A) July 15, 2017, and (B) the date that is three business days prior to the earliest date (after giving effect to any applicable cure periods or any waivers or other types of extensions) that an event of default would arise under the indentures for our 6.5% senior subordinated notes, 6.375% senior subordinated notes and 7.25% senior notes as a result of the failure to timely deliver such financial statements and (iii) extend the deadlines for delivery of the financial statements for the quarter ended March 31, 2017 to the earliest of (A) the date that is ten business days after delivery of the financial statements for the fiscal year ended December 31, 2016, (B) the date that is three business days prior to the earliest date (after giving effect to any applicable cure periods or any waivers or other types of extensions) that an event of default would arise under the indentures for the our 6.5% senior subordinated notes, 6.375% senior subordinated notes and 7.25% senior notes as a result of the failure to timely deliver the financial statements for the quarter ended March 31, 2017 and (C) July 28, 2017.
Subsequent Events [Member]
Subsequent Event [Line Items]
Fees and expenses associated with third amendment						$ 3,300,000
Consent aggregate payments per 1,000 principal amount				$ 1	$ 2.5
Trustee or holders obligation payment percentage of Notes	25.00%	25.00%
Aggregate amount of consent fee				$ 23,000,000
Fourth amendment consent fee, percentage of outstanding and credit commitment amount			0.25%
6.375% Notes First Consent Fee [Member] | Subsequent Events [Member]
Subsequent Event [Line Items]
Consent aggregate payments per 1,000 principal amount		$ 20
Senior subordinated notes, interest rate		6.375%
6.50% Notes First Consent Fee [Member] | Subsequent Events [Member]
Subsequent Event [Line Items]
Consent aggregate payments per 1,000 principal amount		$ 15
Senior subordinated notes, interest rate		6.50%
7.250% Notes First Consent Fee [Member] | Subsequent Events [Member]
Subsequent Event [Line Items]
Consent aggregate payments per 1,000 principal amount		$ 12.50
Senior subordinated notes, interest rate		7.25%
Second Consent Fee [Member] | Subsequent Events [Member]
Subsequent Event [Line Items]
Consent aggregate payments per 1,000 principal amount		$ 5
Third Consent Fee [Member] | Subsequent Events [Member]
Subsequent Event [Line Items]
Consent aggregate payments per 1,000 principal amount		$ 7.50